CINXE.COM

<!DOCTYPE html> <html lang="en" xmlns:fb="http://www.facebook.com/2008/fbml" class="wf-loading"> <head prefix="og: https://ogp.me/ns# fb: https://ogp.me/ns/fb# academia: https://ogp.me/ns/fb/academia#"> <meta charset="utf-8"> <meta name=viewport content="width=device-width, initial-scale=1"> <meta rel="search" type="application/opensearchdescription+xml" href="/open_search.xml" title="Academia.edu"> <title>Aksel Siva | Istanbul University - Academia.edu</title>  <link href="//a.academia-assets.com/images/favicons/favicon-production.ico" rel="shortcut icon" type="image/vnd.microsoft.icon"> <link rel="apple-touch-icon" sizes="57x57" href="//a.academia-assets.com/images/favicons/apple-touch-icon-57x57.png"> <link rel="apple-touch-icon" sizes="60x60" href="//a.academia-assets.com/images/favicons/apple-touch-icon-60x60.png"> <link rel="apple-touch-icon" sizes="72x72" href="//a.academia-assets.com/images/favicons/apple-touch-icon-72x72.png"> <link rel="apple-touch-icon" sizes="76x76" href="//a.academia-assets.com/images/favicons/apple-touch-icon-76x76.png"> <link rel="apple-touch-icon" sizes="114x114" href="//a.academia-assets.com/images/favicons/apple-touch-icon-114x114.png"> <link rel="apple-touch-icon" sizes="120x120" href="//a.academia-assets.com/images/favicons/apple-touch-icon-120x120.png"> <link rel="apple-touch-icon" sizes="144x144" href="//a.academia-assets.com/images/favicons/apple-touch-icon-144x144.png"> <link rel="apple-touch-icon" sizes="152x152" href="//a.academia-assets.com/images/favicons/apple-touch-icon-152x152.png"> <link rel="apple-touch-icon" sizes="180x180" href="//a.academia-assets.com/images/favicons/apple-touch-icon-180x180.png"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/favicon-32x32.png" sizes="32x32"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/favicon-194x194.png" sizes="194x194"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/favicon-96x96.png" sizes="96x96"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/android-chrome-192x192.png" sizes="192x192"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/favicon-16x16.png" sizes="16x16"> <link rel="manifest" href="//a.academia-assets.com/images/favicons/manifest.json"> <meta name="msapplication-TileColor" content="#2b5797"> <meta name="msapplication-TileImage" content="//a.academia-assets.com/images/favicons/mstile-144x144.png"> <meta name="theme-color" content="#ffffff"> <script> window.performance && window.performance.measure && window.performance.measure("Time To First Byte", "requestStart", "responseStart"); </script> <script> (function() { if (!window.URLSearchParams || !window.history || !window.history.replaceState) { return; } var searchParams = new URLSearchParams(window.location.search); var paramsToDelete = [ 'fs', 'sm', 'swp', 'iid', 'nbs', 'rcc', // related content category 'rcpos', // related content carousel position 'rcpg', // related carousel page 'rchid', // related content hit id 'f_ri', // research interest id, for SEO tracking 'f_fri', // featured research interest, for SEO tracking (param key without value) 'f_rid', // from research interest directory for SEO tracking 'f_loswp', // from research interest pills on LOSWP sidebar for SEO tracking 'rhid', // referrring hit id ]; if (paramsToDelete.every((key) => searchParams.get(key) === null)) { return; } paramsToDelete.forEach((key) => { searchParams.delete(key); }); var cleanUrl = new URL(window.location.href); cleanUrl.search = searchParams.toString(); history.replaceState({}, document.title, cleanUrl); })(); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-5VKX33P2DS"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-5VKX33P2DS', { cookie_domain: 'academia.edu', send_page_view: false, }); gtag('event', 'page_view', { 'controller': "profiles/works", 'action': "summary", 'controller_action': 'profiles/works#summary', 'logged_in': 'false', 'edge': 'unknown', // Send nil if there is no A/B test bucket, in case some records get logged // with missing data - that way we can distinguish between the two cases. // ab_test_bucket should be of the form <ab_test_name>:<bucket> 'ab_test_bucket': null, }) </script> <script type="text/javascript"> window.sendUserTiming = function(timingName) { if (!(window.performance && window.performance.measure)) return; var entries = window.performance.getEntriesByName(timingName, "measure"); if (entries.length !== 1) return; var timingValue = Math.round(entries[0].duration); gtag('event', 'timing_complete', { name: timingName, value: timingValue, event_category: 'User-centric', }); }; window.sendUserTiming("Time To First Byte"); </script> <meta name="csrf-param" content="authenticity_token" /> <meta name="csrf-token" content="m1Jhx1ppy2NyMZ2Pop3MKXxsA0Fj7EQzprm8foqg9VGavPnVg-sZPDMP1Frd8zVIUDp6E9z_-RY7FgrSliecEw" /> <link rel="stylesheet" href="//a.academia-assets.com/assets/wow-3d36c19b4875b226bfed0fcba1dcea3f2fe61148383d97c0465c016b8c969290.css" media="all" /><link rel="stylesheet" href="//a.academia-assets.com/assets/social/home-79e78ce59bef0a338eb6540ec3d93b4a7952115b56c57f1760943128f4544d42.css" media="all" /><link rel="stylesheet" href="//a.academia-assets.com/assets/single_work_page/figure_carousel-2004283e0948681916eefa74772df54f56cb5c7413d82b160212231c2f474bb3.css" media="all" /><script type="application/ld+json">{"@context":"https://schema.org","@type":"ProfilePage","mainEntity":{"@context":"https://schema.org","@type":"Person","name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva","sameAs":[]},"dateCreated":"2015-07-20T14:59:31-07:00","dateModified":"2019-01-09T13:22:55-08:00","name":"Aksel Siva","description":"","sameAs":[],"relatedLink":"https://www.academia.edu/14318115/CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes"}</script><link rel="stylesheet" href="//a.academia-assets.com/assets/design_system/heading-95367dc03b794f6737f30123738a886cf53b7a65cdef98a922a98591d60063e3.css" media="all" /><link rel="stylesheet" href="//a.academia-assets.com/assets/design_system/button-8c9ae4b5c8a2531640c354d92a1f3579c8ff103277ef74913e34c8a76d4e6c00.css" media="all" /><link rel="stylesheet" href="//a.academia-assets.com/assets/design_system/body-170d1319f0e354621e81ca17054bb147da2856ec0702fe440a99af314a6338c5.css" media="all" /><style type="text/css">@media(max-width: 567px){:root{--token-mode: Parity;--dropshadow: 0 2px 4px 0 #22223340;--primary-brand: #0645b1;--error-dark: #b60000;--success-dark: #05b01c;--inactive-fill: #ebebee;--hover: #0c3b8d;--pressed: #082f75;--button-primary-fill-inactive: #ebebee;--button-primary-fill: #0645b1;--button-primary-text: #ffffff;--button-primary-fill-hover: #0c3b8d;--button-primary-fill-press: #082f75;--button-primary-icon: #ffffff;--button-primary-fill-inverse: #ffffff;--button-primary-text-inverse: #082f75;--button-primary-icon-inverse: #0645b1;--button-primary-fill-inverse-hover: #cddaef;--button-primary-stroke-inverse-pressed: #0645b1;--button-secondary-stroke-inactive: #b1b1ba;--button-secondary-fill: #eef2f9;--button-secondary-text: #082f75;--button-secondary-fill-press: #cddaef;--button-secondary-fill-inactive: #ebebee;--button-secondary-stroke: #cddaef;--button-secondary-stroke-hover: #386ac1;--button-secondary-stroke-press: #0645b1;--button-secondary-text-inactive: #b1b1ba;--button-secondary-icon: #082f75;--button-secondary-fill-hover: #e6ecf7;--button-secondary-stroke-inverse: #ffffff;--button-secondary-fill-inverse: rgba(255, 255, 255, 0);--button-secondary-icon-inverse: #ffffff;--button-secondary-icon-hover: #082f75;--button-secondary-icon-press: #082f75;--button-secondary-text-inverse: #ffffff;--button-secondary-text-hover: #082f75;--button-secondary-text-press: #082f75;--button-secondary-fill-inverse-hover: #043059;--button-xs-stroke: #141413;--button-xs-stroke-hover: #0c3b8d;--button-xs-stroke-press: #082f75;--button-xs-stroke-inactive: #ebebee;--button-xs-text: #141413;--button-xs-text-hover: #0c3b8d;--button-xs-text-press: #082f75;--button-xs-text-inactive: #91919e;--button-xs-icon: #141413;--button-xs-icon-hover: #0c3b8d;--button-xs-icon-press: #082f75;--button-xs-icon-inactive: #91919e;--button-xs-fill: #ffffff;--button-xs-fill-hover: #f4f7fc;--button-xs-fill-press: #eef2f9;--buttons-button-text-inactive: #91919e;--buttons-button-focus: #0645b1;--buttons-button-icon-inactive: #91919e;--buttons-small-buttons-corner-radius: 8px;--buttons-small-buttons-l-r-padding: 12px;--buttons-small-buttons-height: 44px;--buttons-small-buttons-gap: 8px;--buttons-small-buttons-icon-only-width: 44px;--buttons-small-buttons-icon-size: 20px;--buttons-small-buttons-stroke-default: 1px;--buttons-small-buttons-stroke-thick: 2px;--buttons-large-buttons-l-r-padding: 20px;--buttons-large-buttons-height: 54px;--buttons-large-buttons-icon-only-width: 54px;--buttons-large-buttons-icon-size: 20px;--buttons-large-buttons-gap: 8px;--buttons-large-buttons-corner-radius: 8px;--buttons-large-buttons-stroke-default: 1px;--buttons-large-buttons-stroke-thick: 2px;--buttons-extra-small-buttons-l-r-padding: 8px;--buttons-extra-small-buttons-height: 32px;--buttons-extra-small-buttons-icon-size: 16px;--buttons-extra-small-buttons-gap: 4px;--buttons-extra-small-buttons-corner-radius: 8px;--buttons-stroke-default: 1px;--buttons-stroke-thick: 2px;--background-beige: #f9f7f4;--error-light: #fff2f2;--text-placeholder: #6d6d7d;--stroke-dark: #141413;--stroke-light: #dddde2;--stroke-medium: #535366;--accent-green: #ccffd4;--accent-turquoise: #ccf7ff;--accent-yellow: #f7ffcc;--accent-peach: #ffd4cc;--accent-violet: #f7ccff;--accent-purple: #f4f7fc;--text-primary: #141413;--secondary-brand: #141413;--text-hover: #0c3b8d;--text-white: #ffffff;--text-link: #0645b1;--text-press: #082f75;--success-light: #f0f8f1;--background-light-blue: #eef2f9;--background-white: #ffffff;--premium-dark: #877440;--premium-light: #f9f6ed;--stroke-white: #ffffff;--inactive-content: #b1b1ba;--annotate-light: #a35dff;--annotate-dark: #824acc;--grid: #eef2f9;--inactive-stroke: #ebebee;--shadow: rgba(34, 34, 51, 0.25);--text-inactive: #6d6d7d;--text-error: #b60000;--stroke-error: #b60000;--background-error: #fff2f2;--background-black: #141413;--icon-default: #141413;--icon-blue: #0645b1;--background-grey: #dddde2;--icon-grey: #b1b1ba;--text-focus: #082f75;--brand-colors-neutral-black: #141413;--brand-colors-neutral-900: #535366;--brand-colors-neutral-800: #6d6d7d;--brand-colors-neutral-700: #91919e;--brand-colors-neutral-600: #b1b1ba;--brand-colors-neutral-500: #c8c8cf;--brand-colors-neutral-400: #dddde2;--brand-colors-neutral-300: #ebebee;--brand-colors-neutral-200: #f8f8fb;--brand-colors-neutral-100: #fafafa;--brand-colors-neutral-white: #ffffff;--brand-colors-blue-900: #043059;--brand-colors-blue-800: #082f75;--brand-colors-blue-700: #0c3b8d;--brand-colors-blue-600: #0645b1;--brand-colors-blue-500: #386ac1;--brand-colors-blue-400: #cddaef;--brand-colors-blue-300: #e6ecf7;--brand-colors-blue-200: #eef2f9;--brand-colors-blue-100: #f4f7fc;--brand-colors-gold-500: #877440;--brand-colors-gold-400: #e9e3d4;--brand-colors-gold-300: #f2efe8;--brand-colors-gold-200: #f9f6ed;--brand-colors-gold-100: #f9f7f4;--brand-colors-error-900: #920000;--brand-colors-error-500: #b60000;--brand-colors-success-900: #035c0f;--brand-colors-green: #ccffd4;--brand-colors-turquoise: #ccf7ff;--brand-colors-yellow: #f7ffcc;--brand-colors-peach: #ffd4cc;--brand-colors-violet: #f7ccff;--brand-colors-error-100: #fff2f2;--brand-colors-success-500: #05b01c;--brand-colors-success-100: #f0f8f1;--text-secondary: #535366;--icon-white: #ffffff;--background-beige-darker: #f2efe8;--icon-dark-grey: #535366;--type-font-family-sans-serif: Roboto;--type-font-family-serif: Georgia;--type-font-family-mono: IBM Plex Mono;--type-weights-300: 300;--type-weights-400: 400;--type-weights-500: 500;--type-weights-700: 700;--type-sizes-12: 12px;--type-sizes-14: 14px;--type-sizes-16: 16px;--type-sizes-18: 18px;--type-sizes-20: 20px;--type-sizes-22: 22px;--type-sizes-24: 24px;--type-sizes-28: 28px;--type-sizes-30: 30px;--type-sizes-32: 32px;--type-sizes-40: 40px;--type-sizes-42: 42px;--type-sizes-48-2: 48px;--type-line-heights-16: 16px;--type-line-heights-20: 20px;--type-line-heights-23: 23px;--type-line-heights-24: 24px;--type-line-heights-25: 25px;--type-line-heights-26: 26px;--type-line-heights-29: 29px;--type-line-heights-30: 30px;--type-line-heights-32: 32px;--type-line-heights-34: 34px;--type-line-heights-35: 35px;--type-line-heights-36: 36px;--type-line-heights-38: 38px;--type-line-heights-40: 40px;--type-line-heights-46: 46px;--type-line-heights-48: 48px;--type-line-heights-52: 52px;--type-line-heights-58: 58px;--type-line-heights-68: 68px;--type-line-heights-74: 74px;--type-line-heights-82: 82px;--type-paragraph-spacings-0: 0px;--type-paragraph-spacings-4: 4px;--type-paragraph-spacings-8: 8px;--type-paragraph-spacings-16: 16px;--type-sans-serif-xl-font-weight: 400;--type-sans-serif-xl-size: 32px;--type-sans-serif-xl-line-height: 46px;--type-sans-serif-xl-paragraph-spacing: 16px;--type-sans-serif-lg-font-weight: 400;--type-sans-serif-lg-size: 30px;--type-sans-serif-lg-line-height: 36px;--type-sans-serif-lg-paragraph-spacing: 16px;--type-sans-serif-md-font-weight: 400;--type-sans-serif-md-line-height: 30px;--type-sans-serif-md-paragraph-spacing: 16px;--type-sans-serif-md-size: 24px;--type-sans-serif-xs-font-weight: 700;--type-sans-serif-xs-line-height: 24px;--type-sans-serif-xs-paragraph-spacing: 0px;--type-sans-serif-xs-size: 18px;--type-sans-serif-sm-font-weight: 400;--type-sans-serif-sm-line-height: 32px;--type-sans-serif-sm-paragraph-spacing: 16px;--type-sans-serif-sm-size: 20px;--type-body-xl-font-weight: 400;--type-body-xl-size: 24px;--type-body-xl-line-height: 36px;--type-body-xl-paragraph-spacing: 0px;--type-body-sm-font-weight: 400;--type-body-sm-size: 14px;--type-body-sm-line-height: 20px;--type-body-sm-paragraph-spacing: 8px;--type-body-xs-font-weight: 400;--type-body-xs-size: 12px;--type-body-xs-line-height: 16px;--type-body-xs-paragraph-spacing: 0px;--type-body-md-font-weight: 400;--type-body-md-size: 16px;--type-body-md-line-height: 20px;--type-body-md-paragraph-spacing: 4px;--type-body-lg-font-weight: 400;--type-body-lg-size: 20px;--type-body-lg-line-height: 26px;--type-body-lg-paragraph-spacing: 16px;--type-body-lg-medium-font-weight: 500;--type-body-lg-medium-size: 20px;--type-body-lg-medium-line-height: 32px;--type-body-lg-medium-paragraph-spacing: 16px;--type-body-md-medium-font-weight: 500;--type-body-md-medium-size: 16px;--type-body-md-medium-line-height: 20px;--type-body-md-medium-paragraph-spacing: 4px;--type-body-sm-bold-font-weight: 700;--type-body-sm-bold-size: 14px;--type-body-sm-bold-line-height: 20px;--type-body-sm-bold-paragraph-spacing: 8px;--type-body-sm-medium-font-weight: 500;--type-body-sm-medium-size: 14px;--type-body-sm-medium-line-height: 20px;--type-body-sm-medium-paragraph-spacing: 8px;--type-serif-md-font-weight: 400;--type-serif-md-size: 32px;--type-serif-md-paragraph-spacing: 0px;--type-serif-md-line-height: 40px;--type-serif-sm-font-weight: 400;--type-serif-sm-size: 24px;--type-serif-sm-paragraph-spacing: 0px;--type-serif-sm-line-height: 26px;--type-serif-lg-font-weight: 400;--type-serif-lg-size: 48px;--type-serif-lg-paragraph-spacing: 0px;--type-serif-lg-line-height: 52px;--type-serif-xs-font-weight: 400;--type-serif-xs-size: 18px;--type-serif-xs-line-height: 24px;--type-serif-xs-paragraph-spacing: 0px;--type-serif-xl-font-weight: 400;--type-serif-xl-size: 48px;--type-serif-xl-paragraph-spacing: 0px;--type-serif-xl-line-height: 58px;--type-mono-md-font-weight: 400;--type-mono-md-size: 22px;--type-mono-md-line-height: 24px;--type-mono-md-paragraph-spacing: 0px;--type-mono-lg-font-weight: 400;--type-mono-lg-size: 40px;--type-mono-lg-line-height: 40px;--type-mono-lg-paragraph-spacing: 0px;--type-mono-sm-font-weight: 400;--type-mono-sm-size: 14px;--type-mono-sm-line-height: 24px;--type-mono-sm-paragraph-spacing: 0px;--spacing-xs-4: 4px;--spacing-xs-8: 8px;--spacing-xs-16: 16px;--spacing-sm-24: 24px;--spacing-sm-32: 32px;--spacing-md-40: 40px;--spacing-md-48: 48px;--spacing-lg-64: 64px;--spacing-lg-80: 80px;--spacing-xlg-104: 104px;--spacing-xlg-152: 152px;--spacing-xs-12: 12px;--spacing-page-section: 80px;--spacing-card-list-spacing: 48px;--spacing-text-section-spacing: 64px;--spacing-md-xs-headings: 40px;--corner-radius-radius-lg: 16px;--corner-radius-radius-sm: 4px;--corner-radius-radius-md: 8px;--corner-radius-radius-round: 104px}}@media(min-width: 568px)and (max-width: 1279px){:root{--token-mode: Parity;--dropshadow: 0 2px 4px 0 #22223340;--primary-brand: #0645b1;--error-dark: #b60000;--success-dark: #05b01c;--inactive-fill: #ebebee;--hover: #0c3b8d;--pressed: #082f75;--button-primary-fill-inactive: #ebebee;--button-primary-fill: #0645b1;--button-primary-text: #ffffff;--button-primary-fill-hover: #0c3b8d;--button-primary-fill-press: #082f75;--button-primary-icon: #ffffff;--button-primary-fill-inverse: #ffffff;--button-primary-text-inverse: #082f75;--button-primary-icon-inverse: #0645b1;--button-primary-fill-inverse-hover: #cddaef;--button-primary-stroke-inverse-pressed: #0645b1;--button-secondary-stroke-inactive: #b1b1ba;--button-secondary-fill: #eef2f9;--button-secondary-text: #082f75;--button-secondary-fill-press: #cddaef;--button-secondary-fill-inactive: #ebebee;--button-secondary-stroke: #cddaef;--button-secondary-stroke-hover: #386ac1;--button-secondary-stroke-press: #0645b1;--button-secondary-text-inactive: #b1b1ba;--button-secondary-icon: #082f75;--button-secondary-fill-hover: #e6ecf7;--button-secondary-stroke-inverse: #ffffff;--button-secondary-fill-inverse: rgba(255, 255, 255, 0);--button-secondary-icon-inverse: #ffffff;--button-secondary-icon-hover: #082f75;--button-secondary-icon-press: #082f75;--button-secondary-text-inverse: #ffffff;--button-secondary-text-hover: #082f75;--button-secondary-text-press: #082f75;--button-secondary-fill-inverse-hover: #043059;--button-xs-stroke: #141413;--button-xs-stroke-hover: #0c3b8d;--button-xs-stroke-press: #082f75;--button-xs-stroke-inactive: #ebebee;--button-xs-text: #141413;--button-xs-text-hover: #0c3b8d;--button-xs-text-press: #082f75;--button-xs-text-inactive: #91919e;--button-xs-icon: #141413;--button-xs-icon-hover: #0c3b8d;--button-xs-icon-press: #082f75;--button-xs-icon-inactive: #91919e;--button-xs-fill: #ffffff;--button-xs-fill-hover: #f4f7fc;--button-xs-fill-press: #eef2f9;--buttons-button-text-inactive: #91919e;--buttons-button-focus: #0645b1;--buttons-button-icon-inactive: #91919e;--buttons-small-buttons-corner-radius: 8px;--buttons-small-buttons-l-r-padding: 12px;--buttons-small-buttons-height: 44px;--buttons-small-buttons-gap: 8px;--buttons-small-buttons-icon-only-width: 44px;--buttons-small-buttons-icon-size: 20px;--buttons-small-buttons-stroke-default: 1px;--buttons-small-buttons-stroke-thick: 2px;--buttons-large-buttons-l-r-padding: 20px;--buttons-large-buttons-height: 54px;--buttons-large-buttons-icon-only-width: 54px;--buttons-large-buttons-icon-size: 20px;--buttons-large-buttons-gap: 8px;--buttons-large-buttons-corner-radius: 8px;--buttons-large-buttons-stroke-default: 1px;--buttons-large-buttons-stroke-thick: 2px;--buttons-extra-small-buttons-l-r-padding: 8px;--buttons-extra-small-buttons-height: 32px;--buttons-extra-small-buttons-icon-size: 16px;--buttons-extra-small-buttons-gap: 4px;--buttons-extra-small-buttons-corner-radius: 8px;--buttons-stroke-default: 1px;--buttons-stroke-thick: 2px;--background-beige: #f9f7f4;--error-light: #fff2f2;--text-placeholder: #6d6d7d;--stroke-dark: #141413;--stroke-light: #dddde2;--stroke-medium: #535366;--accent-green: #ccffd4;--accent-turquoise: #ccf7ff;--accent-yellow: #f7ffcc;--accent-peach: #ffd4cc;--accent-violet: #f7ccff;--accent-purple: #f4f7fc;--text-primary: #141413;--secondary-brand: #141413;--text-hover: #0c3b8d;--text-white: #ffffff;--text-link: #0645b1;--text-press: #082f75;--success-light: #f0f8f1;--background-light-blue: #eef2f9;--background-white: #ffffff;--premium-dark: #877440;--premium-light: #f9f6ed;--stroke-white: #ffffff;--inactive-content: #b1b1ba;--annotate-light: #a35dff;--annotate-dark: #824acc;--grid: #eef2f9;--inactive-stroke: #ebebee;--shadow: rgba(34, 34, 51, 0.25);--text-inactive: #6d6d7d;--text-error: #b60000;--stroke-error: #b60000;--background-error: #fff2f2;--background-black: #141413;--icon-default: #141413;--icon-blue: #0645b1;--background-grey: #dddde2;--icon-grey: #b1b1ba;--text-focus: #082f75;--brand-colors-neutral-black: #141413;--brand-colors-neutral-900: #535366;--brand-colors-neutral-800: #6d6d7d;--brand-colors-neutral-700: #91919e;--brand-colors-neutral-600: #b1b1ba;--brand-colors-neutral-500: #c8c8cf;--brand-colors-neutral-400: #dddde2;--brand-colors-neutral-300: #ebebee;--brand-colors-neutral-200: #f8f8fb;--brand-colors-neutral-100: #fafafa;--brand-colors-neutral-white: #ffffff;--brand-colors-blue-900: #043059;--brand-colors-blue-800: #082f75;--brand-colors-blue-700: #0c3b8d;--brand-colors-blue-600: #0645b1;--brand-colors-blue-500: #386ac1;--brand-colors-blue-400: #cddaef;--brand-colors-blue-300: #e6ecf7;--brand-colors-blue-200: #eef2f9;--brand-colors-blue-100: #f4f7fc;--brand-colors-gold-500: #877440;--brand-colors-gold-400: #e9e3d4;--brand-colors-gold-300: #f2efe8;--brand-colors-gold-200: #f9f6ed;--brand-colors-gold-100: #f9f7f4;--brand-colors-error-900: #920000;--brand-colors-error-500: #b60000;--brand-colors-success-900: #035c0f;--brand-colors-green: #ccffd4;--brand-colors-turquoise: #ccf7ff;--brand-colors-yellow: #f7ffcc;--brand-colors-peach: #ffd4cc;--brand-colors-violet: #f7ccff;--brand-colors-error-100: #fff2f2;--brand-colors-success-500: #05b01c;--brand-colors-success-100: #f0f8f1;--text-secondary: #535366;--icon-white: #ffffff;--background-beige-darker: #f2efe8;--icon-dark-grey: #535366;--type-font-family-sans-serif: Roboto;--type-font-family-serif: Georgia;--type-font-family-mono: IBM Plex Mono;--type-weights-300: 300;--type-weights-400: 400;--type-weights-500: 500;--type-weights-700: 700;--type-sizes-12: 12px;--type-sizes-14: 14px;--type-sizes-16: 16px;--type-sizes-18: 18px;--type-sizes-20: 20px;--type-sizes-22: 22px;--type-sizes-24: 24px;--type-sizes-28: 28px;--type-sizes-30: 30px;--type-sizes-32: 32px;--type-sizes-40: 40px;--type-sizes-42: 42px;--type-sizes-48-2: 48px;--type-line-heights-16: 16px;--type-line-heights-20: 20px;--type-line-heights-23: 23px;--type-line-heights-24: 24px;--type-line-heights-25: 25px;--type-line-heights-26: 26px;--type-line-heights-29: 29px;--type-line-heights-30: 30px;--type-line-heights-32: 32px;--type-line-heights-34: 34px;--type-line-heights-35: 35px;--type-line-heights-36: 36px;--type-line-heights-38: 38px;--type-line-heights-40: 40px;--type-line-heights-46: 46px;--type-line-heights-48: 48px;--type-line-heights-52: 52px;--type-line-heights-58: 58px;--type-line-heights-68: 68px;--type-line-heights-74: 74px;--type-line-heights-82: 82px;--type-paragraph-spacings-0: 0px;--type-paragraph-spacings-4: 4px;--type-paragraph-spacings-8: 8px;--type-paragraph-spacings-16: 16px;--type-sans-serif-xl-font-weight: 400;--type-sans-serif-xl-size: 42px;--type-sans-serif-xl-line-height: 46px;--type-sans-serif-xl-paragraph-spacing: 16px;--type-sans-serif-lg-font-weight: 400;--type-sans-serif-lg-size: 32px;--type-sans-serif-lg-line-height: 36px;--type-sans-serif-lg-paragraph-spacing: 16px;--type-sans-serif-md-font-weight: 400;--type-sans-serif-md-line-height: 34px;--type-sans-serif-md-paragraph-spacing: 16px;--type-sans-serif-md-size: 28px;--type-sans-serif-xs-font-weight: 700;--type-sans-serif-xs-line-height: 25px;--type-sans-serif-xs-paragraph-spacing: 0px;--type-sans-serif-xs-size: 20px;--type-sans-serif-sm-font-weight: 400;--type-sans-serif-sm-line-height: 30px;--type-sans-serif-sm-paragraph-spacing: 16px;--type-sans-serif-sm-size: 24px;--type-body-xl-font-weight: 400;--type-body-xl-size: 24px;--type-body-xl-line-height: 36px;--type-body-xl-paragraph-spacing: 0px;--type-body-sm-font-weight: 400;--type-body-sm-size: 14px;--type-body-sm-line-height: 20px;--type-body-sm-paragraph-spacing: 8px;--type-body-xs-font-weight: 400;--type-body-xs-size: 12px;--type-body-xs-line-height: 16px;--type-body-xs-paragraph-spacing: 0px;--type-body-md-font-weight: 400;--type-body-md-size: 16px;--type-body-md-line-height: 20px;--type-body-md-paragraph-spacing: 4px;--type-body-lg-font-weight: 400;--type-body-lg-size: 20px;--type-body-lg-line-height: 26px;--type-body-lg-paragraph-spacing: 16px;--type-body-lg-medium-font-weight: 500;--type-body-lg-medium-size: 20px;--type-body-lg-medium-line-height: 32px;--type-body-lg-medium-paragraph-spacing: 16px;--type-body-md-medium-font-weight: 500;--type-body-md-medium-size: 16px;--type-body-md-medium-line-height: 20px;--type-body-md-medium-paragraph-spacing: 4px;--type-body-sm-bold-font-weight: 700;--type-body-sm-bold-size: 14px;--type-body-sm-bold-line-height: 20px;--type-body-sm-bold-paragraph-spacing: 8px;--type-body-sm-medium-font-weight: 500;--type-body-sm-medium-size: 14px;--type-body-sm-medium-line-height: 20px;--type-body-sm-medium-paragraph-spacing: 8px;--type-serif-md-font-weight: 400;--type-serif-md-size: 40px;--type-serif-md-paragraph-spacing: 0px;--type-serif-md-line-height: 48px;--type-serif-sm-font-weight: 400;--type-serif-sm-size: 28px;--type-serif-sm-paragraph-spacing: 0px;--type-serif-sm-line-height: 32px;--type-serif-lg-font-weight: 400;--type-serif-lg-size: 58px;--type-serif-lg-paragraph-spacing: 0px;--type-serif-lg-line-height: 68px;--type-serif-xs-font-weight: 400;--type-serif-xs-size: 18px;--type-serif-xs-line-height: 24px;--type-serif-xs-paragraph-spacing: 0px;--type-serif-xl-font-weight: 400;--type-serif-xl-size: 74px;--type-serif-xl-paragraph-spacing: 0px;--type-serif-xl-line-height: 82px;--type-mono-md-font-weight: 400;--type-mono-md-size: 22px;--type-mono-md-line-height: 24px;--type-mono-md-paragraph-spacing: 0px;--type-mono-lg-font-weight: 400;--type-mono-lg-size: 40px;--type-mono-lg-line-height: 40px;--type-mono-lg-paragraph-spacing: 0px;--type-mono-sm-font-weight: 400;--type-mono-sm-size: 14px;--type-mono-sm-line-height: 24px;--type-mono-sm-paragraph-spacing: 0px;--spacing-xs-4: 4px;--spacing-xs-8: 8px;--spacing-xs-16: 16px;--spacing-sm-24: 24px;--spacing-sm-32: 32px;--spacing-md-40: 40px;--spacing-md-48: 48px;--spacing-lg-64: 64px;--spacing-lg-80: 80px;--spacing-xlg-104: 104px;--spacing-xlg-152: 152px;--spacing-xs-12: 12px;--spacing-page-section: 104px;--spacing-card-list-spacing: 48px;--spacing-text-section-spacing: 80px;--spacing-md-xs-headings: 40px;--corner-radius-radius-lg: 16px;--corner-radius-radius-sm: 4px;--corner-radius-radius-md: 8px;--corner-radius-radius-round: 104px}}@media(min-width: 1280px){:root{--token-mode: Parity;--dropshadow: 0 2px 4px 0 #22223340;--primary-brand: #0645b1;--error-dark: #b60000;--success-dark: #05b01c;--inactive-fill: #ebebee;--hover: #0c3b8d;--pressed: #082f75;--button-primary-fill-inactive: #ebebee;--button-primary-fill: #0645b1;--button-primary-text: #ffffff;--button-primary-fill-hover: #0c3b8d;--button-primary-fill-press: #082f75;--button-primary-icon: #ffffff;--button-primary-fill-inverse: #ffffff;--button-primary-text-inverse: #082f75;--button-primary-icon-inverse: #0645b1;--button-primary-fill-inverse-hover: #cddaef;--button-primary-stroke-inverse-pressed: #0645b1;--button-secondary-stroke-inactive: #b1b1ba;--button-secondary-fill: #eef2f9;--button-secondary-text: #082f75;--button-secondary-fill-press: #cddaef;--button-secondary-fill-inactive: #ebebee;--button-secondary-stroke: #cddaef;--button-secondary-stroke-hover: #386ac1;--button-secondary-stroke-press: #0645b1;--button-secondary-text-inactive: #b1b1ba;--button-secondary-icon: #082f75;--button-secondary-fill-hover: #e6ecf7;--button-secondary-stroke-inverse: #ffffff;--button-secondary-fill-inverse: rgba(255, 255, 255, 0);--button-secondary-icon-inverse: #ffffff;--button-secondary-icon-hover: #082f75;--button-secondary-icon-press: #082f75;--button-secondary-text-inverse: #ffffff;--button-secondary-text-hover: #082f75;--button-secondary-text-press: #082f75;--button-secondary-fill-inverse-hover: #043059;--button-xs-stroke: #141413;--button-xs-stroke-hover: #0c3b8d;--button-xs-stroke-press: #082f75;--button-xs-stroke-inactive: #ebebee;--button-xs-text: #141413;--button-xs-text-hover: #0c3b8d;--button-xs-text-press: #082f75;--button-xs-text-inactive: #91919e;--button-xs-icon: #141413;--button-xs-icon-hover: #0c3b8d;--button-xs-icon-press: #082f75;--button-xs-icon-inactive: #91919e;--button-xs-fill: #ffffff;--button-xs-fill-hover: #f4f7fc;--button-xs-fill-press: #eef2f9;--buttons-button-text-inactive: #91919e;--buttons-button-focus: #0645b1;--buttons-button-icon-inactive: #91919e;--buttons-small-buttons-corner-radius: 8px;--buttons-small-buttons-l-r-padding: 12px;--buttons-small-buttons-height: 44px;--buttons-small-buttons-gap: 8px;--buttons-small-buttons-icon-only-width: 44px;--buttons-small-buttons-icon-size: 20px;--buttons-small-buttons-stroke-default: 1px;--buttons-small-buttons-stroke-thick: 2px;--buttons-large-buttons-l-r-padding: 20px;--buttons-large-buttons-height: 54px;--buttons-large-buttons-icon-only-width: 54px;--buttons-large-buttons-icon-size: 20px;--buttons-large-buttons-gap: 8px;--buttons-large-buttons-corner-radius: 8px;--buttons-large-buttons-stroke-default: 1px;--buttons-large-buttons-stroke-thick: 2px;--buttons-extra-small-buttons-l-r-padding: 8px;--buttons-extra-small-buttons-height: 32px;--buttons-extra-small-buttons-icon-size: 16px;--buttons-extra-small-buttons-gap: 4px;--buttons-extra-small-buttons-corner-radius: 8px;--buttons-stroke-default: 1px;--buttons-stroke-thick: 2px;--background-beige: #f9f7f4;--error-light: #fff2f2;--text-placeholder: #6d6d7d;--stroke-dark: #141413;--stroke-light: #dddde2;--stroke-medium: #535366;--accent-green: #ccffd4;--accent-turquoise: #ccf7ff;--accent-yellow: #f7ffcc;--accent-peach: #ffd4cc;--accent-violet: #f7ccff;--accent-purple: #f4f7fc;--text-primary: #141413;--secondary-brand: #141413;--text-hover: #0c3b8d;--text-white: #ffffff;--text-link: #0645b1;--text-press: #082f75;--success-light: #f0f8f1;--background-light-blue: #eef2f9;--background-white: #ffffff;--premium-dark: #877440;--premium-light: #f9f6ed;--stroke-white: #ffffff;--inactive-content: #b1b1ba;--annotate-light: #a35dff;--annotate-dark: #824acc;--grid: #eef2f9;--inactive-stroke: #ebebee;--shadow: rgba(34, 34, 51, 0.25);--text-inactive: #6d6d7d;--text-error: #b60000;--stroke-error: #b60000;--background-error: #fff2f2;--background-black: #141413;--icon-default: #141413;--icon-blue: #0645b1;--background-grey: #dddde2;--icon-grey: #b1b1ba;--text-focus: #082f75;--brand-colors-neutral-black: #141413;--brand-colors-neutral-900: #535366;--brand-colors-neutral-800: #6d6d7d;--brand-colors-neutral-700: #91919e;--brand-colors-neutral-600: #b1b1ba;--brand-colors-neutral-500: #c8c8cf;--brand-colors-neutral-400: #dddde2;--brand-colors-neutral-300: #ebebee;--brand-colors-neutral-200: #f8f8fb;--brand-colors-neutral-100: #fafafa;--brand-colors-neutral-white: #ffffff;--brand-colors-blue-900: #043059;--brand-colors-blue-800: #082f75;--brand-colors-blue-700: #0c3b8d;--brand-colors-blue-600: #0645b1;--brand-colors-blue-500: #386ac1;--brand-colors-blue-400: #cddaef;--brand-colors-blue-300: #e6ecf7;--brand-colors-blue-200: #eef2f9;--brand-colors-blue-100: #f4f7fc;--brand-colors-gold-500: #877440;--brand-colors-gold-400: #e9e3d4;--brand-colors-gold-300: #f2efe8;--brand-colors-gold-200: #f9f6ed;--brand-colors-gold-100: #f9f7f4;--brand-colors-error-900: #920000;--brand-colors-error-500: #b60000;--brand-colors-success-900: #035c0f;--brand-colors-green: #ccffd4;--brand-colors-turquoise: #ccf7ff;--brand-colors-yellow: #f7ffcc;--brand-colors-peach: #ffd4cc;--brand-colors-violet: #f7ccff;--brand-colors-error-100: #fff2f2;--brand-colors-success-500: #05b01c;--brand-colors-success-100: #f0f8f1;--text-secondary: #535366;--icon-white: #ffffff;--background-beige-darker: #f2efe8;--icon-dark-grey: #535366;--type-font-family-sans-serif: Roboto;--type-font-family-serif: Georgia;--type-font-family-mono: IBM Plex Mono;--type-weights-300: 300;--type-weights-400: 400;--type-weights-500: 500;--type-weights-700: 700;--type-sizes-12: 12px;--type-sizes-14: 14px;--type-sizes-16: 16px;--type-sizes-18: 18px;--type-sizes-20: 20px;--type-sizes-22: 22px;--type-sizes-24: 24px;--type-sizes-28: 28px;--type-sizes-30: 30px;--type-sizes-32: 32px;--type-sizes-40: 40px;--type-sizes-42: 42px;--type-sizes-48-2: 48px;--type-line-heights-16: 16px;--type-line-heights-20: 20px;--type-line-heights-23: 23px;--type-line-heights-24: 24px;--type-line-heights-25: 25px;--type-line-heights-26: 26px;--type-line-heights-29: 29px;--type-line-heights-30: 30px;--type-line-heights-32: 32px;--type-line-heights-34: 34px;--type-line-heights-35: 35px;--type-line-heights-36: 36px;--type-line-heights-38: 38px;--type-line-heights-40: 40px;--type-line-heights-46: 46px;--type-line-heights-48: 48px;--type-line-heights-52: 52px;--type-line-heights-58: 58px;--type-line-heights-68: 68px;--type-line-heights-74: 74px;--type-line-heights-82: 82px;--type-paragraph-spacings-0: 0px;--type-paragraph-spacings-4: 4px;--type-paragraph-spacings-8: 8px;--type-paragraph-spacings-16: 16px;--type-sans-serif-xl-font-weight: 400;--type-sans-serif-xl-size: 42px;--type-sans-serif-xl-line-height: 46px;--type-sans-serif-xl-paragraph-spacing: 16px;--type-sans-serif-lg-font-weight: 400;--type-sans-serif-lg-size: 32px;--type-sans-serif-lg-line-height: 38px;--type-sans-serif-lg-paragraph-spacing: 16px;--type-sans-serif-md-font-weight: 400;--type-sans-serif-md-line-height: 34px;--type-sans-serif-md-paragraph-spacing: 16px;--type-sans-serif-md-size: 28px;--type-sans-serif-xs-font-weight: 700;--type-sans-serif-xs-line-height: 25px;--type-sans-serif-xs-paragraph-spacing: 0px;--type-sans-serif-xs-size: 20px;--type-sans-serif-sm-font-weight: 400;--type-sans-serif-sm-line-height: 30px;--type-sans-serif-sm-paragraph-spacing: 16px;--type-sans-serif-sm-size: 24px;--type-body-xl-font-weight: 400;--type-body-xl-size: 24px;--type-body-xl-line-height: 36px;--type-body-xl-paragraph-spacing: 0px;--type-body-sm-font-weight: 400;--type-body-sm-size: 14px;--type-body-sm-line-height: 20px;--type-body-sm-paragraph-spacing: 8px;--type-body-xs-font-weight: 400;--type-body-xs-size: 12px;--type-body-xs-line-height: 16px;--type-body-xs-paragraph-spacing: 0px;--type-body-md-font-weight: 400;--type-body-md-size: 16px;--type-body-md-line-height: 20px;--type-body-md-paragraph-spacing: 4px;--type-body-lg-font-weight: 400;--type-body-lg-size: 20px;--type-body-lg-line-height: 26px;--type-body-lg-paragraph-spacing: 16px;--type-body-lg-medium-font-weight: 500;--type-body-lg-medium-size: 20px;--type-body-lg-medium-line-height: 32px;--type-body-lg-medium-paragraph-spacing: 16px;--type-body-md-medium-font-weight: 500;--type-body-md-medium-size: 16px;--type-body-md-medium-line-height: 20px;--type-body-md-medium-paragraph-spacing: 4px;--type-body-sm-bold-font-weight: 700;--type-body-sm-bold-size: 14px;--type-body-sm-bold-line-height: 20px;--type-body-sm-bold-paragraph-spacing: 8px;--type-body-sm-medium-font-weight: 500;--type-body-sm-medium-size: 14px;--type-body-sm-medium-line-height: 20px;--type-body-sm-medium-paragraph-spacing: 8px;--type-serif-md-font-weight: 400;--type-serif-md-size: 40px;--type-serif-md-paragraph-spacing: 0px;--type-serif-md-line-height: 48px;--type-serif-sm-font-weight: 400;--type-serif-sm-size: 28px;--type-serif-sm-paragraph-spacing: 0px;--type-serif-sm-line-height: 32px;--type-serif-lg-font-weight: 400;--type-serif-lg-size: 58px;--type-serif-lg-paragraph-spacing: 0px;--type-serif-lg-line-height: 68px;--type-serif-xs-font-weight: 400;--type-serif-xs-size: 18px;--type-serif-xs-line-height: 24px;--type-serif-xs-paragraph-spacing: 0px;--type-serif-xl-font-weight: 400;--type-serif-xl-size: 74px;--type-serif-xl-paragraph-spacing: 0px;--type-serif-xl-line-height: 82px;--type-mono-md-font-weight: 400;--type-mono-md-size: 22px;--type-mono-md-line-height: 24px;--type-mono-md-paragraph-spacing: 0px;--type-mono-lg-font-weight: 400;--type-mono-lg-size: 40px;--type-mono-lg-line-height: 40px;--type-mono-lg-paragraph-spacing: 0px;--type-mono-sm-font-weight: 400;--type-mono-sm-size: 14px;--type-mono-sm-line-height: 24px;--type-mono-sm-paragraph-spacing: 0px;--spacing-xs-4: 4px;--spacing-xs-8: 8px;--spacing-xs-16: 16px;--spacing-sm-24: 24px;--spacing-sm-32: 32px;--spacing-md-40: 40px;--spacing-md-48: 48px;--spacing-lg-64: 64px;--spacing-lg-80: 80px;--spacing-xlg-104: 104px;--spacing-xlg-152: 152px;--spacing-xs-12: 12px;--spacing-page-section: 152px;--spacing-card-list-spacing: 48px;--spacing-text-section-spacing: 80px;--spacing-md-xs-headings: 40px;--corner-radius-radius-lg: 16px;--corner-radius-radius-sm: 4px;--corner-radius-radius-md: 8px;--corner-radius-radius-round: 104px}}</style><link crossorigin="" href="https://fonts.gstatic.com/" rel="preconnect" /><link href="https://fonts.googleapis.com/css2?family=DM+Sans:ital,opsz,wght@0,9..40,100..1000;1,9..40,100..1000&family=Gupter:wght@400;500;700&family=IBM+Plex+Mono:wght@300;400&family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20,400,0,0&display=swap" rel="stylesheet" /><link rel="stylesheet" href="//a.academia-assets.com/assets/design_system/common-57f9da13cef3fd4e2a8b655342c6488eded3e557e823fe67571f2ac77acd7b6f.css" media="all" /> <meta name="author" content="aksel siva" /> <meta name="description" content="Aksel Siva, Istanbul University: 31 Followers, 14 Following, 25 Research papers. Research interests: Neurology, History of Medicine, and Immunology." /> <meta name="google-site-verification" content="bKJMBZA7E43xhDOopFZkssMMkBRjvYERV-NaN4R6mrs" /> <script> var $controller_name = 'works'; var $action_name = "summary"; var $rails_env = 'production'; var $app_rev = '1a30b693c48043cdf7e41f1832fac9a11fadc12b'; var $domain = 'academia.edu'; var $app_host = "academia.edu"; var $asset_host = "academia-assets.com"; var $start_time = new Date().getTime(); var $recaptcha_key = "6LdxlRMTAAAAADnu_zyLhLg0YF9uACwz78shpjJB"; var $recaptcha_invisible_key = "6Lf3KHUUAAAAACggoMpmGJdQDtiyrjVlvGJ6BbAj"; var $disableClientRecordHit = false; </script> <script> window.Aedu = { hit_data: null }; window.Aedu.SiteStats = {"premium_universities_count":13902,"monthly_visitors":"31 million","monthly_visitor_count":31300000,"monthly_visitor_count_in_millions":31,"user_count":286209405,"paper_count":55203019,"paper_count_in_millions":55,"page_count":432000000,"page_count_in_millions":432,"pdf_count":16500000,"pdf_count_in_millions":16}; window.Aedu.serverRenderTime = new Date(1743600196000); window.Aedu.timeDifference = new Date().getTime() - 1743600196000; window.Aedu.isUsingCssV1 = false; window.Aedu.enableLocalization = true; window.Aedu.activateFullstory = false; window.Aedu.serviceAvailability = { status: {"attention_db":"on","bibliography_db":"on","contacts_db":"on","email_db":"on","indexability_db":"on","mentions_db":"on","news_db":"on","notifications_db":"on","offsite_mentions_db":"on","redshift":"on","redshift_exports_db":"on","related_works_db":"on","ring_db":"on","user_tests_db":"on"}, serviceEnabled: function(service) { return this.status[service] === "on"; }, readEnabled: function(service) { return this.serviceEnabled(service) || this.status[service] === "read_only"; }, }; window.Aedu.viewApmTrace = function() { // Check if x-apm-trace-id meta tag is set, and open the trace in APM // in a new window if it is. var apmTraceId = document.head.querySelector('meta[name="x-apm-trace-id"]'); if (apmTraceId) { var traceId = apmTraceId.content; // Use trace ID to construct URL, an example URL looks like: // https://app.datadoghq.com/apm/traces?query=trace_id%31298410148923562634 var apmUrl = 'https://app.datadoghq.com/apm/traces?query=trace_id%3A' + traceId; window.open(apmUrl, '_blank'); } }; </script>  <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet"> <link rel="preload" href="//maxcdn.bootstrapcdn.com/font-awesome/4.3.0/css/font-awesome.min.css" as="style" onload="this.rel='stylesheet'"> <link rel="stylesheet" href="//a.academia-assets.com/assets/libraries-a9675dcb01ec4ef6aa807ba772c7a5a00c1820d3ff661c1038a20f80d06bb4e4.css" media="all" /> <link rel="stylesheet" href="//a.academia-assets.com/assets/academia-9982828ed1de4777566441c35ccf7157c55ca779141fce69380d727ebdbbb926.css" media="all" /> <link rel="stylesheet" href="//a.academia-assets.com/assets/design_system_legacy-056a9113b9a0f5343d013b29ee1929d5a18be35fdcdceb616600b4db8bd20054.css" media="all" /> <script src="//a.academia-assets.com/assets/webpack_bundles/runtime-bundle-005434038af4252ca37c527588411a3d6a0eabb5f727fac83f8bbe7fd88d93bb.js"></script> <script src="//a.academia-assets.com/assets/webpack_bundles/webpack_libraries_and_infrequently_changed.wjs-bundle-d4c85e621b8bf4de9d00992b6e343550022a135eb512ccf66e7b5d8a67a65f0d.js"></script> <script src="//a.academia-assets.com/assets/webpack_bundles/core_webpack.wjs-bundle-e94cf4c6a5cc17bae92cd463c6a27ba854937d08345e4010eca69ba0053b7599.js"></script> <script src="//a.academia-assets.com/assets/webpack_bundles/sentry.wjs-bundle-5fe03fddca915c8ba0f7edbe64c194308e8ce5abaed7bffe1255ff37549c4808.js"></script> <script> jade = window.jade || {}; jade.helpers = window.$h; jade._ = window._; </script>  <script id="tag-manager-head-root">(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer_old','GTM-5G9JF7Z');</script>  <script> window.gptadslots = []; window.googletag = window.googletag || {}; window.googletag.cmd = window.googletag.cmd || []; </script> <script type="text/javascript"> // TODO(jacob): This should be defined, may be rare load order problem. // Checking if null is just a quick fix, will default to en if unset. // Better fix is to run this immedietely after I18n is set. if (window.I18n != null) { I18n.defaultLocale = "en"; I18n.locale = "en"; I18n.fallbacks = true; } </script> <link rel="canonical" href="https://istanbul.academia.edu/AkselSiva" /> </head>   <body class='c-profiles/works a-summary logged_out'>  <div id="fb-root"></div><script>window.fbAsyncInit = function() { FB.init({ appId: "2369844204", version: "v8.0", status: true, cookie: true, xfbml: true }); // Additional initialization code. if (window.InitFacebook) { // facebook.ts already loaded, set it up. window.InitFacebook(); } else { // Set a flag for facebook.ts to find when it loads. window.academiaAuthReadyFacebook = true; } };</script><script>window.fbAsyncLoad = function() { // Protection against double calling of this function if (window.FB) { return; } (function(d, s, id){ var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) {return;} js = d.createElement(s); js.id = id; js.src = "//connect.facebook.net/en_US/sdk.js"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk')); } if (!window.defer_facebook) { // Autoload if not deferred window.fbAsyncLoad(); } else { // Defer loading by 5 seconds setTimeout(function() { window.fbAsyncLoad(); }, 5000); }</script> <div id="google-root"></div><script>window.loadGoogle = function() { if (window.InitGoogle) { // google.ts already loaded, set it up. window.InitGoogle("331998490334-rsn3chp12mbkiqhl6e7lu2q0mlbu0f1b"); } else { // Set a flag for google.ts to use when it loads. window.GoogleClientID = "331998490334-rsn3chp12mbkiqhl6e7lu2q0mlbu0f1b"; } };</script><script>window.googleAsyncLoad = function() { // Protection against double calling of this function (function(d) { var js; var id = 'google-jssdk'; var ref = d.getElementsByTagName('script')[0]; if (d.getElementById(id)) { return; } js = d.createElement('script'); js.id = id; js.async = true; js.onload = loadGoogle; js.src = "https://accounts.google.com/gsi/client" ref.parentNode.insertBefore(js, ref); }(document)); } if (!window.defer_google) { // Autoload if not deferred window.googleAsyncLoad(); } else { // Defer loading by 5 seconds setTimeout(function() { window.googleAsyncLoad(); }, 5000); }</script> <div id="tag-manager-body-root">  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5G9JF7Z" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>   <script> window.addEventListener('load', function() { if (document.querySelector('input[name="commit"]')) { document.querySelector('input[name="commit"]').addEventListener('click', function() { gtag('event', 'click', { event_category: 'button', event_label: 'Log In' }) }) } }); </script> </div> <script>var _comscore = _comscore || []; _comscore.push({ c1: "2", c2: "26766707" }); (function() { var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true; s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js"; el.parentNode.insertBefore(s, el); })();</script><img src="https://sb.scorecardresearch.com/p?c1=2&c2=26766707&cv=2.0&cj=1" style="position: absolute; visibility: hidden" /> <div id='react-modal'></div> <div class='DesignSystem'> <a class='u-showOnFocus' href='#site'> Skip to main content </a> </div> <div id="upgrade_ie_banner" style="display: none;"><p>Academia.edu no longer supports Internet Explorer.</p><p>To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to <a href="https://www.academia.edu/upgrade-browser">upgrade your browser</a>.</p></div><script>// Show this banner for all versions of IE if (!!window.MSInputMethodContext || /(MSIE)/.test(navigator.userAgent)) { document.getElementById('upgrade_ie_banner').style.display = 'block'; }</script> <div class="DesignSystem bootstrap ShrinkableNav"><div class="navbar navbar-default main-header"><div class="container-wrapper" id="main-header-container"><div class="container"><div class="navbar-header"><div class="nav-left-wrapper u-mt0x"><div class="nav-logo"><a data-main-header-link-target="logo_home" href="https://www.academia.edu/"><img class="visible-xs-inline-block" style="height: 24px;" alt="Academia.edu" src="//a.academia-assets.com/images/academia-logo-redesign-2015-A.svg" width="24" height="24" /><img width="145.2" height="18" class="hidden-xs" style="height: 24px;" alt="Academia.edu" src="//a.academia-assets.com/images/academia-logo-redesign-2015.svg" /></a></div><div class="nav-search"><div class="SiteSearch-wrapper select2-no-default-pills"><form class="js-SiteSearch-form DesignSystem" action="https://www.academia.edu/search" accept-charset="UTF-8" method="get"><i class="SiteSearch-icon fa fa-search u-fw700 u-positionAbsolute u-tcGrayDark"></i><input class="js-SiteSearch-form-input SiteSearch-form-input form-control" data-main-header-click-target="search_input" name="q" placeholder="Search" type="text" value="" /></form></div></div></div><div class="nav-right-wrapper pull-right"><ul class="NavLinks js-main-nav list-unstyled"><li class="NavLinks-link"><a class="js-header-login-url Button Button--inverseGray Button--sm u-mb4x" id="nav_log_in" rel="nofollow" href="https://www.academia.edu/login">Log In</a></li><li class="NavLinks-link u-p0x"><a class="Button Button--inverseGray Button--sm u-mb4x" rel="nofollow" href="https://www.academia.edu/signup">Sign Up</a></li></ul><button class="hidden-lg hidden-md hidden-sm u-ml4x navbar-toggle collapsed" data-target=".js-mobile-header-links" data-toggle="collapse" type="button"><span class="icon-bar"></span><span class="icon-bar"></span><span class="icon-bar"></span></button></div></div><div class="collapse navbar-collapse js-mobile-header-links"><ul class="nav navbar-nav"><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/login">Log In</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/signup">Sign Up</a></li><li class="u-borderColorGrayLight u-borderBottom1 js-mobile-nav-expand-trigger"><a href="#">more&nbsp<span class="caret"></span></a></li><li><ul class="js-mobile-nav-expand-section nav navbar-nav u-m0x collapse"><li class="u-borderColorGrayLight u-borderBottom1"><a rel="false" href="https://www.academia.edu/about">About</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/press">Press</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="false" href="https://www.academia.edu/documents">Papers</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/terms">Terms</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/privacy">Privacy</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/copyright">Copyright</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/hiring"><i class="fa fa-briefcase"></i> We're Hiring!</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://support.academia.edu/hc/en-us"><i class="fa fa-question-circle"></i> Help Center</a></li><li class="js-mobile-nav-collapse-trigger u-borderColorGrayLight u-borderBottom1 dropup" style="display:none"><a href="#">less&nbsp<span class="caret"></span></a></li></ul></li></ul></div></div></div><script>(function(){ var $moreLink = $(".js-mobile-nav-expand-trigger"); var $lessLink = $(".js-mobile-nav-collapse-trigger"); var $section = $('.js-mobile-nav-expand-section'); $moreLink.click(function(ev){ ev.preventDefault(); $moreLink.hide(); $lessLink.show(); $section.collapse('show'); }); $lessLink.click(function(ev){ ev.preventDefault(); $moreLink.show(); $lessLink.hide(); $section.collapse('hide'); }); })() if ($a.is_logged_in() || false) { new Aedu.NavigationController({ el: '.js-main-nav', showHighlightedNotification: false }); } else { $(".js-header-login-url").attr("href", $a.loginUrlWithRedirect()); } Aedu.autocompleteSearch = new AutocompleteSearch({el: '.js-SiteSearch-form'});</script></div></div> <div id='site' class='fixed'> <div id="content" class="clearfix"> <script>document.addEventListener('DOMContentLoaded', function(){ var $dismissible = $(".dismissible_banner"); $dismissible.click(function(ev) { $dismissible.hide(); }); });</script> <script src="//a.academia-assets.com/assets/webpack_bundles/profile.wjs-bundle-dce8a7ae353874d32d1eb17f410a5a2ba4fdde445c9e332e0e138def9774857c.js" defer="defer"></script><script>$viewedUser = Aedu.User.set_viewed( {"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva","photo":"/images/s65_no_pic.png","has_photo":false,"department":{"id":394991,"name":"Cerrahpasa Medical Faculty Department of Neurology","url":"https://istanbul.academia.edu/Departments/Cerrahpasa_Medical_Faculty_Department_of_Neurology/Documents","university":{"id":935,"name":"Istanbul University","url":"https://istanbul.academia.edu/"}},"position":"Faculty Member","position_id":1,"is_analytics_public":false,"interests":[{"id":623,"name":"Neurology","url":"https://www.academia.edu/Documents/in/Neurology"},{"id":2273,"name":"History of Medicine","url":"https://www.academia.edu/Documents/in/History_of_Medicine"},{"id":1290,"name":"Immunology","url":"https://www.academia.edu/Documents/in/Immunology"},{"id":182022,"name":"Clinical Neurology","url":"https://www.academia.edu/Documents/in/Clinical_Neurology"},{"id":61234,"name":"Stroke","url":"https://www.academia.edu/Documents/in/Stroke"}]} ); if ($a.is_logged_in() && $viewedUser.is_current_user()) { $('body').addClass('profile-viewed-by-owner'); } $socialProfiles = []</script><div id="js-react-on-rails-context" style="display:none" data-rails-context="{"inMailer":false,"i18nLocale":"en","i18nDefaultLocale":"en","href":"https://istanbul.academia.edu/AkselSiva","location":"/AkselSiva","scheme":"https","host":"istanbul.academia.edu","port":null,"pathname":"/AkselSiva","search":null,"httpAcceptLanguage":null,"serverSide":false}"></div> <div class="js-react-on-rails-component" style="display:none" data-component-name="ProfileCheckPaperUpdate" data-props="{}" data-trace="false" data-dom-id="ProfileCheckPaperUpdate-react-component-2a92c3be-736e-427f-b519-11995189f7b4"></div> <div id="ProfileCheckPaperUpdate-react-component-2a92c3be-736e-427f-b519-11995189f7b4"></div> <div class="DesignSystem"><div class="onsite-ping" id="onsite-ping"></div></div><div class="profile-user-info DesignSystem"><div class="social-profile-container"><div class="left-panel-container"><div class="user-info-component-wrapper"><div class="user-summary-cta-container"><div class="user-summary-container"><div class="social-profile-avatar-container"><img class="profile-avatar u-positionAbsolute" border="0" alt="" src="//a.academia-assets.com/images/s200_no_pic.png" /></div><div class="title-container"><h1 class="ds2-5-heading-sans-serif-sm">Aksel Siva</h1><div class="affiliations-container fake-truncate js-profile-affiliations"><div><a class="u-tcGrayDarker" href="https://istanbul.academia.edu/">Istanbul University</a>, <a class="u-tcGrayDarker" href="https://istanbul.academia.edu/Departments/Cerrahpasa_Medical_Faculty_Department_of_Neurology/Documents">Cerrahpasa Medical Faculty Department of Neurology</a>, <span class="u-tcGrayDarker">Faculty Member</span></div></div></div></div><div class="sidebar-cta-container"><button class="ds2-5-button hidden profile-cta-button grow js-profile-follow-button" data-broccoli-component="user-info.follow-button" data-click-track="profile-user-info-follow-button" data-follow-user-fname="Aksel" data-follow-user-id="33207160" data-follow-user-source="profile_button" data-has-google="false"><span class="material-symbols-outlined" style="font-size: 20px" translate="no">add</span>Follow</button><button class="ds2-5-button hidden profile-cta-button grow js-profile-unfollow-button" data-broccoli-component="user-info.unfollow-button" data-click-track="profile-user-info-unfollow-button" data-unfollow-user-id="33207160"><span class="material-symbols-outlined" style="font-size: 20px" translate="no">done</span>Following</button></div></div><div class="user-stats-container"><a><div class="stat-container js-profile-followers"><p class="label">Followers</p><p class="data">31</p></div></a><a><div class="stat-container js-profile-followees" data-broccoli-component="user-info.followees-count" data-click-track="profile-expand-user-info-following"><p class="label">Following</p><p class="data">14</p></div></a><a><div class="stat-container js-profile-coauthors" data-broccoli-component="user-info.coauthors-count" data-click-track="profile-expand-user-info-coauthors"><p class="label">Co-authors</p><p class="data">14</p></div></a><span><div class="stat-container"><p class="label"><span class="js-profile-total-view-text">Public Views</span></p><p class="data"><span class="js-profile-view-count"></span></p></div></span></div><div class="suggested-academics-container"><div class="suggested-academics--header"><h3 class="ds2-5-heading-sans-serif-xs">Related Authors</h3></div><ul class="suggested-user-card-list" data-nosnippet="true"><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a data-nosnippet="" href="https://independent.academia.edu/TrojanoTrojano"><img class="profile-avatar u-positionAbsolute" alt="Trojano, Trojano related author profile picture" border="0" onerror="if (this.src != '//a.academia-assets.com/images/s200_no_pic.png') this.src = '//a.academia-assets.com/images/s200_no_pic.png';" width="200" height="200" src="https://0.academia-photos.com/37829898/94172580/83101948/s200_trojano_.trojano.jpeg" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://independent.academia.edu/TrojanoTrojano">Trojano, Trojano</a></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a data-nosnippet="" href="https://independent.academia.edu/AQualtieri"><img class="profile-avatar u-positionAbsolute" alt="A. Qualtieri related author profile picture" border="0" src="//a.academia-assets.com/images/s200_no_pic.png" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://independent.academia.edu/AQualtieri">A. Qualtieri</a></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a data-nosnippet="" href="https://griffith.academia.edu/SimonBroadley"><img class="profile-avatar u-positionAbsolute" alt="Simon Broadley related author profile picture" border="0" src="//a.academia-assets.com/images/s200_no_pic.png" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://griffith.academia.edu/SimonBroadley">Simon Broadley</a><p class="suggested-user-card__user-info__subheader ds2-5-body-xs">Griffith University</p></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a data-nosnippet="" href="https://independent.academia.edu/CarlosRiveros18"><img class="profile-avatar u-positionAbsolute" alt="Carlos Riveros related author profile picture" border="0" onerror="if (this.src != '//a.academia-assets.com/images/s200_no_pic.png') this.src = '//a.academia-assets.com/images/s200_no_pic.png';" src="https://gravatar.com/avatar/0e92b104565f658e3bd56d560882ed48?s=200" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://independent.academia.edu/CarlosRiveros18">Carlos Riveros</a></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a data-nosnippet="" href="https://independent.academia.edu/YahyaVaezpour"><img class="profile-avatar u-positionAbsolute" alt="Yahya Vaezpour related author profile picture" border="0" src="//a.academia-assets.com/images/s200_no_pic.png" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://independent.academia.edu/YahyaVaezpour">Yahya Vaezpour</a></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a data-nosnippet="" href="https://independent.academia.edu/RodneyScott4"><img class="profile-avatar u-positionAbsolute" alt="Rodney Scott related author profile picture" border="0" src="//a.academia-assets.com/images/s200_no_pic.png" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://independent.academia.edu/RodneyScott4">Rodney Scott</a></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a data-nosnippet="" href="https://tudelft.academia.edu/rogierburger"><img class="profile-avatar u-positionAbsolute" alt="rogier burger related author profile picture" border="0" src="//a.academia-assets.com/images/s200_no_pic.png" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://tudelft.academia.edu/rogierburger">rogier burger</a><p class="suggested-user-card__user-info__subheader ds2-5-body-xs">Delft University of Technology</p></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a data-nosnippet="" href="https://ifo.academia.edu/FedericoMarco"><img class="profile-avatar u-positionAbsolute" alt="Federico De Marco related author profile picture" border="0" onerror="if (this.src != '//a.academia-assets.com/images/s200_no_pic.png') this.src = '//a.academia-assets.com/images/s200_no_pic.png';" width="200" height="200" src="https://0.academia-photos.com/32421681/11229585/12529695/s200_federico.de_marco.jpg" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://ifo.academia.edu/FedericoMarco">Federico De Marco</a><p class="suggested-user-card__user-info__subheader ds2-5-body-xs">Regina Elena national cancer Institute</p></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a data-nosnippet="" href="https://independent.academia.edu/CesiraFoppoli"><img class="profile-avatar u-positionAbsolute" alt="Cesira Foppoli related author profile picture" border="0" src="//a.academia-assets.com/images/s200_no_pic.png" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://independent.academia.edu/CesiraFoppoli">Cesira Foppoli</a></div></div><div class="suggested-user-card"><div class="suggested-user-card__avatar social-profile-avatar-container"><a data-nosnippet="" href="https://ki.academia.edu/TaherDarrehshori"><img class="profile-avatar u-positionAbsolute" alt="Taher Darreh-shori related author profile picture" border="0" onerror="if (this.src != '//a.academia-assets.com/images/s200_no_pic.png') this.src = '//a.academia-assets.com/images/s200_no_pic.png';" width="200" height="200" src="https://0.academia-photos.com/32261758/9650358/10748845/s200_taher.darreh-shori.jpg" /></a></div><div class="suggested-user-card__user-info"><a class="suggested-user-card__user-info__header ds2-5-body-sm-bold ds2-5-body-link" href="https://ki.academia.edu/TaherDarrehshori">Taher Darreh-shori</a><p class="suggested-user-card__user-info__subheader ds2-5-body-xs">Karolinska Institutet</p></div></div></ul></div><style type="text/css">.suggested-academics--header h3{font-size:16px;font-weight:500;line-height:20px}</style><div class="ri-section"><div class="ri-section-header"><span>Interests</span></div><div class="ri-tags-container"><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="33207160" href="https://www.academia.edu/Documents/in/Neurology"><div id="js-react-on-rails-context" style="display:none" data-rails-context="{"inMailer":false,"i18nLocale":"en","i18nDefaultLocale":"en","href":"https://istanbul.academia.edu/AkselSiva","location":"/AkselSiva","scheme":"https","host":"istanbul.academia.edu","port":null,"pathname":"/AkselSiva","search":null,"httpAcceptLanguage":null,"serverSide":false}"></div> <div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Neurology"]}" data-trace="false" data-dom-id="Pill-react-component-f0d1f59a-9ba7-4d41-9a6c-76ef7625e3ca"></div> <div id="Pill-react-component-f0d1f59a-9ba7-4d41-9a6c-76ef7625e3ca"></div> </a><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="33207160" href="https://www.academia.edu/Documents/in/History_of_Medicine"><div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["History of Medicine"]}" data-trace="false" data-dom-id="Pill-react-component-d973ae22-f6e4-4339-9dbd-61433868bb9f"></div> <div id="Pill-react-component-d973ae22-f6e4-4339-9dbd-61433868bb9f"></div> </a><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="33207160" href="https://www.academia.edu/Documents/in/Immunology"><div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Immunology"]}" data-trace="false" data-dom-id="Pill-react-component-54d12a3a-cada-42e7-a77f-c950121a56c5"></div> <div id="Pill-react-component-54d12a3a-cada-42e7-a77f-c950121a56c5"></div> </a><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="33207160" href="https://www.academia.edu/Documents/in/Clinical_Neurology"><div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Clinical Neurology"]}" data-trace="false" data-dom-id="Pill-react-component-616bd742-cfb7-428c-acae-7140938240e4"></div> <div id="Pill-react-component-616bd742-cfb7-428c-acae-7140938240e4"></div> </a></div></div></div></div><div class="right-panel-container"><div class="user-content-wrapper"><div class="uploads-container" id="social-redesign-work-container"><div class="upload-header"><h2 class="ds2-5-heading-sans-serif-xs">Uploads</h2></div><div class="documents-container backbone-social-profile-documents" style="width: 100%;"><div class="u-taCenter"></div><div class="profile--tab_content_container js-tab-pane tab-pane active" id="all"><div class="profile--tab_heading_container js-section-heading" data-section="Papers" id="Papers"><h3 class="profile--tab_heading_container">Papers by Aksel Siva</h3></div><div class="js-work-strip profile--work_container" data-work-id="14318109"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/14318109/The_Burden_of_Headache_in_Neurology_Outpatient_Clinics_in_Turkey"><img alt="Research paper thumbnail of The Burden of Headache in Neurology Outpatient Clinics in Turkey" class="work-thumbnail" src="https://attachments.academia-assets.com/44325654/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/14318109/The_Burden_of_Headache_in_Neurology_Outpatient_Clinics_in_Turkey">The Burden of Headache in Neurology Outpatient Clinics in Turkey</a></div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a> and <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a></span></div><div class="wp-workCard_item"><span>Pain Practice</span><span>, 2007</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Background and Aim: The aim of the study was to investigate the burden of headache in neurology o...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Background and Aim: The aim of the study was to investigate the burden of headache in neurology outpatient clinics (NOCs) regardless of their primary complaint. Methods: Patients presenting for their routine appointments in 41 NOCs were screened during the course of 1 week. All eligible subjects (n = 3682; 61.9% female, mean age 45.2 1 16.5 years) were evaluated by a neurologist for the headache diagnosis and some demographic characteristics. Results: Of all patients, 66.4% reported headache, and in 35.1% headache was the primary cause for admitting to the NOC. Of 3682 patients, 917 (24.9%) were diagnosed as migraine according to International Headache Society (IHS) criteria. Thirty-three and nine-tenths percent of all patients admitted and 56% of the migraineurs according to IHS had severe headaches. As the headache severity increases, the ratio of the patients admitted with headache as the primary complaint increases significantly. The distribution of burden and other characteristics of headache did not differ in seven geographic regions and 41 different centers. Conclusion: Headache complaint caused at least 1/3 of all neurological outpatient visits in Turkey and 2/3 of all patients admitted to NOC had headache. Of these patients, 1/4 had migraine according to IHS with substantial disability and severity level.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="ab801f2cc27d11e159f77045c7065a16" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":44325654,"asset_id":14318109,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/44325654/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14318109"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14318109"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14318109; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14318109]").text(description); $(".js-view-count[data-work-id=14318109]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14318109; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14318109']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "ab801f2cc27d11e159f77045c7065a16" } } $('.js-work-strip[data-work-id=14318109]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14318109,"title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey","translated_title":"","metadata":{"grobid_abstract":"Background and Aim: The aim of the study was to investigate the burden of headache in neurology outpatient clinics (NOCs) regardless of their primary complaint. Methods: Patients presenting for their routine appointments in 41 NOCs were screened during the course of 1 week. All eligible subjects (n = 3682; 61.9% female, mean age 45.2 1 16.5 years) were evaluated by a neurologist for the headache diagnosis and some demographic characteristics. Results: Of all patients, 66.4% reported headache, and in 35.1% headache was the primary cause for admitting to the NOC. Of 3682 patients, 917 (24.9%) were diagnosed as migraine according to International Headache Society (IHS) criteria. Thirty-three and nine-tenths percent of all patients admitted and 56% of the migraineurs according to IHS had severe headaches. As the headache severity increases, the ratio of the patients admitted with headache as the primary complaint increases significantly. The distribution of burden and other characteristics of headache did not differ in seven geographic regions and 41 different centers. Conclusion: Headache complaint caused at least 1/3 of all neurological outpatient visits in Turkey and 2/3 of all patients admitted to NOC had headache. Of these patients, 1/4 had migraine according to IHS with substantial disability and severity level.","publication_date":{"day":null,"month":null,"year":2007,"errors":{}},"publication_name":"Pain Practice","grobid_abstract_attachment_id":44325654},"translated_abstract":null,"internal_url":"https://www.academia.edu/14318109/The_Burden_of_Headache_in_Neurology_Outpatient_Clinics_in_Turkey","translated_internal_url":"","created_at":"2015-07-22T22:34:46.526-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33272291,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3691329,"work_id":14318109,"tagging_user_id":33272291,"tagged_user_id":33021815,"co_author_invite_id":null,"email":"m***f@uludag.edu.tr","affiliation":"Uludag University","display_order":0,"name":"M. Zarifoğlu","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"},{"id":3691335,"work_id":14318109,"tagging_user_id":33272291,"tagged_user_id":33025639,"co_author_invite_id":null,"email":"n***i@uludag.edu.tr","display_order":4194304,"name":"N. Karli","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"},{"id":3691339,"work_id":14318109,"tagging_user_id":33272291,"tagged_user_id":33207160,"co_author_invite_id":null,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":6291456,"name":"Aksel Siva","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"},{"id":3691346,"work_id":14318109,"tagging_user_id":33272291,"tagged_user_id":41556982,"co_author_invite_id":721598,"email":"m***s@superonline.com","display_order":7340032,"name":"M. Ertas","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"},{"id":3691362,"work_id":14318109,"tagging_user_id":33272291,"tagged_user_id":null,"co_author_invite_id":287979,"email":"b***n@yahoo.com","display_order":7864320,"name":"Betul Baykan","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"}],"downloadable_attachments":[{"id":44325654,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325654/thumbnails/1.jpg","file_name":"j.1533-2500.2007.00154.x.pdf20160402-21810-y49bgo","download_url":"https://www.academia.edu/attachments/44325654/download_file","bulk_download_file_name":"The_Burden_of_Headache_in_Neurology_Outp.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325654/j.1533-2500.2007.00154.x-libre.pdf20160402-21810-y49bgo?1459602633=\u0026response-content-disposition=attachment%3B+filename%3DThe_Burden_of_Headache_in_Neurology_Outp.pdf\u0026Expires=1743574093\u0026Signature=BtZih55UnM87tvU5MLnBgPDI7XIB6dR47ecMvKjF3l6CA1ooiAcWe8NBkrL6I2E~G9~SAcXMdk5McrwTne-oLcOJiZFYF-YvCOFUlMBphwvfY4SCF3dYksqI3SUha3WwxJQGJFA4stgeO~E1uoLtSag0jk6ltbgNbsTzMRFwErMDlfBoAQunQ88iI9CirDuxeetG326K8r~znYcMiRKSUh2P5~-ZBfL58DEfEr4QOJC148lE6Bh6q6xOPuD5ZqbOTjHFu4kpjUlviGSbAOkEYXxnD-5aZqh6Zybpr6W6HJFzMBJxt1l5EvnX7dgxJWIPu9T4kS~QHhPydo5VOqJRyQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"The_Burden_of_Headache_in_Neurology_Outpatient_Clinics_in_Turkey","translated_slug":"","page_count":11,"language":"en","content_type":"Work","summary":"Background and Aim: The aim of the study was to investigate the burden of headache in neurology outpatient clinics (NOCs) regardless of their primary complaint. Methods: Patients presenting for their routine appointments in 41 NOCs were screened during the course of 1 week. All eligible subjects (n = 3682; 61.9% female, mean age 45.2 1 16.5 years) were evaluated by a neurologist for the headache diagnosis and some demographic characteristics. Results: Of all patients, 66.4% reported headache, and in 35.1% headache was the primary cause for admitting to the NOC. Of 3682 patients, 917 (24.9%) were diagnosed as migraine according to International Headache Society (IHS) criteria. Thirty-three and nine-tenths percent of all patients admitted and 56% of the migraineurs according to IHS had severe headaches. As the headache severity increases, the ratio of the patients admitted with headache as the primary complaint increases significantly. The distribution of burden and other characteristics of headache did not differ in seven geographic regions and 41 different centers. Conclusion: Headache complaint caused at least 1/3 of all neurological outpatient visits in Turkey and 2/3 of all patients admitted to NOC had headache. Of these patients, 1/4 had migraine according to IHS with substantial disability and severity level.","owner":{"id":33272291,"first_name":"Sabahattin","middle_initials":null,"last_name":"Saip","page_name":"SabahattinSaip","domain_name":"istanbul","created_at":"2015-07-22T22:34:11.561-07:00","display_name":"Sabahattin Saip","url":"https://istanbul.academia.edu/SabahattinSaip"},"attachments":[{"id":44325654,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325654/thumbnails/1.jpg","file_name":"j.1533-2500.2007.00154.x.pdf20160402-21810-y49bgo","download_url":"https://www.academia.edu/attachments/44325654/download_file","bulk_download_file_name":"The_Burden_of_Headache_in_Neurology_Outp.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325654/j.1533-2500.2007.00154.x-libre.pdf20160402-21810-y49bgo?1459602633=\u0026response-content-disposition=attachment%3B+filename%3DThe_Burden_of_Headache_in_Neurology_Outp.pdf\u0026Expires=1743574093\u0026Signature=BtZih55UnM87tvU5MLnBgPDI7XIB6dR47ecMvKjF3l6CA1ooiAcWe8NBkrL6I2E~G9~SAcXMdk5McrwTne-oLcOJiZFYF-YvCOFUlMBphwvfY4SCF3dYksqI3SUha3WwxJQGJFA4stgeO~E1uoLtSag0jk6ltbgNbsTzMRFwErMDlfBoAQunQ88iI9CirDuxeetG326K8r~znYcMiRKSUh2P5~-ZBfL58DEfEr4QOJC148lE6Bh6q6xOPuD5ZqbOTjHFu4kpjUlviGSbAOkEYXxnD-5aZqh6Zybpr6W6HJFzMBJxt1l5EvnX7dgxJWIPu9T4kS~QHhPydo5VOqJRyQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":623,"name":"Neurology","url":"https://www.academia.edu/Documents/in/Neurology"},{"id":2898,"name":"Pain","url":"https://www.academia.edu/Documents/in/Pain"},{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":289330,"name":"Prevalence","url":"https://www.academia.edu/Documents/in/Prevalence"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14318109-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14318112"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/14318112/One_year_prevalence_and_the_impact_of_migraine_and_tension_type_headache_in_Turkey_a_nationwide_home_based_study_in_adults"><img alt="Research paper thumbnail of One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults" class="work-thumbnail" src="https://attachments.academia-assets.com/44325642/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/14318112/One_year_prevalence_and_the_impact_of_migraine_and_tension_type_headache_in_Turkey_a_nationwide_home_based_study_in_adults">One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults</a></div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a>, and <a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/MErtas1">M. Ertas</a></span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Several studies have shown that the prevalence of migraine and tension-type headache (TTH) varied...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Several studies have shown that the prevalence of migraine and tension-type headache (TTH) varied between different geographical regions. Therefore, there is a need of a nationwide prevalence study for headache in our country, located between Asia and Europe. This nationwide study was designed to estimate the 1-year prevalence of migraine and TTH and analyse the clinical features, the impact as well as the demographic and socio-economic characteristics of the participant households in Turkey. We planned to investigate 6,000 representative households in 21 cities of Turkey; and a total of 5,323 households (response rate of 89%) aged between 18 and 65 years were examined for headache by 33 trained physicians at home on the basis of the diagnostic criteria of the second edition of the International Classification of Headache Disorders (ICHD-II). The electronically registered questionnaire was based on the headache features, the associated symptoms, demographic and socio-economic situation and history. Of 5,323 participants (48.8% women; mean age 35.9 ± 12 years) 44.6% reported recurrent headaches during the last 1 year and 871 were diagnosed with migraine at a prevalence rate of 16.4% (8.5% in men and 24.6% in women), whereas only 270 were diagnosed with TTH at a prevalence rate of 5.1% (5.7% in men and 4.5% in women). The 1-year prevalence of probable migraine was 12.4% and probable TTH was 9.5% additionally. The rate of migraine with aura among migraineurs was 21.5%. The prevalence of migraine was highest among 35-40-year-old women while there were no differences in age groups among men and in TTH overall. More than 2/3 of migraineurs had ever consulted a physician whereas only 1/3 of patients with TTH had ever consulted a physician. For women, the migraine prevalence was higher among the ones with a lower income, while among men, it did not show any change by income. Migraine prevalence was lower in those with a lower educational status compared to those with a high educational status. Chronic daily headache was present in 3.3% and the prevalence of medication overuse headache was 2.1% in our population. There was an important impact of migraine with a monthly frequency of 5.9 ± 6, and an attack duration of 35.1 ± 72 h, but only 4.9% were on prophylactic treatment. The one-year prevalence of migraine estimated as 16.4% was similar or even higher than worldwide reported migraine prevalence figures and identical to a previous nation-wide study conducted in 1998, whereas the TTH prevalence was much lower using the same methodology with the ICHD-II criteria.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="b090f7e14a537844f0f08b9c8606b49d" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":44325642,"asset_id":14318112,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/44325642/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14318112"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14318112"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14318112; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14318112]").text(description); $(".js-view-count[data-work-id=14318112]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14318112; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14318112']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "b090f7e14a537844f0f08b9c8606b49d" } } $('.js-work-strip[data-work-id=14318112]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14318112,"title":"One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults","translated_title":"","metadata":{"ai_title_tag":"Migraine and TTH Prevalence in Turkey","grobid_abstract":"Several studies have shown that the prevalence of migraine and tension-type headache (TTH) varied between different geographical regions. Therefore, there is a need of a nationwide prevalence study for headache in our country, located between Asia and Europe. This nationwide study was designed to estimate the 1-year prevalence of migraine and TTH and analyse the clinical features, the impact as well as the demographic and socio-economic characteristics of the participant households in Turkey. We planned to investigate 6,000 representative households in 21 cities of Turkey; and a total of 5,323 households (response rate of 89%) aged between 18 and 65 years were examined for headache by 33 trained physicians at home on the basis of the diagnostic criteria of the second edition of the International Classification of Headache Disorders (ICHD-II). The electronically registered questionnaire was based on the headache features, the associated symptoms, demographic and socio-economic situation and history. Of 5,323 participants (48.8% women; mean age 35.9 ± 12 years) 44.6% reported recurrent headaches during the last 1 year and 871 were diagnosed with migraine at a prevalence rate of 16.4% (8.5% in men and 24.6% in women), whereas only 270 were diagnosed with TTH at a prevalence rate of 5.1% (5.7% in men and 4.5% in women). The 1-year prevalence of probable migraine was 12.4% and probable TTH was 9.5% additionally. The rate of migraine with aura among migraineurs was 21.5%. The prevalence of migraine was highest among 35-40-year-old women while there were no differences in age groups among men and in TTH overall. More than 2/3 of migraineurs had ever consulted a physician whereas only 1/3 of patients with TTH had ever consulted a physician. For women, the migraine prevalence was higher among the ones with a lower income, while among men, it did not show any change by income. Migraine prevalence was lower in those with a lower educational status compared to those with a high educational status. Chronic daily headache was present in 3.3% and the prevalence of medication overuse headache was 2.1% in our population. There was an important impact of migraine with a monthly frequency of 5.9 ± 6, and an attack duration of 35.1 ± 72 h, but only 4.9% were on prophylactic treatment. The one-year prevalence of migraine estimated as 16.4% was similar or even higher than worldwide reported migraine prevalence figures and identical to a previous nation-wide study conducted in 1998, whereas the TTH prevalence was much lower using the same methodology with the ICHD-II criteria.","publication_date":{"day":1,"month":3,"year":2012,"errors":{}},"grobid_abstract_attachment_id":44325642},"translated_abstract":null,"internal_url":"https://www.academia.edu/14318112/One_year_prevalence_and_the_impact_of_migraine_and_tension_type_headache_in_Turkey_a_nationwide_home_based_study_in_adults","translated_internal_url":"","created_at":"2015-07-22T22:34:46.835-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33272291,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3691331,"work_id":14318112,"tagging_user_id":33272291,"tagged_user_id":33021815,"co_author_invite_id":null,"email":"m***f@uludag.edu.tr","affiliation":"Uludag University","display_order":0,"name":"M. Zarifoğlu","title":"One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults"},{"id":3691337,"work_id":14318112,"tagging_user_id":33272291,"tagged_user_id":33025639,"co_author_invite_id":null,"email":"n***i@uludag.edu.tr","display_order":4194304,"name":"N. Karli","title":"One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults"},{"id":3691345,"work_id":14318112,"tagging_user_id":33272291,"tagged_user_id":33207160,"co_author_invite_id":null,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":6291456,"name":"Aksel Siva","title":"One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults"},{"id":3691348,"work_id":14318112,"tagging_user_id":33272291,"tagged_user_id":41556982,"co_author_invite_id":721598,"email":"m***s@superonline.com","display_order":7340032,"name":"M. Ertas","title":"One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults"},{"id":3691364,"work_id":14318112,"tagging_user_id":33272291,"tagged_user_id":null,"co_author_invite_id":287979,"email":"b***n@yahoo.com","display_order":7864320,"name":"Betul Baykan","title":"One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults"}],"downloadable_attachments":[{"id":44325642,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325642/thumbnails/1.jpg","file_name":"One-year_prevalence_and_the_impact_of_mi20160402-17957-2rryec.pdf","download_url":"https://www.academia.edu/attachments/44325642/download_file","bulk_download_file_name":"One_year_prevalence_and_the_impact_of_mi.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325642/One-year_prevalence_and_the_impact_of_mi20160402-17957-2rryec-libre.pdf?1459602633=\u0026response-content-disposition=attachment%3B+filename%3DOne_year_prevalence_and_the_impact_of_mi.pdf\u0026Expires=1743574093\u0026Signature=PV4pxCqC0czfOYcAF9MkiAzIwqixpUOC5wEhF-0s6I547egjyqT4yrYvr~6cCLqPR0zKfyyaPkoo-q5tjYg7sT1MmaAO~vugLy227CYsvyg2fHwqBtU7dAs16mcy0T8IYIhM8Wrgush1mxqfvhD6B3PlD4hYYYsorqvnxaiJHW-p~aNyOyYosaOB7XkHlWoH0DUrU8RXqM9ZAng~QLIMMwIX4iib4-KYNxV0KNWgcGxoQqkb3E-J77EtI4U3om2YxTFQCb-pyPkiBm7Wt1pobXd0K2ZhDVMRPnVlugMO4rAwrfN8QA7fltSPmmso2kqtJmwtnXf7nJjkT7SS7jrBvQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"One_year_prevalence_and_the_impact_of_migraine_and_tension_type_headache_in_Turkey_a_nationwide_home_based_study_in_adults","translated_slug":"","page_count":11,"language":"en","content_type":"Work","summary":"Several studies have shown that the prevalence of migraine and tension-type headache (TTH) varied between different geographical regions. Therefore, there is a need of a nationwide prevalence study for headache in our country, located between Asia and Europe. This nationwide study was designed to estimate the 1-year prevalence of migraine and TTH and analyse the clinical features, the impact as well as the demographic and socio-economic characteristics of the participant households in Turkey. We planned to investigate 6,000 representative households in 21 cities of Turkey; and a total of 5,323 households (response rate of 89%) aged between 18 and 65 years were examined for headache by 33 trained physicians at home on the basis of the diagnostic criteria of the second edition of the International Classification of Headache Disorders (ICHD-II). The electronically registered questionnaire was based on the headache features, the associated symptoms, demographic and socio-economic situation and history. Of 5,323 participants (48.8% women; mean age 35.9 ± 12 years) 44.6% reported recurrent headaches during the last 1 year and 871 were diagnosed with migraine at a prevalence rate of 16.4% (8.5% in men and 24.6% in women), whereas only 270 were diagnosed with TTH at a prevalence rate of 5.1% (5.7% in men and 4.5% in women). The 1-year prevalence of probable migraine was 12.4% and probable TTH was 9.5% additionally. The rate of migraine with aura among migraineurs was 21.5%. The prevalence of migraine was highest among 35-40-year-old women while there were no differences in age groups among men and in TTH overall. More than 2/3 of migraineurs had ever consulted a physician whereas only 1/3 of patients with TTH had ever consulted a physician. For women, the migraine prevalence was higher among the ones with a lower income, while among men, it did not show any change by income. Migraine prevalence was lower in those with a lower educational status compared to those with a high educational status. Chronic daily headache was present in 3.3% and the prevalence of medication overuse headache was 2.1% in our population. There was an important impact of migraine with a monthly frequency of 5.9 ± 6, and an attack duration of 35.1 ± 72 h, but only 4.9% were on prophylactic treatment. The one-year prevalence of migraine estimated as 16.4% was similar or even higher than worldwide reported migraine prevalence figures and identical to a previous nation-wide study conducted in 1998, whereas the TTH prevalence was much lower using the same methodology with the ICHD-II criteria.","owner":{"id":33272291,"first_name":"Sabahattin","middle_initials":null,"last_name":"Saip","page_name":"SabahattinSaip","domain_name":"istanbul","created_at":"2015-07-22T22:34:11.561-07:00","display_name":"Sabahattin Saip","url":"https://istanbul.academia.edu/SabahattinSaip"},"attachments":[{"id":44325642,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325642/thumbnails/1.jpg","file_name":"One-year_prevalence_and_the_impact_of_mi20160402-17957-2rryec.pdf","download_url":"https://www.academia.edu/attachments/44325642/download_file","bulk_download_file_name":"One_year_prevalence_and_the_impact_of_mi.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325642/One-year_prevalence_and_the_impact_of_mi20160402-17957-2rryec-libre.pdf?1459602633=\u0026response-content-disposition=attachment%3B+filename%3DOne_year_prevalence_and_the_impact_of_mi.pdf\u0026Expires=1743574093\u0026Signature=PV4pxCqC0czfOYcAF9MkiAzIwqixpUOC5wEhF-0s6I547egjyqT4yrYvr~6cCLqPR0zKfyyaPkoo-q5tjYg7sT1MmaAO~vugLy227CYsvyg2fHwqBtU7dAs16mcy0T8IYIhM8Wrgush1mxqfvhD6B3PlD4hYYYsorqvnxaiJHW-p~aNyOyYosaOB7XkHlWoH0DUrU8RXqM9ZAng~QLIMMwIX4iib4-KYNxV0KNWgcGxoQqkb3E-J77EtI4U3om2YxTFQCb-pyPkiBm7Wt1pobXd0K2ZhDVMRPnVlugMO4rAwrfN8QA7fltSPmmso2kqtJmwtnXf7nJjkT7SS7jrBvQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":22506,"name":"Adolescent","url":"https://www.academia.edu/Documents/in/Adolescent"},{"id":26879,"name":"Social Class","url":"https://www.academia.edu/Documents/in/Social_Class"},{"id":133057,"name":"Young Adult","url":"https://www.academia.edu/Documents/in/Young_Adult"},{"id":161176,"name":"The","url":"https://www.academia.edu/Documents/in/The"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":289330,"name":"Prevalence","url":"https://www.academia.edu/Documents/in/Prevalence"},{"id":327850,"name":"Questionnaires","url":"https://www.academia.edu/Documents/in/Questionnaires"},{"id":612548,"name":"Tension-Type Headache","url":"https://www.academia.edu/Documents/in/Tension-Type_Headache"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14318112-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14318108"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/14318108/The_validation_of_ID_migraine_screener_in_neurology_outpatient_clinics_in_Turkey"><img alt="Research paper thumbnail of The validation of ID migraine™ screener in neurology outpatient clinics in Turkey" class="work-thumbnail" src="https://attachments.academia-assets.com/44325658/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/14318108/The_validation_of_ID_migraine_screener_in_neurology_outpatient_clinics_in_Turkey">The validation of ID migraine™ screener in neurology outpatient clinics in Turkey</a></div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://uludag.academia.edu/MZarifo%C4%9Flu">M. Zarifoğlu</a>, and <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a></span></div><div class="wp-workCard_item"><span>The Journal of Headache and Pain</span><span>, 2007</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">The aim of this study was to investigate the validity of the ID Migraine™ test in neurology outpa...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">The aim of this study was to investigate the validity of the ID Migraine™ test in neurology outpatient clinics (NOCs), regardless of their presenting complaints. Patients admitted to 41 NOCs were screened. Eligible subjects (n=3682) were evaluated by a neurologist for headache diagnosis according to the International Headache Society criteria and asked the 3-item screening questions of the ID Migraine™ test. Of 3682 patients, 917 (24.9%) were diagnosed as migraine, whereas 1171 (31.8%) were ID Migraine™ test positive. The sensitivity of the ID Migraine™ test for neurologist's diagnosis of migraine was 91.8%, specificity was 63.4%, positive predictive value was 71.9% and negative predictive value was 88.4%. The ID Migraine™ test is easy to use and a practical test that could alert the neurologist to diagnose patients having other complaints. This test would help to increase the diagnosis and treatment rate of undiagnosed migraine patients in NOCs.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="02a551ef26a1764ba42970ede40aa9ca" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":44325658,"asset_id":14318108,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/44325658/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14318108"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14318108"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14318108; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14318108]").text(description); $(".js-view-count[data-work-id=14318108]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14318108; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14318108']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "02a551ef26a1764ba42970ede40aa9ca" } } $('.js-work-strip[data-work-id=14318108]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14318108,"title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey","translated_title":"","metadata":{"grobid_abstract":"The aim of this study was to investigate the validity of the ID Migraine™ test in neurology outpatient clinics (NOCs), regardless of their presenting complaints. Patients admitted to 41 NOCs were screened. Eligible subjects (n=3682) were evaluated by a neurologist for headache diagnosis according to the International Headache Society criteria and asked the 3-item screening questions of the ID Migraine™ test. Of 3682 patients, 917 (24.9%) were diagnosed as migraine, whereas 1171 (31.8%) were ID Migraine™ test positive. The sensitivity of the ID Migraine™ test for neurologist's diagnosis of migraine was 91.8%, specificity was 63.4%, positive predictive value was 71.9% and negative predictive value was 88.4%. The ID Migraine™ test is easy to use and a practical test that could alert the neurologist to diagnose patients having other complaints. This test would help to increase the diagnosis and treatment rate of undiagnosed migraine patients in NOCs.","publication_date":{"day":null,"month":null,"year":2007,"errors":{}},"publication_name":"The Journal of Headache and Pain","grobid_abstract_attachment_id":44325658},"translated_abstract":null,"internal_url":"https://www.academia.edu/14318108/The_validation_of_ID_migraine_screener_in_neurology_outpatient_clinics_in_Turkey","translated_internal_url":"","created_at":"2015-07-22T22:34:46.430-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33272291,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3691330,"work_id":14318108,"tagging_user_id":33272291,"tagged_user_id":33021815,"co_author_invite_id":null,"email":"m***f@uludag.edu.tr","affiliation":"Uludag University","display_order":0,"name":"M. Zarifoğlu","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"},{"id":3691336,"work_id":14318108,"tagging_user_id":33272291,"tagged_user_id":33025639,"co_author_invite_id":null,"email":"n***i@uludag.edu.tr","display_order":4194304,"name":"N. Karli","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"},{"id":3691341,"work_id":14318108,"tagging_user_id":33272291,"tagged_user_id":33207160,"co_author_invite_id":null,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":6291456,"name":"Aksel Siva","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"},{"id":3691347,"work_id":14318108,"tagging_user_id":33272291,"tagged_user_id":41556982,"co_author_invite_id":721598,"email":"m***s@superonline.com","display_order":7340032,"name":"M. Ertas","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"},{"id":3691363,"work_id":14318108,"tagging_user_id":33272291,"tagged_user_id":null,"co_author_invite_id":287979,"email":"b***n@yahoo.com","display_order":7864320,"name":"Betul Baykan","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"}],"downloadable_attachments":[{"id":44325658,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325658/thumbnails/1.jpg","file_name":"The_validation_of_ID_Migraine_TM_scree20160402-21821-z7561z.pdf","download_url":"https://www.academia.edu/attachments/44325658/download_file","bulk_download_file_name":"The_validation_of_ID_migraine_screener_i.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325658/The_validation_of_ID_Migraine_TM_scree20160402-21821-z7561z-libre.pdf?1459602632=\u0026response-content-disposition=attachment%3B+filename%3DThe_validation_of_ID_migraine_screener_i.pdf\u0026Expires=1743574093\u0026Signature=Cg~LsaD2yNMwwcvK1B1XEqUWiON~JnYdVN90sPatEQ1eV3q842F9MFxSCWq3PfRRYLQxoIAv2FFNsihtsDdoBL9ykzAkgFqWOaFF1sSp6TN2nWEayB2yJeQJzPMp60a4U~sY~Se5LviD0btPYi~kgOMVwLBln2xcs~M67ZfW~O4S-hnQIdVSelp5xlURj0df-PPJUggAR7KYx-q8AffqCehkl7Izrdxou~f6mUZMMnxq-hf-myKZx91E3HkNCcg~8ASAC97fQDiVBkNtoKu9GPzHJdi14~0OdLacnAWRkxVAAEGv~6JZgCKv4ezkkB8DwOwye7bNOaSZdIHYkD4m1Q__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"The_validation_of_ID_migraine_screener_in_neurology_outpatient_clinics_in_Turkey","translated_slug":"","page_count":7,"language":"en","content_type":"Work","summary":"The aim of this study was to investigate the validity of the ID Migraine™ test in neurology outpatient clinics (NOCs), regardless of their presenting complaints. Patients admitted to 41 NOCs were screened. Eligible subjects (n=3682) were evaluated by a neurologist for headache diagnosis according to the International Headache Society criteria and asked the 3-item screening questions of the ID Migraine™ test. Of 3682 patients, 917 (24.9%) were diagnosed as migraine, whereas 1171 (31.8%) were ID Migraine™ test positive. The sensitivity of the ID Migraine™ test for neurologist's diagnosis of migraine was 91.8%, specificity was 63.4%, positive predictive value was 71.9% and negative predictive value was 88.4%. The ID Migraine™ test is easy to use and a practical test that could alert the neurologist to diagnose patients having other complaints. This test would help to increase the diagnosis and treatment rate of undiagnosed migraine patients in NOCs.","owner":{"id":33272291,"first_name":"Sabahattin","middle_initials":null,"last_name":"Saip","page_name":"SabahattinSaip","domain_name":"istanbul","created_at":"2015-07-22T22:34:11.561-07:00","display_name":"Sabahattin Saip","url":"https://istanbul.academia.edu/SabahattinSaip"},"attachments":[{"id":44325658,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325658/thumbnails/1.jpg","file_name":"The_validation_of_ID_Migraine_TM_scree20160402-21821-z7561z.pdf","download_url":"https://www.academia.edu/attachments/44325658/download_file","bulk_download_file_name":"The_validation_of_ID_migraine_screener_i.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325658/The_validation_of_ID_Migraine_TM_scree20160402-21821-z7561z-libre.pdf?1459602632=\u0026response-content-disposition=attachment%3B+filename%3DThe_validation_of_ID_migraine_screener_i.pdf\u0026Expires=1743574093\u0026Signature=Cg~LsaD2yNMwwcvK1B1XEqUWiON~JnYdVN90sPatEQ1eV3q842F9MFxSCWq3PfRRYLQxoIAv2FFNsihtsDdoBL9ykzAkgFqWOaFF1sSp6TN2nWEayB2yJeQJzPMp60a4U~sY~Se5LviD0btPYi~kgOMVwLBln2xcs~M67ZfW~O4S-hnQIdVSelp5xlURj0df-PPJUggAR7KYx-q8AffqCehkl7Izrdxou~f6mUZMMnxq-hf-myKZx91E3HkNCcg~8ASAC97fQDiVBkNtoKu9GPzHJdi14~0OdLacnAWRkxVAAEGv~6JZgCKv4ezkkB8DwOwye7bNOaSZdIHYkD4m1Q__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":623,"name":"Neurology","url":"https://www.academia.edu/Documents/in/Neurology"},{"id":8942,"name":"Treatment","url":"https://www.academia.edu/Documents/in/Treatment"},{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":144833,"name":"Validity","url":"https://www.academia.edu/Documents/in/Validity"},{"id":161176,"name":"The","url":"https://www.academia.edu/Documents/in/The"},{"id":254203,"name":"Ambulatory","url":"https://www.academia.edu/Documents/in/Ambulatory"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":289330,"name":"Prevalence","url":"https://www.academia.edu/Documents/in/Prevalence"},{"id":327850,"name":"Questionnaires","url":"https://www.academia.edu/Documents/in/Questionnaires"},{"id":401947,"name":"Sensitivity","url":"https://www.academia.edu/Documents/in/Sensitivity"},{"id":549280,"name":"Reproducibility of Results","url":"https://www.academia.edu/Documents/in/Reproducibility_of_Results"},{"id":901876,"name":"Sensitivity and Specificity","url":"https://www.academia.edu/Documents/in/Sensitivity_and_Specificity"},{"id":1318932,"name":"Predictive value of tests","url":"https://www.academia.edu/Documents/in/Predictive_value_of_tests"},{"id":1318938,"name":"Positive predictive value","url":"https://www.academia.edu/Documents/in/Positive_predictive_value"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14318108-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14318110"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14318110/Neuro_Beh%C3%A7et_syndrome"><img alt="Research paper thumbnail of Neuro-Behçet syndrome" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Neuro-Behçet syndrome</div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a> and <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a></span></div><div class="wp-workCard_item"><span>Handbook of Clinical Neurology</span><span>, 2014</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Behçet syndrome (BS) is an idiopathic chronic relapsing multisystem vascular-inflammatory disease...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Behçet syndrome (BS) is an idiopathic chronic relapsing multisystem vascular-inflammatory disease of unknown origin. As the disease affects many organs and systems and shows a wide range of clinical manifestations and presentations, it is prefereable to call Behçet&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s a syndrome (BS) rather than a disease. Nervous system involvement, known as &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;quot;neuro-BS&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;quot; (NBS), is seen in about 5-10% of all cases. Clinical and imaging evidence suggests that primary neurologic involvement in BS may be subclassified into two major forms: the first, which is seen in the majority of patients, may be characterized as a vascular-inflammatory central nervous system disease with focal or multifocal parenchymal involvement, mostly presenting with a subacute brainstem syndrome and hemiparesis (intra-axial NBS); the other, which has few symptoms and a better neurologic prognosis, may be caused by isolated cerebral venous sinus thrombosis and intracranial hypertension (extra-axial NBS), occurring in 10-20% of the cases. These two types are rarely seen in the same individual, and their pathogenesis is likely to be different. Isolated behavioral syndromes and peripheral nervous system involvement are rare, whereas a vascular type headache is relatively common and independent from neurologic involvement. Neurologic complications secondary to systemic involvement of BS, as well as neurologic complications related to BS treatments are considered as secondary neurologic involvement of the syndrome. The core histopathologic phenomenon seems to be a vasculitic involvement in some cases, and low-grade chronic nonspecific inflammation in others. As the neurologic involvement in this syndrome is so heterogeneous, it is difficult to predict its course and prognosis, and its response to treatment. Currently, treatment options for NBS are limited to attack therapies with high-dose intravenous methylprednisolone followed by a prolonged oral taper, symptomatic management, and generally the use of azathioprine, cyclophosphamide, interferon-α and anti-TNF agents for long-term preventive treatment, although there no evidence for their efficacy.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14318110"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14318110"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14318110; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14318110]").text(description); $(".js-view-count[data-work-id=14318110]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14318110; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14318110']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14318110]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14318110,"title":"Neuro-Behçet syndrome","translated_title":"","metadata":{"abstract":"Behçet syndrome (BS) is an idiopathic chronic relapsing multisystem vascular-inflammatory disease of unknown origin. As the disease affects many organs and systems and shows a wide range of clinical manifestations and presentations, it is prefereable to call Behçet\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s a syndrome (BS) rather than a disease. Nervous system involvement, known as \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;quot;neuro-BS\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;quot; (NBS), is seen in about 5-10% of all cases. Clinical and imaging evidence suggests that primary neurologic involvement in BS may be subclassified into two major forms: the first, which is seen in the majority of patients, may be characterized as a vascular-inflammatory central nervous system disease with focal or multifocal parenchymal involvement, mostly presenting with a subacute brainstem syndrome and hemiparesis (intra-axial NBS); the other, which has few symptoms and a better neurologic prognosis, may be caused by isolated cerebral venous sinus thrombosis and intracranial hypertension (extra-axial NBS), occurring in 10-20% of the cases. These two types are rarely seen in the same individual, and their pathogenesis is likely to be different. Isolated behavioral syndromes and peripheral nervous system involvement are rare, whereas a vascular type headache is relatively common and independent from neurologic involvement. Neurologic complications secondary to systemic involvement of BS, as well as neurologic complications related to BS treatments are considered as secondary neurologic involvement of the syndrome. The core histopathologic phenomenon seems to be a vasculitic involvement in some cases, and low-grade chronic nonspecific inflammation in others. As the neurologic involvement in this syndrome is so heterogeneous, it is difficult to predict its course and prognosis, and its response to treatment. Currently, treatment options for NBS are limited to attack therapies with high-dose intravenous methylprednisolone followed by a prolonged oral taper, symptomatic management, and generally the use of azathioprine, cyclophosphamide, interferon-α and anti-TNF agents for long-term preventive treatment, although there no evidence for their efficacy.","publication_date":{"day":null,"month":null,"year":2014,"errors":{}},"publication_name":"Handbook of Clinical Neurology"},"translated_abstract":"Behçet syndrome (BS) is an idiopathic chronic relapsing multisystem vascular-inflammatory disease of unknown origin. As the disease affects many organs and systems and shows a wide range of clinical manifestations and presentations, it is prefereable to call Behçet\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s a syndrome (BS) rather than a disease. Nervous system involvement, known as \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;quot;neuro-BS\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;quot; (NBS), is seen in about 5-10% of all cases. Clinical and imaging evidence suggests that primary neurologic involvement in BS may be subclassified into two major forms: the first, which is seen in the majority of patients, may be characterized as a vascular-inflammatory central nervous system disease with focal or multifocal parenchymal involvement, mostly presenting with a subacute brainstem syndrome and hemiparesis (intra-axial NBS); the other, which has few symptoms and a better neurologic prognosis, may be caused by isolated cerebral venous sinus thrombosis and intracranial hypertension (extra-axial NBS), occurring in 10-20% of the cases. These two types are rarely seen in the same individual, and their pathogenesis is likely to be different. Isolated behavioral syndromes and peripheral nervous system involvement are rare, whereas a vascular type headache is relatively common and independent from neurologic involvement. Neurologic complications secondary to systemic involvement of BS, as well as neurologic complications related to BS treatments are considered as secondary neurologic involvement of the syndrome. The core histopathologic phenomenon seems to be a vasculitic involvement in some cases, and low-grade chronic nonspecific inflammation in others. As the neurologic involvement in this syndrome is so heterogeneous, it is difficult to predict its course and prognosis, and its response to treatment. Currently, treatment options for NBS are limited to attack therapies with high-dose intravenous methylprednisolone followed by a prolonged oral taper, symptomatic management, and generally the use of azathioprine, cyclophosphamide, interferon-α and anti-TNF agents for long-term preventive treatment, although there no evidence for their efficacy.","internal_url":"https://www.academia.edu/14318110/Neuro_Beh%C3%A7et_syndrome","translated_internal_url":"","created_at":"2015-07-22T22:34:46.605-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33272291,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3691343,"work_id":14318110,"tagging_user_id":33272291,"tagged_user_id":33207160,"co_author_invite_id":null,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":0,"name":"Aksel Siva","title":"Neuro-Behçet syndrome"},{"id":3691356,"work_id":14318110,"tagging_user_id":33272291,"tagged_user_id":31879554,"co_author_invite_id":null,"email":"a***r@gmail.com","display_order":4194304,"name":"gulsen akman-demir","title":"Neuro-Behçet syndrome"}],"downloadable_attachments":[],"slug":"Neuro_Behçet_syndrome","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"Behçet syndrome (BS) is an idiopathic chronic relapsing multisystem vascular-inflammatory disease of unknown origin. As the disease affects many organs and systems and shows a wide range of clinical manifestations and presentations, it is prefereable to call Behçet\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s a syndrome (BS) rather than a disease. Nervous system involvement, known as \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;quot;neuro-BS\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;quot; (NBS), is seen in about 5-10% of all cases. Clinical and imaging evidence suggests that primary neurologic involvement in BS may be subclassified into two major forms: the first, which is seen in the majority of patients, may be characterized as a vascular-inflammatory central nervous system disease with focal or multifocal parenchymal involvement, mostly presenting with a subacute brainstem syndrome and hemiparesis (intra-axial NBS); the other, which has few symptoms and a better neurologic prognosis, may be caused by isolated cerebral venous sinus thrombosis and intracranial hypertension (extra-axial NBS), occurring in 10-20% of the cases. These two types are rarely seen in the same individual, and their pathogenesis is likely to be different. Isolated behavioral syndromes and peripheral nervous system involvement are rare, whereas a vascular type headache is relatively common and independent from neurologic involvement. Neurologic complications secondary to systemic involvement of BS, as well as neurologic complications related to BS treatments are considered as secondary neurologic involvement of the syndrome. The core histopathologic phenomenon seems to be a vasculitic involvement in some cases, and low-grade chronic nonspecific inflammation in others. As the neurologic involvement in this syndrome is so heterogeneous, it is difficult to predict its course and prognosis, and its response to treatment. Currently, treatment options for NBS are limited to attack therapies with high-dose intravenous methylprednisolone followed by a prolonged oral taper, symptomatic management, and generally the use of azathioprine, cyclophosphamide, interferon-α and anti-TNF agents for long-term preventive treatment, although there no evidence for their efficacy.","owner":{"id":33272291,"first_name":"Sabahattin","middle_initials":null,"last_name":"Saip","page_name":"SabahattinSaip","domain_name":"istanbul","created_at":"2015-07-22T22:34:11.561-07:00","display_name":"Sabahattin Saip","url":"https://istanbul.academia.edu/SabahattinSaip"},"attachments":[],"research_interests":[{"id":2639,"name":"Neuroimaging","url":"https://www.academia.edu/Documents/in/Neuroimaging"},{"id":162159,"name":"Differential Diagnosis","url":"https://www.academia.edu/Documents/in/Differential_Diagnosis"},{"id":489727,"name":"Prognosis","url":"https://www.academia.edu/Documents/in/Prognosis"},{"id":1423078,"name":"Nervous System Diseases","url":"https://www.academia.edu/Documents/in/Nervous_System_Diseases"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14318110-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14318107"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14318107/A_patient_with_established_primary_progressive_multiple_sclerosis_transitions_to_secondary_relapsing_remitting_disease_course_following_a_fulminant_demyelinating_episode"><img alt="Research paper thumbnail of A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode</div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a>, and <a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/DemirciN">N. Demirci</a></span></div><div class="wp-workCard_item"><span>Multiple Sclerosis Journal</span><span>, 2011</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Primary progressive multiple sclerosis (PPMS), relapsing remitting MS (RRMS) and acute disseminat...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Primary progressive multiple sclerosis (PPMS), relapsing remitting MS (RRMS) and acute disseminated encephalomyelitis (ADEM) are clinically and immunopathogenetically distinct phenotypes of inflammatory demyelinating disorders of the central nervous system. Progression following RRMS is well described as secondary progressive MS. We report a patient with unexpected transition from long established PPMS to clinically and radiologically active RRMS after an ADEM-like fulminant demyelinating episode despite an immunosuppressive treatment preceding relapses. We note clearly accelerated brain atrophy after the RRMS course ensues. The unique disease course in this patient illustrates the dissociation of the biology and disability impact of relapses and progression.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14318107"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14318107"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14318107; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14318107]").text(description); $(".js-view-count[data-work-id=14318107]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14318107; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14318107']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14318107]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14318107,"title":"A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode","translated_title":"","metadata":{"abstract":"Primary progressive multiple sclerosis (PPMS), relapsing remitting MS (RRMS) and acute disseminated encephalomyelitis (ADEM) are clinically and immunopathogenetically distinct phenotypes of inflammatory demyelinating disorders of the central nervous system. Progression following RRMS is well described as secondary progressive MS. We report a patient with unexpected transition from long established PPMS to clinically and radiologically active RRMS after an ADEM-like fulminant demyelinating episode despite an immunosuppressive treatment preceding relapses. We note clearly accelerated brain atrophy after the RRMS course ensues. The unique disease course in this patient illustrates the dissociation of the biology and disability impact of relapses and progression.","publication_date":{"day":null,"month":null,"year":2011,"errors":{}},"publication_name":"Multiple Sclerosis Journal"},"translated_abstract":"Primary progressive multiple sclerosis (PPMS), relapsing remitting MS (RRMS) and acute disseminated encephalomyelitis (ADEM) are clinically and immunopathogenetically distinct phenotypes of inflammatory demyelinating disorders of the central nervous system. Progression following RRMS is well described as secondary progressive MS. We report a patient with unexpected transition from long established PPMS to clinically and radiologically active RRMS after an ADEM-like fulminant demyelinating episode despite an immunosuppressive treatment preceding relapses. We note clearly accelerated brain atrophy after the RRMS course ensues. The unique disease course in this patient illustrates the dissociation of the biology and disability impact of relapses and progression.","internal_url":"https://www.academia.edu/14318107/A_patient_with_established_primary_progressive_multiple_sclerosis_transitions_to_secondary_relapsing_remitting_disease_course_following_a_fulminant_demyelinating_episode","translated_internal_url":"","created_at":"2015-07-22T22:34:46.339-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33272291,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3691338,"work_id":14318107,"tagging_user_id":33272291,"tagged_user_id":33207160,"co_author_invite_id":null,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":0,"name":"Aksel Siva","title":"A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode"},{"id":3691351,"work_id":14318107,"tagging_user_id":33272291,"tagged_user_id":43685187,"co_author_invite_id":892619,"email":"n***i@hotmail.com","display_order":4194304,"name":"N. Demirci","title":"A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode"},{"id":3691353,"work_id":14318107,"tagging_user_id":33272291,"tagged_user_id":8740446,"co_author_invite_id":null,"email":"f***i@hotmail.com","display_order":6291456,"name":"Fulya Özer","title":"A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode"},{"id":3691354,"work_id":14318107,"tagging_user_id":33272291,"tagged_user_id":null,"co_author_invite_id":892620,"email":"o***n@workshopdergi.com","display_order":7340032,"name":"O. Kantarci","title":"A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode"},{"id":3691360,"work_id":14318107,"tagging_user_id":33272291,"tagged_user_id":null,"co_author_invite_id":892622,"email":"m***u@gmail.com","display_order":7864320,"name":"M. Tutuncu","title":"A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode"}],"downloadable_attachments":[],"slug":"A_patient_with_established_primary_progressive_multiple_sclerosis_transitions_to_secondary_relapsing_remitting_disease_course_following_a_fulminant_demyelinating_episode","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"Primary progressive multiple sclerosis (PPMS), relapsing remitting MS (RRMS) and acute disseminated encephalomyelitis (ADEM) are clinically and immunopathogenetically distinct phenotypes of inflammatory demyelinating disorders of the central nervous system. Progression following RRMS is well described as secondary progressive MS. We report a patient with unexpected transition from long established PPMS to clinically and radiologically active RRMS after an ADEM-like fulminant demyelinating episode despite an immunosuppressive treatment preceding relapses. We note clearly accelerated brain atrophy after the RRMS course ensues. The unique disease course in this patient illustrates the dissociation of the biology and disability impact of relapses and progression.","owner":{"id":33272291,"first_name":"Sabahattin","middle_initials":null,"last_name":"Saip","page_name":"SabahattinSaip","domain_name":"istanbul","created_at":"2015-07-22T22:34:11.561-07:00","display_name":"Sabahattin Saip","url":"https://istanbul.academia.edu/SabahattinSaip"},"attachments":[],"research_interests":[{"id":3097,"name":"Multiple sclerosis","url":"https://www.academia.edu/Documents/in/Multiple_sclerosis"},{"id":133057,"name":"Young Adult","url":"https://www.academia.edu/Documents/in/Young_Adult"},{"id":158884,"name":"Urinary Tract Infections","url":"https://www.academia.edu/Documents/in/Urinary_Tract_Infections"},{"id":234187,"name":"Recurrence","url":"https://www.academia.edu/Documents/in/Recurrence"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":509782,"name":"Respiratory Tract Infections","url":"https://www.academia.edu/Documents/in/Respiratory_Tract_Infections"},{"id":584615,"name":"Disease Progression","url":"https://www.academia.edu/Documents/in/Disease_Progression"},{"id":1239755,"name":"Neurosciences","url":"https://www.academia.edu/Documents/in/Neurosciences"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14318107-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14318115"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/14318115/CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes"><img alt="Research paper thumbnail of CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes" class="work-thumbnail" src="https://attachments.academia-assets.com/44325633/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/14318115/CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes">CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes</a></div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a>, and <a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/DemirciN">N. Demirci</a></span></div><div class="wp-workCard_item"><span>PLOS ONE</span><span>, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Multiple sclerosis (MS) is an immune-mediated, neuro-inflammatory, demyelinating and neurodegener...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Multiple sclerosis (MS) is an immune-mediated, neuro-inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS) with a heterogeneous clinical presentation and course. There is a remarkable phenotypic heterogeneity in MS, and the molecular mechanisms underlying it remain unknown. We aimed to investigate further the etiopathogenesis related molecular pathways in subclinical types of MS using proteomic and bioinformatics approaches in cerebrospinal fluids of patients with clinically isolated syndrome, relapsing remitting MS and progressive MS (n=179). Comparison of disease groups with controls revealed a total of 151 proteins that are differentially expressed in clinically different MS subtypes. KEGG analysis using PANOGA tool revealed the disease related pathways including aldosterone-regulated sodium reabsorption (p=8.02x10 -5 ) which is important in the immune cell migration, renin-angiotensin (p=6.88x10 -5 ) system that induces Th17 dependent immunity, notch signaling (p=1.83x10 -10 ) pathway indicating the activated remyelination and vitamin digestion and absorption pathways (p=1.73x10 -5 ). An emerging theme from our studies is that whilst all MS clinical forms share common biological pathways, there are also clinical subtypes specific and pathophysiology related pathways which may have further therapeutic implications.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="b14c02a8a0b788584787d9c62dcdf2ac" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":44325633,"asset_id":14318115,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/44325633/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14318115"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14318115"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14318115; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14318115]").text(description); $(".js-view-count[data-work-id=14318115]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14318115; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14318115']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "b14c02a8a0b788584787d9c62dcdf2ac" } } $('.js-work-strip[data-work-id=14318115]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14318115,"title":"CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes","translated_title":"","metadata":{"ai_title_tag":"CSF Proteomics Reveals Pathways in Multiple Sclerosis Subtypes","grobid_abstract":"Multiple sclerosis (MS) is an immune-mediated, neuro-inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS) with a heterogeneous clinical presentation and course. There is a remarkable phenotypic heterogeneity in MS, and the molecular mechanisms underlying it remain unknown. We aimed to investigate further the etiopathogenesis related molecular pathways in subclinical types of MS using proteomic and bioinformatics approaches in cerebrospinal fluids of patients with clinically isolated syndrome, relapsing remitting MS and progressive MS (n=179). Comparison of disease groups with controls revealed a total of 151 proteins that are differentially expressed in clinically different MS subtypes. KEGG analysis using PANOGA tool revealed the disease related pathways including aldosterone-regulated sodium reabsorption (p=8.02x10 -5 ) which is important in the immune cell migration, renin-angiotensin (p=6.88x10 -5 ) system that induces Th17 dependent immunity, notch signaling (p=1.83x10 -10 ) pathway indicating the activated remyelination and vitamin digestion and absorption pathways (p=1.73x10 -5 ). An emerging theme from our studies is that whilst all MS clinical forms share common biological pathways, there are also clinical subtypes specific and pathophysiology related pathways which may have further therapeutic implications.","publication_date":{"day":null,"month":null,"year":2015,"errors":{}},"publication_name":"PLOS ONE","grobid_abstract_attachment_id":44325633},"translated_abstract":null,"internal_url":"https://www.academia.edu/14318115/CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes","translated_internal_url":"","created_at":"2015-07-22T22:34:47.081-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33272291,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3691342,"work_id":14318115,"tagging_user_id":33272291,"tagged_user_id":33207160,"co_author_invite_id":null,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":0,"name":"Aksel Siva","title":"CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes"},{"id":3691352,"work_id":14318115,"tagging_user_id":33272291,"tagged_user_id":43685187,"co_author_invite_id":892619,"email":"n***i@hotmail.com","display_order":4194304,"name":"N. Demirci","title":"CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes"},{"id":3691357,"work_id":14318115,"tagging_user_id":33272291,"tagged_user_id":null,"co_author_invite_id":892621,"email":"t***e@itu.edu.tr","display_order":6291456,"name":"Eda Turanlı","title":"CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes"},{"id":3691361,"work_id":14318115,"tagging_user_id":33272291,"tagged_user_id":null,"co_author_invite_id":892622,"email":"m***u@gmail.com","display_order":7340032,"name":"M. Tutuncu","title":"CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes"}],"downloadable_attachments":[{"id":44325633,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325633/thumbnails/1.jpg","file_name":"CSF_Proteomics_Identifies_Specific_and_S20160402-32742-qgoavx.pdf","download_url":"https://www.academia.edu/attachments/44325633/download_file","bulk_download_file_name":"CSF_Proteomics_Identifies_Specific_and_S.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325633/CSF_Proteomics_Identifies_Specific_and_S20160402-32742-qgoavx-libre.pdf?1459602634=\u0026response-content-disposition=attachment%3B+filename%3DCSF_Proteomics_Identifies_Specific_and_S.pdf\u0026Expires=1743603792\u0026Signature=K16DBAdCf6p0YQULAWwd87zE2v4-jfYva0lYZ-KCYZczn7jmixhfJLT-y7s8OMepmy7o3zyhYeciD7PkjgjbH6AMibHH9Bdu-xMiXQD8tz0GVFN0T946pCllh73qGk9DLsanb-WI4yrZcXDKw3IMVxbH9NeCHYgmuR9okMNxU8zNZYwGAZ2lTFDbE-RXtxgOnN-lJxxU0Iuyuwov8COUytz4Tge~IKoPSTSNLBUj28SoSRcH09sL6Sv0l6tWlUla-7d1gC1SjVvvgzSsgzug8EqQyqy-SHQtqgz426f6hH708fte5d2-8oibIQqTLo3jxldtUua9U8EdooL~uLMHpg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes","translated_slug":"","page_count":18,"language":"en","content_type":"Work","summary":"Multiple sclerosis (MS) is an immune-mediated, neuro-inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS) with a heterogeneous clinical presentation and course. There is a remarkable phenotypic heterogeneity in MS, and the molecular mechanisms underlying it remain unknown. We aimed to investigate further the etiopathogenesis related molecular pathways in subclinical types of MS using proteomic and bioinformatics approaches in cerebrospinal fluids of patients with clinically isolated syndrome, relapsing remitting MS and progressive MS (n=179). Comparison of disease groups with controls revealed a total of 151 proteins that are differentially expressed in clinically different MS subtypes. KEGG analysis using PANOGA tool revealed the disease related pathways including aldosterone-regulated sodium reabsorption (p=8.02x10 -5 ) which is important in the immune cell migration, renin-angiotensin (p=6.88x10 -5 ) system that induces Th17 dependent immunity, notch signaling (p=1.83x10 -10 ) pathway indicating the activated remyelination and vitamin digestion and absorption pathways (p=1.73x10 -5 ). An emerging theme from our studies is that whilst all MS clinical forms share common biological pathways, there are also clinical subtypes specific and pathophysiology related pathways which may have further therapeutic implications.","owner":{"id":33272291,"first_name":"Sabahattin","middle_initials":null,"last_name":"Saip","page_name":"SabahattinSaip","domain_name":"istanbul","created_at":"2015-07-22T22:34:11.561-07:00","display_name":"Sabahattin Saip","url":"https://istanbul.academia.edu/SabahattinSaip"},"attachments":[{"id":44325633,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325633/thumbnails/1.jpg","file_name":"CSF_Proteomics_Identifies_Specific_and_S20160402-32742-qgoavx.pdf","download_url":"https://www.academia.edu/attachments/44325633/download_file","bulk_download_file_name":"CSF_Proteomics_Identifies_Specific_and_S.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325633/CSF_Proteomics_Identifies_Specific_and_S20160402-32742-qgoavx-libre.pdf?1459602634=\u0026response-content-disposition=attachment%3B+filename%3DCSF_Proteomics_Identifies_Specific_and_S.pdf\u0026Expires=1743603792\u0026Signature=K16DBAdCf6p0YQULAWwd87zE2v4-jfYva0lYZ-KCYZczn7jmixhfJLT-y7s8OMepmy7o3zyhYeciD7PkjgjbH6AMibHH9Bdu-xMiXQD8tz0GVFN0T946pCllh73qGk9DLsanb-WI4yrZcXDKw3IMVxbH9NeCHYgmuR9okMNxU8zNZYwGAZ2lTFDbE-RXtxgOnN-lJxxU0Iuyuwov8COUytz4Tge~IKoPSTSNLBUj28SoSRcH09sL6Sv0l6tWlUla-7d1gC1SjVvvgzSsgzug8EqQyqy-SHQtqgz426f6hH708fte5d2-8oibIQqTLo3jxldtUua9U8EdooL~uLMHpg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":28235,"name":"Multidisciplinary","url":"https://www.academia.edu/Documents/in/Multidisciplinary"},{"id":220780,"name":"PLoS one","url":"https://www.academia.edu/Documents/in/PLoS_one"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14318115-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14318114"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14318114/Beh%C3%A7ets_Disease"><img alt="Research paper thumbnail of Behçet's Disease" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Behçet's Disease</div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a> and <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a></span></div><div class="wp-workCard_item"><span>Current treatment options in neurology</span><span>, 2011</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Neurologic involvement in Behçet&#39;s disease (BD) is seen in about 5% to 10% of all BD patients...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Neurologic involvement in Behçet&#39;s disease (BD) is seen in about 5% to 10% of all BD patients. Clinical and imaging data suggest that neurologic involvement in BD presents in two major forms. The first, central nervous system (CNS) parenchymal involvement with a predilection to brainstem-diencephalic regions, is seen in the majority of patients with neuro-BD (NBD). The second form is cerebral venous sinus thrombosis (CVST), which is seen in up to 20% of cases. BD is very rare in children, but when it does occur, the patterns are reversed: most children with NBD present with CVST. Other syndromes such as spinal cord involvement, arterial CNS involvement, optic neuritis, aseptic meningitis, and peripheral neuropathies may be seen, but are rare. Venous sinus thrombosis in BD has a significantly better neurologic prognosis than parenchymal CNS involvement. There is no Class I evidence regarding treatment of parenchymal CNS involvement or CVST in BD. Current treatment applications ar...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14318114"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14318114"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14318114; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14318114]").text(description); $(".js-view-count[data-work-id=14318114]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14318114; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14318114']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14318114]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14318114,"title":"Behçet's Disease","translated_title":"","metadata":{"abstract":"Neurologic involvement in Behçet\u0026#39;s disease (BD) is seen in about 5% to 10% of all BD patients. Clinical and imaging data suggest that neurologic involvement in BD presents in two major forms. The first, central nervous system (CNS) parenchymal involvement with a predilection to brainstem-diencephalic regions, is seen in the majority of patients with neuro-BD (NBD). The second form is cerebral venous sinus thrombosis (CVST), which is seen in up to 20% of cases. BD is very rare in children, but when it does occur, the patterns are reversed: most children with NBD present with CVST. Other syndromes such as spinal cord involvement, arterial CNS involvement, optic neuritis, aseptic meningitis, and peripheral neuropathies may be seen, but are rare. Venous sinus thrombosis in BD has a significantly better neurologic prognosis than parenchymal CNS involvement. There is no Class I evidence regarding treatment of parenchymal CNS involvement or CVST in BD. Current treatment applications ar...","publication_date":{"day":null,"month":null,"year":2011,"errors":{}},"publication_name":"Current treatment options in neurology"},"translated_abstract":"Neurologic involvement in Behçet\u0026#39;s disease (BD) is seen in about 5% to 10% of all BD patients. Clinical and imaging data suggest that neurologic involvement in BD presents in two major forms. The first, central nervous system (CNS) parenchymal involvement with a predilection to brainstem-diencephalic regions, is seen in the majority of patients with neuro-BD (NBD). The second form is cerebral venous sinus thrombosis (CVST), which is seen in up to 20% of cases. BD is very rare in children, but when it does occur, the patterns are reversed: most children with NBD present with CVST. Other syndromes such as spinal cord involvement, arterial CNS involvement, optic neuritis, aseptic meningitis, and peripheral neuropathies may be seen, but are rare. Venous sinus thrombosis in BD has a significantly better neurologic prognosis than parenchymal CNS involvement. There is no Class I evidence regarding treatment of parenchymal CNS involvement or CVST in BD. Current treatment applications ar...","internal_url":"https://www.academia.edu/14318114/Beh%C3%A7ets_Disease","translated_internal_url":"","created_at":"2015-07-22T22:34:47.000-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33272291,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3691340,"work_id":14318114,"tagging_user_id":33272291,"tagged_user_id":33207160,"co_author_invite_id":null,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":0,"name":"Aksel Siva","title":"Behçet's Disease"},{"id":3691355,"work_id":14318114,"tagging_user_id":33272291,"tagged_user_id":31879554,"co_author_invite_id":null,"email":"a***r@gmail.com","display_order":4194304,"name":"gulsen akman-demir","title":"Behçet's Disease"}],"downloadable_attachments":[],"slug":"Behçets_Disease","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"Neurologic involvement in Behçet\u0026#39;s disease (BD) is seen in about 5% to 10% of all BD patients. Clinical and imaging data suggest that neurologic involvement in BD presents in two major forms. The first, central nervous system (CNS) parenchymal involvement with a predilection to brainstem-diencephalic regions, is seen in the majority of patients with neuro-BD (NBD). The second form is cerebral venous sinus thrombosis (CVST), which is seen in up to 20% of cases. BD is very rare in children, but when it does occur, the patterns are reversed: most children with NBD present with CVST. Other syndromes such as spinal cord involvement, arterial CNS involvement, optic neuritis, aseptic meningitis, and peripheral neuropathies may be seen, but are rare. Venous sinus thrombosis in BD has a significantly better neurologic prognosis than parenchymal CNS involvement. There is no Class I evidence regarding treatment of parenchymal CNS involvement or CVST in BD. Current treatment applications ar...","owner":{"id":33272291,"first_name":"Sabahattin","middle_initials":null,"last_name":"Saip","page_name":"SabahattinSaip","domain_name":"istanbul","created_at":"2015-07-22T22:34:11.561-07:00","display_name":"Sabahattin Saip","url":"https://istanbul.academia.edu/SabahattinSaip"},"attachments":[],"research_interests":[],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14318114-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14318106"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/14318106/Headache_in_Beh_ets_Syndrome"><img alt="Research paper thumbnail of Headache in Beh�et's Syndrome" class="work-thumbnail" src="https://attachments.academia-assets.com/44325639/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/14318106/Headache_in_Beh_ets_Syndrome">Headache in Beh�et's Syndrome</a></div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a> and <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a></span></div><div class="wp-workCard_item"><span>Headache: The Journal of Head and Face Pain</span><span>, 2005</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Objective.-To study the frequencies and characteristics of different headache types seen in patie...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Objective.-To study the frequencies and characteristics of different headache types seen in patients with Behçet's syndrome (BS) in a large cohort of patients.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="a9526ccf52a690075050945466456e2c" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":44325639,"asset_id":14318106,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/44325639/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14318106"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14318106"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14318106; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14318106]").text(description); $(".js-view-count[data-work-id=14318106]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14318106; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14318106']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "a9526ccf52a690075050945466456e2c" } } $('.js-work-strip[data-work-id=14318106]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14318106,"title":"Headache in Beh�et's Syndrome","translated_title":"","metadata":{"ai_title_tag":"Headache Types in Behçet's Syndrome: A Cohort Study","grobid_abstract":"Objective.-To study the frequencies and characteristics of different headache types seen in patients with Behçet's syndrome (BS) in a large cohort of patients.","publication_date":{"day":null,"month":null,"year":2005,"errors":{}},"publication_name":"Headache: The Journal of Head and Face Pain","grobid_abstract_attachment_id":44325639},"translated_abstract":null,"internal_url":"https://www.academia.edu/14318106/Headache_in_Beh_ets_Syndrome","translated_internal_url":"","created_at":"2015-07-22T22:34:46.139-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33272291,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3691334,"work_id":14318106,"tagging_user_id":33272291,"tagged_user_id":451513,"co_author_invite_id":null,"email":"a***s@istanbul.edu.tr","affiliation":"Koç University","display_order":0,"name":"Ayse Altintas","title":"Headache in Beh�et's Syndrome"},{"id":3691344,"work_id":14318106,"tagging_user_id":33272291,"tagged_user_id":33207160,"co_author_invite_id":null,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":4194304,"name":"Aksel Siva","title":"Headache in Beh�et's Syndrome"},{"id":3691359,"work_id":14318106,"tagging_user_id":33272291,"tagged_user_id":null,"co_author_invite_id":823078,"email":"h***i@attglobal.net","display_order":6291456,"name":"Hasan Yazici","title":"Headache in Beh�et's Syndrome"}],"downloadable_attachments":[{"id":44325639,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325639/thumbnails/1.jpg","file_name":"Headache_in_Behets_Syndrome20160402-30516-13ohi8c.pdf","download_url":"https://www.academia.edu/attachments/44325639/download_file","bulk_download_file_name":"Headache_in_Beh_ets_Syndrome.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325639/Headache_in_Behets_Syndrome20160402-30516-13ohi8c-libre.pdf?1459602633=\u0026response-content-disposition=attachment%3B+filename%3DHeadache_in_Beh_ets_Syndrome.pdf\u0026Expires=1743574094\u0026Signature=MiD083609ukGFPTr1QWiL6ruTBXnNY6xd8sHnwPx-Ia2d4ddHDvrlbhn1cTSP8nodG~mYk5rtDGvkvL95BsmXFjFd9iTy~cwryk9YIMXNKUQKcBeALLzg7DATmQp4ATPhdfeeCd0FfRD5TFXPja1FpQfq6sGp-vfM800KMORZZ5dZpVzVTf8qVmJsxR36BrVoKEff-kDaYrVgNBwP9aRlhvubGp25oVqr7lhhg4JbjCNa3pemF1vlBDRYfgt~zupMO4t56nwPfHKHMmmsk42fpbg5TIkTXkrMM2AWFBmbffK1ku~aneSTPpIUcS2ulbwCMm~~zvOu0taeSlB0j5tkg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Headache_in_Beh_ets_Syndrome","translated_slug":"","page_count":9,"language":"en","content_type":"Work","summary":"Objective.-To study the frequencies and characteristics of different headache types seen in patients with Behçet's syndrome (BS) in a large cohort of patients.","owner":{"id":33272291,"first_name":"Sabahattin","middle_initials":null,"last_name":"Saip","page_name":"SabahattinSaip","domain_name":"istanbul","created_at":"2015-07-22T22:34:11.561-07:00","display_name":"Sabahattin Saip","url":"https://istanbul.academia.edu/SabahattinSaip"},"attachments":[{"id":44325639,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325639/thumbnails/1.jpg","file_name":"Headache_in_Behets_Syndrome20160402-30516-13ohi8c.pdf","download_url":"https://www.academia.edu/attachments/44325639/download_file","bulk_download_file_name":"Headache_in_Beh_ets_Syndrome.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325639/Headache_in_Behets_Syndrome20160402-30516-13ohi8c-libre.pdf?1459602633=\u0026response-content-disposition=attachment%3B+filename%3DHeadache_in_Beh_ets_Syndrome.pdf\u0026Expires=1743574094\u0026Signature=MiD083609ukGFPTr1QWiL6ruTBXnNY6xd8sHnwPx-Ia2d4ddHDvrlbhn1cTSP8nodG~mYk5rtDGvkvL95BsmXFjFd9iTy~cwryk9YIMXNKUQKcBeALLzg7DATmQp4ATPhdfeeCd0FfRD5TFXPja1FpQfq6sGp-vfM800KMORZZ5dZpVzVTf8qVmJsxR36BrVoKEff-kDaYrVgNBwP9aRlhvubGp25oVqr7lhhg4JbjCNa3pemF1vlBDRYfgt~zupMO4t56nwPfHKHMmmsk42fpbg5TIkTXkrMM2AWFBmbffK1ku~aneSTPpIUcS2ulbwCMm~~zvOu0taeSlB0j5tkg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":103108,"name":"Headache","url":"https://www.academia.edu/Documents/in/Headache"},{"id":161176,"name":"The","url":"https://www.academia.edu/Documents/in/The"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":289330,"name":"Prevalence","url":"https://www.academia.edu/Documents/in/Prevalence"},{"id":612548,"name":"Tension-Type Headache","url":"https://www.academia.edu/Documents/in/Tension-Type_Headache"},{"id":1819400,"name":"Cohort Studies","url":"https://www.academia.edu/Documents/in/Cohort_Studies"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14318106-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233406"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/14233406/CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes"><img alt="Research paper thumbnail of CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes" class="work-thumbnail" src="https://attachments.academia-assets.com/44424607/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/14233406/CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes">CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes</a></div><div class="wp-workCard_item"><span>PLOS ONE</span><span>, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Multiple sclerosis (MS) is an immune-mediated, neuro-inflammatory, demyelinating and neurodegener...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Multiple sclerosis (MS) is an immune-mediated, neuro-inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS) with a heterogeneous clinical presentation and course. There is a remarkable phenotypic heterogeneity in MS, and the molecular mechanisms underlying it remain unknown. We aimed to investigate further the etiopathogenesis related molecular pathways in subclinical types of MS using proteomic and bioinformatics approaches in cerebrospinal fluids of patients with clinically isolated syndrome, relapsing remitting MS and progressive MS (n=179). Comparison of disease groups with controls revealed a total of 151 proteins that are differentially expressed in clinically different MS subtypes. KEGG analysis using PANOGA tool revealed the disease related pathways including aldosterone-regulated sodium reabsorption (p=8.02x10 -5 ) which is important in the immune cell migration, renin-angiotensin (p=6.88x10 -5 ) system that induces Th17 dependent immunity, notch signaling (p=1.83x10 -10 ) pathway indicating the activated remyelination and vitamin digestion and absorption pathways (p=1.73x10 -5 ). An emerging theme from our studies is that whilst all MS clinical forms share common biological pathways, there are also clinical subtypes specific and pathophysiology related pathways which may have further therapeutic implications.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="854adf0f7b372df387548985e4b96ad8" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":44424607,"asset_id":14233406,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/44424607/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233406"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233406"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233406; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233406]").text(description); $(".js-view-count[data-work-id=14233406]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233406; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233406']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "854adf0f7b372df387548985e4b96ad8" } } $('.js-work-strip[data-work-id=14233406]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233406,"title":"CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes","translated_title":"","metadata":{"ai_title_tag":"CSF Proteomics Reveals MS Pathways and Subtypes","grobid_abstract":"Multiple sclerosis (MS) is an immune-mediated, neuro-inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS) with a heterogeneous clinical presentation and course. There is a remarkable phenotypic heterogeneity in MS, and the molecular mechanisms underlying it remain unknown. We aimed to investigate further the etiopathogenesis related molecular pathways in subclinical types of MS using proteomic and bioinformatics approaches in cerebrospinal fluids of patients with clinically isolated syndrome, relapsing remitting MS and progressive MS (n=179). Comparison of disease groups with controls revealed a total of 151 proteins that are differentially expressed in clinically different MS subtypes. KEGG analysis using PANOGA tool revealed the disease related pathways including aldosterone-regulated sodium reabsorption (p=8.02x10 -5 ) which is important in the immune cell migration, renin-angiotensin (p=6.88x10 -5 ) system that induces Th17 dependent immunity, notch signaling (p=1.83x10 -10 ) pathway indicating the activated remyelination and vitamin digestion and absorption pathways (p=1.73x10 -5 ). An emerging theme from our studies is that whilst all MS clinical forms share common biological pathways, there are also clinical subtypes specific and pathophysiology related pathways which may have further therapeutic implications.","publication_date":{"day":null,"month":null,"year":2015,"errors":{}},"publication_name":"PLOS ONE","grobid_abstract_attachment_id":44424607},"translated_abstract":null,"internal_url":"https://www.academia.edu/14233406/CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes","translated_internal_url":"","created_at":"2015-07-20T14:59:55.669-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":44424607,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44424607/thumbnails/1.jpg","file_name":"CSF_Proteomics_Identifies_Specific_and_S20160405-13963-emfyfj.pdf","download_url":"https://www.academia.edu/attachments/44424607/download_file","bulk_download_file_name":"CSF_Proteomics_Identifies_Specific_and_S.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44424607/CSF_Proteomics_Identifies_Specific_and_S20160405-13963-emfyfj-libre.pdf?1459843938=\u0026response-content-disposition=attachment%3B+filename%3DCSF_Proteomics_Identifies_Specific_and_S.pdf\u0026Expires=1743603792\u0026Signature=NqjvFyisOnH9nG3Xjp-HyM~RCpzIuRTDJlE7AP0GjVIt-To5gm0dovce3r2P7O6z8Af3jDsaCy~QoHzm-sVPotzxzeixjJMdy2s8bd5V7ldfvcEA77ssdYaxtUjstMnWpGC95ouePcodIfOmYXmsj2tQi8u-1OG-7ok9jfi2g71sIVVHh~RTWnM9WTLVgph-pm9so5IRXjjK5biyXXsJyG4LlOjSGJ6nn8ZbxpLGt-rM96GiYksvBtolEqihDs3IgD38RKr-opZrG11Q3YLFvzHd2jzZRzuGV~LXvS~O0wROv7ELlmMg59ZID0Z3jVV-3dzhl4gA0G0oVnGaAn8Frg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes","translated_slug":"","page_count":18,"language":"en","content_type":"Work","summary":"Multiple sclerosis (MS) is an immune-mediated, neuro-inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS) with a heterogeneous clinical presentation and course. There is a remarkable phenotypic heterogeneity in MS, and the molecular mechanisms underlying it remain unknown. We aimed to investigate further the etiopathogenesis related molecular pathways in subclinical types of MS using proteomic and bioinformatics approaches in cerebrospinal fluids of patients with clinically isolated syndrome, relapsing remitting MS and progressive MS (n=179). Comparison of disease groups with controls revealed a total of 151 proteins that are differentially expressed in clinically different MS subtypes. KEGG analysis using PANOGA tool revealed the disease related pathways including aldosterone-regulated sodium reabsorption (p=8.02x10 -5 ) which is important in the immune cell migration, renin-angiotensin (p=6.88x10 -5 ) system that induces Th17 dependent immunity, notch signaling (p=1.83x10 -10 ) pathway indicating the activated remyelination and vitamin digestion and absorption pathways (p=1.73x10 -5 ). An emerging theme from our studies is that whilst all MS clinical forms share common biological pathways, there are also clinical subtypes specific and pathophysiology related pathways which may have further therapeutic implications.","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[{"id":44424607,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44424607/thumbnails/1.jpg","file_name":"CSF_Proteomics_Identifies_Specific_and_S20160405-13963-emfyfj.pdf","download_url":"https://www.academia.edu/attachments/44424607/download_file","bulk_download_file_name":"CSF_Proteomics_Identifies_Specific_and_S.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44424607/CSF_Proteomics_Identifies_Specific_and_S20160405-13963-emfyfj-libre.pdf?1459843938=\u0026response-content-disposition=attachment%3B+filename%3DCSF_Proteomics_Identifies_Specific_and_S.pdf\u0026Expires=1743603792\u0026Signature=NqjvFyisOnH9nG3Xjp-HyM~RCpzIuRTDJlE7AP0GjVIt-To5gm0dovce3r2P7O6z8Af3jDsaCy~QoHzm-sVPotzxzeixjJMdy2s8bd5V7ldfvcEA77ssdYaxtUjstMnWpGC95ouePcodIfOmYXmsj2tQi8u-1OG-7ok9jfi2g71sIVVHh~RTWnM9WTLVgph-pm9so5IRXjjK5biyXXsJyG4LlOjSGJ6nn8ZbxpLGt-rM96GiYksvBtolEqihDs3IgD38RKr-opZrG11Q3YLFvzHd2jzZRzuGV~LXvS~O0wROv7ELlmMg59ZID0Z3jVV-3dzhl4gA0G0oVnGaAn8Frg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":28235,"name":"Multidisciplinary","url":"https://www.academia.edu/Documents/in/Multidisciplinary"},{"id":220780,"name":"PLoS one","url":"https://www.academia.edu/Documents/in/PLoS_one"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233406-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233405"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/14233405/Early_CNS_neurodegeneration_in_radiologically_isolated_syndrome"><img alt="Research paper thumbnail of Early CNS neurodegeneration in radiologically isolated syndrome" class="work-thumbnail" src="https://attachments.academia-assets.com/44424617/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/14233405/Early_CNS_neurodegeneration_in_radiologically_isolated_syndrome">Early CNS neurodegeneration in radiologically isolated syndrome</a></div><div class="wp-workCard_item"><span>Neurology® neuroimmunology & neuroinflammation</span><span>, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Increasing evidence indicates that the thalamus may be a location of early neurodegeneration in m...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Increasing evidence indicates that the thalamus may be a location of early neurodegeneration in multiple sclerosis (MS). Our objective was to identify the presence of gray matter volume loss and thinning in patients with radiologically isolated syndrome (RIS). Sixty-three participants were included in this case-control study. Twenty-one patients with RIS were age- and sex-matched to 42 healthy controls in a 1:2 ratio. All participants underwent brain MRIs on a single 3T scanner. After lesion segmentation and inpainting, 1 mm(3)-isometric T1-weighted images were submitted to FreeSurfer (v5.2). Normalized cortical and deep gray matter volumes were compared between patients with RIS and controls using t tests, and thalamic volumes were correlated with white matter lesion volumes using Pearson correlation. Exploratory cortical thickness maps were created. Although traditional normalized total gray and white matter volumes were not statistically different between patients with RIS and co...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="c978763772bb8b145a0532e77372f829" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":44424617,"asset_id":14233405,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/44424617/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233405"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233405"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233405; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233405]").text(description); $(".js-view-count[data-work-id=14233405]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233405; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233405']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "c978763772bb8b145a0532e77372f829" } } $('.js-work-strip[data-work-id=14233405]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233405,"title":"Early CNS neurodegeneration in radiologically isolated syndrome","translated_title":"","metadata":{"abstract":"Increasing evidence indicates that the thalamus may be a location of early neurodegeneration in multiple sclerosis (MS). Our objective was to identify the presence of gray matter volume loss and thinning in patients with radiologically isolated syndrome (RIS). Sixty-three participants were included in this case-control study. Twenty-one patients with RIS were age- and sex-matched to 42 healthy controls in a 1:2 ratio. All participants underwent brain MRIs on a single 3T scanner. After lesion segmentation and inpainting, 1 mm(3)-isometric T1-weighted images were submitted to FreeSurfer (v5.2). Normalized cortical and deep gray matter volumes were compared between patients with RIS and controls using t tests, and thalamic volumes were correlated with white matter lesion volumes using Pearson correlation. Exploratory cortical thickness maps were created. Although traditional normalized total gray and white matter volumes were not statistically different between patients with RIS and co...","publication_date":{"day":null,"month":null,"year":2015,"errors":{}},"publication_name":"Neurology® neuroimmunology \u0026 neuroinflammation"},"translated_abstract":"Increasing evidence indicates that the thalamus may be a location of early neurodegeneration in multiple sclerosis (MS). Our objective was to identify the presence of gray matter volume loss and thinning in patients with radiologically isolated syndrome (RIS). Sixty-three participants were included in this case-control study. Twenty-one patients with RIS were age- and sex-matched to 42 healthy controls in a 1:2 ratio. All participants underwent brain MRIs on a single 3T scanner. After lesion segmentation and inpainting, 1 mm(3)-isometric T1-weighted images were submitted to FreeSurfer (v5.2). Normalized cortical and deep gray matter volumes were compared between patients with RIS and controls using t tests, and thalamic volumes were correlated with white matter lesion volumes using Pearson correlation. Exploratory cortical thickness maps were created. Although traditional normalized total gray and white matter volumes were not statistically different between patients with RIS and co...","internal_url":"https://www.academia.edu/14233405/Early_CNS_neurodegeneration_in_radiologically_isolated_syndrome","translated_internal_url":"","created_at":"2015-07-20T14:59:55.585-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":44424617,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44424617/thumbnails/1.jpg","file_name":"Early_CNS_neurodegeneration_in_radiologi20160405-9240-n4i7i8.pdf","download_url":"https://www.academia.edu/attachments/44424617/download_file","bulk_download_file_name":"Early_CNS_neurodegeneration_in_radiologi.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44424617/Early_CNS_neurodegeneration_in_radiologi20160405-9240-n4i7i8-libre.pdf?1459843937=\u0026response-content-disposition=attachment%3B+filename%3DEarly_CNS_neurodegeneration_in_radiologi.pdf\u0026Expires=1743585185\u0026Signature=enLrYC2at4TOVhmU3-KCoDYclqJAqrH7kduWucoFRWujBcN6L5KsjMgcY~ImiR2YYKIqMyJ27rv~dAnYlHjHZgR~-hP6c01GR0N6kuisqi7zGrW7btnMPeVtXeFMtP~CcKVon-QCKJFIMXkt-oWOHGHVfVnLu3C4jP0pklgqnWz~SDWl73Z0j2uus1VwYJQuQxlD4LbnjQ6FEyMGgsp8y8FnVovUNRi~2btpuqGBwz-PUEiDi27~yOpJH0imKtowVjVSRktQuTejSm9aBwtN-QVdFywclxJ2Kg~4fss-YK~pRUuWdgbws1K0W5OCL58enTOWQnK8XDu3HyAg2fV7gw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Early_CNS_neurodegeneration_in_radiologically_isolated_syndrome","translated_slug":"","page_count":5,"language":"en","content_type":"Work","summary":"Increasing evidence indicates that the thalamus may be a location of early neurodegeneration in multiple sclerosis (MS). Our objective was to identify the presence of gray matter volume loss and thinning in patients with radiologically isolated syndrome (RIS). Sixty-three participants were included in this case-control study. Twenty-one patients with RIS were age- and sex-matched to 42 healthy controls in a 1:2 ratio. All participants underwent brain MRIs on a single 3T scanner. After lesion segmentation and inpainting, 1 mm(3)-isometric T1-weighted images were submitted to FreeSurfer (v5.2). Normalized cortical and deep gray matter volumes were compared between patients with RIS and controls using t tests, and thalamic volumes were correlated with white matter lesion volumes using Pearson correlation. Exploratory cortical thickness maps were created. Although traditional normalized total gray and white matter volumes were not statistically different between patients with RIS and co...","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[{"id":44424617,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44424617/thumbnails/1.jpg","file_name":"Early_CNS_neurodegeneration_in_radiologi20160405-9240-n4i7i8.pdf","download_url":"https://www.academia.edu/attachments/44424617/download_file","bulk_download_file_name":"Early_CNS_neurodegeneration_in_radiologi.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44424617/Early_CNS_neurodegeneration_in_radiologi20160405-9240-n4i7i8-libre.pdf?1459843937=\u0026response-content-disposition=attachment%3B+filename%3DEarly_CNS_neurodegeneration_in_radiologi.pdf\u0026Expires=1743585185\u0026Signature=enLrYC2at4TOVhmU3-KCoDYclqJAqrH7kduWucoFRWujBcN6L5KsjMgcY~ImiR2YYKIqMyJ27rv~dAnYlHjHZgR~-hP6c01GR0N6kuisqi7zGrW7btnMPeVtXeFMtP~CcKVon-QCKJFIMXkt-oWOHGHVfVnLu3C4jP0pklgqnWz~SDWl73Z0j2uus1VwYJQuQxlD4LbnjQ6FEyMGgsp8y8FnVovUNRi~2btpuqGBwz-PUEiDi27~yOpJH0imKtowVjVSRktQuTejSm9aBwtN-QVdFywclxJ2Kg~4fss-YK~pRUuWdgbws1K0W5OCL58enTOWQnK8XDu3HyAg2fV7gw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233405-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233404"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14233404/Beh%C3%A7ets_Disease"><img alt="Research paper thumbnail of Behçet's Disease" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Behçet's Disease</div><div class="wp-workCard_item"><span>Current Treatment Options in Neurology</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">OPINION STATEMENT: Neurologic involvement in Behçet&#39;s disease (BD) is seen in about 5% to 10%...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">OPINION STATEMENT: Neurologic involvement in Behçet&#39;s disease (BD) is seen in about 5% to 10% of all BD patients. Clinical and imaging data suggest that neurologic involvement in BD presents in two major forms. The first, central nervous system (CNS) parenchymal involvement with a predilection to brainstem-diencephalic regions, is seen in the majority of patients with neuro-BD (NBD). The second form is cerebral venous sinus thrombosis (CVST), which is seen in up to 20% of cases. BD is very rare in children, but when it does occur, the patterns are reversed: most children with NBD present with CVST. Other syndromes such as spinal cord involvement, arterial CNS involvement, optic neuritis, aseptic meningitis, and peripheral neuropathies may be seen, but are rare. Venous sinus thrombosis in BD has a significantly better neurologic prognosis than parenchymal CNS involvement. There is no Class I evidence regarding treatment of parenchymal CNS involvement or CVST in BD. Current treatm...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233404"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233404"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233404; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233404]").text(description); $(".js-view-count[data-work-id=14233404]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233404; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233404']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14233404]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233404,"title":"Behçet's Disease","translated_title":"","metadata":{"abstract":"OPINION STATEMENT: Neurologic involvement in Behçet\u0026#39;s disease (BD) is seen in about 5% to 10% of all BD patients. Clinical and imaging data suggest that neurologic involvement in BD presents in two major forms. The first, central nervous system (CNS) parenchymal involvement with a predilection to brainstem-diencephalic regions, is seen in the majority of patients with neuro-BD (NBD). The second form is cerebral venous sinus thrombosis (CVST), which is seen in up to 20% of cases. BD is very rare in children, but when it does occur, the patterns are reversed: most children with NBD present with CVST. Other syndromes such as spinal cord involvement, arterial CNS involvement, optic neuritis, aseptic meningitis, and peripheral neuropathies may be seen, but are rare. Venous sinus thrombosis in BD has a significantly better neurologic prognosis than parenchymal CNS involvement. There is no Class I evidence regarding treatment of parenchymal CNS involvement or CVST in BD. Current treatm...","publication_name":"Current Treatment Options in Neurology"},"translated_abstract":"OPINION STATEMENT: Neurologic involvement in Behçet\u0026#39;s disease (BD) is seen in about 5% to 10% of all BD patients. Clinical and imaging data suggest that neurologic involvement in BD presents in two major forms. The first, central nervous system (CNS) parenchymal involvement with a predilection to brainstem-diencephalic regions, is seen in the majority of patients with neuro-BD (NBD). The second form is cerebral venous sinus thrombosis (CVST), which is seen in up to 20% of cases. BD is very rare in children, but when it does occur, the patterns are reversed: most children with NBD present with CVST. Other syndromes such as spinal cord involvement, arterial CNS involvement, optic neuritis, aseptic meningitis, and peripheral neuropathies may be seen, but are rare. Venous sinus thrombosis in BD has a significantly better neurologic prognosis than parenchymal CNS involvement. There is no Class I evidence regarding treatment of parenchymal CNS involvement or CVST in BD. Current treatm...","internal_url":"https://www.academia.edu/14233404/Beh%C3%A7ets_Disease","translated_internal_url":"","created_at":"2015-07-20T14:59:55.499-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Behçets_Disease","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"OPINION STATEMENT: Neurologic involvement in Behçet\u0026#39;s disease (BD) is seen in about 5% to 10% of all BD patients. Clinical and imaging data suggest that neurologic involvement in BD presents in two major forms. The first, central nervous system (CNS) parenchymal involvement with a predilection to brainstem-diencephalic regions, is seen in the majority of patients with neuro-BD (NBD). The second form is cerebral venous sinus thrombosis (CVST), which is seen in up to 20% of cases. BD is very rare in children, but when it does occur, the patterns are reversed: most children with NBD present with CVST. Other syndromes such as spinal cord involvement, arterial CNS involvement, optic neuritis, aseptic meningitis, and peripheral neuropathies may be seen, but are rare. Venous sinus thrombosis in BD has a significantly better neurologic prognosis than parenchymal CNS involvement. There is no Class I evidence regarding treatment of parenchymal CNS involvement or CVST in BD. Current treatm...","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[],"research_interests":[],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233404-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233403"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14233403/Gender_influences_headache_characteristics_with_increasing_age_in_migraine_patients"><img alt="Research paper thumbnail of Gender influences headache characteristics with increasing age in migraine patients" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Gender influences headache characteristics with increasing age in migraine patients</div><div class="wp-workCard_item"><span>Cephalalgia</span><span>, 2014</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Migraine headache is one of the most common primary headache disorders and is three times more pr...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Migraine headache is one of the most common primary headache disorders and is three times more prevalent in women than in men, especially during the reproductive ages. The neurobiological basis of the female dominance has been partly established. The present study aimed to investigate the effect of gender on the headache manifestations in migraine patients. The study group consisted of 2082 adult patients from five different hospitals&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39; tertiary care-based headache clinics. The relationship between headache characteristics and gender was evaluated in migraine with aura (MwA) and migraine without aura (MwoA). The duration, severity, frequency of headache and associated symptoms were evaluated in both genders and age-dependent variations and analyzed in two subgroups. Women with migraine were prone to significantly longer duration and intensity of headache attacks. Nausea, phonophobia and photophobia were more prevalent in women. Median headache duration was also longer in women than in men in MwA (p = 0.013) and MwoA (p &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.001). Median headache intensity was higher in women than in men in MwA (p = 0.010) and MwoA (p = 0.009). The frequency of nausea was significantly higher in women than in men in MwA (p = 0.049). Throbbing headache quality and associated features (nausea, photophobia, and phonophobia) were significantly more frequent in women than in men in MwoA. The gender impact varied across age groups and significant changes were seen in female migraineurs after age 30. No age-dependent variation was observed in male migraineurs. Gender has an influence on the characteristics of the headache as well as on the associated symptoms in migraine patients, and this impact varies across the age groups, particularly in women.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233403"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233403"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233403; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233403]").text(description); $(".js-view-count[data-work-id=14233403]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233403; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233403']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14233403]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233403,"title":"Gender influences headache characteristics with increasing age in migraine patients","translated_title":"","metadata":{"abstract":"Migraine headache is one of the most common primary headache disorders and is three times more prevalent in women than in men, especially during the reproductive ages. The neurobiological basis of the female dominance has been partly established. The present study aimed to investigate the effect of gender on the headache manifestations in migraine patients. The study group consisted of 2082 adult patients from five different hospitals\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39; tertiary care-based headache clinics. The relationship between headache characteristics and gender was evaluated in migraine with aura (MwA) and migraine without aura (MwoA). The duration, severity, frequency of headache and associated symptoms were evaluated in both genders and age-dependent variations and analyzed in two subgroups. Women with migraine were prone to significantly longer duration and intensity of headache attacks. Nausea, phonophobia and photophobia were more prevalent in women. Median headache duration was also longer in women than in men in MwA (p = 0.013) and MwoA (p \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.001). Median headache intensity was higher in women than in men in MwA (p = 0.010) and MwoA (p = 0.009). The frequency of nausea was significantly higher in women than in men in MwA (p = 0.049). Throbbing headache quality and associated features (nausea, photophobia, and phonophobia) were significantly more frequent in women than in men in MwoA. The gender impact varied across age groups and significant changes were seen in female migraineurs after age 30. No age-dependent variation was observed in male migraineurs. Gender has an influence on the characteristics of the headache as well as on the associated symptoms in migraine patients, and this impact varies across the age groups, particularly in women.","publication_date":{"day":null,"month":null,"year":2014,"errors":{}},"publication_name":"Cephalalgia"},"translated_abstract":"Migraine headache is one of the most common primary headache disorders and is three times more prevalent in women than in men, especially during the reproductive ages. The neurobiological basis of the female dominance has been partly established. The present study aimed to investigate the effect of gender on the headache manifestations in migraine patients. The study group consisted of 2082 adult patients from five different hospitals\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39; tertiary care-based headache clinics. The relationship between headache characteristics and gender was evaluated in migraine with aura (MwA) and migraine without aura (MwoA). The duration, severity, frequency of headache and associated symptoms were evaluated in both genders and age-dependent variations and analyzed in two subgroups. Women with migraine were prone to significantly longer duration and intensity of headache attacks. Nausea, phonophobia and photophobia were more prevalent in women. Median headache duration was also longer in women than in men in MwA (p = 0.013) and MwoA (p \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.001). Median headache intensity was higher in women than in men in MwA (p = 0.010) and MwoA (p = 0.009). The frequency of nausea was significantly higher in women than in men in MwA (p = 0.049). Throbbing headache quality and associated features (nausea, photophobia, and phonophobia) were significantly more frequent in women than in men in MwoA. The gender impact varied across age groups and significant changes were seen in female migraineurs after age 30. No age-dependent variation was observed in male migraineurs. Gender has an influence on the characteristics of the headache as well as on the associated symptoms in migraine patients, and this impact varies across the age groups, particularly in women.","internal_url":"https://www.academia.edu/14233403/Gender_influences_headache_characteristics_with_increasing_age_in_migraine_patients","translated_internal_url":"","created_at":"2015-07-20T14:59:55.417-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Gender_influences_headache_characteristics_with_increasing_age_in_migraine_patients","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"Migraine headache is one of the most common primary headache disorders and is three times more prevalent in women than in men, especially during the reproductive ages. The neurobiological basis of the female dominance has been partly established. The present study aimed to investigate the effect of gender on the headache manifestations in migraine patients. The study group consisted of 2082 adult patients from five different hospitals\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39; tertiary care-based headache clinics. The relationship between headache characteristics and gender was evaluated in migraine with aura (MwA) and migraine without aura (MwoA). The duration, severity, frequency of headache and associated symptoms were evaluated in both genders and age-dependent variations and analyzed in two subgroups. Women with migraine were prone to significantly longer duration and intensity of headache attacks. Nausea, phonophobia and photophobia were more prevalent in women. Median headache duration was also longer in women than in men in MwA (p = 0.013) and MwoA (p \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.001). Median headache intensity was higher in women than in men in MwA (p = 0.010) and MwoA (p = 0.009). The frequency of nausea was significantly higher in women than in men in MwA (p = 0.049). Throbbing headache quality and associated features (nausea, photophobia, and phonophobia) were significantly more frequent in women than in men in MwoA. The gender impact varied across age groups and significant changes were seen in female migraineurs after age 30. No age-dependent variation was observed in male migraineurs. Gender has an influence on the characteristics of the headache as well as on the associated symptoms in migraine patients, and this impact varies across the age groups, particularly in women.","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[],"research_interests":[{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":1239755,"name":"Neurosciences","url":"https://www.academia.edu/Documents/in/Neurosciences"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233403-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233402"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14233402/Corticosteroid_therapy_augments_gastroduodenal_permeability_to_sucrose"><img alt="Research paper thumbnail of Corticosteroid therapy augments gastroduodenal permeability to sucrose" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Corticosteroid therapy augments gastroduodenal permeability to sucrose</div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a> and <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a></span></div><div class="wp-workCard_item"><span>The American Journal of Gastroenterology</span><span>, 1998</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">The aim of the present study was to investigate whether corticosteroid therapy alters gastroduode...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">The aim of the present study was to investigate whether corticosteroid therapy alters gastroduodenal mucosal permeability and whether permeability alteration is associated with macroscopic mucosal damage. Eight patients taking oral corticosteroid therapy (total prednisone-equivalent dose, 1.5+/-0.1 g; duration, approximately 30 days), nine patients with multiple sclerosis taking high-dose intravenous methyl-prednisolone therapy (total dose, 11.7+/-0.5 g; duration, approximately 9 days), and 20 age- and gender-matched controls were studied. Gastroduodenal permeability was determined using sucrose as a site-specific permeability probe. Five-hour urine was collected after ingesting 100 g of sucrose and its urinary excretion rate was measured using high-pressure liquid chromatography. Gastroduodenal endoscopy was performed before steroid therapy to exclude subjects with evidence of macroscopic mucosal lesions. The sucrose test and endoscopy were repeated after completion of corticosteroid therapy. The urinary sucrose excretion rates were similar in the control group and in patient groups before corticosteroid therapy. The median excretion rate of sucrose increased four (one to 28)- and eight (two to 35)-fold, respectively, as compared with pretreatment values in patients taking oral steroid and high-dose intravenous methyl-prednisolone therapy (p &amp;amp;amp;lt; 0.01). Considering all patients together, subjects who received a mean prednisone-equivalent dose of 8.4+/-1.5 g exhibited mucosal lesions, whereas patients who received 3.3+/-1.8 g did not (p = 0.06). The post-therapy increments in sucrose excretion rates were associated with neither the presence of macroscopic lesions nor with the total steroid dose received. Corticosteroid therapy augments gastroduodenal permeability and high doses are associated with macroscopic mucosal lesions. Steroid-induced permeability increase does not appear to be associated with the presence of macroscopic mucosal lesions.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233402"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233402"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233402; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233402]").text(description); $(".js-view-count[data-work-id=14233402]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233402; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233402']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14233402]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233402,"title":"Corticosteroid therapy augments gastroduodenal permeability to sucrose","translated_title":"","metadata":{"abstract":"The aim of the present study was to investigate whether corticosteroid therapy alters gastroduodenal mucosal permeability and whether permeability alteration is associated with macroscopic mucosal damage. Eight patients taking oral corticosteroid therapy (total prednisone-equivalent dose, 1.5+/-0.1 g; duration, approximately 30 days), nine patients with multiple sclerosis taking high-dose intravenous methyl-prednisolone therapy (total dose, 11.7+/-0.5 g; duration, approximately 9 days), and 20 age- and gender-matched controls were studied. Gastroduodenal permeability was determined using sucrose as a site-specific permeability probe. Five-hour urine was collected after ingesting 100 g of sucrose and its urinary excretion rate was measured using high-pressure liquid chromatography. Gastroduodenal endoscopy was performed before steroid therapy to exclude subjects with evidence of macroscopic mucosal lesions. The sucrose test and endoscopy were repeated after completion of corticosteroid therapy. The urinary sucrose excretion rates were similar in the control group and in patient groups before corticosteroid therapy. The median excretion rate of sucrose increased four (one to 28)- and eight (two to 35)-fold, respectively, as compared with pretreatment values in patients taking oral steroid and high-dose intravenous methyl-prednisolone therapy (p \u0026amp;amp;amp;lt; 0.01). Considering all patients together, subjects who received a mean prednisone-equivalent dose of 8.4+/-1.5 g exhibited mucosal lesions, whereas patients who received 3.3+/-1.8 g did not (p = 0.06). The post-therapy increments in sucrose excretion rates were associated with neither the presence of macroscopic lesions nor with the total steroid dose received. Corticosteroid therapy augments gastroduodenal permeability and high doses are associated with macroscopic mucosal lesions. Steroid-induced permeability increase does not appear to be associated with the presence of macroscopic mucosal lesions.","publication_date":{"day":null,"month":null,"year":1998,"errors":{}},"publication_name":"The American Journal of Gastroenterology"},"translated_abstract":"The aim of the present study was to investigate whether corticosteroid therapy alters gastroduodenal mucosal permeability and whether permeability alteration is associated with macroscopic mucosal damage. Eight patients taking oral corticosteroid therapy (total prednisone-equivalent dose, 1.5+/-0.1 g; duration, approximately 30 days), nine patients with multiple sclerosis taking high-dose intravenous methyl-prednisolone therapy (total dose, 11.7+/-0.5 g; duration, approximately 9 days), and 20 age- and gender-matched controls were studied. Gastroduodenal permeability was determined using sucrose as a site-specific permeability probe. Five-hour urine was collected after ingesting 100 g of sucrose and its urinary excretion rate was measured using high-pressure liquid chromatography. Gastroduodenal endoscopy was performed before steroid therapy to exclude subjects with evidence of macroscopic mucosal lesions. The sucrose test and endoscopy were repeated after completion of corticosteroid therapy. The urinary sucrose excretion rates were similar in the control group and in patient groups before corticosteroid therapy. The median excretion rate of sucrose increased four (one to 28)- and eight (two to 35)-fold, respectively, as compared with pretreatment values in patients taking oral steroid and high-dose intravenous methyl-prednisolone therapy (p \u0026amp;amp;amp;lt; 0.01). Considering all patients together, subjects who received a mean prednisone-equivalent dose of 8.4+/-1.5 g exhibited mucosal lesions, whereas patients who received 3.3+/-1.8 g did not (p = 0.06). The post-therapy increments in sucrose excretion rates were associated with neither the presence of macroscopic lesions nor with the total steroid dose received. Corticosteroid therapy augments gastroduodenal permeability and high doses are associated with macroscopic mucosal lesions. Steroid-induced permeability increase does not appear to be associated with the presence of macroscopic mucosal lesions.","internal_url":"https://www.academia.edu/14233402/Corticosteroid_therapy_augments_gastroduodenal_permeability_to_sucrose","translated_internal_url":"","created_at":"2015-07-20T14:59:55.315-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3517906,"work_id":14233402,"tagging_user_id":33207160,"tagged_user_id":33272291,"co_author_invite_id":765886,"email":"p***p@superonline.com","affiliation":"Istanbul University","display_order":0,"name":"Sabahattin Saip","title":"Corticosteroid therapy augments gastroduodenal permeability to sucrose"}],"downloadable_attachments":[],"slug":"Corticosteroid_therapy_augments_gastroduodenal_permeability_to_sucrose","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"The aim of the present study was to investigate whether corticosteroid therapy alters gastroduodenal mucosal permeability and whether permeability alteration is associated with macroscopic mucosal damage. Eight patients taking oral corticosteroid therapy (total prednisone-equivalent dose, 1.5+/-0.1 g; duration, approximately 30 days), nine patients with multiple sclerosis taking high-dose intravenous methyl-prednisolone therapy (total dose, 11.7+/-0.5 g; duration, approximately 9 days), and 20 age- and gender-matched controls were studied. Gastroduodenal permeability was determined using sucrose as a site-specific permeability probe. Five-hour urine was collected after ingesting 100 g of sucrose and its urinary excretion rate was measured using high-pressure liquid chromatography. Gastroduodenal endoscopy was performed before steroid therapy to exclude subjects with evidence of macroscopic mucosal lesions. The sucrose test and endoscopy were repeated after completion of corticosteroid therapy. The urinary sucrose excretion rates were similar in the control group and in patient groups before corticosteroid therapy. The median excretion rate of sucrose increased four (one to 28)- and eight (two to 35)-fold, respectively, as compared with pretreatment values in patients taking oral steroid and high-dose intravenous methyl-prednisolone therapy (p \u0026amp;amp;amp;lt; 0.01). Considering all patients together, subjects who received a mean prednisone-equivalent dose of 8.4+/-1.5 g exhibited mucosal lesions, whereas patients who received 3.3+/-1.8 g did not (p = 0.06). The post-therapy increments in sucrose excretion rates were associated with neither the presence of macroscopic lesions nor with the total steroid dose received. Corticosteroid therapy augments gastroduodenal permeability and high doses are associated with macroscopic mucosal lesions. Steroid-induced permeability increase does not appear to be associated with the presence of macroscopic mucosal lesions.","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[],"research_interests":[{"id":3097,"name":"Multiple sclerosis","url":"https://www.academia.edu/Documents/in/Multiple_sclerosis"},{"id":71471,"name":"Intestinal Mucosa","url":"https://www.academia.edu/Documents/in/Intestinal_Mucosa"},{"id":83972,"name":"Permeability","url":"https://www.academia.edu/Documents/in/Permeability"},{"id":162196,"name":"Sucrose","url":"https://www.academia.edu/Documents/in/Sucrose"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":246560,"name":"High Pressure Liquid Chromatography","url":"https://www.academia.edu/Documents/in/High_Pressure_Liquid_Chromatography"},{"id":1030661,"name":"Stomach","url":"https://www.academia.edu/Documents/in/Stomach"},{"id":1293308,"name":"Glucocorticoids","url":"https://www.academia.edu/Documents/in/Glucocorticoids"},{"id":1631043,"name":"Control Group","url":"https://www.academia.edu/Documents/in/Control_Group"},{"id":1863718,"name":"The American","url":"https://www.academia.edu/Documents/in/The_American"},{"id":2090674,"name":"Duodenum","url":"https://www.academia.edu/Documents/in/Duodenum"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233402-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233401"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14233401/Relapses_and_disability_accumulation_in_progressive_multiple_sclerosis"><img alt="Research paper thumbnail of Relapses and disability accumulation in progressive multiple sclerosis" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Relapses and disability accumulation in progressive multiple sclerosis</div><div class="wp-workCard_item"><span>Neurology</span><span>, Jan 6, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">We examined the effect of relapses-before and after progression onset-on the rate of postprogress...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">We examined the effect of relapses-before and after progression onset-on the rate of postprogression disability accrual in a progressive multiple sclerosis (MS) cohort. We studied patients with primary progressive MS (n = 322) and bout-onset progressive MS (BOPMS) including single-attack progressive MS (n = 112) and secondary progressive MS (n = 421). The effect of relapses on time to Expanded Disability Status Scale (EDSS) score of 6 was studied using multivariate Cox regression analysis (sex, age at progression, and immunomodulation modeled as covariates). Kaplan-Meier analysis was performed using EDSS 6 as endpoint. Preprogression relapses (hazard ratio [HR]: 1.63; 95% confidence interval [CI]: 1.34-1.98), postprogression relapses (HR: 1.37; 95% CI: 1.11-1.70), female sex (HR: 1.19; 95% CI: 1.00-1.43), and progression onset after age 50 years (HR: 1.47; 95% CI: 1.21-1.78) were associated with shorter time to EDSS 6. Postprogression relapses occurred in 29.5% of secondary progress...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233401"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233401"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233401; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233401]").text(description); $(".js-view-count[data-work-id=14233401]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233401; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233401']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14233401]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233401,"title":"Relapses and disability accumulation in progressive multiple sclerosis","translated_title":"","metadata":{"abstract":"We examined the effect of relapses-before and after progression onset-on the rate of postprogression disability accrual in a progressive multiple sclerosis (MS) cohort. We studied patients with primary progressive MS (n = 322) and bout-onset progressive MS (BOPMS) including single-attack progressive MS (n = 112) and secondary progressive MS (n = 421). The effect of relapses on time to Expanded Disability Status Scale (EDSS) score of 6 was studied using multivariate Cox regression analysis (sex, age at progression, and immunomodulation modeled as covariates). Kaplan-Meier analysis was performed using EDSS 6 as endpoint. Preprogression relapses (hazard ratio [HR]: 1.63; 95% confidence interval [CI]: 1.34-1.98), postprogression relapses (HR: 1.37; 95% CI: 1.11-1.70), female sex (HR: 1.19; 95% CI: 1.00-1.43), and progression onset after age 50 years (HR: 1.47; 95% CI: 1.21-1.78) were associated with shorter time to EDSS 6. Postprogression relapses occurred in 29.5% of secondary progress...","publication_date":{"day":6,"month":1,"year":2015,"errors":{}},"publication_name":"Neurology"},"translated_abstract":"We examined the effect of relapses-before and after progression onset-on the rate of postprogression disability accrual in a progressive multiple sclerosis (MS) cohort. We studied patients with primary progressive MS (n = 322) and bout-onset progressive MS (BOPMS) including single-attack progressive MS (n = 112) and secondary progressive MS (n = 421). The effect of relapses on time to Expanded Disability Status Scale (EDSS) score of 6 was studied using multivariate Cox regression analysis (sex, age at progression, and immunomodulation modeled as covariates). Kaplan-Meier analysis was performed using EDSS 6 as endpoint. Preprogression relapses (hazard ratio [HR]: 1.63; 95% confidence interval [CI]: 1.34-1.98), postprogression relapses (HR: 1.37; 95% CI: 1.11-1.70), female sex (HR: 1.19; 95% CI: 1.00-1.43), and progression onset after age 50 years (HR: 1.47; 95% CI: 1.21-1.78) were associated with shorter time to EDSS 6. Postprogression relapses occurred in 29.5% of secondary progress...","internal_url":"https://www.academia.edu/14233401/Relapses_and_disability_accumulation_in_progressive_multiple_sclerosis","translated_internal_url":"","created_at":"2015-07-20T14:59:55.237-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Relapses_and_disability_accumulation_in_progressive_multiple_sclerosis","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"We examined the effect of relapses-before and after progression onset-on the rate of postprogression disability accrual in a progressive multiple sclerosis (MS) cohort. We studied patients with primary progressive MS (n = 322) and bout-onset progressive MS (BOPMS) including single-attack progressive MS (n = 112) and secondary progressive MS (n = 421). The effect of relapses on time to Expanded Disability Status Scale (EDSS) score of 6 was studied using multivariate Cox regression analysis (sex, age at progression, and immunomodulation modeled as covariates). Kaplan-Meier analysis was performed using EDSS 6 as endpoint. Preprogression relapses (hazard ratio [HR]: 1.63; 95% confidence interval [CI]: 1.34-1.98), postprogression relapses (HR: 1.37; 95% CI: 1.11-1.70), female sex (HR: 1.19; 95% CI: 1.00-1.43), and progression onset after age 50 years (HR: 1.47; 95% CI: 1.21-1.78) were associated with shorter time to EDSS 6. Postprogression relapses occurred in 29.5% of secondary progress...","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[],"research_interests":[{"id":237,"name":"Cognitive Science","url":"https://www.academia.edu/Documents/in/Cognitive_Science"},{"id":623,"name":"Neurology","url":"https://www.academia.edu/Documents/in/Neurology"},{"id":12426,"name":"Treatment Outcome","url":"https://www.academia.edu/Documents/in/Treatment_Outcome"},{"id":41482,"name":"Multivariate Analysis","url":"https://www.academia.edu/Documents/in/Multivariate_Analysis"},{"id":133057,"name":"Young Adult","url":"https://www.academia.edu/Documents/in/Young_Adult"},{"id":234187,"name":"Recurrence","url":"https://www.academia.edu/Documents/in/Recurrence"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":584615,"name":"Disease Progression","url":"https://www.academia.edu/Documents/in/Disease_Progression"},{"id":1239755,"name":"Neurosciences","url":"https://www.academia.edu/Documents/in/Neurosciences"},{"id":1272981,"name":"Proportional Hazards Models","url":"https://www.academia.edu/Documents/in/Proportional_Hazards_Models"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233401-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="13983336"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/13983336/The_Burden_of_Headache_in_Neurology_Outpatient_Clinics_in_Turkey"><img alt="Research paper thumbnail of The Burden of Headache in Neurology Outpatient Clinics in Turkey" class="work-thumbnail" src="https://attachments.academia-assets.com/44737981/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/13983336/The_Burden_of_Headache_in_Neurology_Outpatient_Clinics_in_Turkey">The Burden of Headache in Neurology Outpatient Clinics in Turkey</a></div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/NKarli">N. Karli</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/MErtas1">M. Ertas</a>, and <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a></span></div><div class="wp-workCard_item"><span>Pain Practice</span><span>, 2007</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Background and Aim: The aim of the study was to investigate the burden of headache in neurology o...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Background and Aim: The aim of the study was to investigate the burden of headache in neurology outpatient clinics (NOCs) regardless of their primary complaint. Methods: Patients presenting for their routine appointments in 41 NOCs were screened during the course of 1 week. All eligible subjects (n = 3682; 61.9% female, mean age 45.2 1 16.5 years) were evaluated by a neurologist for the headache diagnosis and some demographic characteristics. Results: Of all patients, 66.4% reported headache, and in 35.1% headache was the primary cause for admitting to the NOC. Of 3682 patients, 917 (24.9%) were diagnosed as migraine according to International Headache Society (IHS) criteria. Thirty-three and nine-tenths percent of all patients admitted and 56% of the migraineurs according to IHS had severe headaches. As the headache severity increases, the ratio of the patients admitted with headache as the primary complaint increases significantly. The distribution of burden and other characteristics of headache did not differ in seven geographic regions and 41 different centers. Conclusion: Headache complaint caused at least 1/3 of all neurological outpatient visits in Turkey and 2/3 of all patients admitted to NOC had headache. Of these patients, 1/4 had migraine according to IHS with substantial disability and severity level.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="c526d598d2586a289164141c97f5ef5b" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":44737981,"asset_id":13983336,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/44737981/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="13983336"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="13983336"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 13983336; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=13983336]").text(description); $(".js-view-count[data-work-id=13983336]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 13983336; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='13983336']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "c526d598d2586a289164141c97f5ef5b" } } $('.js-work-strip[data-work-id=13983336]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":13983336,"title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey","translated_title":"","metadata":{"grobid_abstract":"Background and Aim: The aim of the study was to investigate the burden of headache in neurology outpatient clinics (NOCs) regardless of their primary complaint. Methods: Patients presenting for their routine appointments in 41 NOCs were screened during the course of 1 week. All eligible subjects (n = 3682; 61.9% female, mean age 45.2 1 16.5 years) were evaluated by a neurologist for the headache diagnosis and some demographic characteristics. Results: Of all patients, 66.4% reported headache, and in 35.1% headache was the primary cause for admitting to the NOC. Of 3682 patients, 917 (24.9%) were diagnosed as migraine according to International Headache Society (IHS) criteria. Thirty-three and nine-tenths percent of all patients admitted and 56% of the migraineurs according to IHS had severe headaches. As the headache severity increases, the ratio of the patients admitted with headache as the primary complaint increases significantly. The distribution of burden and other characteristics of headache did not differ in seven geographic regions and 41 different centers. Conclusion: Headache complaint caused at least 1/3 of all neurological outpatient visits in Turkey and 2/3 of all patients admitted to NOC had headache. Of these patients, 1/4 had migraine according to IHS with substantial disability and severity level.","publication_date":{"day":null,"month":null,"year":2007,"errors":{}},"publication_name":"Pain Practice","grobid_abstract_attachment_id":44737981},"translated_abstract":null,"internal_url":"https://www.academia.edu/13983336/The_Burden_of_Headache_in_Neurology_Outpatient_Clinics_in_Turkey","translated_internal_url":"","created_at":"2015-07-13T04:26:14.930-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33025639,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3018291,"work_id":13983336,"tagging_user_id":33025639,"tagged_user_id":33021815,"co_author_invite_id":null,"email":"m***f@uludag.edu.tr","affiliation":"Uludag University","display_order":0,"name":"M. Zarifoğlu","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"},{"id":3018299,"work_id":13983336,"tagging_user_id":33025639,"tagged_user_id":41556982,"co_author_invite_id":721598,"email":"m***s@superonline.com","display_order":4194304,"name":"M. Ertas","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"},{"id":3018302,"work_id":13983336,"tagging_user_id":33025639,"tagged_user_id":null,"co_author_invite_id":212337,"email":"o***n@gata.edu.tr","display_order":6291456,"name":"Ozlem Uzunkaya","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"},{"id":3018304,"work_id":13983336,"tagging_user_id":33025639,"tagged_user_id":33207160,"co_author_invite_id":765891,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":7340032,"name":"Aksel Siva","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"}],"downloadable_attachments":[{"id":44737981,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44737981/thumbnails/1.jpg","file_name":"j.1533-2500.2007.00154.x.pdf20160414-19802-p7nvan","download_url":"https://www.academia.edu/attachments/44737981/download_file","bulk_download_file_name":"The_Burden_of_Headache_in_Neurology_Outp.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44737981/j.1533-2500.2007.00154.x-libre.pdf20160414-19802-p7nvan?1460663870=\u0026response-content-disposition=attachment%3B+filename%3DThe_Burden_of_Headache_in_Neurology_Outp.pdf\u0026Expires=1743585185\u0026Signature=TMwnGKaSO2v6gqS3BVN7M6w7b4lyTH0Oc8PmUUQXFGo16w7k1vEluX57-k1d0F~d15hWYbUv3mvSxlJ8PZn6uFaonyTRDeZyy12vppjQa6T62s6b40boNmpTl2o843W2DDrbJeknYaPzprOWxBFevfEiRTAaFP2gnxp98blEPgrXgj1cwqpOuAYl0kJE-5DWcGJrFamfKUJzf7edYMl4JPJoFqYlKsIDdNhE-qH1D7I5zF4zMn24NN2j-ltiTWeFiaUr8ffCW1lTu1O9Kp3tm-qnTrdJAMZBXM9FSFmfPrYUPxMGDL0TqO2ek843dqfXBm5aWR4W4rMuSneA--CW6Q__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"The_Burden_of_Headache_in_Neurology_Outpatient_Clinics_in_Turkey","translated_slug":"","page_count":11,"language":"en","content_type":"Work","summary":"Background and Aim: The aim of the study was to investigate the burden of headache in neurology outpatient clinics (NOCs) regardless of their primary complaint. Methods: Patients presenting for their routine appointments in 41 NOCs were screened during the course of 1 week. All eligible subjects (n = 3682; 61.9% female, mean age 45.2 1 16.5 years) were evaluated by a neurologist for the headache diagnosis and some demographic characteristics. Results: Of all patients, 66.4% reported headache, and in 35.1% headache was the primary cause for admitting to the NOC. Of 3682 patients, 917 (24.9%) were diagnosed as migraine according to International Headache Society (IHS) criteria. Thirty-three and nine-tenths percent of all patients admitted and 56% of the migraineurs according to IHS had severe headaches. As the headache severity increases, the ratio of the patients admitted with headache as the primary complaint increases significantly. The distribution of burden and other characteristics of headache did not differ in seven geographic regions and 41 different centers. Conclusion: Headache complaint caused at least 1/3 of all neurological outpatient visits in Turkey and 2/3 of all patients admitted to NOC had headache. Of these patients, 1/4 had migraine according to IHS with substantial disability and severity level.","owner":{"id":33025639,"first_name":"N.","middle_initials":null,"last_name":"Karli","page_name":"NKarli","domain_name":"independent","created_at":"2015-07-13T04:19:58.878-07:00","display_name":"N. Karli","url":"https://independent.academia.edu/NKarli"},"attachments":[{"id":44737981,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44737981/thumbnails/1.jpg","file_name":"j.1533-2500.2007.00154.x.pdf20160414-19802-p7nvan","download_url":"https://www.academia.edu/attachments/44737981/download_file","bulk_download_file_name":"The_Burden_of_Headache_in_Neurology_Outp.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44737981/j.1533-2500.2007.00154.x-libre.pdf20160414-19802-p7nvan?1460663870=\u0026response-content-disposition=attachment%3B+filename%3DThe_Burden_of_Headache_in_Neurology_Outp.pdf\u0026Expires=1743585185\u0026Signature=TMwnGKaSO2v6gqS3BVN7M6w7b4lyTH0Oc8PmUUQXFGo16w7k1vEluX57-k1d0F~d15hWYbUv3mvSxlJ8PZn6uFaonyTRDeZyy12vppjQa6T62s6b40boNmpTl2o843W2DDrbJeknYaPzprOWxBFevfEiRTAaFP2gnxp98blEPgrXgj1cwqpOuAYl0kJE-5DWcGJrFamfKUJzf7edYMl4JPJoFqYlKsIDdNhE-qH1D7I5zF4zMn24NN2j-ltiTWeFiaUr8ffCW1lTu1O9Kp3tm-qnTrdJAMZBXM9FSFmfPrYUPxMGDL0TqO2ek843dqfXBm5aWR4W4rMuSneA--CW6Q__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":623,"name":"Neurology","url":"https://www.academia.edu/Documents/in/Neurology"},{"id":2898,"name":"Pain","url":"https://www.academia.edu/Documents/in/Pain"},{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":289330,"name":"Prevalence","url":"https://www.academia.edu/Documents/in/Prevalence"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-13983336-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="13983334"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/13983334/The_validation_of_ID_migraine_screener_in_neurology_outpatient_clinics_in_Turkey"><img alt="Research paper thumbnail of The validation of ID migraine™ screener in neurology outpatient clinics in Turkey" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">The validation of ID migraine™ screener in neurology outpatient clinics in Turkey</div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/NKarli">N. Karli</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/MErtas1">M. Ertas</a>, and <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a></span></div><div class="wp-workCard_item"><span>The Journal of Headache and Pain</span><span>, 2007</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">The aim of this study was to investigate the validity of the ID Migraine test in neurology outpat...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">The aim of this study was to investigate the validity of the ID Migraine test in neurology outpatient clinics (NOCs), regardless of their presenting complaints. Patients admitted to 41 NOCs were screened. Eligible subjects (n=3682) were evaluated by a neurologist for headache diagnosis according to the International Headache Society criteria and asked the 3-item screening questions of the ID Migraine test. Of 3682 patients, 917 (24.9%) were diagnosed as migraine, whereas 1171 (31.8%) were ID Migraine test positive. The sensitivity of the ID Migraine test for neurologist&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s diagnosis of migraine was 91.8%, specificity was 63.4%, positive predictive value was 71.9% and negative predictive value was 88.4%. The ID Migraine test is easy to use and a practical test that could alert the neurologist to diagnose patients having other complaints. This test would help to increase the diagnosis and treatment rate of undiagnosed migraine patients in NOCs.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="13983334"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="13983334"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 13983334; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=13983334]").text(description); $(".js-view-count[data-work-id=13983334]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 13983334; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='13983334']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=13983334]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":13983334,"title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey","translated_title":"","metadata":{"abstract":"The aim of this study was to investigate the validity of the ID Migraine test in neurology outpatient clinics (NOCs), regardless of their presenting complaints. Patients admitted to 41 NOCs were screened. Eligible subjects (n=3682) were evaluated by a neurologist for headache diagnosis according to the International Headache Society criteria and asked the 3-item screening questions of the ID Migraine test. Of 3682 patients, 917 (24.9%) were diagnosed as migraine, whereas 1171 (31.8%) were ID Migraine test positive. The sensitivity of the ID Migraine test for neurologist\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s diagnosis of migraine was 91.8%, specificity was 63.4%, positive predictive value was 71.9% and negative predictive value was 88.4%. The ID Migraine test is easy to use and a practical test that could alert the neurologist to diagnose patients having other complaints. This test would help to increase the diagnosis and treatment rate of undiagnosed migraine patients in NOCs.","publication_date":{"day":null,"month":null,"year":2007,"errors":{}},"publication_name":"The Journal of Headache and Pain"},"translated_abstract":"The aim of this study was to investigate the validity of the ID Migraine test in neurology outpatient clinics (NOCs), regardless of their presenting complaints. Patients admitted to 41 NOCs were screened. Eligible subjects (n=3682) were evaluated by a neurologist for headache diagnosis according to the International Headache Society criteria and asked the 3-item screening questions of the ID Migraine test. Of 3682 patients, 917 (24.9%) were diagnosed as migraine, whereas 1171 (31.8%) were ID Migraine test positive. The sensitivity of the ID Migraine test for neurologist\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s diagnosis of migraine was 91.8%, specificity was 63.4%, positive predictive value was 71.9% and negative predictive value was 88.4%. The ID Migraine test is easy to use and a practical test that could alert the neurologist to diagnose patients having other complaints. This test would help to increase the diagnosis and treatment rate of undiagnosed migraine patients in NOCs.","internal_url":"https://www.academia.edu/13983334/The_validation_of_ID_migraine_screener_in_neurology_outpatient_clinics_in_Turkey","translated_internal_url":"","created_at":"2015-07-13T04:26:14.799-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33025639,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3018294,"work_id":13983334,"tagging_user_id":33025639,"tagged_user_id":33021815,"co_author_invite_id":null,"email":"m***f@uludag.edu.tr","affiliation":"Uludag University","display_order":0,"name":"M. Zarifoğlu","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"},{"id":3018301,"work_id":13983334,"tagging_user_id":33025639,"tagged_user_id":41556982,"co_author_invite_id":721598,"email":"m***s@superonline.com","display_order":4194304,"name":"M. Ertas","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"},{"id":3018303,"work_id":13983334,"tagging_user_id":33025639,"tagged_user_id":null,"co_author_invite_id":212337,"email":"o***n@gata.edu.tr","display_order":6291456,"name":"Ozlem Uzunkaya","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"},{"id":3018306,"work_id":13983334,"tagging_user_id":33025639,"tagged_user_id":33207160,"co_author_invite_id":765891,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":7340032,"name":"Aksel Siva","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"}],"downloadable_attachments":[],"slug":"The_validation_of_ID_migraine_screener_in_neurology_outpatient_clinics_in_Turkey","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"The aim of this study was to investigate the validity of the ID Migraine test in neurology outpatient clinics (NOCs), regardless of their presenting complaints. Patients admitted to 41 NOCs were screened. Eligible subjects (n=3682) were evaluated by a neurologist for headache diagnosis according to the International Headache Society criteria and asked the 3-item screening questions of the ID Migraine test. Of 3682 patients, 917 (24.9%) were diagnosed as migraine, whereas 1171 (31.8%) were ID Migraine test positive. The sensitivity of the ID Migraine test for neurologist\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s diagnosis of migraine was 91.8%, specificity was 63.4%, positive predictive value was 71.9% and negative predictive value was 88.4%. The ID Migraine test is easy to use and a practical test that could alert the neurologist to diagnose patients having other complaints. This test would help to increase the diagnosis and treatment rate of undiagnosed migraine patients in NOCs.","owner":{"id":33025639,"first_name":"N.","middle_initials":null,"last_name":"Karli","page_name":"NKarli","domain_name":"independent","created_at":"2015-07-13T04:19:58.878-07:00","display_name":"N. Karli","url":"https://independent.academia.edu/NKarli"},"attachments":[],"research_interests":[{"id":623,"name":"Neurology","url":"https://www.academia.edu/Documents/in/Neurology"},{"id":8942,"name":"Treatment","url":"https://www.academia.edu/Documents/in/Treatment"},{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":144833,"name":"Validity","url":"https://www.academia.edu/Documents/in/Validity"},{"id":161176,"name":"The","url":"https://www.academia.edu/Documents/in/The"},{"id":254203,"name":"Ambulatory","url":"https://www.academia.edu/Documents/in/Ambulatory"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":289330,"name":"Prevalence","url":"https://www.academia.edu/Documents/in/Prevalence"},{"id":327850,"name":"Questionnaires","url":"https://www.academia.edu/Documents/in/Questionnaires"},{"id":401947,"name":"Sensitivity","url":"https://www.academia.edu/Documents/in/Sensitivity"},{"id":549280,"name":"Reproducibility of Results","url":"https://www.academia.edu/Documents/in/Reproducibility_of_Results"},{"id":901876,"name":"Sensitivity and Specificity","url":"https://www.academia.edu/Documents/in/Sensitivity_and_Specificity"},{"id":1318932,"name":"Predictive value of tests","url":"https://www.academia.edu/Documents/in/Predictive_value_of_tests"},{"id":1318938,"name":"Positive predictive value","url":"https://www.academia.edu/Documents/in/Positive_predictive_value"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-13983334-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233400"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14233400/Radiologically_Isolated_Syndrome_5_Year_Risk_for_an_Initial_Clinical_Event"><img alt="Research paper thumbnail of Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event</div><div class="wp-workCard_item"><span>PLoS ONE</span><span>, 2014</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">To report the 5-year risk and to identify risk factors for the development of a seminal acute or ...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">To report the 5-year risk and to identify risk factors for the development of a seminal acute or progressive clinical event in a multi-national cohort of asymptomatic subjects meeting 2009 RIS Criteria. Retrospectively identified RIS subjects from 22 databases within 5 countries were evaluated. Time to the first clinical event related to demyelination (acute or 12-month progression of neurological deficits) was compared across different groups by univariate and multivariate analyses utilizing a Cox regression model. Data were available in 451 RIS subjects (F: 354 (78.5%)). The mean age at from the time of the first brain MRI revealing anomalies suggestive of MS was 37.2 years (y) (median: 37.1 y, range: 11-74 y) with mean clinical follow-up time of 4.4 y (median: 2.8 y, range: 0.01-21.1 y). Clinical events were identified in 34% (standard error=3%) of individuals within a 5-year period from the first brain MRI study. Of those who developed symptoms, 9.6% fulfilled criteria for primary progressive MS. In the multivariate model, age [hazard ratio (HR): 0.98 (95% CI: 0.96-0.99); p=0.03], sex (male) [HR: 1.93 (1.24-2.99); p=0.004], and lesions within the cervical or thoracic spinal cord [HR: 3.08 (2.06-4.62); p=&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;0.001] were identified as significant predictors for the development of a first clinical event. These data provide supportive evidence that a meaningful number of RIS subjects evolve to a first clinical symptom. An age &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;37 y, male sex, and spinal cord involvement appear to be the most important independent predictors of symptom onset.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233400"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233400"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233400; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233400]").text(description); $(".js-view-count[data-work-id=14233400]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233400; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233400']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14233400]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233400,"title":"Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event","translated_title":"","metadata":{"abstract":"To report the 5-year risk and to identify risk factors for the development of a seminal acute or progressive clinical event in a multi-national cohort of asymptomatic subjects meeting 2009 RIS Criteria. Retrospectively identified RIS subjects from 22 databases within 5 countries were evaluated. Time to the first clinical event related to demyelination (acute or 12-month progression of neurological deficits) was compared across different groups by univariate and multivariate analyses utilizing a Cox regression model. Data were available in 451 RIS subjects (F: 354 (78.5%)). The mean age at from the time of the first brain MRI revealing anomalies suggestive of MS was 37.2 years (y) (median: 37.1 y, range: 11-74 y) with mean clinical follow-up time of 4.4 y (median: 2.8 y, range: 0.01-21.1 y). Clinical events were identified in 34% (standard error=3%) of individuals within a 5-year period from the first brain MRI study. Of those who developed symptoms, 9.6% fulfilled criteria for primary progressive MS. In the multivariate model, age [hazard ratio (HR): 0.98 (95% CI: 0.96-0.99); p=0.03], sex (male) [HR: 1.93 (1.24-2.99); p=0.004], and lesions within the cervical or thoracic spinal cord [HR: 3.08 (2.06-4.62); p=\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;0.001] were identified as significant predictors for the development of a first clinical event. These data provide supportive evidence that a meaningful number of RIS subjects evolve to a first clinical symptom. An age \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;37 y, male sex, and spinal cord involvement appear to be the most important independent predictors of symptom onset.","publication_date":{"day":null,"month":null,"year":2014,"errors":{}},"publication_name":"PLoS ONE"},"translated_abstract":"To report the 5-year risk and to identify risk factors for the development of a seminal acute or progressive clinical event in a multi-national cohort of asymptomatic subjects meeting 2009 RIS Criteria. Retrospectively identified RIS subjects from 22 databases within 5 countries were evaluated. Time to the first clinical event related to demyelination (acute or 12-month progression of neurological deficits) was compared across different groups by univariate and multivariate analyses utilizing a Cox regression model. Data were available in 451 RIS subjects (F: 354 (78.5%)). The mean age at from the time of the first brain MRI revealing anomalies suggestive of MS was 37.2 years (y) (median: 37.1 y, range: 11-74 y) with mean clinical follow-up time of 4.4 y (median: 2.8 y, range: 0.01-21.1 y). Clinical events were identified in 34% (standard error=3%) of individuals within a 5-year period from the first brain MRI study. Of those who developed symptoms, 9.6% fulfilled criteria for primary progressive MS. In the multivariate model, age [hazard ratio (HR): 0.98 (95% CI: 0.96-0.99); p=0.03], sex (male) [HR: 1.93 (1.24-2.99); p=0.004], and lesions within the cervical or thoracic spinal cord [HR: 3.08 (2.06-4.62); p=\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;0.001] were identified as significant predictors for the development of a first clinical event. These data provide supportive evidence that a meaningful number of RIS subjects evolve to a first clinical symptom. An age \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;37 y, male sex, and spinal cord involvement appear to be the most important independent predictors of symptom onset.","internal_url":"https://www.academia.edu/14233400/Radiologically_Isolated_Syndrome_5_Year_Risk_for_an_Initial_Clinical_Event","translated_internal_url":"","created_at":"2015-07-20T14:59:54.951-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Radiologically_Isolated_Syndrome_5_Year_Risk_for_an_Initial_Clinical_Event","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"To report the 5-year risk and to identify risk factors for the development of a seminal acute or progressive clinical event in a multi-national cohort of asymptomatic subjects meeting 2009 RIS Criteria. Retrospectively identified RIS subjects from 22 databases within 5 countries were evaluated. Time to the first clinical event related to demyelination (acute or 12-month progression of neurological deficits) was compared across different groups by univariate and multivariate analyses utilizing a Cox regression model. Data were available in 451 RIS subjects (F: 354 (78.5%)). The mean age at from the time of the first brain MRI revealing anomalies suggestive of MS was 37.2 years (y) (median: 37.1 y, range: 11-74 y) with mean clinical follow-up time of 4.4 y (median: 2.8 y, range: 0.01-21.1 y). Clinical events were identified in 34% (standard error=3%) of individuals within a 5-year period from the first brain MRI study. Of those who developed symptoms, 9.6% fulfilled criteria for primary progressive MS. In the multivariate model, age [hazard ratio (HR): 0.98 (95% CI: 0.96-0.99); p=0.03], sex (male) [HR: 1.93 (1.24-2.99); p=0.004], and lesions within the cervical or thoracic spinal cord [HR: 3.08 (2.06-4.62); p=\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;0.001] were identified as significant predictors for the development of a first clinical event. These data provide supportive evidence that a meaningful number of RIS subjects evolve to a first clinical symptom. An age \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;37 y, male sex, and spinal cord involvement appear to be the most important independent predictors of symptom onset.","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[],"research_interests":[{"id":3097,"name":"Multiple sclerosis","url":"https://www.academia.edu/Documents/in/Multiple_sclerosis"},{"id":6200,"name":"Magnetic Resonance Imaging","url":"https://www.academia.edu/Documents/in/Magnetic_Resonance_Imaging"},{"id":22506,"name":"Adolescent","url":"https://www.academia.edu/Documents/in/Adolescent"},{"id":28235,"name":"Multidisciplinary","url":"https://www.academia.edu/Documents/in/Multidisciplinary"},{"id":41482,"name":"Multivariate Analysis","url":"https://www.academia.edu/Documents/in/Multivariate_Analysis"},{"id":64933,"name":"Child","url":"https://www.academia.edu/Documents/in/Child"},{"id":99421,"name":"Spinal Cord","url":"https://www.academia.edu/Documents/in/Spinal_Cord"},{"id":111629,"name":"Incidental Findings","url":"https://www.academia.edu/Documents/in/Incidental_Findings"},{"id":133057,"name":"Young Adult","url":"https://www.academia.edu/Documents/in/Young_Adult"},{"id":192721,"name":"Risk factors","url":"https://www.academia.edu/Documents/in/Risk_factors"},{"id":220780,"name":"PLoS one","url":"https://www.academia.edu/Documents/in/PLoS_one"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":469105,"name":"Retrospective Studies","url":"https://www.academia.edu/Documents/in/Retrospective_Studies"},{"id":584615,"name":"Disease Progression","url":"https://www.academia.edu/Documents/in/Disease_Progression"},{"id":620049,"name":"Risk Factors","url":"https://www.academia.edu/Documents/in/Risk_Factors-1"},{"id":1272981,"name":"Proportional Hazards Models","url":"https://www.academia.edu/Documents/in/Proportional_Hazards_Models"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233400-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233399"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14233399/Clinical_characteristics_of_pediatric_onset_neuro_Behcet_disease"><img alt="Research paper thumbnail of Clinical characteristics of pediatric-onset neuro-Behcet disease" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Clinical characteristics of pediatric-onset neuro-Behcet disease</div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a>, and <a class="" data-click-track="profile-work-strip-authors" href="https://usih.academia.edu/HuriOzdogan">Huri Ozdogan</a></span></div><div class="wp-workCard_item"><span>Neurology</span><span>, 2011</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Neurologic involvement in the pediatric population with Behçet disease (BD) is limited to case re...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Neurologic involvement in the pediatric population with Behçet disease (BD) is limited to case reports. The aim of this study is to examine the frequency and type of neurologic involvement in pediatric patients with BD. Medical records of 728 patients with a diagnosis of neuro-BD (NBD) of 2 large BD cohorts followed in Istanbul University were included in the study. Patients with an onset of both systemic and neurologic symptoms at or before age 16 (pediatric neuro-BD) were identified. Demographic and clinical characteristics of pediatric patients with NBD were compared with adult patients with NBD. There were 26 cases with pediatric BD (3.6%) and 702 (96.4%) adult-onset patients. Gender ratio was equal in the general pediatric BD cohort, whereas male/female ratio was 5.5/1 in pediatric NBD cases. Mean age at BD onset and neurologic involvement onset were 13.0 ± 3.0 and 13.5 ± 2.4, respectively, and in the adult population mean age at onset of BD was 26.7 ± 8.0 and neurologic involvement occurred a mean of 5.3 ± 4.5 years later. Clinical and MRI evaluation revealed that 3 children had CNS parenchymal involvement and 23 had dural venous sinus thrombosis (88.5%). We observed parenchymal involvement in 74.8% of the adults, contrary to the low 17.2% of cases with venous sinus thrombosis. Pediatric NBD comprises 3.6% of our whole NBD cohort, with a male predominance, mainly in the form of dural venous sinus thrombosis, whereas in the adult NBD population the dominant form of neurologic involvement is parenchymal, suggesting that the pathogenesis of NBD may be different according to the age at disease onset.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233399"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233399"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233399; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233399]").text(description); $(".js-view-count[data-work-id=14233399]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233399; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233399']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14233399]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233399,"title":"Clinical characteristics of pediatric-onset neuro-Behcet disease","translated_title":"","metadata":{"abstract":"Neurologic involvement in the pediatric population with Behçet disease (BD) is limited to case reports. The aim of this study is to examine the frequency and type of neurologic involvement in pediatric patients with BD. Medical records of 728 patients with a diagnosis of neuro-BD (NBD) of 2 large BD cohorts followed in Istanbul University were included in the study. Patients with an onset of both systemic and neurologic symptoms at or before age 16 (pediatric neuro-BD) were identified. Demographic and clinical characteristics of pediatric patients with NBD were compared with adult patients with NBD. There were 26 cases with pediatric BD (3.6%) and 702 (96.4%) adult-onset patients. Gender ratio was equal in the general pediatric BD cohort, whereas male/female ratio was 5.5/1 in pediatric NBD cases. Mean age at BD onset and neurologic involvement onset were 13.0 ± 3.0 and 13.5 ± 2.4, respectively, and in the adult population mean age at onset of BD was 26.7 ± 8.0 and neurologic involvement occurred a mean of 5.3 ± 4.5 years later. Clinical and MRI evaluation revealed that 3 children had CNS parenchymal involvement and 23 had dural venous sinus thrombosis (88.5%). We observed parenchymal involvement in 74.8% of the adults, contrary to the low 17.2% of cases with venous sinus thrombosis. Pediatric NBD comprises 3.6% of our whole NBD cohort, with a male predominance, mainly in the form of dural venous sinus thrombosis, whereas in the adult NBD population the dominant form of neurologic involvement is parenchymal, suggesting that the pathogenesis of NBD may be different according to the age at disease onset.","publication_date":{"day":null,"month":null,"year":2011,"errors":{}},"publication_name":"Neurology"},"translated_abstract":"Neurologic involvement in the pediatric population with Behçet disease (BD) is limited to case reports. The aim of this study is to examine the frequency and type of neurologic involvement in pediatric patients with BD. Medical records of 728 patients with a diagnosis of neuro-BD (NBD) of 2 large BD cohorts followed in Istanbul University were included in the study. Patients with an onset of both systemic and neurologic symptoms at or before age 16 (pediatric neuro-BD) were identified. Demographic and clinical characteristics of pediatric patients with NBD were compared with adult patients with NBD. There were 26 cases with pediatric BD (3.6%) and 702 (96.4%) adult-onset patients. Gender ratio was equal in the general pediatric BD cohort, whereas male/female ratio was 5.5/1 in pediatric NBD cases. Mean age at BD onset and neurologic involvement onset were 13.0 ± 3.0 and 13.5 ± 2.4, respectively, and in the adult population mean age at onset of BD was 26.7 ± 8.0 and neurologic involvement occurred a mean of 5.3 ± 4.5 years later. Clinical and MRI evaluation revealed that 3 children had CNS parenchymal involvement and 23 had dural venous sinus thrombosis (88.5%). We observed parenchymal involvement in 74.8% of the adults, contrary to the low 17.2% of cases with venous sinus thrombosis. Pediatric NBD comprises 3.6% of our whole NBD cohort, with a male predominance, mainly in the form of dural venous sinus thrombosis, whereas in the adult NBD population the dominant form of neurologic involvement is parenchymal, suggesting that the pathogenesis of NBD may be different according to the age at disease onset.","internal_url":"https://www.academia.edu/14233399/Clinical_characteristics_of_pediatric_onset_neuro_Behcet_disease","translated_internal_url":"","created_at":"2015-07-20T14:59:54.848-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3517902,"work_id":14233399,"tagging_user_id":33207160,"tagged_user_id":33272291,"co_author_invite_id":765886,"email":"p***p@superonline.com","affiliation":"Istanbul University","display_order":0,"name":"Sabahattin Saip","title":"Clinical characteristics of pediatric-onset neuro-Behcet disease"},{"id":3517907,"work_id":14233399,"tagging_user_id":33207160,"tagged_user_id":33234624,"co_author_invite_id":846352,"email":"h***n@yahoo.com","affiliation":"University of Istanbul","display_order":4194304,"name":"Huri Ozdogan","title":"Clinical characteristics of pediatric-onset neuro-Behcet disease"},{"id":3517908,"work_id":14233399,"tagging_user_id":33207160,"tagged_user_id":null,"co_author_invite_id":262337,"email":"a***m@istanbul.edu.tr","display_order":6291456,"name":"G. Akman-demir","title":"Clinical characteristics of pediatric-onset neuro-Behcet disease"}],"downloadable_attachments":[],"slug":"Clinical_characteristics_of_pediatric_onset_neuro_Behcet_disease","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"Neurologic involvement in the pediatric population with Behçet disease (BD) is limited to case reports. The aim of this study is to examine the frequency and type of neurologic involvement in pediatric patients with BD. Medical records of 728 patients with a diagnosis of neuro-BD (NBD) of 2 large BD cohorts followed in Istanbul University were included in the study. Patients with an onset of both systemic and neurologic symptoms at or before age 16 (pediatric neuro-BD) were identified. Demographic and clinical characteristics of pediatric patients with NBD were compared with adult patients with NBD. There were 26 cases with pediatric BD (3.6%) and 702 (96.4%) adult-onset patients. Gender ratio was equal in the general pediatric BD cohort, whereas male/female ratio was 5.5/1 in pediatric NBD cases. Mean age at BD onset and neurologic involvement onset were 13.0 ± 3.0 and 13.5 ± 2.4, respectively, and in the adult population mean age at onset of BD was 26.7 ± 8.0 and neurologic involvement occurred a mean of 5.3 ± 4.5 years later. Clinical and MRI evaluation revealed that 3 children had CNS parenchymal involvement and 23 had dural venous sinus thrombosis (88.5%). We observed parenchymal involvement in 74.8% of the adults, contrary to the low 17.2% of cases with venous sinus thrombosis. Pediatric NBD comprises 3.6% of our whole NBD cohort, with a male predominance, mainly in the form of dural venous sinus thrombosis, whereas in the adult NBD population the dominant form of neurologic involvement is parenchymal, suggesting that the pathogenesis of NBD may be different according to the age at disease onset.","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[],"research_interests":[{"id":237,"name":"Cognitive Science","url":"https://www.academia.edu/Documents/in/Cognitive_Science"},{"id":623,"name":"Neurology","url":"https://www.academia.edu/Documents/in/Neurology"},{"id":631,"name":"Pediatrics","url":"https://www.academia.edu/Documents/in/Pediatrics"},{"id":6200,"name":"Magnetic Resonance Imaging","url":"https://www.academia.edu/Documents/in/Magnetic_Resonance_Imaging"},{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":22506,"name":"Adolescent","url":"https://www.academia.edu/Documents/in/Adolescent"},{"id":64933,"name":"Child","url":"https://www.academia.edu/Documents/in/Child"},{"id":133057,"name":"Young Adult","url":"https://www.academia.edu/Documents/in/Young_Adult"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":469105,"name":"Retrospective Studies","url":"https://www.academia.edu/Documents/in/Retrospective_Studies"},{"id":1239755,"name":"Neurosciences","url":"https://www.academia.edu/Documents/in/Neurosciences"},{"id":1423078,"name":"Nervous System Diseases","url":"https://www.academia.edu/Documents/in/Nervous_System_Diseases"},{"id":1489115,"name":"Age of Onset","url":"https://www.academia.edu/Documents/in/Age_of_Onset"},{"id":1819400,"name":"Cohort Studies","url":"https://www.academia.edu/Documents/in/Cohort_Studies"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233399-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233398"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14233398/Validity_of_the_ID_Migraine_screener_in_the_workplace"><img alt="Research paper thumbnail of Validity of the ID-Migraine screener in the workplace" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Validity of the ID-Migraine screener in the workplace</div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a> and <a class="" data-click-track="profile-work-strip-authors" href="https://uludag.academia.edu/MZarifo%C4%9Flu">M. Zarifoğlu</a></span></div><div class="wp-workCard_item"><span>Neurology</span><span>, 2008</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">The impact of migraine on physical, social, and emotional performance is considerable, yet it rem...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">The impact of migraine on physical, social, and emotional performance is considerable, yet it remains an underdiagnosed disorder. ID-Migraine is a validated migraine-screening tool developed to facilitate diagnosis. This study evaluated the validity and use of the Turkish version of the ID-Migraine screener (ID-Ms) in the workplace, and measured the impact of headache on disability, productivity, and quality of life among the workforce. A total of 465 employees from four companies were interviewed for screening with the ID-Ms. Subjects were included in the study if they reported two or more headaches in the past 3 months and gave a positive answer to one of the two ID-Ms prescreening questions. Eligible subjects completed the ID-Ms, the Migraine Disability Assessment Questionnaire, and the Medical Outcomes Study 36-Item Short Form Health Survey. Subjects were then evaluated for confirmation of their diagnosis according to the International Classification of Headache Disorders, 2nd edition (ICHD-2) criteria. A total of 227 subjects (mean age 31.9 +/- 5.9 years; 65.6% women) completed the study. Migraine was diagnosed in 106 of the 227 subjects (46.7%) according to the ID-Ms and in 117 of the 227 subjects (51.5%) according to ICHD-2 criteria. The sensitivity of the ID-Ms was 70.9%, specificity was 79.1% and Cohen kappa value was 0.50. Workdays lost over the previous 3 months due to headache amounted to 8.7 +/- 9.5 days for migraine-positive and 4.9 +/- 6.6 days for migraine-negative subjects. The Turkish version of the ID-Migraine screener is a valid tool for identifying subjects with migraine in the workplace.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233398"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233398"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233398; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233398]").text(description); $(".js-view-count[data-work-id=14233398]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233398; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233398']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14233398]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233398,"title":"Validity of the ID-Migraine screener in the workplace","translated_title":"","metadata":{"abstract":"The impact of migraine on physical, social, and emotional performance is considerable, yet it remains an underdiagnosed disorder. ID-Migraine is a validated migraine-screening tool developed to facilitate diagnosis. This study evaluated the validity and use of the Turkish version of the ID-Migraine screener (ID-Ms) in the workplace, and measured the impact of headache on disability, productivity, and quality of life among the workforce. A total of 465 employees from four companies were interviewed for screening with the ID-Ms. Subjects were included in the study if they reported two or more headaches in the past 3 months and gave a positive answer to one of the two ID-Ms prescreening questions. Eligible subjects completed the ID-Ms, the Migraine Disability Assessment Questionnaire, and the Medical Outcomes Study 36-Item Short Form Health Survey. Subjects were then evaluated for confirmation of their diagnosis according to the International Classification of Headache Disorders, 2nd edition (ICHD-2) criteria. A total of 227 subjects (mean age 31.9 +/- 5.9 years; 65.6% women) completed the study. Migraine was diagnosed in 106 of the 227 subjects (46.7%) according to the ID-Ms and in 117 of the 227 subjects (51.5%) according to ICHD-2 criteria. The sensitivity of the ID-Ms was 70.9%, specificity was 79.1% and Cohen kappa value was 0.50. Workdays lost over the previous 3 months due to headache amounted to 8.7 +/- 9.5 days for migraine-positive and 4.9 +/- 6.6 days for migraine-negative subjects. The Turkish version of the ID-Migraine screener is a valid tool for identifying subjects with migraine in the workplace.","publication_date":{"day":null,"month":null,"year":2008,"errors":{}},"publication_name":"Neurology"},"translated_abstract":"The impact of migraine on physical, social, and emotional performance is considerable, yet it remains an underdiagnosed disorder. ID-Migraine is a validated migraine-screening tool developed to facilitate diagnosis. This study evaluated the validity and use of the Turkish version of the ID-Migraine screener (ID-Ms) in the workplace, and measured the impact of headache on disability, productivity, and quality of life among the workforce. A total of 465 employees from four companies were interviewed for screening with the ID-Ms. Subjects were included in the study if they reported two or more headaches in the past 3 months and gave a positive answer to one of the two ID-Ms prescreening questions. Eligible subjects completed the ID-Ms, the Migraine Disability Assessment Questionnaire, and the Medical Outcomes Study 36-Item Short Form Health Survey. Subjects were then evaluated for confirmation of their diagnosis according to the International Classification of Headache Disorders, 2nd edition (ICHD-2) criteria. A total of 227 subjects (mean age 31.9 +/- 5.9 years; 65.6% women) completed the study. Migraine was diagnosed in 106 of the 227 subjects (46.7%) according to the ID-Ms and in 117 of the 227 subjects (51.5%) according to ICHD-2 criteria. The sensitivity of the ID-Ms was 70.9%, specificity was 79.1% and Cohen kappa value was 0.50. Workdays lost over the previous 3 months due to headache amounted to 8.7 +/- 9.5 days for migraine-positive and 4.9 +/- 6.6 days for migraine-negative subjects. The Turkish version of the ID-Migraine screener is a valid tool for identifying subjects with migraine in the workplace.","internal_url":"https://www.academia.edu/14233398/Validity_of_the_ID_Migraine_screener_in_the_workplace","translated_internal_url":"","created_at":"2015-07-20T14:59:54.709-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3517879,"work_id":14233398,"tagging_user_id":33207160,"tagged_user_id":33025639,"co_author_invite_id":null,"email":"n***i@uludag.edu.tr","display_order":0,"name":"N. Karli","title":"Validity of the ID-Migraine screener in the workplace"},{"id":3517880,"work_id":14233398,"tagging_user_id":33207160,"tagged_user_id":33021815,"co_author_invite_id":null,"email":"m***f@uludag.edu.tr","affiliation":"Uludag University","display_order":4194304,"name":"M. Zarifoğlu","title":"Validity of the ID-Migraine screener in the workplace"},{"id":3517900,"work_id":14233398,"tagging_user_id":33207160,"tagged_user_id":33138161,"co_author_invite_id":null,"email":"d***s@gmail.com","affiliation":"Istanbul University","display_order":6291456,"name":"Mustafa ERTAŞ","title":"Validity of the ID-Migraine screener in the workplace"},{"id":3517901,"work_id":14233398,"tagging_user_id":33207160,"tagged_user_id":null,"co_author_invite_id":287979,"email":"b***n@yahoo.com","display_order":7340032,"name":"Betül Baykan","title":"Validity of the ID-Migraine screener in the workplace"},{"id":3517903,"work_id":14233398,"tagging_user_id":33207160,"tagged_user_id":33272291,"co_author_invite_id":765886,"email":"p***p@superonline.com","affiliation":"Istanbul University","display_order":7864320,"name":"Sabahattin Saip","title":"Validity of the ID-Migraine screener in the workplace"}],"downloadable_attachments":[],"slug":"Validity_of_the_ID_Migraine_screener_in_the_workplace","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"The impact of migraine on physical, social, and emotional performance is considerable, yet it remains an underdiagnosed disorder. ID-Migraine is a validated migraine-screening tool developed to facilitate diagnosis. This study evaluated the validity and use of the Turkish version of the ID-Migraine screener (ID-Ms) in the workplace, and measured the impact of headache on disability, productivity, and quality of life among the workforce. A total of 465 employees from four companies were interviewed for screening with the ID-Ms. Subjects were included in the study if they reported two or more headaches in the past 3 months and gave a positive answer to one of the two ID-Ms prescreening questions. Eligible subjects completed the ID-Ms, the Migraine Disability Assessment Questionnaire, and the Medical Outcomes Study 36-Item Short Form Health Survey. Subjects were then evaluated for confirmation of their diagnosis according to the International Classification of Headache Disorders, 2nd edition (ICHD-2) criteria. A total of 227 subjects (mean age 31.9 +/- 5.9 years; 65.6% women) completed the study. Migraine was diagnosed in 106 of the 227 subjects (46.7%) according to the ID-Ms and in 117 of the 227 subjects (51.5%) according to ICHD-2 criteria. The sensitivity of the ID-Ms was 70.9%, specificity was 79.1% and Cohen kappa value was 0.50. Workdays lost over the previous 3 months due to headache amounted to 8.7 +/- 9.5 days for migraine-positive and 4.9 +/- 6.6 days for migraine-negative subjects. The Turkish version of the ID-Migraine screener is a valid tool for identifying subjects with migraine in the workplace.","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[],"research_interests":[{"id":237,"name":"Cognitive Science","url":"https://www.academia.edu/Documents/in/Cognitive_Science"},{"id":623,"name":"Neurology","url":"https://www.academia.edu/Documents/in/Neurology"},{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":22506,"name":"Adolescent","url":"https://www.academia.edu/Documents/in/Adolescent"},{"id":56122,"name":"Workplace","url":"https://www.academia.edu/Documents/in/Workplace"},{"id":85280,"name":"Industry","url":"https://www.academia.edu/Documents/in/Industry"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":557260,"name":"Health surveys","url":"https://www.academia.edu/Documents/in/Health_surveys"},{"id":1239755,"name":"Neurosciences","url":"https://www.academia.edu/Documents/in/Neurosciences"},{"id":1262481,"name":"Pain Measurement","url":"https://www.academia.edu/Documents/in/Pain_Measurement"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233398-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="13976532"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/13976532/Economic_impact_of_primary_headaches_in_Turkey_a_university_hospital_based_study_part_II"><img alt="Research paper thumbnail of Economic impact of primary headaches in Turkey: a university hospital based study: part II" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Economic impact of primary headaches in Turkey: a university hospital based study: part II</div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://uludag.academia.edu/MZarifo%C4%9Flu">M. Zarifoğlu</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://deu.academia.edu/VesileOzt%C3%BCrk">Vesile Oztürk</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/SebnemBi%C3%A7ak%C3%A7i">Sebnem Biçakçi</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/CavitBoz">Cavit Boz</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a>, and <a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/NebahatTa%C5%9Fdemir">Nebahat Taşdemir</a></span></div><div class="wp-workCard_item"><span>The journal of headache and pain</span><span>, 2006</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">This study was planned to investigate the economic impact of headache on Turkish headache suffere...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">This study was planned to investigate the economic impact of headache on Turkish headache sufferers attending a tertiary care outpatient headache clinic.A total of 937 headache patients were included in this study and questioned using a questionnaire for the profile of patients and headache, quality of life of patients and economic impact of headache. The median total direct cost was found to be 88.0 USD and the median total cost was 160.7 USD. The drug treatment cost was the highest item followed by the specialist outpatient care cost. The average lost and inefficient work/school days was 1.5 (0-45) and 8.4 (0-100) days for one year. It was shown that loss of productivity was higher for migraine without aura group when compared with the episodic and chronic tension-type headache groups. The results of this nationwide university hospital based study methshowed that headache, especially migraine, has considerable economic impact on patients.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="13976532"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="13976532"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 13976532; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=13976532]").text(description); $(".js-view-count[data-work-id=13976532]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 13976532; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='13976532']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=13976532]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":13976532,"title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II","translated_title":"","metadata":{"abstract":"This study was planned to investigate the economic impact of headache on Turkish headache sufferers attending a tertiary care outpatient headache clinic.A total of 937 headache patients were included in this study and questioned using a questionnaire for the profile of patients and headache, quality of life of patients and economic impact of headache. The median total direct cost was found to be 88.0 USD and the median total cost was 160.7 USD. The drug treatment cost was the highest item followed by the specialist outpatient care cost. The average lost and inefficient work/school days was 1.5 (0-45) and 8.4 (0-100) days for one year. It was shown that loss of productivity was higher for migraine without aura group when compared with the episodic and chronic tension-type headache groups. The results of this nationwide university hospital based study methshowed that headache, especially migraine, has considerable economic impact on patients.","publisher":"ncbi.nlm.nih.gov","publication_date":{"day":null,"month":null,"year":2006,"errors":{}},"publication_name":"The journal of headache and pain"},"translated_abstract":"This study was planned to investigate the economic impact of headache on Turkish headache sufferers attending a tertiary care outpatient headache clinic.A total of 937 headache patients were included in this study and questioned using a questionnaire for the profile of patients and headache, quality of life of patients and economic impact of headache. The median total direct cost was found to be 88.0 USD and the median total cost was 160.7 USD. The drug treatment cost was the highest item followed by the specialist outpatient care cost. The average lost and inefficient work/school days was 1.5 (0-45) and 8.4 (0-100) days for one year. It was shown that loss of productivity was higher for migraine without aura group when compared with the episodic and chronic tension-type headache groups. The results of this nationwide university hospital based study methshowed that headache, especially migraine, has considerable economic impact on patients.","internal_url":"https://www.academia.edu/13976532/Economic_impact_of_primary_headaches_in_Turkey_a_university_hospital_based_study_part_II","translated_internal_url":"","created_at":"2015-07-13T01:27:16.094-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33021815,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3004204,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":null,"co_author_invite_id":765882,"email":"n***r@deu.edu.tr","display_order":0,"name":"N. Uzuner","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004205,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":null,"co_author_invite_id":765883,"email":"n***i@yahoo.com","display_order":4194304,"name":"Necdet Karli","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004214,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":33272291,"co_author_invite_id":765886,"email":"p***p@superonline.com","affiliation":"Istanbul University","display_order":6291456,"name":"Sabahattin Saip","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004215,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":33245428,"co_author_invite_id":765887,"email":"v***k@deu.edu.tr","affiliation":"Dokuz Eylül University","display_order":7340032,"name":"Vesile Oztürk","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004216,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":33105926,"co_author_invite_id":765888,"email":"s***b@mail.cu.edu.tr","display_order":7864320,"name":"Sebnem Biçakçi","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004217,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":43415196,"co_author_invite_id":556570,"email":"c***b@yahoo.com","display_order":8126464,"name":"Cavit Boz","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004218,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":null,"co_author_invite_id":765889,"email":"d***i@hotmail.com","display_order":8257536,"name":"Denit Selçuki","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004219,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":null,"co_author_invite_id":765890,"email":"a***o@iname.com","display_order":8323072,"name":"Atilla Oğuzhanoğlu","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004220,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":null,"co_author_invite_id":758554,"email":"n***l@superonline.com","display_order":8355840,"name":"Münife Neyal","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004221,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":33207160,"co_author_invite_id":765891,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":8372224,"name":"Aksel Siva","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004222,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":null,"co_author_invite_id":765892,"email":"c***c@yahoo.com","display_order":8380416,"name":"Ceyla Irkeç","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004223,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":978293,"co_author_invite_id":null,"email":"t***u@hacettepe.edu.tr","affiliation":"Hacettepe University","display_order":8384512,"name":"Tulay Kansu","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004224,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":null,"co_author_invite_id":765893,"email":"y***a@e-kolay.net","display_order":8386560,"name":"Yakup Sarica","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004225,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":33755151,"co_author_invite_id":765894,"email":"n***t@dicle.edu.tr","display_order":8387584,"name":"Nebahat Taşdemir","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004226,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":null,"co_author_invite_id":765895,"email":"s***b@cu.edu.tr","display_order":8388096,"name":"Ş. Bıçakçı","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004227,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":33138161,"co_author_invite_id":699618,"email":"d***s@gmail.com","affiliation":"Istanbul University","display_order":8388352,"name":"Mustafa ERTAŞ","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"}],"downloadable_attachments":[],"slug":"Economic_impact_of_primary_headaches_in_Turkey_a_university_hospital_based_study_part_II","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"This study was planned to investigate the economic impact of headache on Turkish headache sufferers attending a tertiary care outpatient headache clinic.A total of 937 headache patients were included in this study and questioned using a questionnaire for the profile of patients and headache, quality of life of patients and economic impact of headache. The median total direct cost was found to be 88.0 USD and the median total cost was 160.7 USD. The drug treatment cost was the highest item followed by the specialist outpatient care cost. The average lost and inefficient work/school days was 1.5 (0-45) and 8.4 (0-100) days for one year. It was shown that loss of productivity was higher for migraine without aura group when compared with the episodic and chronic tension-type headache groups. The results of this nationwide university hospital based study methshowed that headache, especially migraine, has considerable economic impact on patients.","owner":{"id":33021815,"first_name":"M.","middle_initials":null,"last_name":"Zarifoğlu","page_name":"MZarifoğlu","domain_name":"uludag","created_at":"2015-07-13T01:26:36.416-07:00","display_name":"M. Zarifoğlu","url":"https://uludag.academia.edu/MZarifo%C4%9Flu"},"attachments":[],"research_interests":[{"id":7470,"name":"Quality of life","url":"https://www.academia.edu/Documents/in/Quality_of_life"},{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":22506,"name":"Adolescent","url":"https://www.academia.edu/Documents/in/Adolescent"},{"id":66744,"name":"Biomedical Research","url":"https://www.academia.edu/Documents/in/Biomedical_Research"},{"id":149214,"name":"Economic Impact","url":"https://www.academia.edu/Documents/in/Economic_Impact"},{"id":161176,"name":"The","url":"https://www.academia.edu/Documents/in/The"},{"id":612548,"name":"Tension-Type Headache","url":"https://www.academia.edu/Documents/in/Tension-Type_Headache"},{"id":886573,"name":"Cost of Illness","url":"https://www.academia.edu/Documents/in/Cost_of_Illness"},{"id":1034181,"name":"Cross Sectional Studies","url":"https://www.academia.edu/Documents/in/Cross_Sectional_Studies"},{"id":1592916,"name":"Drug treatment","url":"https://www.academia.edu/Documents/in/Drug_treatment"}],"urls":[{"id":4967877,"url":"http://dx.doi.org/10.1007/s10194-006-0273-7"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-13976532-figures'); } }); </script> </div><div class="profile--tab_content_container js-tab-pane tab-pane" data-section-id="3252814" id="papers"><div class="js-work-strip profile--work_container" data-work-id="14318109"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/14318109/The_Burden_of_Headache_in_Neurology_Outpatient_Clinics_in_Turkey"><img alt="Research paper thumbnail of The Burden of Headache in Neurology Outpatient Clinics in Turkey" class="work-thumbnail" src="https://attachments.academia-assets.com/44325654/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/14318109/The_Burden_of_Headache_in_Neurology_Outpatient_Clinics_in_Turkey">The Burden of Headache in Neurology Outpatient Clinics in Turkey</a></div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a> and <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a></span></div><div class="wp-workCard_item"><span>Pain Practice</span><span>, 2007</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Background and Aim: The aim of the study was to investigate the burden of headache in neurology o...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Background and Aim: The aim of the study was to investigate the burden of headache in neurology outpatient clinics (NOCs) regardless of their primary complaint. Methods: Patients presenting for their routine appointments in 41 NOCs were screened during the course of 1 week. All eligible subjects (n = 3682; 61.9% female, mean age 45.2 1 16.5 years) were evaluated by a neurologist for the headache diagnosis and some demographic characteristics. Results: Of all patients, 66.4% reported headache, and in 35.1% headache was the primary cause for admitting to the NOC. Of 3682 patients, 917 (24.9%) were diagnosed as migraine according to International Headache Society (IHS) criteria. Thirty-three and nine-tenths percent of all patients admitted and 56% of the migraineurs according to IHS had severe headaches. As the headache severity increases, the ratio of the patients admitted with headache as the primary complaint increases significantly. The distribution of burden and other characteristics of headache did not differ in seven geographic regions and 41 different centers. Conclusion: Headache complaint caused at least 1/3 of all neurological outpatient visits in Turkey and 2/3 of all patients admitted to NOC had headache. Of these patients, 1/4 had migraine according to IHS with substantial disability and severity level.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="ab801f2cc27d11e159f77045c7065a16" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":44325654,"asset_id":14318109,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/44325654/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14318109"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14318109"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14318109; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14318109]").text(description); $(".js-view-count[data-work-id=14318109]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14318109; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14318109']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "ab801f2cc27d11e159f77045c7065a16" } } $('.js-work-strip[data-work-id=14318109]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14318109,"title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey","translated_title":"","metadata":{"grobid_abstract":"Background and Aim: The aim of the study was to investigate the burden of headache in neurology outpatient clinics (NOCs) regardless of their primary complaint. Methods: Patients presenting for their routine appointments in 41 NOCs were screened during the course of 1 week. All eligible subjects (n = 3682; 61.9% female, mean age 45.2 1 16.5 years) were evaluated by a neurologist for the headache diagnosis and some demographic characteristics. Results: Of all patients, 66.4% reported headache, and in 35.1% headache was the primary cause for admitting to the NOC. Of 3682 patients, 917 (24.9%) were diagnosed as migraine according to International Headache Society (IHS) criteria. Thirty-three and nine-tenths percent of all patients admitted and 56% of the migraineurs according to IHS had severe headaches. As the headache severity increases, the ratio of the patients admitted with headache as the primary complaint increases significantly. The distribution of burden and other characteristics of headache did not differ in seven geographic regions and 41 different centers. Conclusion: Headache complaint caused at least 1/3 of all neurological outpatient visits in Turkey and 2/3 of all patients admitted to NOC had headache. Of these patients, 1/4 had migraine according to IHS with substantial disability and severity level.","publication_date":{"day":null,"month":null,"year":2007,"errors":{}},"publication_name":"Pain Practice","grobid_abstract_attachment_id":44325654},"translated_abstract":null,"internal_url":"https://www.academia.edu/14318109/The_Burden_of_Headache_in_Neurology_Outpatient_Clinics_in_Turkey","translated_internal_url":"","created_at":"2015-07-22T22:34:46.526-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33272291,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3691329,"work_id":14318109,"tagging_user_id":33272291,"tagged_user_id":33021815,"co_author_invite_id":null,"email":"m***f@uludag.edu.tr","affiliation":"Uludag University","display_order":0,"name":"M. Zarifoğlu","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"},{"id":3691335,"work_id":14318109,"tagging_user_id":33272291,"tagged_user_id":33025639,"co_author_invite_id":null,"email":"n***i@uludag.edu.tr","display_order":4194304,"name":"N. Karli","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"},{"id":3691339,"work_id":14318109,"tagging_user_id":33272291,"tagged_user_id":33207160,"co_author_invite_id":null,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":6291456,"name":"Aksel Siva","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"},{"id":3691346,"work_id":14318109,"tagging_user_id":33272291,"tagged_user_id":41556982,"co_author_invite_id":721598,"email":"m***s@superonline.com","display_order":7340032,"name":"M. Ertas","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"},{"id":3691362,"work_id":14318109,"tagging_user_id":33272291,"tagged_user_id":null,"co_author_invite_id":287979,"email":"b***n@yahoo.com","display_order":7864320,"name":"Betul Baykan","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"}],"downloadable_attachments":[{"id":44325654,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325654/thumbnails/1.jpg","file_name":"j.1533-2500.2007.00154.x.pdf20160402-21810-y49bgo","download_url":"https://www.academia.edu/attachments/44325654/download_file","bulk_download_file_name":"The_Burden_of_Headache_in_Neurology_Outp.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325654/j.1533-2500.2007.00154.x-libre.pdf20160402-21810-y49bgo?1459602633=\u0026response-content-disposition=attachment%3B+filename%3DThe_Burden_of_Headache_in_Neurology_Outp.pdf\u0026Expires=1743574093\u0026Signature=BtZih55UnM87tvU5MLnBgPDI7XIB6dR47ecMvKjF3l6CA1ooiAcWe8NBkrL6I2E~G9~SAcXMdk5McrwTne-oLcOJiZFYF-YvCOFUlMBphwvfY4SCF3dYksqI3SUha3WwxJQGJFA4stgeO~E1uoLtSag0jk6ltbgNbsTzMRFwErMDlfBoAQunQ88iI9CirDuxeetG326K8r~znYcMiRKSUh2P5~-ZBfL58DEfEr4QOJC148lE6Bh6q6xOPuD5ZqbOTjHFu4kpjUlviGSbAOkEYXxnD-5aZqh6Zybpr6W6HJFzMBJxt1l5EvnX7dgxJWIPu9T4kS~QHhPydo5VOqJRyQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"The_Burden_of_Headache_in_Neurology_Outpatient_Clinics_in_Turkey","translated_slug":"","page_count":11,"language":"en","content_type":"Work","summary":"Background and Aim: The aim of the study was to investigate the burden of headache in neurology outpatient clinics (NOCs) regardless of their primary complaint. Methods: Patients presenting for their routine appointments in 41 NOCs were screened during the course of 1 week. All eligible subjects (n = 3682; 61.9% female, mean age 45.2 1 16.5 years) were evaluated by a neurologist for the headache diagnosis and some demographic characteristics. Results: Of all patients, 66.4% reported headache, and in 35.1% headache was the primary cause for admitting to the NOC. Of 3682 patients, 917 (24.9%) were diagnosed as migraine according to International Headache Society (IHS) criteria. Thirty-three and nine-tenths percent of all patients admitted and 56% of the migraineurs according to IHS had severe headaches. As the headache severity increases, the ratio of the patients admitted with headache as the primary complaint increases significantly. The distribution of burden and other characteristics of headache did not differ in seven geographic regions and 41 different centers. Conclusion: Headache complaint caused at least 1/3 of all neurological outpatient visits in Turkey and 2/3 of all patients admitted to NOC had headache. Of these patients, 1/4 had migraine according to IHS with substantial disability and severity level.","owner":{"id":33272291,"first_name":"Sabahattin","middle_initials":null,"last_name":"Saip","page_name":"SabahattinSaip","domain_name":"istanbul","created_at":"2015-07-22T22:34:11.561-07:00","display_name":"Sabahattin Saip","url":"https://istanbul.academia.edu/SabahattinSaip"},"attachments":[{"id":44325654,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325654/thumbnails/1.jpg","file_name":"j.1533-2500.2007.00154.x.pdf20160402-21810-y49bgo","download_url":"https://www.academia.edu/attachments/44325654/download_file","bulk_download_file_name":"The_Burden_of_Headache_in_Neurology_Outp.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325654/j.1533-2500.2007.00154.x-libre.pdf20160402-21810-y49bgo?1459602633=\u0026response-content-disposition=attachment%3B+filename%3DThe_Burden_of_Headache_in_Neurology_Outp.pdf\u0026Expires=1743574093\u0026Signature=BtZih55UnM87tvU5MLnBgPDI7XIB6dR47ecMvKjF3l6CA1ooiAcWe8NBkrL6I2E~G9~SAcXMdk5McrwTne-oLcOJiZFYF-YvCOFUlMBphwvfY4SCF3dYksqI3SUha3WwxJQGJFA4stgeO~E1uoLtSag0jk6ltbgNbsTzMRFwErMDlfBoAQunQ88iI9CirDuxeetG326K8r~znYcMiRKSUh2P5~-ZBfL58DEfEr4QOJC148lE6Bh6q6xOPuD5ZqbOTjHFu4kpjUlviGSbAOkEYXxnD-5aZqh6Zybpr6W6HJFzMBJxt1l5EvnX7dgxJWIPu9T4kS~QHhPydo5VOqJRyQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":623,"name":"Neurology","url":"https://www.academia.edu/Documents/in/Neurology"},{"id":2898,"name":"Pain","url":"https://www.academia.edu/Documents/in/Pain"},{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":289330,"name":"Prevalence","url":"https://www.academia.edu/Documents/in/Prevalence"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14318109-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14318112"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/14318112/One_year_prevalence_and_the_impact_of_migraine_and_tension_type_headache_in_Turkey_a_nationwide_home_based_study_in_adults"><img alt="Research paper thumbnail of One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults" class="work-thumbnail" src="https://attachments.academia-assets.com/44325642/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/14318112/One_year_prevalence_and_the_impact_of_migraine_and_tension_type_headache_in_Turkey_a_nationwide_home_based_study_in_adults">One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults</a></div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a>, and <a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/MErtas1">M. Ertas</a></span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Several studies have shown that the prevalence of migraine and tension-type headache (TTH) varied...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Several studies have shown that the prevalence of migraine and tension-type headache (TTH) varied between different geographical regions. Therefore, there is a need of a nationwide prevalence study for headache in our country, located between Asia and Europe. This nationwide study was designed to estimate the 1-year prevalence of migraine and TTH and analyse the clinical features, the impact as well as the demographic and socio-economic characteristics of the participant households in Turkey. We planned to investigate 6,000 representative households in 21 cities of Turkey; and a total of 5,323 households (response rate of 89%) aged between 18 and 65 years were examined for headache by 33 trained physicians at home on the basis of the diagnostic criteria of the second edition of the International Classification of Headache Disorders (ICHD-II). The electronically registered questionnaire was based on the headache features, the associated symptoms, demographic and socio-economic situation and history. Of 5,323 participants (48.8% women; mean age 35.9 ± 12 years) 44.6% reported recurrent headaches during the last 1 year and 871 were diagnosed with migraine at a prevalence rate of 16.4% (8.5% in men and 24.6% in women), whereas only 270 were diagnosed with TTH at a prevalence rate of 5.1% (5.7% in men and 4.5% in women). The 1-year prevalence of probable migraine was 12.4% and probable TTH was 9.5% additionally. The rate of migraine with aura among migraineurs was 21.5%. The prevalence of migraine was highest among 35-40-year-old women while there were no differences in age groups among men and in TTH overall. More than 2/3 of migraineurs had ever consulted a physician whereas only 1/3 of patients with TTH had ever consulted a physician. For women, the migraine prevalence was higher among the ones with a lower income, while among men, it did not show any change by income. Migraine prevalence was lower in those with a lower educational status compared to those with a high educational status. Chronic daily headache was present in 3.3% and the prevalence of medication overuse headache was 2.1% in our population. There was an important impact of migraine with a monthly frequency of 5.9 ± 6, and an attack duration of 35.1 ± 72 h, but only 4.9% were on prophylactic treatment. The one-year prevalence of migraine estimated as 16.4% was similar or even higher than worldwide reported migraine prevalence figures and identical to a previous nation-wide study conducted in 1998, whereas the TTH prevalence was much lower using the same methodology with the ICHD-II criteria.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="b090f7e14a537844f0f08b9c8606b49d" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":44325642,"asset_id":14318112,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/44325642/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14318112"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14318112"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14318112; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14318112]").text(description); $(".js-view-count[data-work-id=14318112]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14318112; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14318112']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "b090f7e14a537844f0f08b9c8606b49d" } } $('.js-work-strip[data-work-id=14318112]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14318112,"title":"One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults","translated_title":"","metadata":{"ai_title_tag":"Migraine and TTH Prevalence in Turkey","grobid_abstract":"Several studies have shown that the prevalence of migraine and tension-type headache (TTH) varied between different geographical regions. Therefore, there is a need of a nationwide prevalence study for headache in our country, located between Asia and Europe. This nationwide study was designed to estimate the 1-year prevalence of migraine and TTH and analyse the clinical features, the impact as well as the demographic and socio-economic characteristics of the participant households in Turkey. We planned to investigate 6,000 representative households in 21 cities of Turkey; and a total of 5,323 households (response rate of 89%) aged between 18 and 65 years were examined for headache by 33 trained physicians at home on the basis of the diagnostic criteria of the second edition of the International Classification of Headache Disorders (ICHD-II). The electronically registered questionnaire was based on the headache features, the associated symptoms, demographic and socio-economic situation and history. Of 5,323 participants (48.8% women; mean age 35.9 ± 12 years) 44.6% reported recurrent headaches during the last 1 year and 871 were diagnosed with migraine at a prevalence rate of 16.4% (8.5% in men and 24.6% in women), whereas only 270 were diagnosed with TTH at a prevalence rate of 5.1% (5.7% in men and 4.5% in women). The 1-year prevalence of probable migraine was 12.4% and probable TTH was 9.5% additionally. The rate of migraine with aura among migraineurs was 21.5%. The prevalence of migraine was highest among 35-40-year-old women while there were no differences in age groups among men and in TTH overall. More than 2/3 of migraineurs had ever consulted a physician whereas only 1/3 of patients with TTH had ever consulted a physician. For women, the migraine prevalence was higher among the ones with a lower income, while among men, it did not show any change by income. Migraine prevalence was lower in those with a lower educational status compared to those with a high educational status. Chronic daily headache was present in 3.3% and the prevalence of medication overuse headache was 2.1% in our population. There was an important impact of migraine with a monthly frequency of 5.9 ± 6, and an attack duration of 35.1 ± 72 h, but only 4.9% were on prophylactic treatment. The one-year prevalence of migraine estimated as 16.4% was similar or even higher than worldwide reported migraine prevalence figures and identical to a previous nation-wide study conducted in 1998, whereas the TTH prevalence was much lower using the same methodology with the ICHD-II criteria.","publication_date":{"day":1,"month":3,"year":2012,"errors":{}},"grobid_abstract_attachment_id":44325642},"translated_abstract":null,"internal_url":"https://www.academia.edu/14318112/One_year_prevalence_and_the_impact_of_migraine_and_tension_type_headache_in_Turkey_a_nationwide_home_based_study_in_adults","translated_internal_url":"","created_at":"2015-07-22T22:34:46.835-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33272291,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3691331,"work_id":14318112,"tagging_user_id":33272291,"tagged_user_id":33021815,"co_author_invite_id":null,"email":"m***f@uludag.edu.tr","affiliation":"Uludag University","display_order":0,"name":"M. Zarifoğlu","title":"One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults"},{"id":3691337,"work_id":14318112,"tagging_user_id":33272291,"tagged_user_id":33025639,"co_author_invite_id":null,"email":"n***i@uludag.edu.tr","display_order":4194304,"name":"N. Karli","title":"One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults"},{"id":3691345,"work_id":14318112,"tagging_user_id":33272291,"tagged_user_id":33207160,"co_author_invite_id":null,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":6291456,"name":"Aksel Siva","title":"One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults"},{"id":3691348,"work_id":14318112,"tagging_user_id":33272291,"tagged_user_id":41556982,"co_author_invite_id":721598,"email":"m***s@superonline.com","display_order":7340032,"name":"M. Ertas","title":"One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults"},{"id":3691364,"work_id":14318112,"tagging_user_id":33272291,"tagged_user_id":null,"co_author_invite_id":287979,"email":"b***n@yahoo.com","display_order":7864320,"name":"Betul Baykan","title":"One-year prevalence and the impact of migraine and tension-type headache in Turkey: a nationwide home-based study in adults"}],"downloadable_attachments":[{"id":44325642,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325642/thumbnails/1.jpg","file_name":"One-year_prevalence_and_the_impact_of_mi20160402-17957-2rryec.pdf","download_url":"https://www.academia.edu/attachments/44325642/download_file","bulk_download_file_name":"One_year_prevalence_and_the_impact_of_mi.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325642/One-year_prevalence_and_the_impact_of_mi20160402-17957-2rryec-libre.pdf?1459602633=\u0026response-content-disposition=attachment%3B+filename%3DOne_year_prevalence_and_the_impact_of_mi.pdf\u0026Expires=1743574093\u0026Signature=PV4pxCqC0czfOYcAF9MkiAzIwqixpUOC5wEhF-0s6I547egjyqT4yrYvr~6cCLqPR0zKfyyaPkoo-q5tjYg7sT1MmaAO~vugLy227CYsvyg2fHwqBtU7dAs16mcy0T8IYIhM8Wrgush1mxqfvhD6B3PlD4hYYYsorqvnxaiJHW-p~aNyOyYosaOB7XkHlWoH0DUrU8RXqM9ZAng~QLIMMwIX4iib4-KYNxV0KNWgcGxoQqkb3E-J77EtI4U3om2YxTFQCb-pyPkiBm7Wt1pobXd0K2ZhDVMRPnVlugMO4rAwrfN8QA7fltSPmmso2kqtJmwtnXf7nJjkT7SS7jrBvQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"One_year_prevalence_and_the_impact_of_migraine_and_tension_type_headache_in_Turkey_a_nationwide_home_based_study_in_adults","translated_slug":"","page_count":11,"language":"en","content_type":"Work","summary":"Several studies have shown that the prevalence of migraine and tension-type headache (TTH) varied between different geographical regions. Therefore, there is a need of a nationwide prevalence study for headache in our country, located between Asia and Europe. This nationwide study was designed to estimate the 1-year prevalence of migraine and TTH and analyse the clinical features, the impact as well as the demographic and socio-economic characteristics of the participant households in Turkey. We planned to investigate 6,000 representative households in 21 cities of Turkey; and a total of 5,323 households (response rate of 89%) aged between 18 and 65 years were examined for headache by 33 trained physicians at home on the basis of the diagnostic criteria of the second edition of the International Classification of Headache Disorders (ICHD-II). The electronically registered questionnaire was based on the headache features, the associated symptoms, demographic and socio-economic situation and history. Of 5,323 participants (48.8% women; mean age 35.9 ± 12 years) 44.6% reported recurrent headaches during the last 1 year and 871 were diagnosed with migraine at a prevalence rate of 16.4% (8.5% in men and 24.6% in women), whereas only 270 were diagnosed with TTH at a prevalence rate of 5.1% (5.7% in men and 4.5% in women). The 1-year prevalence of probable migraine was 12.4% and probable TTH was 9.5% additionally. The rate of migraine with aura among migraineurs was 21.5%. The prevalence of migraine was highest among 35-40-year-old women while there were no differences in age groups among men and in TTH overall. More than 2/3 of migraineurs had ever consulted a physician whereas only 1/3 of patients with TTH had ever consulted a physician. For women, the migraine prevalence was higher among the ones with a lower income, while among men, it did not show any change by income. Migraine prevalence was lower in those with a lower educational status compared to those with a high educational status. Chronic daily headache was present in 3.3% and the prevalence of medication overuse headache was 2.1% in our population. There was an important impact of migraine with a monthly frequency of 5.9 ± 6, and an attack duration of 35.1 ± 72 h, but only 4.9% were on prophylactic treatment. The one-year prevalence of migraine estimated as 16.4% was similar or even higher than worldwide reported migraine prevalence figures and identical to a previous nation-wide study conducted in 1998, whereas the TTH prevalence was much lower using the same methodology with the ICHD-II criteria.","owner":{"id":33272291,"first_name":"Sabahattin","middle_initials":null,"last_name":"Saip","page_name":"SabahattinSaip","domain_name":"istanbul","created_at":"2015-07-22T22:34:11.561-07:00","display_name":"Sabahattin Saip","url":"https://istanbul.academia.edu/SabahattinSaip"},"attachments":[{"id":44325642,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325642/thumbnails/1.jpg","file_name":"One-year_prevalence_and_the_impact_of_mi20160402-17957-2rryec.pdf","download_url":"https://www.academia.edu/attachments/44325642/download_file","bulk_download_file_name":"One_year_prevalence_and_the_impact_of_mi.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325642/One-year_prevalence_and_the_impact_of_mi20160402-17957-2rryec-libre.pdf?1459602633=\u0026response-content-disposition=attachment%3B+filename%3DOne_year_prevalence_and_the_impact_of_mi.pdf\u0026Expires=1743574093\u0026Signature=PV4pxCqC0czfOYcAF9MkiAzIwqixpUOC5wEhF-0s6I547egjyqT4yrYvr~6cCLqPR0zKfyyaPkoo-q5tjYg7sT1MmaAO~vugLy227CYsvyg2fHwqBtU7dAs16mcy0T8IYIhM8Wrgush1mxqfvhD6B3PlD4hYYYsorqvnxaiJHW-p~aNyOyYosaOB7XkHlWoH0DUrU8RXqM9ZAng~QLIMMwIX4iib4-KYNxV0KNWgcGxoQqkb3E-J77EtI4U3om2YxTFQCb-pyPkiBm7Wt1pobXd0K2ZhDVMRPnVlugMO4rAwrfN8QA7fltSPmmso2kqtJmwtnXf7nJjkT7SS7jrBvQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":22506,"name":"Adolescent","url":"https://www.academia.edu/Documents/in/Adolescent"},{"id":26879,"name":"Social Class","url":"https://www.academia.edu/Documents/in/Social_Class"},{"id":133057,"name":"Young Adult","url":"https://www.academia.edu/Documents/in/Young_Adult"},{"id":161176,"name":"The","url":"https://www.academia.edu/Documents/in/The"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":289330,"name":"Prevalence","url":"https://www.academia.edu/Documents/in/Prevalence"},{"id":327850,"name":"Questionnaires","url":"https://www.academia.edu/Documents/in/Questionnaires"},{"id":612548,"name":"Tension-Type Headache","url":"https://www.academia.edu/Documents/in/Tension-Type_Headache"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14318112-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14318108"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/14318108/The_validation_of_ID_migraine_screener_in_neurology_outpatient_clinics_in_Turkey"><img alt="Research paper thumbnail of The validation of ID migraine™ screener in neurology outpatient clinics in Turkey" class="work-thumbnail" src="https://attachments.academia-assets.com/44325658/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/14318108/The_validation_of_ID_migraine_screener_in_neurology_outpatient_clinics_in_Turkey">The validation of ID migraine™ screener in neurology outpatient clinics in Turkey</a></div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://uludag.academia.edu/MZarifo%C4%9Flu">M. Zarifoğlu</a>, and <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a></span></div><div class="wp-workCard_item"><span>The Journal of Headache and Pain</span><span>, 2007</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">The aim of this study was to investigate the validity of the ID Migraine™ test in neurology outpa...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">The aim of this study was to investigate the validity of the ID Migraine™ test in neurology outpatient clinics (NOCs), regardless of their presenting complaints. Patients admitted to 41 NOCs were screened. Eligible subjects (n=3682) were evaluated by a neurologist for headache diagnosis according to the International Headache Society criteria and asked the 3-item screening questions of the ID Migraine™ test. Of 3682 patients, 917 (24.9%) were diagnosed as migraine, whereas 1171 (31.8%) were ID Migraine™ test positive. The sensitivity of the ID Migraine™ test for neurologist's diagnosis of migraine was 91.8%, specificity was 63.4%, positive predictive value was 71.9% and negative predictive value was 88.4%. The ID Migraine™ test is easy to use and a practical test that could alert the neurologist to diagnose patients having other complaints. This test would help to increase the diagnosis and treatment rate of undiagnosed migraine patients in NOCs.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="02a551ef26a1764ba42970ede40aa9ca" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":44325658,"asset_id":14318108,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/44325658/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14318108"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14318108"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14318108; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14318108]").text(description); $(".js-view-count[data-work-id=14318108]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14318108; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14318108']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "02a551ef26a1764ba42970ede40aa9ca" } } $('.js-work-strip[data-work-id=14318108]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14318108,"title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey","translated_title":"","metadata":{"grobid_abstract":"The aim of this study was to investigate the validity of the ID Migraine™ test in neurology outpatient clinics (NOCs), regardless of their presenting complaints. Patients admitted to 41 NOCs were screened. Eligible subjects (n=3682) were evaluated by a neurologist for headache diagnosis according to the International Headache Society criteria and asked the 3-item screening questions of the ID Migraine™ test. Of 3682 patients, 917 (24.9%) were diagnosed as migraine, whereas 1171 (31.8%) were ID Migraine™ test positive. The sensitivity of the ID Migraine™ test for neurologist's diagnosis of migraine was 91.8%, specificity was 63.4%, positive predictive value was 71.9% and negative predictive value was 88.4%. The ID Migraine™ test is easy to use and a practical test that could alert the neurologist to diagnose patients having other complaints. This test would help to increase the diagnosis and treatment rate of undiagnosed migraine patients in NOCs.","publication_date":{"day":null,"month":null,"year":2007,"errors":{}},"publication_name":"The Journal of Headache and Pain","grobid_abstract_attachment_id":44325658},"translated_abstract":null,"internal_url":"https://www.academia.edu/14318108/The_validation_of_ID_migraine_screener_in_neurology_outpatient_clinics_in_Turkey","translated_internal_url":"","created_at":"2015-07-22T22:34:46.430-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33272291,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3691330,"work_id":14318108,"tagging_user_id":33272291,"tagged_user_id":33021815,"co_author_invite_id":null,"email":"m***f@uludag.edu.tr","affiliation":"Uludag University","display_order":0,"name":"M. Zarifoğlu","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"},{"id":3691336,"work_id":14318108,"tagging_user_id":33272291,"tagged_user_id":33025639,"co_author_invite_id":null,"email":"n***i@uludag.edu.tr","display_order":4194304,"name":"N. Karli","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"},{"id":3691341,"work_id":14318108,"tagging_user_id":33272291,"tagged_user_id":33207160,"co_author_invite_id":null,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":6291456,"name":"Aksel Siva","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"},{"id":3691347,"work_id":14318108,"tagging_user_id":33272291,"tagged_user_id":41556982,"co_author_invite_id":721598,"email":"m***s@superonline.com","display_order":7340032,"name":"M. Ertas","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"},{"id":3691363,"work_id":14318108,"tagging_user_id":33272291,"tagged_user_id":null,"co_author_invite_id":287979,"email":"b***n@yahoo.com","display_order":7864320,"name":"Betul Baykan","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"}],"downloadable_attachments":[{"id":44325658,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325658/thumbnails/1.jpg","file_name":"The_validation_of_ID_Migraine_TM_scree20160402-21821-z7561z.pdf","download_url":"https://www.academia.edu/attachments/44325658/download_file","bulk_download_file_name":"The_validation_of_ID_migraine_screener_i.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325658/The_validation_of_ID_Migraine_TM_scree20160402-21821-z7561z-libre.pdf?1459602632=\u0026response-content-disposition=attachment%3B+filename%3DThe_validation_of_ID_migraine_screener_i.pdf\u0026Expires=1743574093\u0026Signature=Cg~LsaD2yNMwwcvK1B1XEqUWiON~JnYdVN90sPatEQ1eV3q842F9MFxSCWq3PfRRYLQxoIAv2FFNsihtsDdoBL9ykzAkgFqWOaFF1sSp6TN2nWEayB2yJeQJzPMp60a4U~sY~Se5LviD0btPYi~kgOMVwLBln2xcs~M67ZfW~O4S-hnQIdVSelp5xlURj0df-PPJUggAR7KYx-q8AffqCehkl7Izrdxou~f6mUZMMnxq-hf-myKZx91E3HkNCcg~8ASAC97fQDiVBkNtoKu9GPzHJdi14~0OdLacnAWRkxVAAEGv~6JZgCKv4ezkkB8DwOwye7bNOaSZdIHYkD4m1Q__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"The_validation_of_ID_migraine_screener_in_neurology_outpatient_clinics_in_Turkey","translated_slug":"","page_count":7,"language":"en","content_type":"Work","summary":"The aim of this study was to investigate the validity of the ID Migraine™ test in neurology outpatient clinics (NOCs), regardless of their presenting complaints. Patients admitted to 41 NOCs were screened. Eligible subjects (n=3682) were evaluated by a neurologist for headache diagnosis according to the International Headache Society criteria and asked the 3-item screening questions of the ID Migraine™ test. Of 3682 patients, 917 (24.9%) were diagnosed as migraine, whereas 1171 (31.8%) were ID Migraine™ test positive. The sensitivity of the ID Migraine™ test for neurologist's diagnosis of migraine was 91.8%, specificity was 63.4%, positive predictive value was 71.9% and negative predictive value was 88.4%. The ID Migraine™ test is easy to use and a practical test that could alert the neurologist to diagnose patients having other complaints. This test would help to increase the diagnosis and treatment rate of undiagnosed migraine patients in NOCs.","owner":{"id":33272291,"first_name":"Sabahattin","middle_initials":null,"last_name":"Saip","page_name":"SabahattinSaip","domain_name":"istanbul","created_at":"2015-07-22T22:34:11.561-07:00","display_name":"Sabahattin Saip","url":"https://istanbul.academia.edu/SabahattinSaip"},"attachments":[{"id":44325658,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325658/thumbnails/1.jpg","file_name":"The_validation_of_ID_Migraine_TM_scree20160402-21821-z7561z.pdf","download_url":"https://www.academia.edu/attachments/44325658/download_file","bulk_download_file_name":"The_validation_of_ID_migraine_screener_i.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325658/The_validation_of_ID_Migraine_TM_scree20160402-21821-z7561z-libre.pdf?1459602632=\u0026response-content-disposition=attachment%3B+filename%3DThe_validation_of_ID_migraine_screener_i.pdf\u0026Expires=1743574093\u0026Signature=Cg~LsaD2yNMwwcvK1B1XEqUWiON~JnYdVN90sPatEQ1eV3q842F9MFxSCWq3PfRRYLQxoIAv2FFNsihtsDdoBL9ykzAkgFqWOaFF1sSp6TN2nWEayB2yJeQJzPMp60a4U~sY~Se5LviD0btPYi~kgOMVwLBln2xcs~M67ZfW~O4S-hnQIdVSelp5xlURj0df-PPJUggAR7KYx-q8AffqCehkl7Izrdxou~f6mUZMMnxq-hf-myKZx91E3HkNCcg~8ASAC97fQDiVBkNtoKu9GPzHJdi14~0OdLacnAWRkxVAAEGv~6JZgCKv4ezkkB8DwOwye7bNOaSZdIHYkD4m1Q__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":623,"name":"Neurology","url":"https://www.academia.edu/Documents/in/Neurology"},{"id":8942,"name":"Treatment","url":"https://www.academia.edu/Documents/in/Treatment"},{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":144833,"name":"Validity","url":"https://www.academia.edu/Documents/in/Validity"},{"id":161176,"name":"The","url":"https://www.academia.edu/Documents/in/The"},{"id":254203,"name":"Ambulatory","url":"https://www.academia.edu/Documents/in/Ambulatory"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":289330,"name":"Prevalence","url":"https://www.academia.edu/Documents/in/Prevalence"},{"id":327850,"name":"Questionnaires","url":"https://www.academia.edu/Documents/in/Questionnaires"},{"id":401947,"name":"Sensitivity","url":"https://www.academia.edu/Documents/in/Sensitivity"},{"id":549280,"name":"Reproducibility of Results","url":"https://www.academia.edu/Documents/in/Reproducibility_of_Results"},{"id":901876,"name":"Sensitivity and Specificity","url":"https://www.academia.edu/Documents/in/Sensitivity_and_Specificity"},{"id":1318932,"name":"Predictive value of tests","url":"https://www.academia.edu/Documents/in/Predictive_value_of_tests"},{"id":1318938,"name":"Positive predictive value","url":"https://www.academia.edu/Documents/in/Positive_predictive_value"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14318108-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14318110"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14318110/Neuro_Beh%C3%A7et_syndrome"><img alt="Research paper thumbnail of Neuro-Behçet syndrome" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Neuro-Behçet syndrome</div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a> and <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a></span></div><div class="wp-workCard_item"><span>Handbook of Clinical Neurology</span><span>, 2014</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Behçet syndrome (BS) is an idiopathic chronic relapsing multisystem vascular-inflammatory disease...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Behçet syndrome (BS) is an idiopathic chronic relapsing multisystem vascular-inflammatory disease of unknown origin. As the disease affects many organs and systems and shows a wide range of clinical manifestations and presentations, it is prefereable to call Behçet&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s a syndrome (BS) rather than a disease. Nervous system involvement, known as &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;quot;neuro-BS&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;quot; (NBS), is seen in about 5-10% of all cases. Clinical and imaging evidence suggests that primary neurologic involvement in BS may be subclassified into two major forms: the first, which is seen in the majority of patients, may be characterized as a vascular-inflammatory central nervous system disease with focal or multifocal parenchymal involvement, mostly presenting with a subacute brainstem syndrome and hemiparesis (intra-axial NBS); the other, which has few symptoms and a better neurologic prognosis, may be caused by isolated cerebral venous sinus thrombosis and intracranial hypertension (extra-axial NBS), occurring in 10-20% of the cases. These two types are rarely seen in the same individual, and their pathogenesis is likely to be different. Isolated behavioral syndromes and peripheral nervous system involvement are rare, whereas a vascular type headache is relatively common and independent from neurologic involvement. Neurologic complications secondary to systemic involvement of BS, as well as neurologic complications related to BS treatments are considered as secondary neurologic involvement of the syndrome. The core histopathologic phenomenon seems to be a vasculitic involvement in some cases, and low-grade chronic nonspecific inflammation in others. As the neurologic involvement in this syndrome is so heterogeneous, it is difficult to predict its course and prognosis, and its response to treatment. Currently, treatment options for NBS are limited to attack therapies with high-dose intravenous methylprednisolone followed by a prolonged oral taper, symptomatic management, and generally the use of azathioprine, cyclophosphamide, interferon-α and anti-TNF agents for long-term preventive treatment, although there no evidence for their efficacy.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14318110"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14318110"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14318110; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14318110]").text(description); $(".js-view-count[data-work-id=14318110]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14318110; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14318110']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14318110]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14318110,"title":"Neuro-Behçet syndrome","translated_title":"","metadata":{"abstract":"Behçet syndrome (BS) is an idiopathic chronic relapsing multisystem vascular-inflammatory disease of unknown origin. As the disease affects many organs and systems and shows a wide range of clinical manifestations and presentations, it is prefereable to call Behçet\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s a syndrome (BS) rather than a disease. Nervous system involvement, known as \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;quot;neuro-BS\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;quot; (NBS), is seen in about 5-10% of all cases. Clinical and imaging evidence suggests that primary neurologic involvement in BS may be subclassified into two major forms: the first, which is seen in the majority of patients, may be characterized as a vascular-inflammatory central nervous system disease with focal or multifocal parenchymal involvement, mostly presenting with a subacute brainstem syndrome and hemiparesis (intra-axial NBS); the other, which has few symptoms and a better neurologic prognosis, may be caused by isolated cerebral venous sinus thrombosis and intracranial hypertension (extra-axial NBS), occurring in 10-20% of the cases. These two types are rarely seen in the same individual, and their pathogenesis is likely to be different. Isolated behavioral syndromes and peripheral nervous system involvement are rare, whereas a vascular type headache is relatively common and independent from neurologic involvement. Neurologic complications secondary to systemic involvement of BS, as well as neurologic complications related to BS treatments are considered as secondary neurologic involvement of the syndrome. The core histopathologic phenomenon seems to be a vasculitic involvement in some cases, and low-grade chronic nonspecific inflammation in others. As the neurologic involvement in this syndrome is so heterogeneous, it is difficult to predict its course and prognosis, and its response to treatment. Currently, treatment options for NBS are limited to attack therapies with high-dose intravenous methylprednisolone followed by a prolonged oral taper, symptomatic management, and generally the use of azathioprine, cyclophosphamide, interferon-α and anti-TNF agents for long-term preventive treatment, although there no evidence for their efficacy.","publication_date":{"day":null,"month":null,"year":2014,"errors":{}},"publication_name":"Handbook of Clinical Neurology"},"translated_abstract":"Behçet syndrome (BS) is an idiopathic chronic relapsing multisystem vascular-inflammatory disease of unknown origin. As the disease affects many organs and systems and shows a wide range of clinical manifestations and presentations, it is prefereable to call Behçet\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s a syndrome (BS) rather than a disease. Nervous system involvement, known as \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;quot;neuro-BS\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;quot; (NBS), is seen in about 5-10% of all cases. Clinical and imaging evidence suggests that primary neurologic involvement in BS may be subclassified into two major forms: the first, which is seen in the majority of patients, may be characterized as a vascular-inflammatory central nervous system disease with focal or multifocal parenchymal involvement, mostly presenting with a subacute brainstem syndrome and hemiparesis (intra-axial NBS); the other, which has few symptoms and a better neurologic prognosis, may be caused by isolated cerebral venous sinus thrombosis and intracranial hypertension (extra-axial NBS), occurring in 10-20% of the cases. These two types are rarely seen in the same individual, and their pathogenesis is likely to be different. Isolated behavioral syndromes and peripheral nervous system involvement are rare, whereas a vascular type headache is relatively common and independent from neurologic involvement. Neurologic complications secondary to systemic involvement of BS, as well as neurologic complications related to BS treatments are considered as secondary neurologic involvement of the syndrome. The core histopathologic phenomenon seems to be a vasculitic involvement in some cases, and low-grade chronic nonspecific inflammation in others. As the neurologic involvement in this syndrome is so heterogeneous, it is difficult to predict its course and prognosis, and its response to treatment. Currently, treatment options for NBS are limited to attack therapies with high-dose intravenous methylprednisolone followed by a prolonged oral taper, symptomatic management, and generally the use of azathioprine, cyclophosphamide, interferon-α and anti-TNF agents for long-term preventive treatment, although there no evidence for their efficacy.","internal_url":"https://www.academia.edu/14318110/Neuro_Beh%C3%A7et_syndrome","translated_internal_url":"","created_at":"2015-07-22T22:34:46.605-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33272291,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3691343,"work_id":14318110,"tagging_user_id":33272291,"tagged_user_id":33207160,"co_author_invite_id":null,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":0,"name":"Aksel Siva","title":"Neuro-Behçet syndrome"},{"id":3691356,"work_id":14318110,"tagging_user_id":33272291,"tagged_user_id":31879554,"co_author_invite_id":null,"email":"a***r@gmail.com","display_order":4194304,"name":"gulsen akman-demir","title":"Neuro-Behçet syndrome"}],"downloadable_attachments":[],"slug":"Neuro_Behçet_syndrome","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"Behçet syndrome (BS) is an idiopathic chronic relapsing multisystem vascular-inflammatory disease of unknown origin. As the disease affects many organs and systems and shows a wide range of clinical manifestations and presentations, it is prefereable to call Behçet\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s a syndrome (BS) rather than a disease. Nervous system involvement, known as \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;quot;neuro-BS\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;quot; (NBS), is seen in about 5-10% of all cases. Clinical and imaging evidence suggests that primary neurologic involvement in BS may be subclassified into two major forms: the first, which is seen in the majority of patients, may be characterized as a vascular-inflammatory central nervous system disease with focal or multifocal parenchymal involvement, mostly presenting with a subacute brainstem syndrome and hemiparesis (intra-axial NBS); the other, which has few symptoms and a better neurologic prognosis, may be caused by isolated cerebral venous sinus thrombosis and intracranial hypertension (extra-axial NBS), occurring in 10-20% of the cases. These two types are rarely seen in the same individual, and their pathogenesis is likely to be different. Isolated behavioral syndromes and peripheral nervous system involvement are rare, whereas a vascular type headache is relatively common and independent from neurologic involvement. Neurologic complications secondary to systemic involvement of BS, as well as neurologic complications related to BS treatments are considered as secondary neurologic involvement of the syndrome. The core histopathologic phenomenon seems to be a vasculitic involvement in some cases, and low-grade chronic nonspecific inflammation in others. As the neurologic involvement in this syndrome is so heterogeneous, it is difficult to predict its course and prognosis, and its response to treatment. Currently, treatment options for NBS are limited to attack therapies with high-dose intravenous methylprednisolone followed by a prolonged oral taper, symptomatic management, and generally the use of azathioprine, cyclophosphamide, interferon-α and anti-TNF agents for long-term preventive treatment, although there no evidence for their efficacy.","owner":{"id":33272291,"first_name":"Sabahattin","middle_initials":null,"last_name":"Saip","page_name":"SabahattinSaip","domain_name":"istanbul","created_at":"2015-07-22T22:34:11.561-07:00","display_name":"Sabahattin Saip","url":"https://istanbul.academia.edu/SabahattinSaip"},"attachments":[],"research_interests":[{"id":2639,"name":"Neuroimaging","url":"https://www.academia.edu/Documents/in/Neuroimaging"},{"id":162159,"name":"Differential Diagnosis","url":"https://www.academia.edu/Documents/in/Differential_Diagnosis"},{"id":489727,"name":"Prognosis","url":"https://www.academia.edu/Documents/in/Prognosis"},{"id":1423078,"name":"Nervous System Diseases","url":"https://www.academia.edu/Documents/in/Nervous_System_Diseases"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14318110-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14318107"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14318107/A_patient_with_established_primary_progressive_multiple_sclerosis_transitions_to_secondary_relapsing_remitting_disease_course_following_a_fulminant_demyelinating_episode"><img alt="Research paper thumbnail of A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode</div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a>, and <a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/DemirciN">N. Demirci</a></span></div><div class="wp-workCard_item"><span>Multiple Sclerosis Journal</span><span>, 2011</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Primary progressive multiple sclerosis (PPMS), relapsing remitting MS (RRMS) and acute disseminat...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Primary progressive multiple sclerosis (PPMS), relapsing remitting MS (RRMS) and acute disseminated encephalomyelitis (ADEM) are clinically and immunopathogenetically distinct phenotypes of inflammatory demyelinating disorders of the central nervous system. Progression following RRMS is well described as secondary progressive MS. We report a patient with unexpected transition from long established PPMS to clinically and radiologically active RRMS after an ADEM-like fulminant demyelinating episode despite an immunosuppressive treatment preceding relapses. We note clearly accelerated brain atrophy after the RRMS course ensues. The unique disease course in this patient illustrates the dissociation of the biology and disability impact of relapses and progression.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14318107"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14318107"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14318107; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14318107]").text(description); $(".js-view-count[data-work-id=14318107]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14318107; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14318107']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14318107]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14318107,"title":"A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode","translated_title":"","metadata":{"abstract":"Primary progressive multiple sclerosis (PPMS), relapsing remitting MS (RRMS) and acute disseminated encephalomyelitis (ADEM) are clinically and immunopathogenetically distinct phenotypes of inflammatory demyelinating disorders of the central nervous system. Progression following RRMS is well described as secondary progressive MS. We report a patient with unexpected transition from long established PPMS to clinically and radiologically active RRMS after an ADEM-like fulminant demyelinating episode despite an immunosuppressive treatment preceding relapses. We note clearly accelerated brain atrophy after the RRMS course ensues. The unique disease course in this patient illustrates the dissociation of the biology and disability impact of relapses and progression.","publication_date":{"day":null,"month":null,"year":2011,"errors":{}},"publication_name":"Multiple Sclerosis Journal"},"translated_abstract":"Primary progressive multiple sclerosis (PPMS), relapsing remitting MS (RRMS) and acute disseminated encephalomyelitis (ADEM) are clinically and immunopathogenetically distinct phenotypes of inflammatory demyelinating disorders of the central nervous system. Progression following RRMS is well described as secondary progressive MS. We report a patient with unexpected transition from long established PPMS to clinically and radiologically active RRMS after an ADEM-like fulminant demyelinating episode despite an immunosuppressive treatment preceding relapses. We note clearly accelerated brain atrophy after the RRMS course ensues. The unique disease course in this patient illustrates the dissociation of the biology and disability impact of relapses and progression.","internal_url":"https://www.academia.edu/14318107/A_patient_with_established_primary_progressive_multiple_sclerosis_transitions_to_secondary_relapsing_remitting_disease_course_following_a_fulminant_demyelinating_episode","translated_internal_url":"","created_at":"2015-07-22T22:34:46.339-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33272291,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3691338,"work_id":14318107,"tagging_user_id":33272291,"tagged_user_id":33207160,"co_author_invite_id":null,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":0,"name":"Aksel Siva","title":"A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode"},{"id":3691351,"work_id":14318107,"tagging_user_id":33272291,"tagged_user_id":43685187,"co_author_invite_id":892619,"email":"n***i@hotmail.com","display_order":4194304,"name":"N. Demirci","title":"A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode"},{"id":3691353,"work_id":14318107,"tagging_user_id":33272291,"tagged_user_id":8740446,"co_author_invite_id":null,"email":"f***i@hotmail.com","display_order":6291456,"name":"Fulya Özer","title":"A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode"},{"id":3691354,"work_id":14318107,"tagging_user_id":33272291,"tagged_user_id":null,"co_author_invite_id":892620,"email":"o***n@workshopdergi.com","display_order":7340032,"name":"O. Kantarci","title":"A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode"},{"id":3691360,"work_id":14318107,"tagging_user_id":33272291,"tagged_user_id":null,"co_author_invite_id":892622,"email":"m***u@gmail.com","display_order":7864320,"name":"M. Tutuncu","title":"A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode"}],"downloadable_attachments":[],"slug":"A_patient_with_established_primary_progressive_multiple_sclerosis_transitions_to_secondary_relapsing_remitting_disease_course_following_a_fulminant_demyelinating_episode","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"Primary progressive multiple sclerosis (PPMS), relapsing remitting MS (RRMS) and acute disseminated encephalomyelitis (ADEM) are clinically and immunopathogenetically distinct phenotypes of inflammatory demyelinating disorders of the central nervous system. Progression following RRMS is well described as secondary progressive MS. We report a patient with unexpected transition from long established PPMS to clinically and radiologically active RRMS after an ADEM-like fulminant demyelinating episode despite an immunosuppressive treatment preceding relapses. We note clearly accelerated brain atrophy after the RRMS course ensues. The unique disease course in this patient illustrates the dissociation of the biology and disability impact of relapses and progression.","owner":{"id":33272291,"first_name":"Sabahattin","middle_initials":null,"last_name":"Saip","page_name":"SabahattinSaip","domain_name":"istanbul","created_at":"2015-07-22T22:34:11.561-07:00","display_name":"Sabahattin Saip","url":"https://istanbul.academia.edu/SabahattinSaip"},"attachments":[],"research_interests":[{"id":3097,"name":"Multiple sclerosis","url":"https://www.academia.edu/Documents/in/Multiple_sclerosis"},{"id":133057,"name":"Young Adult","url":"https://www.academia.edu/Documents/in/Young_Adult"},{"id":158884,"name":"Urinary Tract Infections","url":"https://www.academia.edu/Documents/in/Urinary_Tract_Infections"},{"id":234187,"name":"Recurrence","url":"https://www.academia.edu/Documents/in/Recurrence"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":509782,"name":"Respiratory Tract Infections","url":"https://www.academia.edu/Documents/in/Respiratory_Tract_Infections"},{"id":584615,"name":"Disease Progression","url":"https://www.academia.edu/Documents/in/Disease_Progression"},{"id":1239755,"name":"Neurosciences","url":"https://www.academia.edu/Documents/in/Neurosciences"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14318107-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14318115"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/14318115/CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes"><img alt="Research paper thumbnail of CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes" class="work-thumbnail" src="https://attachments.academia-assets.com/44325633/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/14318115/CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes">CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes</a></div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a>, and <a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/DemirciN">N. Demirci</a></span></div><div class="wp-workCard_item"><span>PLOS ONE</span><span>, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Multiple sclerosis (MS) is an immune-mediated, neuro-inflammatory, demyelinating and neurodegener...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Multiple sclerosis (MS) is an immune-mediated, neuro-inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS) with a heterogeneous clinical presentation and course. There is a remarkable phenotypic heterogeneity in MS, and the molecular mechanisms underlying it remain unknown. We aimed to investigate further the etiopathogenesis related molecular pathways in subclinical types of MS using proteomic and bioinformatics approaches in cerebrospinal fluids of patients with clinically isolated syndrome, relapsing remitting MS and progressive MS (n=179). Comparison of disease groups with controls revealed a total of 151 proteins that are differentially expressed in clinically different MS subtypes. KEGG analysis using PANOGA tool revealed the disease related pathways including aldosterone-regulated sodium reabsorption (p=8.02x10 -5 ) which is important in the immune cell migration, renin-angiotensin (p=6.88x10 -5 ) system that induces Th17 dependent immunity, notch signaling (p=1.83x10 -10 ) pathway indicating the activated remyelination and vitamin digestion and absorption pathways (p=1.73x10 -5 ). An emerging theme from our studies is that whilst all MS clinical forms share common biological pathways, there are also clinical subtypes specific and pathophysiology related pathways which may have further therapeutic implications.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="b14c02a8a0b788584787d9c62dcdf2ac" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":44325633,"asset_id":14318115,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/44325633/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14318115"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14318115"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14318115; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14318115]").text(description); $(".js-view-count[data-work-id=14318115]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14318115; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14318115']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "b14c02a8a0b788584787d9c62dcdf2ac" } } $('.js-work-strip[data-work-id=14318115]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14318115,"title":"CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes","translated_title":"","metadata":{"ai_title_tag":"CSF Proteomics Reveals Pathways in Multiple Sclerosis Subtypes","grobid_abstract":"Multiple sclerosis (MS) is an immune-mediated, neuro-inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS) with a heterogeneous clinical presentation and course. There is a remarkable phenotypic heterogeneity in MS, and the molecular mechanisms underlying it remain unknown. We aimed to investigate further the etiopathogenesis related molecular pathways in subclinical types of MS using proteomic and bioinformatics approaches in cerebrospinal fluids of patients with clinically isolated syndrome, relapsing remitting MS and progressive MS (n=179). Comparison of disease groups with controls revealed a total of 151 proteins that are differentially expressed in clinically different MS subtypes. KEGG analysis using PANOGA tool revealed the disease related pathways including aldosterone-regulated sodium reabsorption (p=8.02x10 -5 ) which is important in the immune cell migration, renin-angiotensin (p=6.88x10 -5 ) system that induces Th17 dependent immunity, notch signaling (p=1.83x10 -10 ) pathway indicating the activated remyelination and vitamin digestion and absorption pathways (p=1.73x10 -5 ). An emerging theme from our studies is that whilst all MS clinical forms share common biological pathways, there are also clinical subtypes specific and pathophysiology related pathways which may have further therapeutic implications.","publication_date":{"day":null,"month":null,"year":2015,"errors":{}},"publication_name":"PLOS ONE","grobid_abstract_attachment_id":44325633},"translated_abstract":null,"internal_url":"https://www.academia.edu/14318115/CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes","translated_internal_url":"","created_at":"2015-07-22T22:34:47.081-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33272291,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3691342,"work_id":14318115,"tagging_user_id":33272291,"tagged_user_id":33207160,"co_author_invite_id":null,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":0,"name":"Aksel Siva","title":"CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes"},{"id":3691352,"work_id":14318115,"tagging_user_id":33272291,"tagged_user_id":43685187,"co_author_invite_id":892619,"email":"n***i@hotmail.com","display_order":4194304,"name":"N. Demirci","title":"CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes"},{"id":3691357,"work_id":14318115,"tagging_user_id":33272291,"tagged_user_id":null,"co_author_invite_id":892621,"email":"t***e@itu.edu.tr","display_order":6291456,"name":"Eda Turanlı","title":"CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes"},{"id":3691361,"work_id":14318115,"tagging_user_id":33272291,"tagged_user_id":null,"co_author_invite_id":892622,"email":"m***u@gmail.com","display_order":7340032,"name":"M. Tutuncu","title":"CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes"}],"downloadable_attachments":[{"id":44325633,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325633/thumbnails/1.jpg","file_name":"CSF_Proteomics_Identifies_Specific_and_S20160402-32742-qgoavx.pdf","download_url":"https://www.academia.edu/attachments/44325633/download_file","bulk_download_file_name":"CSF_Proteomics_Identifies_Specific_and_S.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325633/CSF_Proteomics_Identifies_Specific_and_S20160402-32742-qgoavx-libre.pdf?1459602634=\u0026response-content-disposition=attachment%3B+filename%3DCSF_Proteomics_Identifies_Specific_and_S.pdf\u0026Expires=1743603792\u0026Signature=K16DBAdCf6p0YQULAWwd87zE2v4-jfYva0lYZ-KCYZczn7jmixhfJLT-y7s8OMepmy7o3zyhYeciD7PkjgjbH6AMibHH9Bdu-xMiXQD8tz0GVFN0T946pCllh73qGk9DLsanb-WI4yrZcXDKw3IMVxbH9NeCHYgmuR9okMNxU8zNZYwGAZ2lTFDbE-RXtxgOnN-lJxxU0Iuyuwov8COUytz4Tge~IKoPSTSNLBUj28SoSRcH09sL6Sv0l6tWlUla-7d1gC1SjVvvgzSsgzug8EqQyqy-SHQtqgz426f6hH708fte5d2-8oibIQqTLo3jxldtUua9U8EdooL~uLMHpg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes","translated_slug":"","page_count":18,"language":"en","content_type":"Work","summary":"Multiple sclerosis (MS) is an immune-mediated, neuro-inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS) with a heterogeneous clinical presentation and course. There is a remarkable phenotypic heterogeneity in MS, and the molecular mechanisms underlying it remain unknown. We aimed to investigate further the etiopathogenesis related molecular pathways in subclinical types of MS using proteomic and bioinformatics approaches in cerebrospinal fluids of patients with clinically isolated syndrome, relapsing remitting MS and progressive MS (n=179). Comparison of disease groups with controls revealed a total of 151 proteins that are differentially expressed in clinically different MS subtypes. KEGG analysis using PANOGA tool revealed the disease related pathways including aldosterone-regulated sodium reabsorption (p=8.02x10 -5 ) which is important in the immune cell migration, renin-angiotensin (p=6.88x10 -5 ) system that induces Th17 dependent immunity, notch signaling (p=1.83x10 -10 ) pathway indicating the activated remyelination and vitamin digestion and absorption pathways (p=1.73x10 -5 ). An emerging theme from our studies is that whilst all MS clinical forms share common biological pathways, there are also clinical subtypes specific and pathophysiology related pathways which may have further therapeutic implications.","owner":{"id":33272291,"first_name":"Sabahattin","middle_initials":null,"last_name":"Saip","page_name":"SabahattinSaip","domain_name":"istanbul","created_at":"2015-07-22T22:34:11.561-07:00","display_name":"Sabahattin Saip","url":"https://istanbul.academia.edu/SabahattinSaip"},"attachments":[{"id":44325633,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325633/thumbnails/1.jpg","file_name":"CSF_Proteomics_Identifies_Specific_and_S20160402-32742-qgoavx.pdf","download_url":"https://www.academia.edu/attachments/44325633/download_file","bulk_download_file_name":"CSF_Proteomics_Identifies_Specific_and_S.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325633/CSF_Proteomics_Identifies_Specific_and_S20160402-32742-qgoavx-libre.pdf?1459602634=\u0026response-content-disposition=attachment%3B+filename%3DCSF_Proteomics_Identifies_Specific_and_S.pdf\u0026Expires=1743603792\u0026Signature=K16DBAdCf6p0YQULAWwd87zE2v4-jfYva0lYZ-KCYZczn7jmixhfJLT-y7s8OMepmy7o3zyhYeciD7PkjgjbH6AMibHH9Bdu-xMiXQD8tz0GVFN0T946pCllh73qGk9DLsanb-WI4yrZcXDKw3IMVxbH9NeCHYgmuR9okMNxU8zNZYwGAZ2lTFDbE-RXtxgOnN-lJxxU0Iuyuwov8COUytz4Tge~IKoPSTSNLBUj28SoSRcH09sL6Sv0l6tWlUla-7d1gC1SjVvvgzSsgzug8EqQyqy-SHQtqgz426f6hH708fte5d2-8oibIQqTLo3jxldtUua9U8EdooL~uLMHpg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":28235,"name":"Multidisciplinary","url":"https://www.academia.edu/Documents/in/Multidisciplinary"},{"id":220780,"name":"PLoS one","url":"https://www.academia.edu/Documents/in/PLoS_one"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14318115-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14318114"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14318114/Beh%C3%A7ets_Disease"><img alt="Research paper thumbnail of Behçet's Disease" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Behçet's Disease</div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a> and <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a></span></div><div class="wp-workCard_item"><span>Current treatment options in neurology</span><span>, 2011</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Neurologic involvement in Behçet&#39;s disease (BD) is seen in about 5% to 10% of all BD patients...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Neurologic involvement in Behçet&#39;s disease (BD) is seen in about 5% to 10% of all BD patients. Clinical and imaging data suggest that neurologic involvement in BD presents in two major forms. The first, central nervous system (CNS) parenchymal involvement with a predilection to brainstem-diencephalic regions, is seen in the majority of patients with neuro-BD (NBD). The second form is cerebral venous sinus thrombosis (CVST), which is seen in up to 20% of cases. BD is very rare in children, but when it does occur, the patterns are reversed: most children with NBD present with CVST. Other syndromes such as spinal cord involvement, arterial CNS involvement, optic neuritis, aseptic meningitis, and peripheral neuropathies may be seen, but are rare. Venous sinus thrombosis in BD has a significantly better neurologic prognosis than parenchymal CNS involvement. There is no Class I evidence regarding treatment of parenchymal CNS involvement or CVST in BD. Current treatment applications ar...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14318114"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14318114"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14318114; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14318114]").text(description); $(".js-view-count[data-work-id=14318114]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14318114; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14318114']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14318114]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14318114,"title":"Behçet's Disease","translated_title":"","metadata":{"abstract":"Neurologic involvement in Behçet\u0026#39;s disease (BD) is seen in about 5% to 10% of all BD patients. Clinical and imaging data suggest that neurologic involvement in BD presents in two major forms. The first, central nervous system (CNS) parenchymal involvement with a predilection to brainstem-diencephalic regions, is seen in the majority of patients with neuro-BD (NBD). The second form is cerebral venous sinus thrombosis (CVST), which is seen in up to 20% of cases. BD is very rare in children, but when it does occur, the patterns are reversed: most children with NBD present with CVST. Other syndromes such as spinal cord involvement, arterial CNS involvement, optic neuritis, aseptic meningitis, and peripheral neuropathies may be seen, but are rare. Venous sinus thrombosis in BD has a significantly better neurologic prognosis than parenchymal CNS involvement. There is no Class I evidence regarding treatment of parenchymal CNS involvement or CVST in BD. Current treatment applications ar...","publication_date":{"day":null,"month":null,"year":2011,"errors":{}},"publication_name":"Current treatment options in neurology"},"translated_abstract":"Neurologic involvement in Behçet\u0026#39;s disease (BD) is seen in about 5% to 10% of all BD patients. Clinical and imaging data suggest that neurologic involvement in BD presents in two major forms. The first, central nervous system (CNS) parenchymal involvement with a predilection to brainstem-diencephalic regions, is seen in the majority of patients with neuro-BD (NBD). The second form is cerebral venous sinus thrombosis (CVST), which is seen in up to 20% of cases. BD is very rare in children, but when it does occur, the patterns are reversed: most children with NBD present with CVST. Other syndromes such as spinal cord involvement, arterial CNS involvement, optic neuritis, aseptic meningitis, and peripheral neuropathies may be seen, but are rare. Venous sinus thrombosis in BD has a significantly better neurologic prognosis than parenchymal CNS involvement. There is no Class I evidence regarding treatment of parenchymal CNS involvement or CVST in BD. Current treatment applications ar...","internal_url":"https://www.academia.edu/14318114/Beh%C3%A7ets_Disease","translated_internal_url":"","created_at":"2015-07-22T22:34:47.000-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33272291,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3691340,"work_id":14318114,"tagging_user_id":33272291,"tagged_user_id":33207160,"co_author_invite_id":null,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":0,"name":"Aksel Siva","title":"Behçet's Disease"},{"id":3691355,"work_id":14318114,"tagging_user_id":33272291,"tagged_user_id":31879554,"co_author_invite_id":null,"email":"a***r@gmail.com","display_order":4194304,"name":"gulsen akman-demir","title":"Behçet's Disease"}],"downloadable_attachments":[],"slug":"Behçets_Disease","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"Neurologic involvement in Behçet\u0026#39;s disease (BD) is seen in about 5% to 10% of all BD patients. Clinical and imaging data suggest that neurologic involvement in BD presents in two major forms. The first, central nervous system (CNS) parenchymal involvement with a predilection to brainstem-diencephalic regions, is seen in the majority of patients with neuro-BD (NBD). The second form is cerebral venous sinus thrombosis (CVST), which is seen in up to 20% of cases. BD is very rare in children, but when it does occur, the patterns are reversed: most children with NBD present with CVST. Other syndromes such as spinal cord involvement, arterial CNS involvement, optic neuritis, aseptic meningitis, and peripheral neuropathies may be seen, but are rare. Venous sinus thrombosis in BD has a significantly better neurologic prognosis than parenchymal CNS involvement. There is no Class I evidence regarding treatment of parenchymal CNS involvement or CVST in BD. Current treatment applications ar...","owner":{"id":33272291,"first_name":"Sabahattin","middle_initials":null,"last_name":"Saip","page_name":"SabahattinSaip","domain_name":"istanbul","created_at":"2015-07-22T22:34:11.561-07:00","display_name":"Sabahattin Saip","url":"https://istanbul.academia.edu/SabahattinSaip"},"attachments":[],"research_interests":[],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14318114-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14318106"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/14318106/Headache_in_Beh_ets_Syndrome"><img alt="Research paper thumbnail of Headache in Beh�et's Syndrome" class="work-thumbnail" src="https://attachments.academia-assets.com/44325639/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/14318106/Headache_in_Beh_ets_Syndrome">Headache in Beh�et's Syndrome</a></div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a> and <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a></span></div><div class="wp-workCard_item"><span>Headache: The Journal of Head and Face Pain</span><span>, 2005</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Objective.-To study the frequencies and characteristics of different headache types seen in patie...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Objective.-To study the frequencies and characteristics of different headache types seen in patients with Behçet's syndrome (BS) in a large cohort of patients.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="a9526ccf52a690075050945466456e2c" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":44325639,"asset_id":14318106,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/44325639/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14318106"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14318106"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14318106; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14318106]").text(description); $(".js-view-count[data-work-id=14318106]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14318106; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14318106']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "a9526ccf52a690075050945466456e2c" } } $('.js-work-strip[data-work-id=14318106]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14318106,"title":"Headache in Beh�et's Syndrome","translated_title":"","metadata":{"ai_title_tag":"Headache Types in Behçet's Syndrome: A Cohort Study","grobid_abstract":"Objective.-To study the frequencies and characteristics of different headache types seen in patients with Behçet's syndrome (BS) in a large cohort of patients.","publication_date":{"day":null,"month":null,"year":2005,"errors":{}},"publication_name":"Headache: The Journal of Head and Face Pain","grobid_abstract_attachment_id":44325639},"translated_abstract":null,"internal_url":"https://www.academia.edu/14318106/Headache_in_Beh_ets_Syndrome","translated_internal_url":"","created_at":"2015-07-22T22:34:46.139-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33272291,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3691334,"work_id":14318106,"tagging_user_id":33272291,"tagged_user_id":451513,"co_author_invite_id":null,"email":"a***s@istanbul.edu.tr","affiliation":"Koç University","display_order":0,"name":"Ayse Altintas","title":"Headache in Beh�et's Syndrome"},{"id":3691344,"work_id":14318106,"tagging_user_id":33272291,"tagged_user_id":33207160,"co_author_invite_id":null,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":4194304,"name":"Aksel Siva","title":"Headache in Beh�et's Syndrome"},{"id":3691359,"work_id":14318106,"tagging_user_id":33272291,"tagged_user_id":null,"co_author_invite_id":823078,"email":"h***i@attglobal.net","display_order":6291456,"name":"Hasan Yazici","title":"Headache in Beh�et's Syndrome"}],"downloadable_attachments":[{"id":44325639,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325639/thumbnails/1.jpg","file_name":"Headache_in_Behets_Syndrome20160402-30516-13ohi8c.pdf","download_url":"https://www.academia.edu/attachments/44325639/download_file","bulk_download_file_name":"Headache_in_Beh_ets_Syndrome.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325639/Headache_in_Behets_Syndrome20160402-30516-13ohi8c-libre.pdf?1459602633=\u0026response-content-disposition=attachment%3B+filename%3DHeadache_in_Beh_ets_Syndrome.pdf\u0026Expires=1743574094\u0026Signature=MiD083609ukGFPTr1QWiL6ruTBXnNY6xd8sHnwPx-Ia2d4ddHDvrlbhn1cTSP8nodG~mYk5rtDGvkvL95BsmXFjFd9iTy~cwryk9YIMXNKUQKcBeALLzg7DATmQp4ATPhdfeeCd0FfRD5TFXPja1FpQfq6sGp-vfM800KMORZZ5dZpVzVTf8qVmJsxR36BrVoKEff-kDaYrVgNBwP9aRlhvubGp25oVqr7lhhg4JbjCNa3pemF1vlBDRYfgt~zupMO4t56nwPfHKHMmmsk42fpbg5TIkTXkrMM2AWFBmbffK1ku~aneSTPpIUcS2ulbwCMm~~zvOu0taeSlB0j5tkg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Headache_in_Beh_ets_Syndrome","translated_slug":"","page_count":9,"language":"en","content_type":"Work","summary":"Objective.-To study the frequencies and characteristics of different headache types seen in patients with Behçet's syndrome (BS) in a large cohort of patients.","owner":{"id":33272291,"first_name":"Sabahattin","middle_initials":null,"last_name":"Saip","page_name":"SabahattinSaip","domain_name":"istanbul","created_at":"2015-07-22T22:34:11.561-07:00","display_name":"Sabahattin Saip","url":"https://istanbul.academia.edu/SabahattinSaip"},"attachments":[{"id":44325639,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44325639/thumbnails/1.jpg","file_name":"Headache_in_Behets_Syndrome20160402-30516-13ohi8c.pdf","download_url":"https://www.academia.edu/attachments/44325639/download_file","bulk_download_file_name":"Headache_in_Beh_ets_Syndrome.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44325639/Headache_in_Behets_Syndrome20160402-30516-13ohi8c-libre.pdf?1459602633=\u0026response-content-disposition=attachment%3B+filename%3DHeadache_in_Beh_ets_Syndrome.pdf\u0026Expires=1743574094\u0026Signature=MiD083609ukGFPTr1QWiL6ruTBXnNY6xd8sHnwPx-Ia2d4ddHDvrlbhn1cTSP8nodG~mYk5rtDGvkvL95BsmXFjFd9iTy~cwryk9YIMXNKUQKcBeALLzg7DATmQp4ATPhdfeeCd0FfRD5TFXPja1FpQfq6sGp-vfM800KMORZZ5dZpVzVTf8qVmJsxR36BrVoKEff-kDaYrVgNBwP9aRlhvubGp25oVqr7lhhg4JbjCNa3pemF1vlBDRYfgt~zupMO4t56nwPfHKHMmmsk42fpbg5TIkTXkrMM2AWFBmbffK1ku~aneSTPpIUcS2ulbwCMm~~zvOu0taeSlB0j5tkg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":103108,"name":"Headache","url":"https://www.academia.edu/Documents/in/Headache"},{"id":161176,"name":"The","url":"https://www.academia.edu/Documents/in/The"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":289330,"name":"Prevalence","url":"https://www.academia.edu/Documents/in/Prevalence"},{"id":612548,"name":"Tension-Type Headache","url":"https://www.academia.edu/Documents/in/Tension-Type_Headache"},{"id":1819400,"name":"Cohort Studies","url":"https://www.academia.edu/Documents/in/Cohort_Studies"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14318106-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233406"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/14233406/CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes"><img alt="Research paper thumbnail of CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes" class="work-thumbnail" src="https://attachments.academia-assets.com/44424607/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/14233406/CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes">CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes</a></div><div class="wp-workCard_item"><span>PLOS ONE</span><span>, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Multiple sclerosis (MS) is an immune-mediated, neuro-inflammatory, demyelinating and neurodegener...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Multiple sclerosis (MS) is an immune-mediated, neuro-inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS) with a heterogeneous clinical presentation and course. There is a remarkable phenotypic heterogeneity in MS, and the molecular mechanisms underlying it remain unknown. We aimed to investigate further the etiopathogenesis related molecular pathways in subclinical types of MS using proteomic and bioinformatics approaches in cerebrospinal fluids of patients with clinically isolated syndrome, relapsing remitting MS and progressive MS (n=179). Comparison of disease groups with controls revealed a total of 151 proteins that are differentially expressed in clinically different MS subtypes. KEGG analysis using PANOGA tool revealed the disease related pathways including aldosterone-regulated sodium reabsorption (p=8.02x10 -5 ) which is important in the immune cell migration, renin-angiotensin (p=6.88x10 -5 ) system that induces Th17 dependent immunity, notch signaling (p=1.83x10 -10 ) pathway indicating the activated remyelination and vitamin digestion and absorption pathways (p=1.73x10 -5 ). An emerging theme from our studies is that whilst all MS clinical forms share common biological pathways, there are also clinical subtypes specific and pathophysiology related pathways which may have further therapeutic implications.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="854adf0f7b372df387548985e4b96ad8" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":44424607,"asset_id":14233406,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/44424607/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233406"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233406"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233406; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233406]").text(description); $(".js-view-count[data-work-id=14233406]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233406; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233406']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "854adf0f7b372df387548985e4b96ad8" } } $('.js-work-strip[data-work-id=14233406]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233406,"title":"CSF Proteomics Identifies Specific and Shared Pathways for Multiple Sclerosis Clinical Subtypes","translated_title":"","metadata":{"ai_title_tag":"CSF Proteomics Reveals MS Pathways and Subtypes","grobid_abstract":"Multiple sclerosis (MS) is an immune-mediated, neuro-inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS) with a heterogeneous clinical presentation and course. There is a remarkable phenotypic heterogeneity in MS, and the molecular mechanisms underlying it remain unknown. We aimed to investigate further the etiopathogenesis related molecular pathways in subclinical types of MS using proteomic and bioinformatics approaches in cerebrospinal fluids of patients with clinically isolated syndrome, relapsing remitting MS and progressive MS (n=179). Comparison of disease groups with controls revealed a total of 151 proteins that are differentially expressed in clinically different MS subtypes. KEGG analysis using PANOGA tool revealed the disease related pathways including aldosterone-regulated sodium reabsorption (p=8.02x10 -5 ) which is important in the immune cell migration, renin-angiotensin (p=6.88x10 -5 ) system that induces Th17 dependent immunity, notch signaling (p=1.83x10 -10 ) pathway indicating the activated remyelination and vitamin digestion and absorption pathways (p=1.73x10 -5 ). An emerging theme from our studies is that whilst all MS clinical forms share common biological pathways, there are also clinical subtypes specific and pathophysiology related pathways which may have further therapeutic implications.","publication_date":{"day":null,"month":null,"year":2015,"errors":{}},"publication_name":"PLOS ONE","grobid_abstract_attachment_id":44424607},"translated_abstract":null,"internal_url":"https://www.academia.edu/14233406/CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes","translated_internal_url":"","created_at":"2015-07-20T14:59:55.669-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":44424607,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44424607/thumbnails/1.jpg","file_name":"CSF_Proteomics_Identifies_Specific_and_S20160405-13963-emfyfj.pdf","download_url":"https://www.academia.edu/attachments/44424607/download_file","bulk_download_file_name":"CSF_Proteomics_Identifies_Specific_and_S.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44424607/CSF_Proteomics_Identifies_Specific_and_S20160405-13963-emfyfj-libre.pdf?1459843938=\u0026response-content-disposition=attachment%3B+filename%3DCSF_Proteomics_Identifies_Specific_and_S.pdf\u0026Expires=1743603792\u0026Signature=NqjvFyisOnH9nG3Xjp-HyM~RCpzIuRTDJlE7AP0GjVIt-To5gm0dovce3r2P7O6z8Af3jDsaCy~QoHzm-sVPotzxzeixjJMdy2s8bd5V7ldfvcEA77ssdYaxtUjstMnWpGC95ouePcodIfOmYXmsj2tQi8u-1OG-7ok9jfi2g71sIVVHh~RTWnM9WTLVgph-pm9so5IRXjjK5biyXXsJyG4LlOjSGJ6nn8ZbxpLGt-rM96GiYksvBtolEqihDs3IgD38RKr-opZrG11Q3YLFvzHd2jzZRzuGV~LXvS~O0wROv7ELlmMg59ZID0Z3jVV-3dzhl4gA0G0oVnGaAn8Frg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"CSF_Proteomics_Identifies_Specific_and_Shared_Pathways_for_Multiple_Sclerosis_Clinical_Subtypes","translated_slug":"","page_count":18,"language":"en","content_type":"Work","summary":"Multiple sclerosis (MS) is an immune-mediated, neuro-inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS) with a heterogeneous clinical presentation and course. There is a remarkable phenotypic heterogeneity in MS, and the molecular mechanisms underlying it remain unknown. We aimed to investigate further the etiopathogenesis related molecular pathways in subclinical types of MS using proteomic and bioinformatics approaches in cerebrospinal fluids of patients with clinically isolated syndrome, relapsing remitting MS and progressive MS (n=179). Comparison of disease groups with controls revealed a total of 151 proteins that are differentially expressed in clinically different MS subtypes. KEGG analysis using PANOGA tool revealed the disease related pathways including aldosterone-regulated sodium reabsorption (p=8.02x10 -5 ) which is important in the immune cell migration, renin-angiotensin (p=6.88x10 -5 ) system that induces Th17 dependent immunity, notch signaling (p=1.83x10 -10 ) pathway indicating the activated remyelination and vitamin digestion and absorption pathways (p=1.73x10 -5 ). An emerging theme from our studies is that whilst all MS clinical forms share common biological pathways, there are also clinical subtypes specific and pathophysiology related pathways which may have further therapeutic implications.","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[{"id":44424607,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44424607/thumbnails/1.jpg","file_name":"CSF_Proteomics_Identifies_Specific_and_S20160405-13963-emfyfj.pdf","download_url":"https://www.academia.edu/attachments/44424607/download_file","bulk_download_file_name":"CSF_Proteomics_Identifies_Specific_and_S.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44424607/CSF_Proteomics_Identifies_Specific_and_S20160405-13963-emfyfj-libre.pdf?1459843938=\u0026response-content-disposition=attachment%3B+filename%3DCSF_Proteomics_Identifies_Specific_and_S.pdf\u0026Expires=1743603792\u0026Signature=NqjvFyisOnH9nG3Xjp-HyM~RCpzIuRTDJlE7AP0GjVIt-To5gm0dovce3r2P7O6z8Af3jDsaCy~QoHzm-sVPotzxzeixjJMdy2s8bd5V7ldfvcEA77ssdYaxtUjstMnWpGC95ouePcodIfOmYXmsj2tQi8u-1OG-7ok9jfi2g71sIVVHh~RTWnM9WTLVgph-pm9so5IRXjjK5biyXXsJyG4LlOjSGJ6nn8ZbxpLGt-rM96GiYksvBtolEqihDs3IgD38RKr-opZrG11Q3YLFvzHd2jzZRzuGV~LXvS~O0wROv7ELlmMg59ZID0Z3jVV-3dzhl4gA0G0oVnGaAn8Frg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":28235,"name":"Multidisciplinary","url":"https://www.academia.edu/Documents/in/Multidisciplinary"},{"id":220780,"name":"PLoS one","url":"https://www.academia.edu/Documents/in/PLoS_one"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233406-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233405"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/14233405/Early_CNS_neurodegeneration_in_radiologically_isolated_syndrome"><img alt="Research paper thumbnail of Early CNS neurodegeneration in radiologically isolated syndrome" class="work-thumbnail" src="https://attachments.academia-assets.com/44424617/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/14233405/Early_CNS_neurodegeneration_in_radiologically_isolated_syndrome">Early CNS neurodegeneration in radiologically isolated syndrome</a></div><div class="wp-workCard_item"><span>Neurology® neuroimmunology & neuroinflammation</span><span>, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Increasing evidence indicates that the thalamus may be a location of early neurodegeneration in m...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Increasing evidence indicates that the thalamus may be a location of early neurodegeneration in multiple sclerosis (MS). Our objective was to identify the presence of gray matter volume loss and thinning in patients with radiologically isolated syndrome (RIS). Sixty-three participants were included in this case-control study. Twenty-one patients with RIS were age- and sex-matched to 42 healthy controls in a 1:2 ratio. All participants underwent brain MRIs on a single 3T scanner. After lesion segmentation and inpainting, 1 mm(3)-isometric T1-weighted images were submitted to FreeSurfer (v5.2). Normalized cortical and deep gray matter volumes were compared between patients with RIS and controls using t tests, and thalamic volumes were correlated with white matter lesion volumes using Pearson correlation. Exploratory cortical thickness maps were created. Although traditional normalized total gray and white matter volumes were not statistically different between patients with RIS and co...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="c978763772bb8b145a0532e77372f829" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":44424617,"asset_id":14233405,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/44424617/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233405"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233405"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233405; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233405]").text(description); $(".js-view-count[data-work-id=14233405]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233405; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233405']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "c978763772bb8b145a0532e77372f829" } } $('.js-work-strip[data-work-id=14233405]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233405,"title":"Early CNS neurodegeneration in radiologically isolated syndrome","translated_title":"","metadata":{"abstract":"Increasing evidence indicates that the thalamus may be a location of early neurodegeneration in multiple sclerosis (MS). Our objective was to identify the presence of gray matter volume loss and thinning in patients with radiologically isolated syndrome (RIS). Sixty-three participants were included in this case-control study. Twenty-one patients with RIS were age- and sex-matched to 42 healthy controls in a 1:2 ratio. All participants underwent brain MRIs on a single 3T scanner. After lesion segmentation and inpainting, 1 mm(3)-isometric T1-weighted images were submitted to FreeSurfer (v5.2). Normalized cortical and deep gray matter volumes were compared between patients with RIS and controls using t tests, and thalamic volumes were correlated with white matter lesion volumes using Pearson correlation. Exploratory cortical thickness maps were created. Although traditional normalized total gray and white matter volumes were not statistically different between patients with RIS and co...","publication_date":{"day":null,"month":null,"year":2015,"errors":{}},"publication_name":"Neurology® neuroimmunology \u0026 neuroinflammation"},"translated_abstract":"Increasing evidence indicates that the thalamus may be a location of early neurodegeneration in multiple sclerosis (MS). Our objective was to identify the presence of gray matter volume loss and thinning in patients with radiologically isolated syndrome (RIS). Sixty-three participants were included in this case-control study. Twenty-one patients with RIS were age- and sex-matched to 42 healthy controls in a 1:2 ratio. All participants underwent brain MRIs on a single 3T scanner. After lesion segmentation and inpainting, 1 mm(3)-isometric T1-weighted images were submitted to FreeSurfer (v5.2). Normalized cortical and deep gray matter volumes were compared between patients with RIS and controls using t tests, and thalamic volumes were correlated with white matter lesion volumes using Pearson correlation. Exploratory cortical thickness maps were created. Although traditional normalized total gray and white matter volumes were not statistically different between patients with RIS and co...","internal_url":"https://www.academia.edu/14233405/Early_CNS_neurodegeneration_in_radiologically_isolated_syndrome","translated_internal_url":"","created_at":"2015-07-20T14:59:55.585-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":44424617,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44424617/thumbnails/1.jpg","file_name":"Early_CNS_neurodegeneration_in_radiologi20160405-9240-n4i7i8.pdf","download_url":"https://www.academia.edu/attachments/44424617/download_file","bulk_download_file_name":"Early_CNS_neurodegeneration_in_radiologi.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44424617/Early_CNS_neurodegeneration_in_radiologi20160405-9240-n4i7i8-libre.pdf?1459843937=\u0026response-content-disposition=attachment%3B+filename%3DEarly_CNS_neurodegeneration_in_radiologi.pdf\u0026Expires=1743585185\u0026Signature=enLrYC2at4TOVhmU3-KCoDYclqJAqrH7kduWucoFRWujBcN6L5KsjMgcY~ImiR2YYKIqMyJ27rv~dAnYlHjHZgR~-hP6c01GR0N6kuisqi7zGrW7btnMPeVtXeFMtP~CcKVon-QCKJFIMXkt-oWOHGHVfVnLu3C4jP0pklgqnWz~SDWl73Z0j2uus1VwYJQuQxlD4LbnjQ6FEyMGgsp8y8FnVovUNRi~2btpuqGBwz-PUEiDi27~yOpJH0imKtowVjVSRktQuTejSm9aBwtN-QVdFywclxJ2Kg~4fss-YK~pRUuWdgbws1K0W5OCL58enTOWQnK8XDu3HyAg2fV7gw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Early_CNS_neurodegeneration_in_radiologically_isolated_syndrome","translated_slug":"","page_count":5,"language":"en","content_type":"Work","summary":"Increasing evidence indicates that the thalamus may be a location of early neurodegeneration in multiple sclerosis (MS). Our objective was to identify the presence of gray matter volume loss and thinning in patients with radiologically isolated syndrome (RIS). Sixty-three participants were included in this case-control study. Twenty-one patients with RIS were age- and sex-matched to 42 healthy controls in a 1:2 ratio. All participants underwent brain MRIs on a single 3T scanner. After lesion segmentation and inpainting, 1 mm(3)-isometric T1-weighted images were submitted to FreeSurfer (v5.2). Normalized cortical and deep gray matter volumes were compared between patients with RIS and controls using t tests, and thalamic volumes were correlated with white matter lesion volumes using Pearson correlation. Exploratory cortical thickness maps were created. Although traditional normalized total gray and white matter volumes were not statistically different between patients with RIS and co...","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[{"id":44424617,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44424617/thumbnails/1.jpg","file_name":"Early_CNS_neurodegeneration_in_radiologi20160405-9240-n4i7i8.pdf","download_url":"https://www.academia.edu/attachments/44424617/download_file","bulk_download_file_name":"Early_CNS_neurodegeneration_in_radiologi.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44424617/Early_CNS_neurodegeneration_in_radiologi20160405-9240-n4i7i8-libre.pdf?1459843937=\u0026response-content-disposition=attachment%3B+filename%3DEarly_CNS_neurodegeneration_in_radiologi.pdf\u0026Expires=1743585185\u0026Signature=enLrYC2at4TOVhmU3-KCoDYclqJAqrH7kduWucoFRWujBcN6L5KsjMgcY~ImiR2YYKIqMyJ27rv~dAnYlHjHZgR~-hP6c01GR0N6kuisqi7zGrW7btnMPeVtXeFMtP~CcKVon-QCKJFIMXkt-oWOHGHVfVnLu3C4jP0pklgqnWz~SDWl73Z0j2uus1VwYJQuQxlD4LbnjQ6FEyMGgsp8y8FnVovUNRi~2btpuqGBwz-PUEiDi27~yOpJH0imKtowVjVSRktQuTejSm9aBwtN-QVdFywclxJ2Kg~4fss-YK~pRUuWdgbws1K0W5OCL58enTOWQnK8XDu3HyAg2fV7gw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233405-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233404"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14233404/Beh%C3%A7ets_Disease"><img alt="Research paper thumbnail of Behçet's Disease" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Behçet's Disease</div><div class="wp-workCard_item"><span>Current Treatment Options in Neurology</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">OPINION STATEMENT: Neurologic involvement in Behçet&#39;s disease (BD) is seen in about 5% to 10%...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">OPINION STATEMENT: Neurologic involvement in Behçet&#39;s disease (BD) is seen in about 5% to 10% of all BD patients. Clinical and imaging data suggest that neurologic involvement in BD presents in two major forms. The first, central nervous system (CNS) parenchymal involvement with a predilection to brainstem-diencephalic regions, is seen in the majority of patients with neuro-BD (NBD). The second form is cerebral venous sinus thrombosis (CVST), which is seen in up to 20% of cases. BD is very rare in children, but when it does occur, the patterns are reversed: most children with NBD present with CVST. Other syndromes such as spinal cord involvement, arterial CNS involvement, optic neuritis, aseptic meningitis, and peripheral neuropathies may be seen, but are rare. Venous sinus thrombosis in BD has a significantly better neurologic prognosis than parenchymal CNS involvement. There is no Class I evidence regarding treatment of parenchymal CNS involvement or CVST in BD. Current treatm...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233404"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233404"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233404; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233404]").text(description); $(".js-view-count[data-work-id=14233404]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233404; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233404']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14233404]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233404,"title":"Behçet's Disease","translated_title":"","metadata":{"abstract":"OPINION STATEMENT: Neurologic involvement in Behçet\u0026#39;s disease (BD) is seen in about 5% to 10% of all BD patients. Clinical and imaging data suggest that neurologic involvement in BD presents in two major forms. The first, central nervous system (CNS) parenchymal involvement with a predilection to brainstem-diencephalic regions, is seen in the majority of patients with neuro-BD (NBD). The second form is cerebral venous sinus thrombosis (CVST), which is seen in up to 20% of cases. BD is very rare in children, but when it does occur, the patterns are reversed: most children with NBD present with CVST. Other syndromes such as spinal cord involvement, arterial CNS involvement, optic neuritis, aseptic meningitis, and peripheral neuropathies may be seen, but are rare. Venous sinus thrombosis in BD has a significantly better neurologic prognosis than parenchymal CNS involvement. There is no Class I evidence regarding treatment of parenchymal CNS involvement or CVST in BD. Current treatm...","publication_name":"Current Treatment Options in Neurology"},"translated_abstract":"OPINION STATEMENT: Neurologic involvement in Behçet\u0026#39;s disease (BD) is seen in about 5% to 10% of all BD patients. Clinical and imaging data suggest that neurologic involvement in BD presents in two major forms. The first, central nervous system (CNS) parenchymal involvement with a predilection to brainstem-diencephalic regions, is seen in the majority of patients with neuro-BD (NBD). The second form is cerebral venous sinus thrombosis (CVST), which is seen in up to 20% of cases. BD is very rare in children, but when it does occur, the patterns are reversed: most children with NBD present with CVST. Other syndromes such as spinal cord involvement, arterial CNS involvement, optic neuritis, aseptic meningitis, and peripheral neuropathies may be seen, but are rare. Venous sinus thrombosis in BD has a significantly better neurologic prognosis than parenchymal CNS involvement. There is no Class I evidence regarding treatment of parenchymal CNS involvement or CVST in BD. Current treatm...","internal_url":"https://www.academia.edu/14233404/Beh%C3%A7ets_Disease","translated_internal_url":"","created_at":"2015-07-20T14:59:55.499-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Behçets_Disease","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"OPINION STATEMENT: Neurologic involvement in Behçet\u0026#39;s disease (BD) is seen in about 5% to 10% of all BD patients. Clinical and imaging data suggest that neurologic involvement in BD presents in two major forms. The first, central nervous system (CNS) parenchymal involvement with a predilection to brainstem-diencephalic regions, is seen in the majority of patients with neuro-BD (NBD). The second form is cerebral venous sinus thrombosis (CVST), which is seen in up to 20% of cases. BD is very rare in children, but when it does occur, the patterns are reversed: most children with NBD present with CVST. Other syndromes such as spinal cord involvement, arterial CNS involvement, optic neuritis, aseptic meningitis, and peripheral neuropathies may be seen, but are rare. Venous sinus thrombosis in BD has a significantly better neurologic prognosis than parenchymal CNS involvement. There is no Class I evidence regarding treatment of parenchymal CNS involvement or CVST in BD. Current treatm...","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[],"research_interests":[],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233404-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233403"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14233403/Gender_influences_headache_characteristics_with_increasing_age_in_migraine_patients"><img alt="Research paper thumbnail of Gender influences headache characteristics with increasing age in migraine patients" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Gender influences headache characteristics with increasing age in migraine patients</div><div class="wp-workCard_item"><span>Cephalalgia</span><span>, 2014</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Migraine headache is one of the most common primary headache disorders and is three times more pr...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Migraine headache is one of the most common primary headache disorders and is three times more prevalent in women than in men, especially during the reproductive ages. The neurobiological basis of the female dominance has been partly established. The present study aimed to investigate the effect of gender on the headache manifestations in migraine patients. The study group consisted of 2082 adult patients from five different hospitals&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39; tertiary care-based headache clinics. The relationship between headache characteristics and gender was evaluated in migraine with aura (MwA) and migraine without aura (MwoA). The duration, severity, frequency of headache and associated symptoms were evaluated in both genders and age-dependent variations and analyzed in two subgroups. Women with migraine were prone to significantly longer duration and intensity of headache attacks. Nausea, phonophobia and photophobia were more prevalent in women. Median headache duration was also longer in women than in men in MwA (p = 0.013) and MwoA (p &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.001). Median headache intensity was higher in women than in men in MwA (p = 0.010) and MwoA (p = 0.009). The frequency of nausea was significantly higher in women than in men in MwA (p = 0.049). Throbbing headache quality and associated features (nausea, photophobia, and phonophobia) were significantly more frequent in women than in men in MwoA. The gender impact varied across age groups and significant changes were seen in female migraineurs after age 30. No age-dependent variation was observed in male migraineurs. Gender has an influence on the characteristics of the headache as well as on the associated symptoms in migraine patients, and this impact varies across the age groups, particularly in women.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233403"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233403"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233403; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233403]").text(description); $(".js-view-count[data-work-id=14233403]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233403; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233403']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14233403]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233403,"title":"Gender influences headache characteristics with increasing age in migraine patients","translated_title":"","metadata":{"abstract":"Migraine headache is one of the most common primary headache disorders and is three times more prevalent in women than in men, especially during the reproductive ages. The neurobiological basis of the female dominance has been partly established. The present study aimed to investigate the effect of gender on the headache manifestations in migraine patients. The study group consisted of 2082 adult patients from five different hospitals\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39; tertiary care-based headache clinics. The relationship between headache characteristics and gender was evaluated in migraine with aura (MwA) and migraine without aura (MwoA). The duration, severity, frequency of headache and associated symptoms were evaluated in both genders and age-dependent variations and analyzed in two subgroups. Women with migraine were prone to significantly longer duration and intensity of headache attacks. Nausea, phonophobia and photophobia were more prevalent in women. Median headache duration was also longer in women than in men in MwA (p = 0.013) and MwoA (p \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.001). Median headache intensity was higher in women than in men in MwA (p = 0.010) and MwoA (p = 0.009). The frequency of nausea was significantly higher in women than in men in MwA (p = 0.049). Throbbing headache quality and associated features (nausea, photophobia, and phonophobia) were significantly more frequent in women than in men in MwoA. The gender impact varied across age groups and significant changes were seen in female migraineurs after age 30. No age-dependent variation was observed in male migraineurs. Gender has an influence on the characteristics of the headache as well as on the associated symptoms in migraine patients, and this impact varies across the age groups, particularly in women.","publication_date":{"day":null,"month":null,"year":2014,"errors":{}},"publication_name":"Cephalalgia"},"translated_abstract":"Migraine headache is one of the most common primary headache disorders and is three times more prevalent in women than in men, especially during the reproductive ages. The neurobiological basis of the female dominance has been partly established. The present study aimed to investigate the effect of gender on the headache manifestations in migraine patients. The study group consisted of 2082 adult patients from five different hospitals\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39; tertiary care-based headache clinics. The relationship between headache characteristics and gender was evaluated in migraine with aura (MwA) and migraine without aura (MwoA). The duration, severity, frequency of headache and associated symptoms were evaluated in both genders and age-dependent variations and analyzed in two subgroups. Women with migraine were prone to significantly longer duration and intensity of headache attacks. Nausea, phonophobia and photophobia were more prevalent in women. Median headache duration was also longer in women than in men in MwA (p = 0.013) and MwoA (p \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.001). Median headache intensity was higher in women than in men in MwA (p = 0.010) and MwoA (p = 0.009). The frequency of nausea was significantly higher in women than in men in MwA (p = 0.049). Throbbing headache quality and associated features (nausea, photophobia, and phonophobia) were significantly more frequent in women than in men in MwoA. The gender impact varied across age groups and significant changes were seen in female migraineurs after age 30. No age-dependent variation was observed in male migraineurs. Gender has an influence on the characteristics of the headache as well as on the associated symptoms in migraine patients, and this impact varies across the age groups, particularly in women.","internal_url":"https://www.academia.edu/14233403/Gender_influences_headache_characteristics_with_increasing_age_in_migraine_patients","translated_internal_url":"","created_at":"2015-07-20T14:59:55.417-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Gender_influences_headache_characteristics_with_increasing_age_in_migraine_patients","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"Migraine headache is one of the most common primary headache disorders and is three times more prevalent in women than in men, especially during the reproductive ages. The neurobiological basis of the female dominance has been partly established. The present study aimed to investigate the effect of gender on the headache manifestations in migraine patients. The study group consisted of 2082 adult patients from five different hospitals\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39; tertiary care-based headache clinics. The relationship between headache characteristics and gender was evaluated in migraine with aura (MwA) and migraine without aura (MwoA). The duration, severity, frequency of headache and associated symptoms were evaluated in both genders and age-dependent variations and analyzed in two subgroups. Women with migraine were prone to significantly longer duration and intensity of headache attacks. Nausea, phonophobia and photophobia were more prevalent in women. Median headache duration was also longer in women than in men in MwA (p = 0.013) and MwoA (p \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt; 0.001). Median headache intensity was higher in women than in men in MwA (p = 0.010) and MwoA (p = 0.009). The frequency of nausea was significantly higher in women than in men in MwA (p = 0.049). Throbbing headache quality and associated features (nausea, photophobia, and phonophobia) were significantly more frequent in women than in men in MwoA. The gender impact varied across age groups and significant changes were seen in female migraineurs after age 30. No age-dependent variation was observed in male migraineurs. Gender has an influence on the characteristics of the headache as well as on the associated symptoms in migraine patients, and this impact varies across the age groups, particularly in women.","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[],"research_interests":[{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":1239755,"name":"Neurosciences","url":"https://www.academia.edu/Documents/in/Neurosciences"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233403-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233402"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14233402/Corticosteroid_therapy_augments_gastroduodenal_permeability_to_sucrose"><img alt="Research paper thumbnail of Corticosteroid therapy augments gastroduodenal permeability to sucrose" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Corticosteroid therapy augments gastroduodenal permeability to sucrose</div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a> and <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a></span></div><div class="wp-workCard_item"><span>The American Journal of Gastroenterology</span><span>, 1998</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">The aim of the present study was to investigate whether corticosteroid therapy alters gastroduode...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">The aim of the present study was to investigate whether corticosteroid therapy alters gastroduodenal mucosal permeability and whether permeability alteration is associated with macroscopic mucosal damage. Eight patients taking oral corticosteroid therapy (total prednisone-equivalent dose, 1.5+/-0.1 g; duration, approximately 30 days), nine patients with multiple sclerosis taking high-dose intravenous methyl-prednisolone therapy (total dose, 11.7+/-0.5 g; duration, approximately 9 days), and 20 age- and gender-matched controls were studied. Gastroduodenal permeability was determined using sucrose as a site-specific permeability probe. Five-hour urine was collected after ingesting 100 g of sucrose and its urinary excretion rate was measured using high-pressure liquid chromatography. Gastroduodenal endoscopy was performed before steroid therapy to exclude subjects with evidence of macroscopic mucosal lesions. The sucrose test and endoscopy were repeated after completion of corticosteroid therapy. The urinary sucrose excretion rates were similar in the control group and in patient groups before corticosteroid therapy. The median excretion rate of sucrose increased four (one to 28)- and eight (two to 35)-fold, respectively, as compared with pretreatment values in patients taking oral steroid and high-dose intravenous methyl-prednisolone therapy (p &amp;amp;amp;lt; 0.01). Considering all patients together, subjects who received a mean prednisone-equivalent dose of 8.4+/-1.5 g exhibited mucosal lesions, whereas patients who received 3.3+/-1.8 g did not (p = 0.06). The post-therapy increments in sucrose excretion rates were associated with neither the presence of macroscopic lesions nor with the total steroid dose received. Corticosteroid therapy augments gastroduodenal permeability and high doses are associated with macroscopic mucosal lesions. Steroid-induced permeability increase does not appear to be associated with the presence of macroscopic mucosal lesions.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233402"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233402"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233402; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233402]").text(description); $(".js-view-count[data-work-id=14233402]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233402; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233402']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14233402]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233402,"title":"Corticosteroid therapy augments gastroduodenal permeability to sucrose","translated_title":"","metadata":{"abstract":"The aim of the present study was to investigate whether corticosteroid therapy alters gastroduodenal mucosal permeability and whether permeability alteration is associated with macroscopic mucosal damage. Eight patients taking oral corticosteroid therapy (total prednisone-equivalent dose, 1.5+/-0.1 g; duration, approximately 30 days), nine patients with multiple sclerosis taking high-dose intravenous methyl-prednisolone therapy (total dose, 11.7+/-0.5 g; duration, approximately 9 days), and 20 age- and gender-matched controls were studied. Gastroduodenal permeability was determined using sucrose as a site-specific permeability probe. Five-hour urine was collected after ingesting 100 g of sucrose and its urinary excretion rate was measured using high-pressure liquid chromatography. Gastroduodenal endoscopy was performed before steroid therapy to exclude subjects with evidence of macroscopic mucosal lesions. The sucrose test and endoscopy were repeated after completion of corticosteroid therapy. The urinary sucrose excretion rates were similar in the control group and in patient groups before corticosteroid therapy. The median excretion rate of sucrose increased four (one to 28)- and eight (two to 35)-fold, respectively, as compared with pretreatment values in patients taking oral steroid and high-dose intravenous methyl-prednisolone therapy (p \u0026amp;amp;amp;lt; 0.01). Considering all patients together, subjects who received a mean prednisone-equivalent dose of 8.4+/-1.5 g exhibited mucosal lesions, whereas patients who received 3.3+/-1.8 g did not (p = 0.06). The post-therapy increments in sucrose excretion rates were associated with neither the presence of macroscopic lesions nor with the total steroid dose received. Corticosteroid therapy augments gastroduodenal permeability and high doses are associated with macroscopic mucosal lesions. Steroid-induced permeability increase does not appear to be associated with the presence of macroscopic mucosal lesions.","publication_date":{"day":null,"month":null,"year":1998,"errors":{}},"publication_name":"The American Journal of Gastroenterology"},"translated_abstract":"The aim of the present study was to investigate whether corticosteroid therapy alters gastroduodenal mucosal permeability and whether permeability alteration is associated with macroscopic mucosal damage. Eight patients taking oral corticosteroid therapy (total prednisone-equivalent dose, 1.5+/-0.1 g; duration, approximately 30 days), nine patients with multiple sclerosis taking high-dose intravenous methyl-prednisolone therapy (total dose, 11.7+/-0.5 g; duration, approximately 9 days), and 20 age- and gender-matched controls were studied. Gastroduodenal permeability was determined using sucrose as a site-specific permeability probe. Five-hour urine was collected after ingesting 100 g of sucrose and its urinary excretion rate was measured using high-pressure liquid chromatography. Gastroduodenal endoscopy was performed before steroid therapy to exclude subjects with evidence of macroscopic mucosal lesions. The sucrose test and endoscopy were repeated after completion of corticosteroid therapy. The urinary sucrose excretion rates were similar in the control group and in patient groups before corticosteroid therapy. The median excretion rate of sucrose increased four (one to 28)- and eight (two to 35)-fold, respectively, as compared with pretreatment values in patients taking oral steroid and high-dose intravenous methyl-prednisolone therapy (p \u0026amp;amp;amp;lt; 0.01). Considering all patients together, subjects who received a mean prednisone-equivalent dose of 8.4+/-1.5 g exhibited mucosal lesions, whereas patients who received 3.3+/-1.8 g did not (p = 0.06). The post-therapy increments in sucrose excretion rates were associated with neither the presence of macroscopic lesions nor with the total steroid dose received. Corticosteroid therapy augments gastroduodenal permeability and high doses are associated with macroscopic mucosal lesions. Steroid-induced permeability increase does not appear to be associated with the presence of macroscopic mucosal lesions.","internal_url":"https://www.academia.edu/14233402/Corticosteroid_therapy_augments_gastroduodenal_permeability_to_sucrose","translated_internal_url":"","created_at":"2015-07-20T14:59:55.315-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3517906,"work_id":14233402,"tagging_user_id":33207160,"tagged_user_id":33272291,"co_author_invite_id":765886,"email":"p***p@superonline.com","affiliation":"Istanbul University","display_order":0,"name":"Sabahattin Saip","title":"Corticosteroid therapy augments gastroduodenal permeability to sucrose"}],"downloadable_attachments":[],"slug":"Corticosteroid_therapy_augments_gastroduodenal_permeability_to_sucrose","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"The aim of the present study was to investigate whether corticosteroid therapy alters gastroduodenal mucosal permeability and whether permeability alteration is associated with macroscopic mucosal damage. Eight patients taking oral corticosteroid therapy (total prednisone-equivalent dose, 1.5+/-0.1 g; duration, approximately 30 days), nine patients with multiple sclerosis taking high-dose intravenous methyl-prednisolone therapy (total dose, 11.7+/-0.5 g; duration, approximately 9 days), and 20 age- and gender-matched controls were studied. Gastroduodenal permeability was determined using sucrose as a site-specific permeability probe. Five-hour urine was collected after ingesting 100 g of sucrose and its urinary excretion rate was measured using high-pressure liquid chromatography. Gastroduodenal endoscopy was performed before steroid therapy to exclude subjects with evidence of macroscopic mucosal lesions. The sucrose test and endoscopy were repeated after completion of corticosteroid therapy. The urinary sucrose excretion rates were similar in the control group and in patient groups before corticosteroid therapy. The median excretion rate of sucrose increased four (one to 28)- and eight (two to 35)-fold, respectively, as compared with pretreatment values in patients taking oral steroid and high-dose intravenous methyl-prednisolone therapy (p \u0026amp;amp;amp;lt; 0.01). Considering all patients together, subjects who received a mean prednisone-equivalent dose of 8.4+/-1.5 g exhibited mucosal lesions, whereas patients who received 3.3+/-1.8 g did not (p = 0.06). The post-therapy increments in sucrose excretion rates were associated with neither the presence of macroscopic lesions nor with the total steroid dose received. Corticosteroid therapy augments gastroduodenal permeability and high doses are associated with macroscopic mucosal lesions. Steroid-induced permeability increase does not appear to be associated with the presence of macroscopic mucosal lesions.","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[],"research_interests":[{"id":3097,"name":"Multiple sclerosis","url":"https://www.academia.edu/Documents/in/Multiple_sclerosis"},{"id":71471,"name":"Intestinal Mucosa","url":"https://www.academia.edu/Documents/in/Intestinal_Mucosa"},{"id":83972,"name":"Permeability","url":"https://www.academia.edu/Documents/in/Permeability"},{"id":162196,"name":"Sucrose","url":"https://www.academia.edu/Documents/in/Sucrose"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":246560,"name":"High Pressure Liquid Chromatography","url":"https://www.academia.edu/Documents/in/High_Pressure_Liquid_Chromatography"},{"id":1030661,"name":"Stomach","url":"https://www.academia.edu/Documents/in/Stomach"},{"id":1293308,"name":"Glucocorticoids","url":"https://www.academia.edu/Documents/in/Glucocorticoids"},{"id":1631043,"name":"Control Group","url":"https://www.academia.edu/Documents/in/Control_Group"},{"id":1863718,"name":"The American","url":"https://www.academia.edu/Documents/in/The_American"},{"id":2090674,"name":"Duodenum","url":"https://www.academia.edu/Documents/in/Duodenum"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233402-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233401"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14233401/Relapses_and_disability_accumulation_in_progressive_multiple_sclerosis"><img alt="Research paper thumbnail of Relapses and disability accumulation in progressive multiple sclerosis" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Relapses and disability accumulation in progressive multiple sclerosis</div><div class="wp-workCard_item"><span>Neurology</span><span>, Jan 6, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">We examined the effect of relapses-before and after progression onset-on the rate of postprogress...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">We examined the effect of relapses-before and after progression onset-on the rate of postprogression disability accrual in a progressive multiple sclerosis (MS) cohort. We studied patients with primary progressive MS (n = 322) and bout-onset progressive MS (BOPMS) including single-attack progressive MS (n = 112) and secondary progressive MS (n = 421). The effect of relapses on time to Expanded Disability Status Scale (EDSS) score of 6 was studied using multivariate Cox regression analysis (sex, age at progression, and immunomodulation modeled as covariates). Kaplan-Meier analysis was performed using EDSS 6 as endpoint. Preprogression relapses (hazard ratio [HR]: 1.63; 95% confidence interval [CI]: 1.34-1.98), postprogression relapses (HR: 1.37; 95% CI: 1.11-1.70), female sex (HR: 1.19; 95% CI: 1.00-1.43), and progression onset after age 50 years (HR: 1.47; 95% CI: 1.21-1.78) were associated with shorter time to EDSS 6. Postprogression relapses occurred in 29.5% of secondary progress...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233401"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233401"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233401; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233401]").text(description); $(".js-view-count[data-work-id=14233401]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233401; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233401']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14233401]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233401,"title":"Relapses and disability accumulation in progressive multiple sclerosis","translated_title":"","metadata":{"abstract":"We examined the effect of relapses-before and after progression onset-on the rate of postprogression disability accrual in a progressive multiple sclerosis (MS) cohort. We studied patients with primary progressive MS (n = 322) and bout-onset progressive MS (BOPMS) including single-attack progressive MS (n = 112) and secondary progressive MS (n = 421). The effect of relapses on time to Expanded Disability Status Scale (EDSS) score of 6 was studied using multivariate Cox regression analysis (sex, age at progression, and immunomodulation modeled as covariates). Kaplan-Meier analysis was performed using EDSS 6 as endpoint. Preprogression relapses (hazard ratio [HR]: 1.63; 95% confidence interval [CI]: 1.34-1.98), postprogression relapses (HR: 1.37; 95% CI: 1.11-1.70), female sex (HR: 1.19; 95% CI: 1.00-1.43), and progression onset after age 50 years (HR: 1.47; 95% CI: 1.21-1.78) were associated with shorter time to EDSS 6. Postprogression relapses occurred in 29.5% of secondary progress...","publication_date":{"day":6,"month":1,"year":2015,"errors":{}},"publication_name":"Neurology"},"translated_abstract":"We examined the effect of relapses-before and after progression onset-on the rate of postprogression disability accrual in a progressive multiple sclerosis (MS) cohort. We studied patients with primary progressive MS (n = 322) and bout-onset progressive MS (BOPMS) including single-attack progressive MS (n = 112) and secondary progressive MS (n = 421). The effect of relapses on time to Expanded Disability Status Scale (EDSS) score of 6 was studied using multivariate Cox regression analysis (sex, age at progression, and immunomodulation modeled as covariates). Kaplan-Meier analysis was performed using EDSS 6 as endpoint. Preprogression relapses (hazard ratio [HR]: 1.63; 95% confidence interval [CI]: 1.34-1.98), postprogression relapses (HR: 1.37; 95% CI: 1.11-1.70), female sex (HR: 1.19; 95% CI: 1.00-1.43), and progression onset after age 50 years (HR: 1.47; 95% CI: 1.21-1.78) were associated with shorter time to EDSS 6. Postprogression relapses occurred in 29.5% of secondary progress...","internal_url":"https://www.academia.edu/14233401/Relapses_and_disability_accumulation_in_progressive_multiple_sclerosis","translated_internal_url":"","created_at":"2015-07-20T14:59:55.237-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Relapses_and_disability_accumulation_in_progressive_multiple_sclerosis","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"We examined the effect of relapses-before and after progression onset-on the rate of postprogression disability accrual in a progressive multiple sclerosis (MS) cohort. We studied patients with primary progressive MS (n = 322) and bout-onset progressive MS (BOPMS) including single-attack progressive MS (n = 112) and secondary progressive MS (n = 421). The effect of relapses on time to Expanded Disability Status Scale (EDSS) score of 6 was studied using multivariate Cox regression analysis (sex, age at progression, and immunomodulation modeled as covariates). Kaplan-Meier analysis was performed using EDSS 6 as endpoint. Preprogression relapses (hazard ratio [HR]: 1.63; 95% confidence interval [CI]: 1.34-1.98), postprogression relapses (HR: 1.37; 95% CI: 1.11-1.70), female sex (HR: 1.19; 95% CI: 1.00-1.43), and progression onset after age 50 years (HR: 1.47; 95% CI: 1.21-1.78) were associated with shorter time to EDSS 6. Postprogression relapses occurred in 29.5% of secondary progress...","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[],"research_interests":[{"id":237,"name":"Cognitive Science","url":"https://www.academia.edu/Documents/in/Cognitive_Science"},{"id":623,"name":"Neurology","url":"https://www.academia.edu/Documents/in/Neurology"},{"id":12426,"name":"Treatment Outcome","url":"https://www.academia.edu/Documents/in/Treatment_Outcome"},{"id":41482,"name":"Multivariate Analysis","url":"https://www.academia.edu/Documents/in/Multivariate_Analysis"},{"id":133057,"name":"Young Adult","url":"https://www.academia.edu/Documents/in/Young_Adult"},{"id":234187,"name":"Recurrence","url":"https://www.academia.edu/Documents/in/Recurrence"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":584615,"name":"Disease Progression","url":"https://www.academia.edu/Documents/in/Disease_Progression"},{"id":1239755,"name":"Neurosciences","url":"https://www.academia.edu/Documents/in/Neurosciences"},{"id":1272981,"name":"Proportional Hazards Models","url":"https://www.academia.edu/Documents/in/Proportional_Hazards_Models"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233401-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="13983336"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/13983336/The_Burden_of_Headache_in_Neurology_Outpatient_Clinics_in_Turkey"><img alt="Research paper thumbnail of The Burden of Headache in Neurology Outpatient Clinics in Turkey" class="work-thumbnail" src="https://attachments.academia-assets.com/44737981/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/13983336/The_Burden_of_Headache_in_Neurology_Outpatient_Clinics_in_Turkey">The Burden of Headache in Neurology Outpatient Clinics in Turkey</a></div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/NKarli">N. Karli</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/MErtas1">M. Ertas</a>, and <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a></span></div><div class="wp-workCard_item"><span>Pain Practice</span><span>, 2007</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Background and Aim: The aim of the study was to investigate the burden of headache in neurology o...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Background and Aim: The aim of the study was to investigate the burden of headache in neurology outpatient clinics (NOCs) regardless of their primary complaint. Methods: Patients presenting for their routine appointments in 41 NOCs were screened during the course of 1 week. All eligible subjects (n = 3682; 61.9% female, mean age 45.2 1 16.5 years) were evaluated by a neurologist for the headache diagnosis and some demographic characteristics. Results: Of all patients, 66.4% reported headache, and in 35.1% headache was the primary cause for admitting to the NOC. Of 3682 patients, 917 (24.9%) were diagnosed as migraine according to International Headache Society (IHS) criteria. Thirty-three and nine-tenths percent of all patients admitted and 56% of the migraineurs according to IHS had severe headaches. As the headache severity increases, the ratio of the patients admitted with headache as the primary complaint increases significantly. The distribution of burden and other characteristics of headache did not differ in seven geographic regions and 41 different centers. Conclusion: Headache complaint caused at least 1/3 of all neurological outpatient visits in Turkey and 2/3 of all patients admitted to NOC had headache. Of these patients, 1/4 had migraine according to IHS with substantial disability and severity level.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="c526d598d2586a289164141c97f5ef5b" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":44737981,"asset_id":13983336,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/44737981/download_file?s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="13983336"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="13983336"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 13983336; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=13983336]").text(description); $(".js-view-count[data-work-id=13983336]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 13983336; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='13983336']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "c526d598d2586a289164141c97f5ef5b" } } $('.js-work-strip[data-work-id=13983336]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":13983336,"title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey","translated_title":"","metadata":{"grobid_abstract":"Background and Aim: The aim of the study was to investigate the burden of headache in neurology outpatient clinics (NOCs) regardless of their primary complaint. Methods: Patients presenting for their routine appointments in 41 NOCs were screened during the course of 1 week. All eligible subjects (n = 3682; 61.9% female, mean age 45.2 1 16.5 years) were evaluated by a neurologist for the headache diagnosis and some demographic characteristics. Results: Of all patients, 66.4% reported headache, and in 35.1% headache was the primary cause for admitting to the NOC. Of 3682 patients, 917 (24.9%) were diagnosed as migraine according to International Headache Society (IHS) criteria. Thirty-three and nine-tenths percent of all patients admitted and 56% of the migraineurs according to IHS had severe headaches. As the headache severity increases, the ratio of the patients admitted with headache as the primary complaint increases significantly. The distribution of burden and other characteristics of headache did not differ in seven geographic regions and 41 different centers. Conclusion: Headache complaint caused at least 1/3 of all neurological outpatient visits in Turkey and 2/3 of all patients admitted to NOC had headache. Of these patients, 1/4 had migraine according to IHS with substantial disability and severity level.","publication_date":{"day":null,"month":null,"year":2007,"errors":{}},"publication_name":"Pain Practice","grobid_abstract_attachment_id":44737981},"translated_abstract":null,"internal_url":"https://www.academia.edu/13983336/The_Burden_of_Headache_in_Neurology_Outpatient_Clinics_in_Turkey","translated_internal_url":"","created_at":"2015-07-13T04:26:14.930-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33025639,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3018291,"work_id":13983336,"tagging_user_id":33025639,"tagged_user_id":33021815,"co_author_invite_id":null,"email":"m***f@uludag.edu.tr","affiliation":"Uludag University","display_order":0,"name":"M. Zarifoğlu","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"},{"id":3018299,"work_id":13983336,"tagging_user_id":33025639,"tagged_user_id":41556982,"co_author_invite_id":721598,"email":"m***s@superonline.com","display_order":4194304,"name":"M. Ertas","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"},{"id":3018302,"work_id":13983336,"tagging_user_id":33025639,"tagged_user_id":null,"co_author_invite_id":212337,"email":"o***n@gata.edu.tr","display_order":6291456,"name":"Ozlem Uzunkaya","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"},{"id":3018304,"work_id":13983336,"tagging_user_id":33025639,"tagged_user_id":33207160,"co_author_invite_id":765891,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":7340032,"name":"Aksel Siva","title":"The Burden of Headache in Neurology Outpatient Clinics in Turkey"}],"downloadable_attachments":[{"id":44737981,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44737981/thumbnails/1.jpg","file_name":"j.1533-2500.2007.00154.x.pdf20160414-19802-p7nvan","download_url":"https://www.academia.edu/attachments/44737981/download_file","bulk_download_file_name":"The_Burden_of_Headache_in_Neurology_Outp.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44737981/j.1533-2500.2007.00154.x-libre.pdf20160414-19802-p7nvan?1460663870=\u0026response-content-disposition=attachment%3B+filename%3DThe_Burden_of_Headache_in_Neurology_Outp.pdf\u0026Expires=1743585185\u0026Signature=TMwnGKaSO2v6gqS3BVN7M6w7b4lyTH0Oc8PmUUQXFGo16w7k1vEluX57-k1d0F~d15hWYbUv3mvSxlJ8PZn6uFaonyTRDeZyy12vppjQa6T62s6b40boNmpTl2o843W2DDrbJeknYaPzprOWxBFevfEiRTAaFP2gnxp98blEPgrXgj1cwqpOuAYl0kJE-5DWcGJrFamfKUJzf7edYMl4JPJoFqYlKsIDdNhE-qH1D7I5zF4zMn24NN2j-ltiTWeFiaUr8ffCW1lTu1O9Kp3tm-qnTrdJAMZBXM9FSFmfPrYUPxMGDL0TqO2ek843dqfXBm5aWR4W4rMuSneA--CW6Q__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"The_Burden_of_Headache_in_Neurology_Outpatient_Clinics_in_Turkey","translated_slug":"","page_count":11,"language":"en","content_type":"Work","summary":"Background and Aim: The aim of the study was to investigate the burden of headache in neurology outpatient clinics (NOCs) regardless of their primary complaint. Methods: Patients presenting for their routine appointments in 41 NOCs were screened during the course of 1 week. All eligible subjects (n = 3682; 61.9% female, mean age 45.2 1 16.5 years) were evaluated by a neurologist for the headache diagnosis and some demographic characteristics. Results: Of all patients, 66.4% reported headache, and in 35.1% headache was the primary cause for admitting to the NOC. Of 3682 patients, 917 (24.9%) were diagnosed as migraine according to International Headache Society (IHS) criteria. Thirty-three and nine-tenths percent of all patients admitted and 56% of the migraineurs according to IHS had severe headaches. As the headache severity increases, the ratio of the patients admitted with headache as the primary complaint increases significantly. The distribution of burden and other characteristics of headache did not differ in seven geographic regions and 41 different centers. Conclusion: Headache complaint caused at least 1/3 of all neurological outpatient visits in Turkey and 2/3 of all patients admitted to NOC had headache. Of these patients, 1/4 had migraine according to IHS with substantial disability and severity level.","owner":{"id":33025639,"first_name":"N.","middle_initials":null,"last_name":"Karli","page_name":"NKarli","domain_name":"independent","created_at":"2015-07-13T04:19:58.878-07:00","display_name":"N. Karli","url":"https://independent.academia.edu/NKarli"},"attachments":[{"id":44737981,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/44737981/thumbnails/1.jpg","file_name":"j.1533-2500.2007.00154.x.pdf20160414-19802-p7nvan","download_url":"https://www.academia.edu/attachments/44737981/download_file","bulk_download_file_name":"The_Burden_of_Headache_in_Neurology_Outp.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/44737981/j.1533-2500.2007.00154.x-libre.pdf20160414-19802-p7nvan?1460663870=\u0026response-content-disposition=attachment%3B+filename%3DThe_Burden_of_Headache_in_Neurology_Outp.pdf\u0026Expires=1743585185\u0026Signature=TMwnGKaSO2v6gqS3BVN7M6w7b4lyTH0Oc8PmUUQXFGo16w7k1vEluX57-k1d0F~d15hWYbUv3mvSxlJ8PZn6uFaonyTRDeZyy12vppjQa6T62s6b40boNmpTl2o843W2DDrbJeknYaPzprOWxBFevfEiRTAaFP2gnxp98blEPgrXgj1cwqpOuAYl0kJE-5DWcGJrFamfKUJzf7edYMl4JPJoFqYlKsIDdNhE-qH1D7I5zF4zMn24NN2j-ltiTWeFiaUr8ffCW1lTu1O9Kp3tm-qnTrdJAMZBXM9FSFmfPrYUPxMGDL0TqO2ek843dqfXBm5aWR4W4rMuSneA--CW6Q__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":623,"name":"Neurology","url":"https://www.academia.edu/Documents/in/Neurology"},{"id":2898,"name":"Pain","url":"https://www.academia.edu/Documents/in/Pain"},{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":289330,"name":"Prevalence","url":"https://www.academia.edu/Documents/in/Prevalence"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-13983336-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="13983334"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/13983334/The_validation_of_ID_migraine_screener_in_neurology_outpatient_clinics_in_Turkey"><img alt="Research paper thumbnail of The validation of ID migraine™ screener in neurology outpatient clinics in Turkey" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">The validation of ID migraine™ screener in neurology outpatient clinics in Turkey</div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/NKarli">N. Karli</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/MErtas1">M. Ertas</a>, and <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a></span></div><div class="wp-workCard_item"><span>The Journal of Headache and Pain</span><span>, 2007</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">The aim of this study was to investigate the validity of the ID Migraine test in neurology outpat...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">The aim of this study was to investigate the validity of the ID Migraine test in neurology outpatient clinics (NOCs), regardless of their presenting complaints. Patients admitted to 41 NOCs were screened. Eligible subjects (n=3682) were evaluated by a neurologist for headache diagnosis according to the International Headache Society criteria and asked the 3-item screening questions of the ID Migraine test. Of 3682 patients, 917 (24.9%) were diagnosed as migraine, whereas 1171 (31.8%) were ID Migraine test positive. The sensitivity of the ID Migraine test for neurologist&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s diagnosis of migraine was 91.8%, specificity was 63.4%, positive predictive value was 71.9% and negative predictive value was 88.4%. The ID Migraine test is easy to use and a practical test that could alert the neurologist to diagnose patients having other complaints. This test would help to increase the diagnosis and treatment rate of undiagnosed migraine patients in NOCs.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="13983334"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="13983334"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 13983334; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=13983334]").text(description); $(".js-view-count[data-work-id=13983334]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 13983334; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='13983334']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=13983334]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":13983334,"title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey","translated_title":"","metadata":{"abstract":"The aim of this study was to investigate the validity of the ID Migraine test in neurology outpatient clinics (NOCs), regardless of their presenting complaints. Patients admitted to 41 NOCs were screened. Eligible subjects (n=3682) were evaluated by a neurologist for headache diagnosis according to the International Headache Society criteria and asked the 3-item screening questions of the ID Migraine test. Of 3682 patients, 917 (24.9%) were diagnosed as migraine, whereas 1171 (31.8%) were ID Migraine test positive. The sensitivity of the ID Migraine test for neurologist\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s diagnosis of migraine was 91.8%, specificity was 63.4%, positive predictive value was 71.9% and negative predictive value was 88.4%. The ID Migraine test is easy to use and a practical test that could alert the neurologist to diagnose patients having other complaints. This test would help to increase the diagnosis and treatment rate of undiagnosed migraine patients in NOCs.","publication_date":{"day":null,"month":null,"year":2007,"errors":{}},"publication_name":"The Journal of Headache and Pain"},"translated_abstract":"The aim of this study was to investigate the validity of the ID Migraine test in neurology outpatient clinics (NOCs), regardless of their presenting complaints. Patients admitted to 41 NOCs were screened. Eligible subjects (n=3682) were evaluated by a neurologist for headache diagnosis according to the International Headache Society criteria and asked the 3-item screening questions of the ID Migraine test. Of 3682 patients, 917 (24.9%) were diagnosed as migraine, whereas 1171 (31.8%) were ID Migraine test positive. The sensitivity of the ID Migraine test for neurologist\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s diagnosis of migraine was 91.8%, specificity was 63.4%, positive predictive value was 71.9% and negative predictive value was 88.4%. The ID Migraine test is easy to use and a practical test that could alert the neurologist to diagnose patients having other complaints. This test would help to increase the diagnosis and treatment rate of undiagnosed migraine patients in NOCs.","internal_url":"https://www.academia.edu/13983334/The_validation_of_ID_migraine_screener_in_neurology_outpatient_clinics_in_Turkey","translated_internal_url":"","created_at":"2015-07-13T04:26:14.799-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33025639,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3018294,"work_id":13983334,"tagging_user_id":33025639,"tagged_user_id":33021815,"co_author_invite_id":null,"email":"m***f@uludag.edu.tr","affiliation":"Uludag University","display_order":0,"name":"M. Zarifoğlu","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"},{"id":3018301,"work_id":13983334,"tagging_user_id":33025639,"tagged_user_id":41556982,"co_author_invite_id":721598,"email":"m***s@superonline.com","display_order":4194304,"name":"M. Ertas","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"},{"id":3018303,"work_id":13983334,"tagging_user_id":33025639,"tagged_user_id":null,"co_author_invite_id":212337,"email":"o***n@gata.edu.tr","display_order":6291456,"name":"Ozlem Uzunkaya","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"},{"id":3018306,"work_id":13983334,"tagging_user_id":33025639,"tagged_user_id":33207160,"co_author_invite_id":765891,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":7340032,"name":"Aksel Siva","title":"The validation of ID migraine™ screener in neurology outpatient clinics in Turkey"}],"downloadable_attachments":[],"slug":"The_validation_of_ID_migraine_screener_in_neurology_outpatient_clinics_in_Turkey","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"The aim of this study was to investigate the validity of the ID Migraine test in neurology outpatient clinics (NOCs), regardless of their presenting complaints. Patients admitted to 41 NOCs were screened. Eligible subjects (n=3682) were evaluated by a neurologist for headache diagnosis according to the International Headache Society criteria and asked the 3-item screening questions of the ID Migraine test. Of 3682 patients, 917 (24.9%) were diagnosed as migraine, whereas 1171 (31.8%) were ID Migraine test positive. The sensitivity of the ID Migraine test for neurologist\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39;s diagnosis of migraine was 91.8%, specificity was 63.4%, positive predictive value was 71.9% and negative predictive value was 88.4%. The ID Migraine test is easy to use and a practical test that could alert the neurologist to diagnose patients having other complaints. This test would help to increase the diagnosis and treatment rate of undiagnosed migraine patients in NOCs.","owner":{"id":33025639,"first_name":"N.","middle_initials":null,"last_name":"Karli","page_name":"NKarli","domain_name":"independent","created_at":"2015-07-13T04:19:58.878-07:00","display_name":"N. Karli","url":"https://independent.academia.edu/NKarli"},"attachments":[],"research_interests":[{"id":623,"name":"Neurology","url":"https://www.academia.edu/Documents/in/Neurology"},{"id":8942,"name":"Treatment","url":"https://www.academia.edu/Documents/in/Treatment"},{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":144833,"name":"Validity","url":"https://www.academia.edu/Documents/in/Validity"},{"id":161176,"name":"The","url":"https://www.academia.edu/Documents/in/The"},{"id":254203,"name":"Ambulatory","url":"https://www.academia.edu/Documents/in/Ambulatory"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":289330,"name":"Prevalence","url":"https://www.academia.edu/Documents/in/Prevalence"},{"id":327850,"name":"Questionnaires","url":"https://www.academia.edu/Documents/in/Questionnaires"},{"id":401947,"name":"Sensitivity","url":"https://www.academia.edu/Documents/in/Sensitivity"},{"id":549280,"name":"Reproducibility of Results","url":"https://www.academia.edu/Documents/in/Reproducibility_of_Results"},{"id":901876,"name":"Sensitivity and Specificity","url":"https://www.academia.edu/Documents/in/Sensitivity_and_Specificity"},{"id":1318932,"name":"Predictive value of tests","url":"https://www.academia.edu/Documents/in/Predictive_value_of_tests"},{"id":1318938,"name":"Positive predictive value","url":"https://www.academia.edu/Documents/in/Positive_predictive_value"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-13983334-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233400"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14233400/Radiologically_Isolated_Syndrome_5_Year_Risk_for_an_Initial_Clinical_Event"><img alt="Research paper thumbnail of Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event</div><div class="wp-workCard_item"><span>PLoS ONE</span><span>, 2014</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">To report the 5-year risk and to identify risk factors for the development of a seminal acute or ...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">To report the 5-year risk and to identify risk factors for the development of a seminal acute or progressive clinical event in a multi-national cohort of asymptomatic subjects meeting 2009 RIS Criteria. Retrospectively identified RIS subjects from 22 databases within 5 countries were evaluated. Time to the first clinical event related to demyelination (acute or 12-month progression of neurological deficits) was compared across different groups by univariate and multivariate analyses utilizing a Cox regression model. Data were available in 451 RIS subjects (F: 354 (78.5%)). The mean age at from the time of the first brain MRI revealing anomalies suggestive of MS was 37.2 years (y) (median: 37.1 y, range: 11-74 y) with mean clinical follow-up time of 4.4 y (median: 2.8 y, range: 0.01-21.1 y). Clinical events were identified in 34% (standard error=3%) of individuals within a 5-year period from the first brain MRI study. Of those who developed symptoms, 9.6% fulfilled criteria for primary progressive MS. In the multivariate model, age [hazard ratio (HR): 0.98 (95% CI: 0.96-0.99); p=0.03], sex (male) [HR: 1.93 (1.24-2.99); p=0.004], and lesions within the cervical or thoracic spinal cord [HR: 3.08 (2.06-4.62); p=&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;0.001] were identified as significant predictors for the development of a first clinical event. These data provide supportive evidence that a meaningful number of RIS subjects evolve to a first clinical symptom. An age &amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;37 y, male sex, and spinal cord involvement appear to be the most important independent predictors of symptom onset.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233400"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233400"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233400; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233400]").text(description); $(".js-view-count[data-work-id=14233400]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233400; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233400']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14233400]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233400,"title":"Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event","translated_title":"","metadata":{"abstract":"To report the 5-year risk and to identify risk factors for the development of a seminal acute or progressive clinical event in a multi-national cohort of asymptomatic subjects meeting 2009 RIS Criteria. Retrospectively identified RIS subjects from 22 databases within 5 countries were evaluated. Time to the first clinical event related to demyelination (acute or 12-month progression of neurological deficits) was compared across different groups by univariate and multivariate analyses utilizing a Cox regression model. Data were available in 451 RIS subjects (F: 354 (78.5%)). The mean age at from the time of the first brain MRI revealing anomalies suggestive of MS was 37.2 years (y) (median: 37.1 y, range: 11-74 y) with mean clinical follow-up time of 4.4 y (median: 2.8 y, range: 0.01-21.1 y). Clinical events were identified in 34% (standard error=3%) of individuals within a 5-year period from the first brain MRI study. Of those who developed symptoms, 9.6% fulfilled criteria for primary progressive MS. In the multivariate model, age [hazard ratio (HR): 0.98 (95% CI: 0.96-0.99); p=0.03], sex (male) [HR: 1.93 (1.24-2.99); p=0.004], and lesions within the cervical or thoracic spinal cord [HR: 3.08 (2.06-4.62); p=\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;0.001] were identified as significant predictors for the development of a first clinical event. These data provide supportive evidence that a meaningful number of RIS subjects evolve to a first clinical symptom. An age \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;37 y, male sex, and spinal cord involvement appear to be the most important independent predictors of symptom onset.","publication_date":{"day":null,"month":null,"year":2014,"errors":{}},"publication_name":"PLoS ONE"},"translated_abstract":"To report the 5-year risk and to identify risk factors for the development of a seminal acute or progressive clinical event in a multi-national cohort of asymptomatic subjects meeting 2009 RIS Criteria. Retrospectively identified RIS subjects from 22 databases within 5 countries were evaluated. Time to the first clinical event related to demyelination (acute or 12-month progression of neurological deficits) was compared across different groups by univariate and multivariate analyses utilizing a Cox regression model. Data were available in 451 RIS subjects (F: 354 (78.5%)). The mean age at from the time of the first brain MRI revealing anomalies suggestive of MS was 37.2 years (y) (median: 37.1 y, range: 11-74 y) with mean clinical follow-up time of 4.4 y (median: 2.8 y, range: 0.01-21.1 y). Clinical events were identified in 34% (standard error=3%) of individuals within a 5-year period from the first brain MRI study. Of those who developed symptoms, 9.6% fulfilled criteria for primary progressive MS. In the multivariate model, age [hazard ratio (HR): 0.98 (95% CI: 0.96-0.99); p=0.03], sex (male) [HR: 1.93 (1.24-2.99); p=0.004], and lesions within the cervical or thoracic spinal cord [HR: 3.08 (2.06-4.62); p=\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;0.001] were identified as significant predictors for the development of a first clinical event. These data provide supportive evidence that a meaningful number of RIS subjects evolve to a first clinical symptom. An age \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;37 y, male sex, and spinal cord involvement appear to be the most important independent predictors of symptom onset.","internal_url":"https://www.academia.edu/14233400/Radiologically_Isolated_Syndrome_5_Year_Risk_for_an_Initial_Clinical_Event","translated_internal_url":"","created_at":"2015-07-20T14:59:54.951-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Radiologically_Isolated_Syndrome_5_Year_Risk_for_an_Initial_Clinical_Event","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"To report the 5-year risk and to identify risk factors for the development of a seminal acute or progressive clinical event in a multi-national cohort of asymptomatic subjects meeting 2009 RIS Criteria. Retrospectively identified RIS subjects from 22 databases within 5 countries were evaluated. Time to the first clinical event related to demyelination (acute or 12-month progression of neurological deficits) was compared across different groups by univariate and multivariate analyses utilizing a Cox regression model. Data were available in 451 RIS subjects (F: 354 (78.5%)). The mean age at from the time of the first brain MRI revealing anomalies suggestive of MS was 37.2 years (y) (median: 37.1 y, range: 11-74 y) with mean clinical follow-up time of 4.4 y (median: 2.8 y, range: 0.01-21.1 y). Clinical events were identified in 34% (standard error=3%) of individuals within a 5-year period from the first brain MRI study. Of those who developed symptoms, 9.6% fulfilled criteria for primary progressive MS. In the multivariate model, age [hazard ratio (HR): 0.98 (95% CI: 0.96-0.99); p=0.03], sex (male) [HR: 1.93 (1.24-2.99); p=0.004], and lesions within the cervical or thoracic spinal cord [HR: 3.08 (2.06-4.62); p=\u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;0.001] were identified as significant predictors for the development of a first clinical event. These data provide supportive evidence that a meaningful number of RIS subjects evolve to a first clinical symptom. An age \u0026amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;37 y, male sex, and spinal cord involvement appear to be the most important independent predictors of symptom onset.","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[],"research_interests":[{"id":3097,"name":"Multiple sclerosis","url":"https://www.academia.edu/Documents/in/Multiple_sclerosis"},{"id":6200,"name":"Magnetic Resonance Imaging","url":"https://www.academia.edu/Documents/in/Magnetic_Resonance_Imaging"},{"id":22506,"name":"Adolescent","url":"https://www.academia.edu/Documents/in/Adolescent"},{"id":28235,"name":"Multidisciplinary","url":"https://www.academia.edu/Documents/in/Multidisciplinary"},{"id":41482,"name":"Multivariate Analysis","url":"https://www.academia.edu/Documents/in/Multivariate_Analysis"},{"id":64933,"name":"Child","url":"https://www.academia.edu/Documents/in/Child"},{"id":99421,"name":"Spinal Cord","url":"https://www.academia.edu/Documents/in/Spinal_Cord"},{"id":111629,"name":"Incidental Findings","url":"https://www.academia.edu/Documents/in/Incidental_Findings"},{"id":133057,"name":"Young Adult","url":"https://www.academia.edu/Documents/in/Young_Adult"},{"id":192721,"name":"Risk factors","url":"https://www.academia.edu/Documents/in/Risk_factors"},{"id":220780,"name":"PLoS one","url":"https://www.academia.edu/Documents/in/PLoS_one"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":469105,"name":"Retrospective Studies","url":"https://www.academia.edu/Documents/in/Retrospective_Studies"},{"id":584615,"name":"Disease Progression","url":"https://www.academia.edu/Documents/in/Disease_Progression"},{"id":620049,"name":"Risk Factors","url":"https://www.academia.edu/Documents/in/Risk_Factors-1"},{"id":1272981,"name":"Proportional Hazards Models","url":"https://www.academia.edu/Documents/in/Proportional_Hazards_Models"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233400-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233399"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14233399/Clinical_characteristics_of_pediatric_onset_neuro_Behcet_disease"><img alt="Research paper thumbnail of Clinical characteristics of pediatric-onset neuro-Behcet disease" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Clinical characteristics of pediatric-onset neuro-Behcet disease</div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a>, and <a class="" data-click-track="profile-work-strip-authors" href="https://usih.academia.edu/HuriOzdogan">Huri Ozdogan</a></span></div><div class="wp-workCard_item"><span>Neurology</span><span>, 2011</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Neurologic involvement in the pediatric population with Behçet disease (BD) is limited to case re...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Neurologic involvement in the pediatric population with Behçet disease (BD) is limited to case reports. The aim of this study is to examine the frequency and type of neurologic involvement in pediatric patients with BD. Medical records of 728 patients with a diagnosis of neuro-BD (NBD) of 2 large BD cohorts followed in Istanbul University were included in the study. Patients with an onset of both systemic and neurologic symptoms at or before age 16 (pediatric neuro-BD) were identified. Demographic and clinical characteristics of pediatric patients with NBD were compared with adult patients with NBD. There were 26 cases with pediatric BD (3.6%) and 702 (96.4%) adult-onset patients. Gender ratio was equal in the general pediatric BD cohort, whereas male/female ratio was 5.5/1 in pediatric NBD cases. Mean age at BD onset and neurologic involvement onset were 13.0 ± 3.0 and 13.5 ± 2.4, respectively, and in the adult population mean age at onset of BD was 26.7 ± 8.0 and neurologic involvement occurred a mean of 5.3 ± 4.5 years later. Clinical and MRI evaluation revealed that 3 children had CNS parenchymal involvement and 23 had dural venous sinus thrombosis (88.5%). We observed parenchymal involvement in 74.8% of the adults, contrary to the low 17.2% of cases with venous sinus thrombosis. Pediatric NBD comprises 3.6% of our whole NBD cohort, with a male predominance, mainly in the form of dural venous sinus thrombosis, whereas in the adult NBD population the dominant form of neurologic involvement is parenchymal, suggesting that the pathogenesis of NBD may be different according to the age at disease onset.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233399"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233399"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233399; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233399]").text(description); $(".js-view-count[data-work-id=14233399]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233399; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233399']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14233399]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233399,"title":"Clinical characteristics of pediatric-onset neuro-Behcet disease","translated_title":"","metadata":{"abstract":"Neurologic involvement in the pediatric population with Behçet disease (BD) is limited to case reports. The aim of this study is to examine the frequency and type of neurologic involvement in pediatric patients with BD. Medical records of 728 patients with a diagnosis of neuro-BD (NBD) of 2 large BD cohorts followed in Istanbul University were included in the study. Patients with an onset of both systemic and neurologic symptoms at or before age 16 (pediatric neuro-BD) were identified. Demographic and clinical characteristics of pediatric patients with NBD were compared with adult patients with NBD. There were 26 cases with pediatric BD (3.6%) and 702 (96.4%) adult-onset patients. Gender ratio was equal in the general pediatric BD cohort, whereas male/female ratio was 5.5/1 in pediatric NBD cases. Mean age at BD onset and neurologic involvement onset were 13.0 ± 3.0 and 13.5 ± 2.4, respectively, and in the adult population mean age at onset of BD was 26.7 ± 8.0 and neurologic involvement occurred a mean of 5.3 ± 4.5 years later. Clinical and MRI evaluation revealed that 3 children had CNS parenchymal involvement and 23 had dural venous sinus thrombosis (88.5%). We observed parenchymal involvement in 74.8% of the adults, contrary to the low 17.2% of cases with venous sinus thrombosis. Pediatric NBD comprises 3.6% of our whole NBD cohort, with a male predominance, mainly in the form of dural venous sinus thrombosis, whereas in the adult NBD population the dominant form of neurologic involvement is parenchymal, suggesting that the pathogenesis of NBD may be different according to the age at disease onset.","publication_date":{"day":null,"month":null,"year":2011,"errors":{}},"publication_name":"Neurology"},"translated_abstract":"Neurologic involvement in the pediatric population with Behçet disease (BD) is limited to case reports. The aim of this study is to examine the frequency and type of neurologic involvement in pediatric patients with BD. Medical records of 728 patients with a diagnosis of neuro-BD (NBD) of 2 large BD cohorts followed in Istanbul University were included in the study. Patients with an onset of both systemic and neurologic symptoms at or before age 16 (pediatric neuro-BD) were identified. Demographic and clinical characteristics of pediatric patients with NBD were compared with adult patients with NBD. There were 26 cases with pediatric BD (3.6%) and 702 (96.4%) adult-onset patients. Gender ratio was equal in the general pediatric BD cohort, whereas male/female ratio was 5.5/1 in pediatric NBD cases. Mean age at BD onset and neurologic involvement onset were 13.0 ± 3.0 and 13.5 ± 2.4, respectively, and in the adult population mean age at onset of BD was 26.7 ± 8.0 and neurologic involvement occurred a mean of 5.3 ± 4.5 years later. Clinical and MRI evaluation revealed that 3 children had CNS parenchymal involvement and 23 had dural venous sinus thrombosis (88.5%). We observed parenchymal involvement in 74.8% of the adults, contrary to the low 17.2% of cases with venous sinus thrombosis. Pediatric NBD comprises 3.6% of our whole NBD cohort, with a male predominance, mainly in the form of dural venous sinus thrombosis, whereas in the adult NBD population the dominant form of neurologic involvement is parenchymal, suggesting that the pathogenesis of NBD may be different according to the age at disease onset.","internal_url":"https://www.academia.edu/14233399/Clinical_characteristics_of_pediatric_onset_neuro_Behcet_disease","translated_internal_url":"","created_at":"2015-07-20T14:59:54.848-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3517902,"work_id":14233399,"tagging_user_id":33207160,"tagged_user_id":33272291,"co_author_invite_id":765886,"email":"p***p@superonline.com","affiliation":"Istanbul University","display_order":0,"name":"Sabahattin Saip","title":"Clinical characteristics of pediatric-onset neuro-Behcet disease"},{"id":3517907,"work_id":14233399,"tagging_user_id":33207160,"tagged_user_id":33234624,"co_author_invite_id":846352,"email":"h***n@yahoo.com","affiliation":"University of Istanbul","display_order":4194304,"name":"Huri Ozdogan","title":"Clinical characteristics of pediatric-onset neuro-Behcet disease"},{"id":3517908,"work_id":14233399,"tagging_user_id":33207160,"tagged_user_id":null,"co_author_invite_id":262337,"email":"a***m@istanbul.edu.tr","display_order":6291456,"name":"G. Akman-demir","title":"Clinical characteristics of pediatric-onset neuro-Behcet disease"}],"downloadable_attachments":[],"slug":"Clinical_characteristics_of_pediatric_onset_neuro_Behcet_disease","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"Neurologic involvement in the pediatric population with Behçet disease (BD) is limited to case reports. The aim of this study is to examine the frequency and type of neurologic involvement in pediatric patients with BD. Medical records of 728 patients with a diagnosis of neuro-BD (NBD) of 2 large BD cohorts followed in Istanbul University were included in the study. Patients with an onset of both systemic and neurologic symptoms at or before age 16 (pediatric neuro-BD) were identified. Demographic and clinical characteristics of pediatric patients with NBD were compared with adult patients with NBD. There were 26 cases with pediatric BD (3.6%) and 702 (96.4%) adult-onset patients. Gender ratio was equal in the general pediatric BD cohort, whereas male/female ratio was 5.5/1 in pediatric NBD cases. Mean age at BD onset and neurologic involvement onset were 13.0 ± 3.0 and 13.5 ± 2.4, respectively, and in the adult population mean age at onset of BD was 26.7 ± 8.0 and neurologic involvement occurred a mean of 5.3 ± 4.5 years later. Clinical and MRI evaluation revealed that 3 children had CNS parenchymal involvement and 23 had dural venous sinus thrombosis (88.5%). We observed parenchymal involvement in 74.8% of the adults, contrary to the low 17.2% of cases with venous sinus thrombosis. Pediatric NBD comprises 3.6% of our whole NBD cohort, with a male predominance, mainly in the form of dural venous sinus thrombosis, whereas in the adult NBD population the dominant form of neurologic involvement is parenchymal, suggesting that the pathogenesis of NBD may be different according to the age at disease onset.","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[],"research_interests":[{"id":237,"name":"Cognitive Science","url":"https://www.academia.edu/Documents/in/Cognitive_Science"},{"id":623,"name":"Neurology","url":"https://www.academia.edu/Documents/in/Neurology"},{"id":631,"name":"Pediatrics","url":"https://www.academia.edu/Documents/in/Pediatrics"},{"id":6200,"name":"Magnetic Resonance Imaging","url":"https://www.academia.edu/Documents/in/Magnetic_Resonance_Imaging"},{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":22506,"name":"Adolescent","url":"https://www.academia.edu/Documents/in/Adolescent"},{"id":64933,"name":"Child","url":"https://www.academia.edu/Documents/in/Child"},{"id":133057,"name":"Young Adult","url":"https://www.academia.edu/Documents/in/Young_Adult"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":469105,"name":"Retrospective Studies","url":"https://www.academia.edu/Documents/in/Retrospective_Studies"},{"id":1239755,"name":"Neurosciences","url":"https://www.academia.edu/Documents/in/Neurosciences"},{"id":1423078,"name":"Nervous System Diseases","url":"https://www.academia.edu/Documents/in/Nervous_System_Diseases"},{"id":1489115,"name":"Age of Onset","url":"https://www.academia.edu/Documents/in/Age_of_Onset"},{"id":1819400,"name":"Cohort Studies","url":"https://www.academia.edu/Documents/in/Cohort_Studies"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233399-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="14233398"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/14233398/Validity_of_the_ID_Migraine_screener_in_the_workplace"><img alt="Research paper thumbnail of Validity of the ID-Migraine screener in the workplace" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Validity of the ID-Migraine screener in the workplace</div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a> and <a class="" data-click-track="profile-work-strip-authors" href="https://uludag.academia.edu/MZarifo%C4%9Flu">M. Zarifoğlu</a></span></div><div class="wp-workCard_item"><span>Neurology</span><span>, 2008</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">The impact of migraine on physical, social, and emotional performance is considerable, yet it rem...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">The impact of migraine on physical, social, and emotional performance is considerable, yet it remains an underdiagnosed disorder. ID-Migraine is a validated migraine-screening tool developed to facilitate diagnosis. This study evaluated the validity and use of the Turkish version of the ID-Migraine screener (ID-Ms) in the workplace, and measured the impact of headache on disability, productivity, and quality of life among the workforce. A total of 465 employees from four companies were interviewed for screening with the ID-Ms. Subjects were included in the study if they reported two or more headaches in the past 3 months and gave a positive answer to one of the two ID-Ms prescreening questions. Eligible subjects completed the ID-Ms, the Migraine Disability Assessment Questionnaire, and the Medical Outcomes Study 36-Item Short Form Health Survey. Subjects were then evaluated for confirmation of their diagnosis according to the International Classification of Headache Disorders, 2nd edition (ICHD-2) criteria. A total of 227 subjects (mean age 31.9 +/- 5.9 years; 65.6% women) completed the study. Migraine was diagnosed in 106 of the 227 subjects (46.7%) according to the ID-Ms and in 117 of the 227 subjects (51.5%) according to ICHD-2 criteria. The sensitivity of the ID-Ms was 70.9%, specificity was 79.1% and Cohen kappa value was 0.50. Workdays lost over the previous 3 months due to headache amounted to 8.7 +/- 9.5 days for migraine-positive and 4.9 +/- 6.6 days for migraine-negative subjects. The Turkish version of the ID-Migraine screener is a valid tool for identifying subjects with migraine in the workplace.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="14233398"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="14233398"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 14233398; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=14233398]").text(description); $(".js-view-count[data-work-id=14233398]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 14233398; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='14233398']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=14233398]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":14233398,"title":"Validity of the ID-Migraine screener in the workplace","translated_title":"","metadata":{"abstract":"The impact of migraine on physical, social, and emotional performance is considerable, yet it remains an underdiagnosed disorder. ID-Migraine is a validated migraine-screening tool developed to facilitate diagnosis. This study evaluated the validity and use of the Turkish version of the ID-Migraine screener (ID-Ms) in the workplace, and measured the impact of headache on disability, productivity, and quality of life among the workforce. A total of 465 employees from four companies were interviewed for screening with the ID-Ms. Subjects were included in the study if they reported two or more headaches in the past 3 months and gave a positive answer to one of the two ID-Ms prescreening questions. Eligible subjects completed the ID-Ms, the Migraine Disability Assessment Questionnaire, and the Medical Outcomes Study 36-Item Short Form Health Survey. Subjects were then evaluated for confirmation of their diagnosis according to the International Classification of Headache Disorders, 2nd edition (ICHD-2) criteria. A total of 227 subjects (mean age 31.9 +/- 5.9 years; 65.6% women) completed the study. Migraine was diagnosed in 106 of the 227 subjects (46.7%) according to the ID-Ms and in 117 of the 227 subjects (51.5%) according to ICHD-2 criteria. The sensitivity of the ID-Ms was 70.9%, specificity was 79.1% and Cohen kappa value was 0.50. Workdays lost over the previous 3 months due to headache amounted to 8.7 +/- 9.5 days for migraine-positive and 4.9 +/- 6.6 days for migraine-negative subjects. The Turkish version of the ID-Migraine screener is a valid tool for identifying subjects with migraine in the workplace.","publication_date":{"day":null,"month":null,"year":2008,"errors":{}},"publication_name":"Neurology"},"translated_abstract":"The impact of migraine on physical, social, and emotional performance is considerable, yet it remains an underdiagnosed disorder. ID-Migraine is a validated migraine-screening tool developed to facilitate diagnosis. This study evaluated the validity and use of the Turkish version of the ID-Migraine screener (ID-Ms) in the workplace, and measured the impact of headache on disability, productivity, and quality of life among the workforce. A total of 465 employees from four companies were interviewed for screening with the ID-Ms. Subjects were included in the study if they reported two or more headaches in the past 3 months and gave a positive answer to one of the two ID-Ms prescreening questions. Eligible subjects completed the ID-Ms, the Migraine Disability Assessment Questionnaire, and the Medical Outcomes Study 36-Item Short Form Health Survey. Subjects were then evaluated for confirmation of their diagnosis according to the International Classification of Headache Disorders, 2nd edition (ICHD-2) criteria. A total of 227 subjects (mean age 31.9 +/- 5.9 years; 65.6% women) completed the study. Migraine was diagnosed in 106 of the 227 subjects (46.7%) according to the ID-Ms and in 117 of the 227 subjects (51.5%) according to ICHD-2 criteria. The sensitivity of the ID-Ms was 70.9%, specificity was 79.1% and Cohen kappa value was 0.50. Workdays lost over the previous 3 months due to headache amounted to 8.7 +/- 9.5 days for migraine-positive and 4.9 +/- 6.6 days for migraine-negative subjects. The Turkish version of the ID-Migraine screener is a valid tool for identifying subjects with migraine in the workplace.","internal_url":"https://www.academia.edu/14233398/Validity_of_the_ID_Migraine_screener_in_the_workplace","translated_internal_url":"","created_at":"2015-07-20T14:59:54.709-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33207160,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3517879,"work_id":14233398,"tagging_user_id":33207160,"tagged_user_id":33025639,"co_author_invite_id":null,"email":"n***i@uludag.edu.tr","display_order":0,"name":"N. Karli","title":"Validity of the ID-Migraine screener in the workplace"},{"id":3517880,"work_id":14233398,"tagging_user_id":33207160,"tagged_user_id":33021815,"co_author_invite_id":null,"email":"m***f@uludag.edu.tr","affiliation":"Uludag University","display_order":4194304,"name":"M. Zarifoğlu","title":"Validity of the ID-Migraine screener in the workplace"},{"id":3517900,"work_id":14233398,"tagging_user_id":33207160,"tagged_user_id":33138161,"co_author_invite_id":null,"email":"d***s@gmail.com","affiliation":"Istanbul University","display_order":6291456,"name":"Mustafa ERTAŞ","title":"Validity of the ID-Migraine screener in the workplace"},{"id":3517901,"work_id":14233398,"tagging_user_id":33207160,"tagged_user_id":null,"co_author_invite_id":287979,"email":"b***n@yahoo.com","display_order":7340032,"name":"Betül Baykan","title":"Validity of the ID-Migraine screener in the workplace"},{"id":3517903,"work_id":14233398,"tagging_user_id":33207160,"tagged_user_id":33272291,"co_author_invite_id":765886,"email":"p***p@superonline.com","affiliation":"Istanbul University","display_order":7864320,"name":"Sabahattin Saip","title":"Validity of the ID-Migraine screener in the workplace"}],"downloadable_attachments":[],"slug":"Validity_of_the_ID_Migraine_screener_in_the_workplace","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"The impact of migraine on physical, social, and emotional performance is considerable, yet it remains an underdiagnosed disorder. ID-Migraine is a validated migraine-screening tool developed to facilitate diagnosis. This study evaluated the validity and use of the Turkish version of the ID-Migraine screener (ID-Ms) in the workplace, and measured the impact of headache on disability, productivity, and quality of life among the workforce. A total of 465 employees from four companies were interviewed for screening with the ID-Ms. Subjects were included in the study if they reported two or more headaches in the past 3 months and gave a positive answer to one of the two ID-Ms prescreening questions. Eligible subjects completed the ID-Ms, the Migraine Disability Assessment Questionnaire, and the Medical Outcomes Study 36-Item Short Form Health Survey. Subjects were then evaluated for confirmation of their diagnosis according to the International Classification of Headache Disorders, 2nd edition (ICHD-2) criteria. A total of 227 subjects (mean age 31.9 +/- 5.9 years; 65.6% women) completed the study. Migraine was diagnosed in 106 of the 227 subjects (46.7%) according to the ID-Ms and in 117 of the 227 subjects (51.5%) according to ICHD-2 criteria. The sensitivity of the ID-Ms was 70.9%, specificity was 79.1% and Cohen kappa value was 0.50. Workdays lost over the previous 3 months due to headache amounted to 8.7 +/- 9.5 days for migraine-positive and 4.9 +/- 6.6 days for migraine-negative subjects. The Turkish version of the ID-Migraine screener is a valid tool for identifying subjects with migraine in the workplace.","owner":{"id":33207160,"first_name":"Aksel","middle_initials":"","last_name":"Siva","page_name":"AkselSiva","domain_name":"istanbul","created_at":"2015-07-20T14:59:31.062-07:00","display_name":"Aksel Siva","url":"https://istanbul.academia.edu/AkselSiva"},"attachments":[],"research_interests":[{"id":237,"name":"Cognitive Science","url":"https://www.academia.edu/Documents/in/Cognitive_Science"},{"id":623,"name":"Neurology","url":"https://www.academia.edu/Documents/in/Neurology"},{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":22506,"name":"Adolescent","url":"https://www.academia.edu/Documents/in/Adolescent"},{"id":56122,"name":"Workplace","url":"https://www.academia.edu/Documents/in/Workplace"},{"id":85280,"name":"Industry","url":"https://www.academia.edu/Documents/in/Industry"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":557260,"name":"Health surveys","url":"https://www.academia.edu/Documents/in/Health_surveys"},{"id":1239755,"name":"Neurosciences","url":"https://www.academia.edu/Documents/in/Neurosciences"},{"id":1262481,"name":"Pain Measurement","url":"https://www.academia.edu/Documents/in/Pain_Measurement"}],"urls":[]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-14233398-figures'); } }); </script> <div class="js-work-strip profile--work_container" data-work-id="13976532"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/13976532/Economic_impact_of_primary_headaches_in_Turkey_a_university_hospital_based_study_part_II"><img alt="Research paper thumbnail of Economic impact of primary headaches in Turkey: a university hospital based study: part II" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title">Economic impact of primary headaches in Turkey: a university hospital based study: part II</div><div class="wp-workCard_item wp-workCard--coauthors"><span>by </span><span><a class="" data-click-track="profile-work-strip-authors" href="https://uludag.academia.edu/MZarifo%C4%9Flu">M. Zarifoğlu</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/SabahattinSaip">Sabahattin Saip</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://deu.academia.edu/VesileOzt%C3%BCrk">Vesile Oztürk</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/SebnemBi%C3%A7ak%C3%A7i">Sebnem Biçakçi</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/CavitBoz">Cavit Boz</a>, <a class="" data-click-track="profile-work-strip-authors" href="https://istanbul.academia.edu/AkselSiva">Aksel Siva</a>, and <a class="" data-click-track="profile-work-strip-authors" href="https://independent.academia.edu/NebahatTa%C5%9Fdemir">Nebahat Taşdemir</a></span></div><div class="wp-workCard_item"><span>The journal of headache and pain</span><span>, 2006</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">This study was planned to investigate the economic impact of headache on Turkish headache suffere...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">This study was planned to investigate the economic impact of headache on Turkish headache sufferers attending a tertiary care outpatient headache clinic.A total of 937 headache patients were included in this study and questioned using a questionnaire for the profile of patients and headache, quality of life of patients and economic impact of headache. The median total direct cost was found to be 88.0 USD and the median total cost was 160.7 USD. The drug treatment cost was the highest item followed by the specialist outpatient care cost. The average lost and inefficient work/school days was 1.5 (0-45) and 8.4 (0-100) days for one year. It was shown that loss of productivity was higher for migraine without aura group when compared with the episodic and chronic tension-type headache groups. The results of this nationwide university hospital based study methshowed that headache, especially migraine, has considerable economic impact on patients.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="13976532"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="13976532"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 13976532; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=13976532]").text(description); $(".js-view-count[data-work-id=13976532]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 13976532; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='13976532']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=13976532]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":13976532,"title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II","translated_title":"","metadata":{"abstract":"This study was planned to investigate the economic impact of headache on Turkish headache sufferers attending a tertiary care outpatient headache clinic.A total of 937 headache patients were included in this study and questioned using a questionnaire for the profile of patients and headache, quality of life of patients and economic impact of headache. The median total direct cost was found to be 88.0 USD and the median total cost was 160.7 USD. The drug treatment cost was the highest item followed by the specialist outpatient care cost. The average lost and inefficient work/school days was 1.5 (0-45) and 8.4 (0-100) days for one year. It was shown that loss of productivity was higher for migraine without aura group when compared with the episodic and chronic tension-type headache groups. The results of this nationwide university hospital based study methshowed that headache, especially migraine, has considerable economic impact on patients.","publisher":"ncbi.nlm.nih.gov","publication_date":{"day":null,"month":null,"year":2006,"errors":{}},"publication_name":"The journal of headache and pain"},"translated_abstract":"This study was planned to investigate the economic impact of headache on Turkish headache sufferers attending a tertiary care outpatient headache clinic.A total of 937 headache patients were included in this study and questioned using a questionnaire for the profile of patients and headache, quality of life of patients and economic impact of headache. The median total direct cost was found to be 88.0 USD and the median total cost was 160.7 USD. The drug treatment cost was the highest item followed by the specialist outpatient care cost. The average lost and inefficient work/school days was 1.5 (0-45) and 8.4 (0-100) days for one year. It was shown that loss of productivity was higher for migraine without aura group when compared with the episodic and chronic tension-type headache groups. The results of this nationwide university hospital based study methshowed that headache, especially migraine, has considerable economic impact on patients.","internal_url":"https://www.academia.edu/13976532/Economic_impact_of_primary_headaches_in_Turkey_a_university_hospital_based_study_part_II","translated_internal_url":"","created_at":"2015-07-13T01:27:16.094-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":33021815,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[{"id":3004204,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":null,"co_author_invite_id":765882,"email":"n***r@deu.edu.tr","display_order":0,"name":"N. Uzuner","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004205,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":null,"co_author_invite_id":765883,"email":"n***i@yahoo.com","display_order":4194304,"name":"Necdet Karli","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004214,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":33272291,"co_author_invite_id":765886,"email":"p***p@superonline.com","affiliation":"Istanbul University","display_order":6291456,"name":"Sabahattin Saip","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004215,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":33245428,"co_author_invite_id":765887,"email":"v***k@deu.edu.tr","affiliation":"Dokuz Eylül University","display_order":7340032,"name":"Vesile Oztürk","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004216,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":33105926,"co_author_invite_id":765888,"email":"s***b@mail.cu.edu.tr","display_order":7864320,"name":"Sebnem Biçakçi","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004217,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":43415196,"co_author_invite_id":556570,"email":"c***b@yahoo.com","display_order":8126464,"name":"Cavit Boz","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004218,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":null,"co_author_invite_id":765889,"email":"d***i@hotmail.com","display_order":8257536,"name":"Denit Selçuki","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004219,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":null,"co_author_invite_id":765890,"email":"a***o@iname.com","display_order":8323072,"name":"Atilla Oğuzhanoğlu","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004220,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":null,"co_author_invite_id":758554,"email":"n***l@superonline.com","display_order":8355840,"name":"Münife Neyal","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004221,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":33207160,"co_author_invite_id":765891,"email":"a***a@turk.net","affiliation":"Istanbul University","display_order":8372224,"name":"Aksel Siva","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004222,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":null,"co_author_invite_id":765892,"email":"c***c@yahoo.com","display_order":8380416,"name":"Ceyla Irkeç","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004223,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":978293,"co_author_invite_id":null,"email":"t***u@hacettepe.edu.tr","affiliation":"Hacettepe University","display_order":8384512,"name":"Tulay Kansu","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004224,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":null,"co_author_invite_id":765893,"email":"y***a@e-kolay.net","display_order":8386560,"name":"Yakup Sarica","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004225,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":33755151,"co_author_invite_id":765894,"email":"n***t@dicle.edu.tr","display_order":8387584,"name":"Nebahat Taşdemir","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004226,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":null,"co_author_invite_id":765895,"email":"s***b@cu.edu.tr","display_order":8388096,"name":"Ş. Bıçakçı","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"},{"id":3004227,"work_id":13976532,"tagging_user_id":33021815,"tagged_user_id":33138161,"co_author_invite_id":699618,"email":"d***s@gmail.com","affiliation":"Istanbul University","display_order":8388352,"name":"Mustafa ERTAŞ","title":"Economic impact of primary headaches in Turkey: a university hospital based study: part II"}],"downloadable_attachments":[],"slug":"Economic_impact_of_primary_headaches_in_Turkey_a_university_hospital_based_study_part_II","translated_slug":"","page_count":null,"language":"en","content_type":"Work","summary":"This study was planned to investigate the economic impact of headache on Turkish headache sufferers attending a tertiary care outpatient headache clinic.A total of 937 headache patients were included in this study and questioned using a questionnaire for the profile of patients and headache, quality of life of patients and economic impact of headache. The median total direct cost was found to be 88.0 USD and the median total cost was 160.7 USD. The drug treatment cost was the highest item followed by the specialist outpatient care cost. The average lost and inefficient work/school days was 1.5 (0-45) and 8.4 (0-100) days for one year. It was shown that loss of productivity was higher for migraine without aura group when compared with the episodic and chronic tension-type headache groups. The results of this nationwide university hospital based study methshowed that headache, especially migraine, has considerable economic impact on patients.","owner":{"id":33021815,"first_name":"M.","middle_initials":null,"last_name":"Zarifoğlu","page_name":"MZarifoğlu","domain_name":"uludag","created_at":"2015-07-13T01:26:36.416-07:00","display_name":"M. Zarifoğlu","url":"https://uludag.academia.edu/MZarifo%C4%9Flu"},"attachments":[],"research_interests":[{"id":7470,"name":"Quality of life","url":"https://www.academia.edu/Documents/in/Quality_of_life"},{"id":10966,"name":"Turkey","url":"https://www.academia.edu/Documents/in/Turkey"},{"id":22506,"name":"Adolescent","url":"https://www.academia.edu/Documents/in/Adolescent"},{"id":66744,"name":"Biomedical Research","url":"https://www.academia.edu/Documents/in/Biomedical_Research"},{"id":149214,"name":"Economic Impact","url":"https://www.academia.edu/Documents/in/Economic_Impact"},{"id":161176,"name":"The","url":"https://www.academia.edu/Documents/in/The"},{"id":612548,"name":"Tension-Type Headache","url":"https://www.academia.edu/Documents/in/Tension-Type_Headache"},{"id":886573,"name":"Cost of Illness","url":"https://www.academia.edu/Documents/in/Cost_of_Illness"},{"id":1034181,"name":"Cross Sectional Studies","url":"https://www.academia.edu/Documents/in/Cross_Sectional_Studies"},{"id":1592916,"name":"Drug treatment","url":"https://www.academia.edu/Documents/in/Drug_treatment"}],"urls":[{"id":4967877,"url":"http://dx.doi.org/10.1007/s10194-006-0273-7"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") if (false) { Aedu.setUpFigureCarousel('profile-work-13976532-figures'); } }); </script> </div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js","https://a.academia-assets.com/assets/google_contacts-0dfb882d836b94dbcb4a2d123d6933fc9533eda5be911641f20b4eb428429600.js"], function() { // from javascript_helper.rb $('.js-google-connect-button').click(function(e) { e.preventDefault(); GoogleContacts.authorize_and_show_contacts(); Aedu.Dismissibles.recordClickthrough("WowProfileImportContactsPrompt"); }); $('.js-update-biography-button').click(function(e) { e.preventDefault(); Aedu.Dismissibles.recordClickthrough("UpdateUserBiographyPrompt"); $.ajax({ url: $r.api_v0_profiles_update_about_path({ subdomain_param: 'api', about: "", }), type: 'PUT', success: function(response) { location.reload(); } }); }); $('.js-work-creator-button').click(function (e) { e.preventDefault(); window.location = $r.upload_funnel_document_path({ source: encodeURIComponent(""), }); }); $('.js-video-upload-button').click(function (e) { e.preventDefault(); window.location = $r.upload_funnel_video_path({ source: encodeURIComponent(""), }); }); $('.js-do-this-later-button').click(function() { $(this).closest('.js-profile-nag-panel').remove(); Aedu.Dismissibles.recordDismissal("WowProfileImportContactsPrompt"); }); $('.js-update-biography-do-this-later-button').click(function(){ $(this).closest('.js-profile-nag-panel').remove(); Aedu.Dismissibles.recordDismissal("UpdateUserBiographyPrompt"); }); $('.wow-profile-mentions-upsell--close').click(function(){ $('.wow-profile-mentions-upsell--panel').hide(); Aedu.Dismissibles.recordDismissal("WowProfileMentionsUpsell"); }); $('.wow-profile-mentions-upsell--button').click(function(){ Aedu.Dismissibles.recordClickthrough("WowProfileMentionsUpsell"); }); new WowProfile.SocialRedesignUserWorks({ initialWorksOffset: 20, allWorksOffset: 20, maxSections: 1 }) }); </script> </div></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile_edit-5ea339ee107c863779f560dd7275595239fed73f1a13d279d2b599a28c0ecd33.js","https://a.academia-assets.com/assets/add_coauthor-22174b608f9cb871d03443cafa7feac496fb50d7df2d66a53f5ee3c04ba67f53.js","https://a.academia-assets.com/assets/tab-dcac0130902f0cc2d8cb403714dd47454f11fc6fb0e99ae6a0827b06613abc20.js","https://a.academia-assets.com/assets/wow_profile-a9bf3a2bc8c89fa2a77156577594264ee8a0f214d74241bc0fcd3f69f8d107ac.js"], function() { // from javascript_helper.rb window.ae = window.ae || {}; window.ae.WowProfile = window.ae.WowProfile || {}; if(Aedu.User.current && Aedu.User.current.id === $viewedUser.id) { window.ae.WowProfile.current_user_edit = {}; new WowProfileEdit.EditUploadView({ el: '.js-edit-upload-button-wrapper', model: window.$current_user, }); new AddCoauthor.AddCoauthorsController(); } var userInfoView = new WowProfile.SocialRedesignUserInfo({ recaptcha_key: "6LdxlRMTAAAAADnu_zyLhLg0YF9uACwz78shpjJB" }); WowProfile.router = new WowProfile.Router({ userInfoView: userInfoView }); Backbone.history.start({ pushState: true, root: "/" + $viewedUser.page_name }); new WowProfile.UserWorksNav() }); </script> </div> <div class="bootstrap login"><div class="modal fade login-modal" id="login-modal"><div class="login-modal-dialog modal-dialog"><div class="modal-content"><div class="modal-header"><button class="close close" data-dismiss="modal" type="button"><span aria-hidden="true">×</span><span class="sr-only">Close</span></button><h4 class="modal-title text-center"><strong>Log In</strong></h4></div><div class="modal-body"><div class="row"><div class="col-xs-10 col-xs-offset-1"><button class="btn btn-fb btn-lg btn-block btn-v-center-content" id="login-facebook-oauth-button"><svg style="float: left; width: 19px; line-height: 1em; margin-right: .3em;" aria-hidden="true" focusable="false" data-prefix="fab" data-icon="facebook-square" class="svg-inline--fa fa-facebook-square fa-w-14" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M400 32H48A48 48 0 0 0 0 80v352a48 48 0 0 0 48 48h137.25V327.69h-63V256h63v-54.64c0-62.15 37-96.48 93.67-96.48 27.14 0 55.52 4.84 55.52 4.84v61h-31.27c-30.81 0-40.42 19.12-40.42 38.73V256h68.78l-11 71.69h-57.78V480H400a48 48 0 0 0 48-48V80a48 48 0 0 0-48-48z"></path></svg><small><strong>Log in</strong> with <strong>Facebook</strong></small></button><br /><button class="btn btn-google btn-lg btn-block btn-v-center-content" id="login-google-oauth-button"><svg style="float: left; width: 22px; line-height: 1em; margin-right: .3em;" aria-hidden="true" focusable="false" data-prefix="fab" data-icon="google-plus" class="svg-inline--fa fa-google-plus fa-w-16" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M256,8C119.1,8,8,119.1,8,256S119.1,504,256,504,504,392.9,504,256,392.9,8,256,8ZM185.3,380a124,124,0,0,1,0-248c31.3,0,60.1,11,83,32.3l-33.6,32.6c-13.2-12.9-31.3-19.1-49.4-19.1-42.9,0-77.2,35.5-77.2,78.1S142.3,334,185.3,334c32.6,0,64.9-19.1,70.1-53.3H185.3V238.1H302.2a109.2,109.2,0,0,1,1.9,20.7c0,70.8-47.5,121.2-118.8,121.2ZM415.5,273.8v35.5H380V273.8H344.5V238.3H380V202.8h35.5v35.5h35.2v35.5Z"></path></svg><small><strong>Log in</strong> with <strong>Google</strong></small></button><br /><style type="text/css">.sign-in-with-apple-button { width: 100%; height: 52px; border-radius: 3px; border: 1px solid black; cursor: pointer; } .sign-in-with-apple-button > div { margin: 0 auto; / This centers the Apple-rendered button horizontally }</style><script src="https://appleid.cdn-apple.com/appleauth/static/jsapi/appleid/1/en_US/appleid.auth.js" type="text/javascript"></script><div class="sign-in-with-apple-button" data-border="false" data-color="white" id="appleid-signin"><span   ="Sign Up with Apple" class="u-fs11"></span></div><script>AppleID.auth.init({ clientId: 'edu.academia.applesignon', scope: 'name email', redirectURI: 'https://www.academia.edu/sessions', state: "3f279706452a473b11e6fba0cfc45a1cf9e8b09ba639062c53d5035e1ba4e7b7", });</script><script>// Hacky way of checking if on fast loswp if (window.loswp == null) { (function() { const Google = window?.Aedu?.Auth?.OauthButton?.Login?.Google; const Facebook = window?.Aedu?.Auth?.OauthButton?.Login?.Facebook; if (Google) { new Google({ el: '#login-google-oauth-button', rememberMeCheckboxId: 'remember_me', track: null }); } if (Facebook) { new Facebook({ el: '#login-facebook-oauth-button', rememberMeCheckboxId: 'remember_me', track: null }); } })(); }</script></div></div></div><div class="modal-body"><div class="row"><div class="col-xs-10 col-xs-offset-1"><div class="hr-heading login-hr-heading"><span class="hr-heading-text">or</span></div></div></div></div><div class="modal-body"><div class="row"><div class="col-xs-10 col-xs-offset-1"><form class="js-login-form" action="https://www.academia.edu/sessions" accept-charset="UTF-8" method="post"><input type="hidden" name="authenticity_token" value="lUfMObbICA6eWRNnh_-AXBkCwtCBC14eOqoNLIos-diUqVQrb0raUd9nWrL4kXk9NVS7gj4Y4zunBbuAlquQmg" autocomplete="off" /><div class="form-group"><label class="control-label" for="login-modal-email-input" style="font-size: 14px;">Email</label><input class="form-control" id="login-modal-email-input" name="login" type="email" /></div><div class="form-group"><label class="control-label" for="login-modal-password-input" style="font-size: 14px;">Password</label><input class="form-control" id="login-modal-password-input" name="password" type="password" /></div><input type="hidden" name="post_login_redirect_url" id="post_login_redirect_url" value="https://istanbul.academia.edu/AkselSiva" autocomplete="off" /><div class="checkbox"><label><input type="checkbox" name="remember_me" id="remember_me" value="1" checked="checked" /><small style="font-size: 12px; margin-top: 2px; display: inline-block;">Remember me on this computer</small></label></div><br><input type="submit" name="commit" value="Log In" class="btn btn-primary btn-block btn-lg js-login-submit" data-disable-with="Log In" /></br></form><script>typeof window?.Aedu?.recaptchaManagedForm === 'function' && window.Aedu.recaptchaManagedForm( document.querySelector('.js-login-form'), document.querySelector('.js-login-submit') );</script><small style="font-size: 12px;"><br />or <a data-target="#login-modal-reset-password-container" data-toggle="collapse" href="javascript:void(0)">reset password</a></small><div class="collapse" id="login-modal-reset-password-container"><br /><div class="well margin-0x"><form class="js-password-reset-form" action="https://www.academia.edu/reset_password" accept-charset="UTF-8" method="post"><input type="hidden" name="authenticity_token" value="_4AWVWMvaxLwK5LGBWz_TAJfRaTRw_K912x6kkleKBX-bo5Huq25TbEV2xN6AgYtLgk89m7QT5hKw8w-VdlBVw" autocomplete="off" /><p>Enter the email address you signed up with and we'll email you a reset link.</p><div class="form-group"><input class="form-control" name="email" type="email" /></div><script src="https://recaptcha.net/recaptcha/api.js" async defer></script> <script> var invisibleRecaptchaSubmit = function () { var closestForm = function (ele) { var curEle = ele.parentNode; while (curEle.nodeName !== 'FORM' && curEle.nodeName !== 'BODY'){ curEle = curEle.parentNode; } return curEle.nodeName === 'FORM' ? curEle : null }; var eles = document.getElementsByClassName('g-recaptcha'); if (eles.length > 0) { var form = closestForm(eles[0]); if (form) { form.submit(); } } }; </script> <input type="submit" data-sitekey="6Lf3KHUUAAAAACggoMpmGJdQDtiyrjVlvGJ6BbAj" data-callback="invisibleRecaptchaSubmit" class="g-recaptcha btn btn-primary btn-block" value="Email me a link" value=""/> </form></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/collapse-45805421cf446ca5adf7aaa1935b08a3a8d1d9a6cc5d91a62a2a3a00b20b3e6a.js"], function() { // from javascript_helper.rb $("#login-modal-reset-password-container").on("shown.bs.collapse", function() { $(this).find("input[type=email]").focus(); }); }); </script> </div></div></div><div class="modal-footer"><div class="text-center"><small style="font-size: 12px;">Need an account? <a rel="nofollow" href="https://www.academia.edu/signup">Click here to sign up</a></small></div></div></div></div></div></div><script>// If we are on subdomain or non-bootstrapped page, redirect to login page instead of showing modal (function(){ if (typeof $ === 'undefined') return; var host = window.location.hostname; if ((host === $domain || host === "www."+$domain) && (typeof $().modal === 'function')) { $("#nav_log_in").click(function(e) { // Don't follow the link and open the modal e.preventDefault(); $("#login-modal").on('shown.bs.modal', function() { $(this).find("#login-modal-email-input").focus() }).modal('show'); }); } })()</script> <div class="bootstrap" id="footer"><div class="footer-content clearfix text-center padding-top-7x" style="width:100%;"><ul class="footer-links-secondary footer-links-wide list-inline margin-bottom-1x"><li><a href="https://www.academia.edu/about">About</a></li><li><a href="https://www.academia.edu/press">Press</a></li><li><a href="https://www.academia.edu/documents">Papers</a></li><li><a href="https://www.academia.edu/topics">Topics</a></li><li><a href="https://www.academia.edu/journals">Academia.edu Journals</a></li><li><a rel="nofollow" href="https://www.academia.edu/hiring"><svg style="width: 13px; height: 13px;" aria-hidden="true" focusable="false" data-prefix="fas" data-icon="briefcase" class="svg-inline--fa fa-briefcase fa-w-16" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M320 336c0 8.84-7.16 16-16 16h-96c-8.84 0-16-7.16-16-16v-48H0v144c0 25.6 22.4 48 48 48h416c25.6 0 48-22.4 48-48V288H320v48zm144-208h-80V80c0-25.6-22.4-48-48-48H176c-25.6 0-48 22.4-48 48v48H48c-25.6 0-48 22.4-48 48v80h512v-80c0-25.6-22.4-48-48-48zm-144 0H192V96h128v32z"></path></svg> <strong>We're Hiring!</strong></a></li><li><a rel="nofollow" href="https://support.academia.edu/hc/en-us"><svg style="width: 12px; height: 12px;" aria-hidden="true" focusable="false" data-prefix="fas" data-icon="question-circle" class="svg-inline--fa fa-question-circle fa-w-16" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M504 256c0 136.997-111.043 248-248 248S8 392.997 8 256C8 119.083 119.043 8 256 8s248 111.083 248 248zM262.655 90c-54.497 0-89.255 22.957-116.549 63.758-3.536 5.286-2.353 12.415 2.715 16.258l34.699 26.31c5.205 3.947 12.621 3.008 16.665-2.122 17.864-22.658 30.113-35.797 57.303-35.797 20.429 0 45.698 13.148 45.698 32.958 0 14.976-12.363 22.667-32.534 33.976C247.128 238.528 216 254.941 216 296v4c0 6.627 5.373 12 12 12h56c6.627 0 12-5.373 12-12v-1.333c0-28.462 83.186-29.647 83.186-106.667 0-58.002-60.165-102-116.531-102zM256 338c-25.365 0-46 20.635-46 46 0 25.364 20.635 46 46 46s46-20.636 46-46c0-25.365-20.635-46-46-46z"></path></svg> <strong>Help Center</strong></a></li></ul><ul class="footer-links-tertiary list-inline margin-bottom-1x"><li class="small">Find new research papers in:</li><li class="small"><a href="https://www.academia.edu/Documents/in/Physics">Physics</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Chemistry">Chemistry</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Biology">Biology</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Health_Sciences">Health Sciences</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Ecology">Ecology</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Earth_Sciences">Earth Sciences</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Cognitive_Science">Cognitive Science</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Mathematics">Mathematics</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Computer_Science">Computer Science</a></li></ul></div></div><div class="DesignSystem" id="credit" style="width:100%;"><ul class="u-pl0x footer-links-legal list-inline"><li><a rel="nofollow" href="https://www.academia.edu/terms">Terms</a></li><li><a rel="nofollow" href="https://www.academia.edu/privacy">Privacy</a></li><li><a rel="nofollow" href="https://www.academia.edu/copyright">Copyright</a></li><li>Academia ©2025</li></ul></div><script> //<![CDATA[ window.detect_gmtoffset = true; window.Academia && window.Academia.set_gmtoffset && Academia.set_gmtoffset('/gmtoffset'); //]]> </script> <div id='overlay_background'></div> <div id='bootstrap-modal-container' class='bootstrap'></div> <div id='ds-modal-container' class='bootstrap DesignSystem'></div> <div id='full-screen-modal'></div> </div> </body> </html>